{"question": "In phase III trials for type 2 diabetes, how does semaglutide compare with dulaglutide in reducing HbA1c and body weight over at least 52 weeks?", "topic": "Drug development/Phase III trials (Diabetes)", "question_type": "efficacy_comparison", "expected_search_terms": ["phase III", "semaglutide", "dulaglutide", "type 2 diabetes", "HbA1c", "52 weeks", "randomized"]}
{"question": "In patients with type 2 diabetes and cardiovascular risk, how does empagliflozin compare with dapagliflozin in reducing hospitalization for heart failure in large phase III outcomes trials?", "topic": "Drug development/Phase III trials (Diabetes/Cardiovascular outcomes)", "question_type": "efficacy_comparison", "expected_search_terms": ["empagliflozin", "dapagliflozin", "heart failure hospitalization", "cardiovascular outcomes", "phase III", "type 2 diabetes"]}
{"question": "In phase III trials of obesity pharmacotherapy, how does tirzepatide compare with semaglutide for percentage weight loss in adults without diabetes?", "topic": "Drug development/Phase III trials (Obesity)", "question_type": "efficacy_comparison", "expected_search_terms": ["tirzepatide", "semaglutide", "obesity", "phase III", "percent weight loss", "randomized trial", "non-diabetic"]}
{"question": "In patients with nonvalvular atrial fibrillation, how do apixaban and rivaroxaban compare for major bleeding risk in phase III randomized trials?", "topic": "Drug development/Phase III trials (Cardiology/Anticoagulation)", "question_type": "efficacy_comparison", "expected_search_terms": ["apixaban", "rivaroxaban", "atrial fibrillation", "phase III", "randomized", "major bleeding"]}
{"question": "In venous thromboembolism treatment, how does edoxaban compare with dabigatran for recurrent VTE prevention in phase III trials?", "topic": "Drug development/Phase III trials (Thrombosis)", "question_type": "efficacy_comparison", "expected_search_terms": ["edoxaban", "dabigatran", "venous thromboembolism", "recurrent", "phase III", "randomized"]}
{"question": "In phase III trials for heart failure with reduced ejection fraction, what is the incremental benefit of adding an SGLT2 inhibitor to standard therapy on the composite of cardiovascular death or heart failure hospitalization?", "topic": "Drug development/Phase III trials (Heart failure)", "question_type": "efficacy_comparison", "expected_search_terms": ["SGLT2 inhibitor", "HFrEF", "phase III", "standard therapy", "cardiovascular death", "heart failure hospitalization"]}
{"question": "In chronic kidney disease phase III trials, how does finerenone compare with placebo in reducing progression to end-stage kidney disease among patients with type 2 diabetes?", "topic": "Drug development/Phase III trials (Nephrology)", "question_type": "efficacy_comparison", "expected_search_terms": ["finerenone", "chronic kidney disease", "type 2 diabetes", "phase III", "end-stage kidney disease", "progression"]}
{"question": "In phase III trials for hypercholesterolemia, how does bempedoic acid compare with ezetimibe in LDL-C reduction in statin-intolerant patients?", "topic": "Drug development/Phase III trials (Lipidology)", "question_type": "efficacy_comparison", "expected_search_terms": ["bempedoic acid", "ezetimibe", "statin intolerance", "LDL cholesterol", "phase III", "randomized"]}
{"question": "In phase III cardiovascular outcomes trials, how do PCSK9 inhibitors compare with placebo in reducing ischemic stroke incidence in patients with atherosclerotic cardiovascular disease?", "topic": "Drug development/Phase III trials (Cardiovascular prevention)", "question_type": "efficacy_comparison", "expected_search_terms": ["PCSK9 inhibitor", "ischemic stroke", "atherosclerotic cardiovascular disease", "phase III", "cardiovascular outcomes", "randomized"]}
{"question": "In phase III trials for hypertension, does combining an ACE inhibitor with a calcium channel blocker provide superior blood pressure control compared with an ACE inhibitor plus thiazide diuretic?", "topic": "Drug development/Phase III trials (Hypertension)", "question_type": "efficacy_comparison", "expected_search_terms": ["ACE inhibitor", "calcium channel blocker", "thiazide", "hypertension", "phase III", "randomized", "combination therapy"]}
{"question": "In moderate-to-severe plaque psoriasis, how does risankizumab compare with secukinumab in achieving PASI 90 at one year in phase III trials?", "topic": "Drug development/Phase III trials (Dermatology)", "question_type": "efficacy_comparison", "expected_search_terms": ["risankizumab", "secukinumab", "psoriasis", "PASI 90", "phase III", "one year", "randomized"]}
{"question": "In atopic dermatitis phase III trials, how does upadacitinib compare with dupilumab for achieving EASI-75 at week 16?", "topic": "Drug development/Phase III trials (Dermatology/Immunology)", "question_type": "efficacy_comparison", "expected_search_terms": ["upadacitinib", "dupilumab", "atopic dermatitis", "EASI-75", "phase III", "week 16", "randomized"]}
{"question": "In ulcerative colitis phase III trials, how does tofacitinib compare with upadacitinib for induction of clinical remission at 8 weeks?", "topic": "Drug development/Phase III trials (Gastroenterology/IBD)", "question_type": "efficacy_comparison", "expected_search_terms": ["tofacitinib", "upadacitinib", "ulcerative colitis", "phase III", "induction", "clinical remission", "8 weeks"]}
{"question": "In Crohn’s disease phase III trials, how does ustekinumab compare with vedolizumab for maintenance of corticosteroid-free remission at one year?", "topic": "Drug development/Phase III trials (Gastroenterology/IBD)", "question_type": "efficacy_comparison", "expected_search_terms": ["ustekinumab", "vedolizumab", "Crohn disease", "phase III", "maintenance", "corticosteroid-free remission", "one year"]}
{"question": "In rheumatoid arthritis phase III trials, how does abatacept compare with a TNF inhibitor for radiographic progression inhibition over 12 months in methotrexate-inadequate responders?", "topic": "Drug development/Phase III trials (Rheumatology)", "question_type": "efficacy_comparison", "expected_search_terms": ["abatacept", "TNF inhibitor", "rheumatoid arthritis", "methotrexate inadequate response", "radiographic progression", "phase III"]}
{"question": "In psoriatic arthritis phase III trials, how does guselkumab compare with adalimumab for achieving ACR50 at 24 weeks?", "topic": "Drug development/Phase III trials (Rheumatology/Dermatology)", "question_type": "efficacy_comparison", "expected_search_terms": ["guselkumab", "adalimumab", "psoriatic arthritis", "ACR50", "phase III", "24 weeks", "randomized"]}
{"question": "In ankylosing spondylitis phase III trials, how does ixekizumab compare with secukinumab for achieving ASAS40 response at week 16?", "topic": "Drug development/Phase III trials (Rheumatology)", "question_type": "efficacy_comparison", "expected_search_terms": ["ixekizumab", "secukinumab", "ankylosing spondylitis", "ASAS40", "phase III", "week 16", "randomized"]}
{"question": "In severe asthma phase III trials, how does benralizumab compare with mepolizumab for reducing annualized exacerbation rates in eosinophilic asthma?", "topic": "Drug development/Phase III trials (Pulmonology)", "question_type": "efficacy_comparison", "expected_search_terms": ["benralizumab", "mepolizumab", "severe asthma", "eosinophilic", "annualized exacerbation rate", "phase III"]}
{"question": "In COPD phase III trials, does triple inhaler therapy (ICS/LABA/LAMA) reduce exacerbations more than dual bronchodilator therapy (LABA/LAMA) in patients with frequent exacerbations?", "topic": "Drug development/Phase III trials (Pulmonology/COPD)", "question_type": "efficacy_comparison", "expected_search_terms": ["COPD", "triple therapy", "ICS LABA LAMA", "LABA LAMA", "phase III", "exacerbation", "randomized"]}
{"question": "In pulmonary arterial hypertension phase III trials, how does initial combination therapy with an endothelin receptor antagonist plus a PDE-5 inhibitor compare with monotherapy for time to clinical worsening?", "topic": "Drug development/Phase III trials (Pulmonary vascular disease)", "question_type": "efficacy_comparison", "expected_search_terms": ["pulmonary arterial hypertension", "endothelin receptor antagonist", "PDE-5 inhibitor", "combination therapy", "phase III", "time to clinical worsening"]}
{"question": "In nonmetastatic castration-resistant prostate cancer, how do apalutamide and enzalutamide compare for metastasis-free survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Prostate)", "question_type": "efficacy_comparison", "expected_search_terms": ["apalutamide", "enzalutamide", "nonmetastatic castration-resistant prostate cancer", "phase III", "metastasis-free survival", "randomized"]}
{"question": "In metastatic hormone-sensitive prostate cancer, how does adding abiraterone to androgen deprivation therapy compare with adding docetaxel for overall survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Prostate)", "question_type": "efficacy_comparison", "expected_search_terms": ["abiraterone", "docetaxel", "androgen deprivation therapy", "metastatic hormone-sensitive prostate cancer", "phase III", "overall survival"]}
{"question": "In first-line metastatic non-small cell lung cancer with high PD-L1 expression, how does pembrolizumab monotherapy compare with chemoimmunotherapy for overall survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Lung)", "question_type": "efficacy_comparison", "expected_search_terms": ["non-small cell lung cancer", "pembrolizumab", "PD-L1 high", "chemoimmunotherapy", "phase III", "overall survival"]}
{"question": "In extensive-stage small cell lung cancer, how does adding a PD-L1 inhibitor to platinum-etoposide chemotherapy compare with chemotherapy alone for overall survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Lung)", "question_type": "efficacy_comparison", "expected_search_terms": ["extensive-stage small cell lung cancer", "PD-L1 inhibitor", "platinum etoposide", "phase III", "overall survival", "randomized"]}
{"question": "In HER2-positive metastatic breast cancer, how does trastuzumab deruxtecan compare with ado-trastuzumab emtansine for progression-free survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Breast)", "question_type": "efficacy_comparison", "expected_search_terms": ["trastuzumab deruxtecan", "ado-trastuzumab emtansine", "HER2-positive", "metastatic breast cancer", "phase III", "progression-free survival"]}
{"question": "In hormone receptor-positive metastatic breast cancer, how do CDK4/6 inhibitors differ in rates of grade 3–4 neutropenia in phase III trials when combined with endocrine therapy?", "topic": "Drug development/Phase III trials (Oncology/Breast)", "question_type": "efficacy_comparison", "expected_search_terms": ["CDK4/6 inhibitor", "palbociclib", "ribociclib", "abemaciclib", "phase III", "neutropenia", "endocrine therapy"]}
{"question": "In adjuvant therapy for early HER2-positive breast cancer, how does dual HER2 blockade compare with trastuzumab alone for invasive disease-free survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Breast)", "question_type": "efficacy_comparison", "expected_search_terms": ["early breast cancer", "HER2", "dual blockade", "trastuzumab", "phase III", "invasive disease-free survival"]}
{"question": "In first-line metastatic colorectal cancer, how does anti-EGFR therapy compare with bevacizumab when combined with chemotherapy in RAS wild-type disease for overall survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/GI)", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic colorectal cancer", "anti-EGFR", "bevacizumab", "RAS wild-type", "phase III", "overall survival", "chemotherapy"]}
{"question": "In hepatocellular carcinoma phase III trials, how does atezolizumab plus bevacizumab compare with tyrosine kinase inhibitor therapy for overall survival in the first-line setting?", "topic": "Drug development/Phase III trials (Oncology/Liver)", "question_type": "efficacy_comparison", "expected_search_terms": ["hepatocellular carcinoma", "atezolizumab", "bevacizumab", "tyrosine kinase inhibitor", "phase III", "first-line", "overall survival"]}
{"question": "In advanced renal cell carcinoma, how do IO/TKI combinations compare with TKI monotherapy for complete response rates in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Kidney)", "question_type": "efficacy_comparison", "expected_search_terms": ["renal cell carcinoma", "immunotherapy", "tyrosine kinase inhibitor", "combination", "phase III", "complete response", "randomized"]}
{"question": "In newly diagnosed multiple myeloma, how does adding daratumumab to standard induction therapy compare with standard therapy alone for minimal residual disease negativity in phase III trials?", "topic": "Drug development/Phase III trials (Hematology/Oncology)", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple myeloma", "daratumumab", "induction therapy", "minimal residual disease", "MRD negativity", "phase III"]}
{"question": "In relapsed or refractory diffuse large B-cell lymphoma, how does CAR T-cell therapy compare with salvage chemotherapy followed by autologous transplant for event-free survival in phase III trials?", "topic": "Drug development/Phase III trials (Hematology/Oncology)", "question_type": "efficacy_comparison", "expected_search_terms": ["diffuse large B-cell lymphoma", "CAR T-cell", "salvage chemotherapy", "autologous transplant", "phase III", "event-free survival"]}
{"question": "In acute myeloid leukemia unfit for intensive chemotherapy, how does azacitidine plus venetoclax compare with azacitidine alone for overall survival in phase III trials?", "topic": "Drug development/Phase III trials (Hematology/Oncology)", "question_type": "efficacy_comparison", "expected_search_terms": ["acute myeloid leukemia", "azacitidine", "venetoclax", "unfit", "phase III", "overall survival", "randomized"]}
{"question": "In maintenance therapy after first-line treatment of advanced ovarian cancer, how do PARP inhibitors compare for progression-free survival benefit in patients with BRCA mutations in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Gynecology)", "question_type": "efficacy_comparison", "expected_search_terms": ["ovarian cancer", "PARP inhibitor", "BRCA mutation", "maintenance", "phase III", "progression-free survival"]}
{"question": "In cervical cancer phase III trials, how does adding an anti-VEGF agent to chemotherapy compare with chemotherapy alone for overall survival in recurrent or metastatic disease?", "topic": "Drug development/Phase III trials (Oncology/Gynecology)", "question_type": "efficacy_comparison", "expected_search_terms": ["cervical cancer", "anti-VEGF", "chemotherapy", "recurrent metastatic", "phase III", "overall survival"]}
{"question": "In first-line advanced gastric cancer, how does PD-1 inhibitor plus chemotherapy compare with chemotherapy alone for overall survival in phase III trials stratified by PD-L1 expression?", "topic": "Drug development/Phase III trials (Oncology/GI)", "question_type": "efficacy_comparison", "expected_search_terms": ["gastric cancer", "PD-1 inhibitor", "chemotherapy", "phase III", "overall survival", "PD-L1", "first-line"]}
{"question": "In glioblastoma phase III trials, does adding tumor-treating fields to temozolomide maintenance improve overall survival compared with temozolomide alone?", "topic": "Drug development/Phase III trials (Neuro-oncology)", "question_type": "efficacy_comparison", "expected_search_terms": ["glioblastoma", "tumor treating fields", "temozolomide", "maintenance", "phase III", "overall survival"]}
{"question": "In relapsing multiple sclerosis, how does ocrelizumab compare with fingolimod for annualized relapse rate reduction in phase III trials?", "topic": "Drug development/Phase III trials (Neurology/MS)", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "ocrelizumab", "fingolimod", "phase III", "annualized relapse rate", "randomized"]}
{"question": "In migraine prevention phase III trials, how do CGRP monoclonal antibodies compare with oral CGRP receptor antagonists for reduction in monthly migraine days?", "topic": "Drug development/Phase III trials (Neurology/Headache)", "question_type": "efficacy_comparison", "expected_search_terms": ["migraine prevention", "CGRP monoclonal antibody", "gepant", "phase III", "monthly migraine days", "randomized"]}
{"question": "In Alzheimer’s disease phase III trials, what is the magnitude of amyloid-lowering antibody effects on clinical decline measured by common cognitive scales over 18 months?", "topic": "Drug development/Phase III trials (Neurology/Neurodegeneration)", "question_type": "efficacy_comparison", "expected_search_terms": ["Alzheimer disease", "amyloid antibody", "phase III", "cognitive scale", "clinical decline", "18 months"]}
{"question": "In acute ischemic stroke phase III trials, how does tenecteplase compare with alteplase for functional independence at 90 days when given within recommended time windows?", "topic": "Drug development/Phase III trials (Neurology/Stroke)", "question_type": "efficacy_comparison", "expected_search_terms": ["tenecteplase", "alteplase", "acute ischemic stroke", "phase III", "90 days", "modified Rankin", "randomized"]}
{"question": "In major depressive disorder phase III trials, how does esketamine nasal spray plus oral antidepressant compare with oral antidepressant plus placebo for response at 4 weeks in treatment-resistant depression?", "topic": "Drug development/Phase III trials (Psychiatry)", "question_type": "efficacy_comparison", "expected_search_terms": ["esketamine", "treatment-resistant depression", "phase III", "response", "4 weeks", "randomized", "nasal spray"]}
{"question": "In schizophrenia phase III trials, how does long-acting injectable aripiprazole compare with long-acting injectable paliperidone for relapse prevention over 12 months?", "topic": "Drug development/Phase III trials (Psychiatry)", "question_type": "efficacy_comparison", "expected_search_terms": ["schizophrenia", "aripiprazole long-acting", "paliperidone palmitate", "phase III", "relapse prevention", "12 months"]}
{"question": "In HIV treatment-naïve adults, how do integrase inhibitor–based regimens compare for rates of virologic suppression at week 48 in phase III trials?", "topic": "Drug development/Phase III trials (Infectious disease/HIV)", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "integrase inhibitor", "treatment-naive", "phase III", "week 48", "virologic suppression", "randomized"]}
{"question": "In chronic hepatitis C, how do pangenotypic direct-acting antiviral regimens compare in sustained virologic response rates in phase III trials across genotypes?", "topic": "Drug development/Phase III trials (Infectious disease/Hepatology)", "question_type": "efficacy_comparison", "expected_search_terms": ["hepatitis C", "pangenotypic", "direct-acting antivirals", "phase III", "SVR12", "genotype", "randomized"]}
{"question": "In hospitalized COVID-19 phase III trials, how does remdesivir compare with standard care for time to clinical recovery in patients requiring supplemental oxygen but not mechanical ventilation?", "topic": "Drug development/Phase III trials (Infectious disease)", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "remdesivir", "phase III", "time to recovery", "supplemental oxygen", "randomized", "standard care"]}
{"question": "In influenza treatment phase III trials, how does baloxavir compare with oseltamivir for reducing symptom duration in otherwise healthy adults?", "topic": "Drug development/Phase III trials (Infectious disease)", "question_type": "efficacy_comparison", "expected_search_terms": ["influenza", "baloxavir", "oseltamivir", "phase III", "symptom duration", "randomized"]}
{"question": "In phase III trials of RSV prevention, how do long-acting monoclonal antibodies compare with placebo in preventing medically attended RSV lower respiratory tract infection in infants?", "topic": "Drug development/Phase III trials (Infectious disease/Pediatrics)", "question_type": "efficacy_comparison", "expected_search_terms": ["RSV", "monoclonal antibody", "long-acting", "infants", "phase III", "lower respiratory tract infection", "prevention"]}
{"question": "In bacterial skin infection phase III trials, how does dalbavancin compare with vancomycin-based therapy for clinical response and need for hospitalization?", "topic": "Drug development/Phase III trials (Infectious disease/Antibiotics)", "question_type": "efficacy_comparison", "expected_search_terms": ["dalbavancin", "vancomycin", "acute bacterial skin and skin structure infection", "phase III", "clinical response", "hospitalization"]}
{"question": "In phase III trials for multidrug-resistant tuberculosis, how does bedaquiline-containing regimens compare with regimens without bedaquiline for culture conversion and safety?", "topic": "Drug development/Phase III trials (Infectious disease/TB)", "question_type": "efficacy_comparison", "expected_search_terms": ["multidrug-resistant tuberculosis", "bedaquiline", "phase III", "culture conversion", "safety", "randomized"]}
{"question": "In osteoporosis phase III trials, how does denosumab compare with zoledronic acid for reducing vertebral fractures in postmenopausal women?", "topic": "Drug development/Phase III trials (Endocrinology/Bone)", "question_type": "efficacy_comparison", "expected_search_terms": ["denosumab", "zoledronic acid", "osteoporosis", "postmenopausal", "vertebral fracture", "phase III", "randomized"]}
{"question": "In phase III trials for anemia in chronic kidney disease, how do HIF prolyl hydroxylase inhibitors compare with erythropoiesis-stimulating agents for maintaining hemoglobin within target ranges?", "topic": "Drug development/Phase III trials (Nephrology/Hematology)", "question_type": "efficacy_comparison", "expected_search_terms": ["HIF prolyl hydroxylase inhibitor", "erythropoiesis-stimulating agent", "chronic kidney disease", "anemia", "phase III", "hemoglobin target"]}
{"question": "In phase III trials for gout, how does febuxostat compare with allopurinol for achieving serum urate targets in patients with renal impairment?", "topic": "Drug development/Phase III trials (Rheumatology/Metabolic)", "question_type": "efficacy_comparison", "expected_search_terms": ["febuxostat", "allopurinol", "gout", "renal impairment", "phase III", "serum urate", "target"]}
{"question": "In benign prostatic hyperplasia phase III trials, does combination therapy with an alpha-blocker plus 5-alpha reductase inhibitor reduce risk of acute urinary retention compared with alpha-blocker alone?", "topic": "Drug development/Phase III trials (Urology)", "question_type": "efficacy_comparison", "expected_search_terms": ["benign prostatic hyperplasia", "alpha blocker", "5-alpha reductase inhibitor", "acute urinary retention", "phase III", "combination"]}
{"question": "In overactive bladder phase III trials, how does mirabegron compare with antimuscarinic therapy for discontinuation due to adverse events?", "topic": "Drug development/Phase III trials (Urology)", "question_type": "efficacy_comparison", "expected_search_terms": ["mirabegron", "antimuscarinic", "overactive bladder", "phase III", "discontinuation", "adverse events"]}
{"question": "In phase III trials for endometriosis-related pain, how do oral GnRH antagonists compare with placebo for reduction in dysmenorrhea scores?", "topic": "Drug development/Phase III trials (Gynecology)", "question_type": "efficacy_comparison", "expected_search_terms": ["endometriosis", "GnRH antagonist", "oral", "phase III", "dysmenorrhea", "pain score", "randomized"]}
{"question": "In phase III trials for postpartum hemorrhage prevention, how does tranexamic acid compare with placebo for reducing severe bleeding when given prophylactically at delivery?", "topic": "Drug development/Phase III trials (Obstetrics)", "question_type": "efficacy_comparison", "expected_search_terms": ["tranexamic acid", "postpartum hemorrhage", "prophylaxis", "phase III", "delivery", "severe bleeding", "randomized"]}
{"question": "In perioperative analgesia phase III trials, how does adding gabapentin to multimodal pain regimens compare with placebo for reducing postoperative opioid consumption?", "topic": "Drug development/Phase III trials (Anesthesiology/Pain)", "question_type": "efficacy_comparison", "expected_search_terms": ["gabapentin", "multimodal analgesia", "postoperative", "opioid consumption", "phase III", "randomized", "perioperative"]}
{"question": "In phase III trials for chemotherapy-induced nausea and vomiting, how does adding olanzapine to standard antiemetic regimens compare with standard therapy alone for complete response in delayed phase?", "topic": "Drug development/Phase III trials (Supportive oncology)", "question_type": "efficacy_comparison", "expected_search_terms": ["chemotherapy-induced nausea vomiting", "olanzapine", "antiemetic", "phase III", "complete response", "delayed phase"]}
{"question": "In phase III trials for chronic spontaneous urticaria, how does omalizumab compare with placebo for itch severity reduction in antihistamine-refractory patients?", "topic": "Drug development/Phase III trials (Allergy/Immunology)", "question_type": "efficacy_comparison", "expected_search_terms": ["chronic spontaneous urticaria", "omalizumab", "placebo", "phase III", "itch severity", "antihistamine refractory"]}
{"question": "In phase III trials for sickle cell disease, how does voxelotor compare with placebo for increasing hemoglobin levels and reducing hemolysis markers?", "topic": "Drug development/Phase III trials (Hematology)", "question_type": "efficacy_comparison", "expected_search_terms": ["sickle cell disease", "voxelotor", "phase III", "hemoglobin", "hemolysis", "randomized", "placebo"]}
{"question": "In phase III trials for hereditary transthyretin amyloidosis, how do RNA-targeting therapies compare for improvement in neuropathy impairment scores?", "topic": "Drug development/Phase III trials (Neuromuscular/Rare disease)", "question_type": "efficacy_comparison", "expected_search_terms": ["transthyretin amyloidosis", "RNA therapy", "siRNA", "antisense", "phase III", "neuropathy impairment score"]}
{"question": "In phase III trials for spinal muscular atrophy, how does gene replacement therapy compare with antisense oligonucleotide therapy for motor milestone acquisition in infants?", "topic": "Drug development/Phase III trials (Neurology/Rare disease)", "question_type": "efficacy_comparison", "expected_search_terms": ["spinal muscular atrophy", "gene therapy", "antisense oligonucleotide", "phase III", "infants", "motor milestones"]}
{"question": "In phase III trials for hemophilia A prophylaxis, how does emicizumab compare with factor VIII prophylaxis for annualized bleeding rate?", "topic": "Drug development/Phase III trials (Hematology)", "question_type": "efficacy_comparison", "expected_search_terms": ["hemophilia A", "emicizumab", "factor VIII", "prophylaxis", "phase III", "annualized bleeding rate"]}
{"question": "In phase III trials for chronic migraine, how does onabotulinumtoxinA compare with CGRP monoclonal antibodies for reduction in headache days?", "topic": "Drug development/Phase III trials (Neurology/Headache)", "question_type": "efficacy_comparison", "expected_search_terms": ["chronic migraine", "onabotulinumtoxinA", "CGRP monoclonal antibody", "phase III", "headache days", "randomized"]}
{"question": "In phase III trials for generalized anxiety disorder, how does pregabalin compare with SSRIs for response rates and discontinuation due to adverse events?", "topic": "Drug development/Phase III trials (Psychiatry)", "question_type": "efficacy_comparison", "expected_search_terms": ["generalized anxiety disorder", "pregabalin", "SSRI", "phase III", "response", "discontinuation", "adverse events"]}
{"question": "In phase III trials of smoking cessation, how does varenicline compare with nicotine replacement therapy for continuous abstinence at 6 months?", "topic": "Drug development/Phase III trials (Addiction medicine)", "question_type": "efficacy_comparison", "expected_search_terms": ["varenicline", "nicotine replacement therapy", "smoking cessation", "phase III", "continuous abstinence", "6 months"]}
{"question": "In phase III trials for opioid use disorder, how does extended-release naltrexone compare with buprenorphine-naloxone for treatment retention at 24 weeks?", "topic": "Drug development/Phase III trials (Addiction medicine)", "question_type": "efficacy_comparison", "expected_search_terms": ["extended-release naltrexone", "buprenorphine naloxone", "opioid use disorder", "phase III", "retention", "24 weeks"]}
{"question": "In phase III trials for severe aplastic anemia, how does adding eltrombopag to immunosuppressive therapy compare with immunosuppression alone for hematologic response rates?", "topic": "Drug development/Phase III trials (Hematology)", "question_type": "efficacy_comparison", "expected_search_terms": ["severe aplastic anemia", "eltrombopag", "immunosuppressive therapy", "phase III", "hematologic response"]}
{"question": "In phase III trials for nonalcoholic steatohepatitis, how do investigational agents compare with placebo for NASH resolution without worsening of fibrosis?", "topic": "Drug development/Phase III trials (Hepatology)", "question_type": "efficacy_comparison", "expected_search_terms": ["NASH", "nonalcoholic steatohepatitis", "phase III", "NASH resolution", "fibrosis", "placebo", "histology"]}
{"question": "In phase III trials for irritable bowel syndrome with constipation, how does linaclotide compare with plecanatide for improvement in abdominal pain scores?", "topic": "Drug development/Phase III trials (Gastroenterology)", "question_type": "efficacy_comparison", "expected_search_terms": ["linaclotide", "plecanatide", "IBS-C", "phase III", "abdominal pain", "randomized"]}
{"question": "In phase III trials for chronic idiopathic constipation, how does prucalopride compare with lubiprostone for achieving spontaneous complete bowel movements?", "topic": "Drug development/Phase III trials (Gastroenterology)", "question_type": "efficacy_comparison", "expected_search_terms": ["prucalopride", "lubiprostone", "chronic idiopathic constipation", "phase III", "spontaneous complete bowel movements"]}
{"question": "In phase III trials for gastroesophageal reflux disease, how does potassium-competitive acid blocker therapy compare with proton pump inhibitors for healing erosive esophagitis?", "topic": "Drug development/Phase III trials (Gastroenterology)", "question_type": "efficacy_comparison", "expected_search_terms": ["potassium-competitive acid blocker", "vonoprazan", "proton pump inhibitor", "erosive esophagitis", "phase III", "healing"]}
{"question": "In phase III trials for prevention of recurrent Clostridioides difficile infection, how does microbiota-based therapy compare with placebo for recurrence rates within 8 weeks?", "topic": "Drug development/Phase III trials (Infectious disease/Gastroenterology)", "question_type": "efficacy_comparison", "expected_search_terms": ["Clostridioides difficile", "recurrent", "microbiota therapy", "phase III", "placebo", "recurrence", "8 weeks"]}
{"question": "In phase III trials for acute pain, how does oral ketorolac compare with ibuprofen for analgesic efficacy and gastrointestinal adverse events?", "topic": "Drug development/Phase III trials (Pain/NSAIDs)", "question_type": "efficacy_comparison", "expected_search_terms": ["ketorolac", "ibuprofen", "acute pain", "phase III", "analgesic efficacy", "gastrointestinal adverse events"]}
{"question": "In phase III trials of perioperative anticoagulation bridging, how does low-molecular-weight heparin bridging compare with no bridging for thromboembolism and major bleeding outcomes?", "topic": "Drug development/Phase III trials (Perioperative medicine/Anticoagulation)", "question_type": "efficacy_comparison", "expected_search_terms": ["bridging anticoagulation", "low-molecular-weight heparin", "no bridging", "phase III", "thromboembolism", "major bleeding"]}
{"question": "What pharmacokinetic mechanism best explains the interaction between ritonavir-boosted regimens and CYP3A-metabolized statins leading to increased myopathy risk?", "topic": "Drug interactions/Clinical pharmacology (HIV/Cardiology)", "question_type": "mechanism", "expected_search_terms": ["ritonavir", "statins", "CYP3A4", "drug interaction", "pharmacokinetics", "myopathy", "rhabdomyolysis"]}
{"question": "What is the mechanism by which proton pump inhibitors reduce exposure to certain oral tyrosine kinase inhibitors, and how is this managed in clinical trials or labeling?", "topic": "Drug interactions/Clinical pharmacology (Oncology)", "question_type": "mechanism", "expected_search_terms": ["proton pump inhibitor", "tyrosine kinase inhibitor", "gastric pH", "absorption", "drug interaction", "pharmacokinetics"]}
{"question": "How does grapefruit juice intake alter the pharmacokinetics of calcium channel blockers through intestinal CYP3A inhibition in controlled clinical studies?", "topic": "Drug interactions/Clinical pharmacology (Cardiology)", "question_type": "mechanism", "expected_search_terms": ["grapefruit juice", "calcium channel blocker", "CYP3A", "intestinal metabolism", "pharmacokinetics", "interaction study"]}
{"question": "What is the pharmacodynamic basis for increased bleeding risk when SSRIs are combined with antiplatelet therapy in clinical outcomes studies?", "topic": "Drug interactions/Clinical pharmacology (Cardiology/Psychiatry)", "question_type": "mechanism", "expected_search_terms": ["SSRI", "antiplatelet", "bleeding risk", "pharmacodynamic interaction", "platelet serotonin", "clinical study"]}
{"question": "How does amiodarone coadministration affect direct oral anticoagulant exposure via P-glycoprotein and CYP pathways in pharmacokinetic studies?", "topic": "Drug interactions/Clinical pharmacology (Cardiology)", "question_type": "mechanism", "expected_search_terms": ["amiodarone", "direct oral anticoagulant", "P-glycoprotein", "CYP3A4", "pharmacokinetics", "drug interaction"]}
{"question": "What evidence from clinical pharmacology studies supports dose adjustment of digoxin when combined with verapamil due to P-glycoprotein inhibition?", "topic": "Drug interactions/Clinical pharmacology (Cardiology)", "question_type": "mechanism", "expected_search_terms": ["digoxin", "verapamil", "P-glycoprotein inhibitor", "drug interaction", "dose adjustment", "pharmacokinetics"]}
{"question": "What is the mechanistic explanation for severe hypotension when PDE-5 inhibitors are taken with nitrates as demonstrated in clinical studies?", "topic": "Drug interactions/Clinical pharmacology (Cardiology/Urology)", "question_type": "mechanism", "expected_search_terms": ["PDE5 inhibitor", "nitrates", "hypotension", "cGMP", "pharmacodynamic interaction", "clinical study"]}
{"question": "How does rifampin coadministration reduce exposure to oral contraceptives through enzyme induction in pharmacokinetic trials?", "topic": "Drug interactions/Clinical pharmacology (Infectious disease/Women's health)", "question_type": "mechanism", "expected_search_terms": ["rifampin", "oral contraceptive", "enzyme induction", "CYP3A4", "pharmacokinetics", "drug interaction"]}
{"question": "What is the mechanism of increased lithium toxicity risk when ACE inhibitors are initiated, based on pharmacology and clinical observations?", "topic": "Drug interactions/Clinical pharmacology (Cardiology/Psychiatry)", "question_type": "mechanism", "expected_search_terms": ["lithium", "ACE inhibitor", "toxicity", "renal clearance", "drug interaction", "pharmacology"]}
{"question": "How does trimethoprim-sulfamethoxazole increase the risk of hyperkalemia when combined with renin-angiotensin system inhibitors in clinical studies?", "topic": "Drug interactions/Clinical pharmacology (Infectious disease/Nephrology)", "question_type": "mechanism", "expected_search_terms": ["trimethoprim sulfamethoxazole", "hyperkalemia", "ACE inhibitor", "ARB", "drug interaction", "mechanism"]}
{"question": "What evidence supports the interaction between metformin and iodinated contrast media leading to lactic acidosis risk, and how do guidelines reflect trial data?", "topic": "Drug interactions/Clinical pharmacology (Endocrinology/Radiology)", "question_type": "review", "expected_search_terms": ["metformin", "iodinated contrast", "lactic acidosis", "drug interaction", "guideline", "clinical evidence"]}
{"question": "How does clopidogrel responsiveness change with concomitant proton pump inhibitor therapy in randomized or pharmacodynamic trials using platelet function testing?", "topic": "Drug interactions/Clinical pharmacology (Cardiology)", "question_type": "mechanism", "expected_search_terms": ["clopidogrel", "proton pump inhibitor", "platelet function", "CYP2C19", "drug interaction", "randomized"]}
{"question": "In phase III trials of immune checkpoint inhibitors, what is the association between baseline corticosteroid use and overall survival outcomes?", "topic": "Clinical trials/Prognostic modifiers (Oncology/Immunotherapy)", "question_type": "prognosis", "expected_search_terms": ["immune checkpoint inhibitor", "baseline corticosteroids", "overall survival", "phase III", "subgroup analysis", "prognostic"]}
{"question": "In phase III oncology trials, how does prior antibiotic exposure influence response rates to immunotherapy-based regimens?", "topic": "Clinical trials/Prognostic modifiers (Oncology/Immunotherapy, drug interaction-like)", "question_type": "prognosis", "expected_search_terms": ["antibiotics", "immunotherapy", "response rate", "phase III", "microbiome", "subgroup"]}
{"question": "In phase III trials of anticoagulants, what patient characteristics most strongly predict major bleeding events during treatment?", "topic": "Clinical trials/Prognosis (Cardiology/Hematology)", "question_type": "prognosis", "expected_search_terms": ["phase III", "anticoagulant", "major bleeding", "predictors", "risk factors", "subgroup analysis"]}
{"question": "In phase III trials of SGLT2 inhibitors, what baseline renal function thresholds modify the magnitude of benefit on kidney disease progression?", "topic": "Clinical trials/Prognosis (Nephrology/Diabetes)", "question_type": "prognosis", "expected_search_terms": ["SGLT2 inhibitor", "phase III", "eGFR", "kidney outcomes", "effect modification", "subgroup"]}
{"question": "In phase III COPD trials, does baseline blood eosinophil count predict exacerbation reduction with inhaled corticosteroid–containing regimens?", "topic": "Clinical trials/Prognostic biomarkers (Pulmonology)", "question_type": "prognosis", "expected_search_terms": ["COPD", "blood eosinophils", "inhaled corticosteroid", "phase III", "exacerbation", "biomarker"]}
{"question": "In phase III trials for severe asthma biologics, how consistently does baseline eosinophil count predict treatment response across different agents?", "topic": "Clinical trials/Prognostic biomarkers (Pulmonology/Immunology)", "question_type": "prognosis", "expected_search_terms": ["severe asthma", "biologic", "eosinophil", "phase III", "predictor", "treatment response"]}
{"question": "In phase III trials of PARP inhibitors, how does homologous recombination deficiency status modify progression-free survival benefit in ovarian cancer?", "topic": "Clinical trials/Prognostic biomarkers (Oncology)", "question_type": "prognosis", "expected_search_terms": ["PARP inhibitor", "homologous recombination deficiency", "ovarian cancer", "phase III", "progression-free survival", "subgroup"]}
{"question": "In phase III trials of PD-1/PD-L1 inhibitors, how does PD-L1 expression level correlate with absolute overall survival benefit across tumor types?", "topic": "Clinical trials/Prognostic biomarkers (Oncology/Immunotherapy)", "question_type": "prognosis", "expected_search_terms": ["PD-1", "PD-L1", "phase III", "overall survival", "biomarker", "subgroup analysis"]}
{"question": "In phase III trials of HER2-targeted therapies, how does hormone receptor status modify outcomes in HER2-positive breast cancer?", "topic": "Clinical trials/Prognosis (Oncology/Breast)", "question_type": "prognosis", "expected_search_terms": ["HER2-positive breast cancer", "hormone receptor status", "phase III", "outcomes", "subgroup", "progression-free survival"]}
{"question": "In phase III trials of GLP-1 receptor agonists, how do gastrointestinal adverse event rates compare across agents at clinically used doses?", "topic": "Clinical trials/Safety (Endocrinology)", "question_type": "epidemiology", "expected_search_terms": ["GLP-1 receptor agonist", "phase III", "gastrointestinal adverse events", "nausea", "vomiting", "dose", "comparative"]}
{"question": "In phase III trials of JAK inhibitors for inflammatory diseases, what is the incidence of venous thromboembolism and how does it vary by dose?", "topic": "Clinical trials/Safety epidemiology (Immunology/Rheumatology)", "question_type": "epidemiology", "expected_search_terms": ["JAK inhibitor", "phase III", "venous thromboembolism", "incidence", "dose", "safety"]}
{"question": "In phase III trials of IL-17 inhibitors, what is the frequency of mucocutaneous candidiasis compared with placebo?", "topic": "Clinical trials/Safety epidemiology (Dermatology/Immunology)", "question_type": "epidemiology", "expected_search_terms": ["IL-17 inhibitor", "phase III", "candidiasis", "mucocutaneous", "placebo", "adverse events"]}
{"question": "In phase III trials of antibody-drug conjugates, what is the reported incidence of interstitial lung disease or pneumonitis across different targets?", "topic": "Clinical trials/Safety epidemiology (Oncology)", "question_type": "epidemiology", "expected_search_terms": ["antibody-drug conjugate", "phase III", "interstitial lung disease", "pneumonitis", "incidence", "adverse events"]}
{"question": "In phase III trials of CAR T-cell therapies, what is the incidence of grade 3–4 cytokine release syndrome with current supportive care practices?", "topic": "Clinical trials/Safety epidemiology (Hematology/Oncology)", "question_type": "epidemiology", "expected_search_terms": ["CAR T", "phase III", "cytokine release syndrome", "grade 3 4", "incidence", "supportive care"]}
{"question": "In phase III trials of SGLT2 inhibitors, what is the incidence of diabetic ketoacidosis and which patient populations are at highest risk?", "topic": "Clinical trials/Safety epidemiology (Endocrinology)", "question_type": "epidemiology", "expected_search_terms": ["SGLT2 inhibitor", "phase III", "diabetic ketoacidosis", "incidence", "risk factors", "population"]}
{"question": "In phase III trials of oral anticoagulants, how does concomitant antiplatelet therapy affect rates of major bleeding compared with anticoagulant alone?", "topic": "Drug interactions within trials (Cardiology/Hematology)", "question_type": "epidemiology", "expected_search_terms": ["oral anticoagulant", "antiplatelet", "major bleeding", "phase III", "concomitant therapy", "subgroup"]}
{"question": "In phase III trials of statins, what is the dose-dependent incidence of new-onset diabetes compared with placebo or lower-intensity statin therapy?", "topic": "Clinical trials/Safety epidemiology (Cardiology/Metabolic)", "question_type": "epidemiology", "expected_search_terms": ["statin", "phase III", "new-onset diabetes", "dose-dependent", "incidence", "placebo"]}
{"question": "In phase III trials of anti-VEGF therapies, what is the incidence of hypertension and proteinuria compared with control arms?", "topic": "Clinical trials/Safety epidemiology (Oncology)", "question_type": "epidemiology", "expected_search_terms": ["anti-VEGF", "bevacizumab", "phase III", "hypertension", "proteinuria", "incidence", "adverse events"]}
{"question": "In phase III trials of checkpoint inhibitors, what is the incidence of immune-related myocarditis and how often is it fatal?", "topic": "Clinical trials/Safety epidemiology (Oncology/Cardio-oncology)", "question_type": "epidemiology", "expected_search_terms": ["immune checkpoint inhibitor", "phase III", "myocarditis", "immune-related adverse event", "incidence", "fatal"]}
{"question": "In phase III trials for cancer therapies, what trial design features most reduce bias in patient-reported outcome endpoints?", "topic": "Clinical trial methodology (PROs)", "question_type": "review", "expected_search_terms": ["phase III", "patient-reported outcomes", "trial design", "bias", "blinding", "methodology"]}
{"question": "How do phase III noninferiority trials in infectious diseases justify and select noninferiority margins, based on published examples and regulatory guidance?", "topic": "Clinical trial methodology (Noninferiority)", "question_type": "review", "expected_search_terms": ["noninferiority", "phase III", "infectious disease", "margin", "regulatory guidance", "trial design"]}
{"question": "What are common reasons phase III oncology trials fail to demonstrate overall survival benefit despite progression-free survival improvement?", "topic": "Clinical trial methodology (Oncology endpoints)", "question_type": "review", "expected_search_terms": ["phase III", "oncology", "overall survival", "progression-free survival", "endpoint surrogacy", "trial failure"]}
{"question": "In cardiovascular phase III trials, how does the use of composite endpoints affect interpretation of clinical benefit compared with single hard endpoints?", "topic": "Clinical trial methodology (Cardiology endpoints)", "question_type": "review", "expected_search_terms": ["phase III", "cardiovascular trial", "composite endpoint", "interpretation", "hard endpoints", "methodology"]}
{"question": "What evidence supports pharmacogenomic-guided dosing of warfarin compared with standard dosing strategies in large randomized clinical trials?", "topic": "Drug development/Clinical trials (Pharmacogenomics)", "question_type": "efficacy_comparison", "expected_search_terms": ["warfarin", "pharmacogenomic", "genotype-guided dosing", "randomized trial", "phase III", "time in therapeutic range"]}
{"question": "How does CYP2C19 genotype modify clinical outcomes in patients receiving clopidogrel in randomized trials and large outcome studies?", "topic": "Drug development/Clinical trials (Pharmacogenomics/Antiplatelets)", "question_type": "prognosis", "expected_search_terms": ["clopidogrel", "CYP2C19", "genotype", "clinical outcomes", "randomized trial", "major adverse cardiovascular events"]}
{"question": "In phase III trials for advanced melanoma, how does nivolumab plus ipilimumab compare with nivolumab alone for overall survival in patients with brain metastases?", "topic": "Drug development/Phase III trials (Oncology/Melanoma)", "question_type": "efficacy_comparison", "expected_search_terms": ["melanoma", "nivolumab", "ipilimumab", "brain metastases", "phase III", "overall survival"]}
{"question": "In metastatic castration-resistant prostate cancer, how does PARP inhibitor therapy plus androgen receptor–targeted therapy compare with androgen receptor–targeted therapy alone for radiographic progression-free survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Prostate)", "question_type": "efficacy_comparison", "expected_search_terms": ["mCRPC", "PARP inhibitor", "androgen receptor targeted", "phase III", "radiographic progression-free survival", "combination"]}
{"question": "In nonmetastatic hormone receptor–positive breast cancer, how does adjuvant CDK4/6 inhibitor plus endocrine therapy compare with endocrine therapy alone for invasive disease-free survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Breast)", "question_type": "efficacy_comparison", "expected_search_terms": ["adjuvant", "CDK4/6 inhibitor", "endocrine therapy", "phase III", "invasive disease-free survival", "HR-positive breast cancer"]}
{"question": "In metastatic triple-negative breast cancer, how does immunotherapy plus chemotherapy compare with chemotherapy alone for overall survival in PD-L1–positive disease in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Breast)", "question_type": "efficacy_comparison", "expected_search_terms": ["triple-negative breast cancer", "immunotherapy", "chemotherapy", "PD-L1 positive", "phase III", "overall survival"]}
{"question": "In metastatic urothelial carcinoma, how does maintenance avelumab after platinum chemotherapy compare with best supportive care for overall survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Urology)", "question_type": "efficacy_comparison", "expected_search_terms": ["urothelial carcinoma", "maintenance", "avelumab", "platinum chemotherapy", "phase III", "overall survival"]}
{"question": "In advanced esophageal or gastroesophageal junction cancer, how does adding PD-1 inhibitor to chemotherapy compare with chemotherapy alone for overall survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/GI)", "question_type": "efficacy_comparison", "expected_search_terms": ["esophageal cancer", "gastroesophageal junction", "PD-1 inhibitor", "chemotherapy", "phase III", "overall survival"]}
{"question": "In chronic myeloid leukemia, how do second-generation TKIs compare with imatinib for achieving deep molecular response at 12 months in phase III trials?", "topic": "Drug development/Phase III trials (Hematology/Oncology)", "question_type": "efficacy_comparison", "expected_search_terms": ["chronic myeloid leukemia", "imatinib", "second-generation TKI", "phase III", "deep molecular response", "12 months"]}
{"question": "In chronic lymphocytic leukemia, how does BTK inhibitor–based therapy compare with chemoimmunotherapy for progression-free survival in phase III trials of treatment-naïve patients?", "topic": "Drug development/Phase III trials (Hematology/Oncology)", "question_type": "efficacy_comparison", "expected_search_terms": ["chronic lymphocytic leukemia", "BTK inhibitor", "chemoimmunotherapy", "phase III", "treatment-naive", "progression-free survival"]}
{"question": "In relapsed multiple myeloma, how does BCMA-targeted therapy compare with standard regimens for overall response rate in phase III trials?", "topic": "Drug development/Phase III trials (Hematology/Oncology)", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple myeloma", "BCMA", "phase III", "overall response rate", "randomized", "relapsed refractory"]}
{"question": "In metastatic pancreatic cancer, how do modified FOLFIRINOX and gemcitabine plus nab-paclitaxel compare for overall survival in phase III trials and large randomized comparisons?", "topic": "Drug development/Phase III trials (Oncology/GI)", "question_type": "efficacy_comparison", "expected_search_terms": ["pancreatic cancer", "FOLFIRINOX", "gemcitabine", "nab-paclitaxel", "phase III", "overall survival"]}
{"question": "In first-line metastatic NSCLC, how does adding bevacizumab to platinum-based chemotherapy compare with chemotherapy alone for progression-free survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Lung)", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "bevacizumab", "platinum chemotherapy", "phase III", "progression-free survival", "randomized"]}
{"question": "In HER2-low metastatic breast cancer, how does antibody-drug conjugate therapy compare with physician’s choice chemotherapy for overall survival in phase III trials?", "topic": "Drug development/Phase III trials (Oncology/Breast)", "question_type": "efficacy_comparison", "expected_search_terms": ["HER2-low", "metastatic breast cancer", "antibody-drug conjugate", "chemotherapy", "phase III", "overall survival"]}
{"question": "In phase III trials for chronic hepatitis B, how does tenofovir alafenamide compare with tenofovir disoproxil fumarate for renal and bone safety outcomes over 96 weeks?", "topic": "Drug development/Phase III trials (Infectious disease/Hepatology)", "question_type": "efficacy_comparison", "expected_search_terms": ["hepatitis B", "tenofovir alafenamide", "tenofovir disoproxil fumarate", "phase III", "renal safety", "bone mineral density", "96 weeks"]}
{"question": "In phase III trials for invasive candidiasis, how do echinocandins compare with azoles for all-cause mortality and hepatotoxicity?", "topic": "Drug development/Phase III trials (Infectious disease/Mycology)", "question_type": "efficacy_comparison", "expected_search_terms": ["invasive candidiasis", "echinocandin", "azole", "phase III", "mortality", "hepatotoxicity", "randomized"]}
{"question": "In phase III trials for community-acquired bacterial pneumonia, how do newer fluoroquinolones compare with beta-lactam plus macrolide therapy for clinical cure rates?", "topic": "Drug development/Phase III trials (Infectious disease)", "question_type": "efficacy_comparison", "expected_search_terms": ["community-acquired pneumonia", "fluoroquinolone", "beta-lactam", "macrolide", "phase III", "clinical cure", "randomized"]}
{"question": "In phase III trials for uncomplicated urinary tract infection, how does nitrofurantoin compare with fosfomycin for microbiologic cure and recurrence rates?", "topic": "Drug development/Phase III trials (Infectious disease/Urology)", "question_type": "efficacy_comparison", "expected_search_terms": ["urinary tract infection", "nitrofurantoin", "fosfomycin", "phase III", "microbiologic cure", "recurrence"]}
{"question": "In phase III trials for ulcerative colitis, how does vedolizumab compare with anti-TNF therapy for serious infection rates during maintenance therapy?", "topic": "Drug development/Phase III trials (Gastroenterology/IBD safety)", "question_type": "epidemiology", "expected_search_terms": ["ulcerative colitis", "vedolizumab", "anti-TNF", "phase III", "serious infection", "maintenance", "safety"]}
{"question": "In phase III rheumatoid arthritis trials, how does methotrexate coadministration influence anti-drug antibody formation to biologic therapies?", "topic": "Drug interactions within trials (Rheumatology/Immunogenicity)", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "methotrexate", "anti-drug antibodies", "immunogenicity", "biologic", "phase III"]}
{"question": "How does food intake affect the pharmacokinetics and tolerability of oral targeted cancer therapies in dedicated food-effect clinical studies?", "topic": "Drug interactions/Clinical pharmacology (Oncology)", "question_type": "mechanism", "expected_search_terms": ["food effect", "oral targeted therapy", "pharmacokinetics", "tolerability", "clinical study", "TKI"]}
{"question": "What is the clinical impact of combining strong CYP3A inhibitors with oral JAK inhibitors on drug exposure and adverse event risk?", "topic": "Drug interactions/Clinical pharmacology (Immunology)", "question_type": "mechanism", "expected_search_terms": ["JAK inhibitor", "CYP3A inhibitor", "drug interaction", "pharmacokinetics", "adverse events", "exposure"]}
{"question": "How do strong CYP3A inducers affect plasma concentrations and efficacy of oral contraceptives in clinical pharmacology trials?", "topic": "Drug interactions/Clinical pharmacology (Women’s health)", "question_type": "mechanism", "expected_search_terms": ["CYP3A inducer", "oral contraceptive", "pharmacokinetics", "drug interaction", "rifampin", "carbamazepine"]}
{"question": "In phase III trials of antidepressants, how does concomitant NSAID use influence rates of gastrointestinal bleeding compared with antidepressant use alone?", "topic": "Drug interactions within trials (Psychiatry/General medicine)", "question_type": "epidemiology", "expected_search_terms": ["antidepressant", "SSRI", "NSAID", "gastrointestinal bleeding", "phase III", "concomitant", "safety"]}
{"question": "In phase III trials of monoclonal antibodies, how frequently do infusion-related reactions occur and what premedication strategies reduce their incidence?", "topic": "Clinical trials/Safety and management (Immunology/Oncology)", "question_type": "review", "expected_search_terms": ["monoclonal antibody", "phase III", "infusion-related reaction", "premedication", "antihistamine", "corticosteroid"]}
{"question": "In phase III trials of oral anticoagulants, how does renal impairment affect dosing, drug exposure, and clinical outcomes compared with normal renal function?", "topic": "Clinical trials/Prognosis and dosing (Cardiology/Nephrology)", "question_type": "prognosis", "expected_search_terms": ["direct oral anticoagulant", "renal impairment", "dose adjustment", "pharmacokinetics", "phase III", "outcomes"]}
{"question": "In phase III trials for heart failure, how does baseline use of mineralocorticoid receptor antagonists modify the observed benefit of ARNI therapy on clinical outcomes?", "topic": "Drug interactions within trials (Cardiology)", "question_type": "prognosis", "expected_search_terms": ["heart failure", "ARNI", "mineralocorticoid receptor antagonist", "phase III", "effect modification", "subgroup"]}
{"question": "In phase III oncology trials, how does primary prophylaxis with G-CSF influence rates of febrile neutropenia compared with no prophylaxis in high-risk regimens?", "topic": "Clinical trials/Supportive care (Oncology)", "question_type": "efficacy_comparison", "expected_search_terms": ["G-CSF", "primary prophylaxis", "febrile neutropenia", "phase III", "chemotherapy", "randomized"]}
{"question": "In phase III trials of oral semaglutide, how does coadministration timing with water and fasting conditions influence drug absorption and glycemic outcomes?", "topic": "Drug interactions/Clinical pharmacology (Endocrinology)", "question_type": "mechanism", "expected_search_terms": ["oral semaglutide", "administration conditions", "fasting", "water volume", "absorption", "pharmacokinetics", "phase III"]}
{"question": "How does coadministration of levothyroxine with calcium or iron supplements alter thyroid hormone levels in clinical studies, and what dosing separation is supported by evidence?", "topic": "Drug interactions/Clinical pharmacology (Endocrinology)", "question_type": "mechanism", "expected_search_terms": ["levothyroxine", "calcium", "iron", "absorption", "drug interaction", "dosing separation", "TSH"]}
{"question": "In phase III trials for migraine, how does concomitant use of triptans affect safety outcomes when used with CGRP receptor antagonists?", "topic": "Drug interactions within trials (Neurology/Headache)", "question_type": "epidemiology", "expected_search_terms": ["CGRP receptor antagonist", "gepant", "triptan", "concomitant use", "phase III", "safety"]}
{"question": "In phase III trials for chronic pain, how does combining opioids with benzodiazepines affect rates of respiratory depression compared with opioids alone?", "topic": "Drug interactions/Safety (Pain medicine)", "question_type": "epidemiology", "expected_search_terms": ["opioid", "benzodiazepine", "respiratory depression", "phase III", "concomitant", "safety"]}
{"question": "In phase III trials of antipsychotics, how does QT prolongation risk compare between ziprasidone and other second-generation antipsychotics at therapeutic doses?", "topic": "Drug development/Phase III trials (Psychiatry/Safety)", "question_type": "efficacy_comparison", "expected_search_terms": ["ziprasidone", "second-generation antipsychotic", "QT prolongation", "phase III", "therapeutic dose", "safety"]}
{"question": "In phase III trials for chronic hepatitis C, how do acid-reducing agents influence the pharmacokinetics and virologic response of pH-dependent antiviral regimens?", "topic": "Drug interactions/Clinical pharmacology (Infectious disease)", "question_type": "mechanism", "expected_search_terms": ["hepatitis C", "acid reducing agents", "proton pump inhibitor", "pharmacokinetics", "virologic response", "drug interaction"]}
{"question": "In phase III oncology trials, what is the impact of dose reductions and interruptions on progression-free survival for oral targeted therapies?", "topic": "Clinical trials/Prognosis and dosing (Oncology)", "question_type": "prognosis", "expected_search_terms": ["oral targeted therapy", "dose reduction", "dose interruption", "phase III", "progression-free survival", "exposure response"]}
{"question": "How do exposure–response analyses from phase III trials inform optimal dosing of monoclonal antibodies in oncology and inflammatory diseases?", "topic": "Drug development/Clinical pharmacology (Dose optimization)", "question_type": "review", "expected_search_terms": ["exposure-response", "phase III", "dose optimization", "monoclonal antibody", "population pharmacokinetics", "modeling"]}
{"question": "In phase III vaccine trials, how does coadministration with seasonal influenza vaccine affect immunogenicity compared with separate administration?", "topic": "Drug development/Phase III trials (Vaccines/Interactions)", "question_type": "efficacy_comparison", "expected_search_terms": ["phase III", "vaccine", "coadministration", "influenza vaccine", "immunogenicity", "antibody titers"]}
{"question": "In phase III trials for osteoporosis, how does sequential therapy with anabolic agent followed by antiresorptive compare with antiresorptive alone for fracture reduction?", "topic": "Drug development/Phase III trials (Bone health)", "question_type": "efficacy_comparison", "expected_search_terms": ["osteoporosis", "sequential therapy", "anabolic", "antiresorptive", "phase III", "fracture reduction"]}
{"question": "In phase III trials for asthma, how does stepping down inhaled corticosteroid dose after biologic initiation compare with maintaining the same dose for exacerbation control?", "topic": "Drug development/Phase III trials (Pulmonology/Strategy)", "question_type": "efficacy_comparison", "expected_search_terms": ["asthma", "biologic", "inhaled corticosteroid", "step-down", "phase III", "exacerbation control"]}
{"question": "In phase III trials for ulcerative colitis, how does therapeutic drug monitoring–guided dose escalation of anti-TNF therapy compare with empiric escalation for achieving remission?", "topic": "Drug development/Clinical trials (IBD/Personalized dosing)", "question_type": "efficacy_comparison", "expected_search_terms": ["ulcerative colitis", "therapeutic drug monitoring", "anti-TNF", "dose escalation", "phase III", "remission"]}
{"question": "In phase III trials of antifungal prophylaxis in hematologic malignancy, how does posaconazole compare with fluconazole for preventing invasive fungal infections?", "topic": "Drug development/Phase III trials (Infectious disease/Oncology supportive care)", "question_type": "efficacy_comparison", "expected_search_terms": ["posaconazole", "fluconazole", "antifungal prophylaxis", "hematologic malignancy", "phase III", "invasive fungal infection"]}
{"question": "In phase III trials for COVID-19 antivirals, how does coadministration with strong CYP3A inhibitors or inducers affect antiviral exposure and recommended dosing?", "topic": "Drug interactions/Clinical pharmacology (Infectious disease)", "question_type": "mechanism", "expected_search_terms": ["COVID-19 antiviral", "CYP3A inhibitor", "CYP3A inducer", "pharmacokinetics", "drug interaction", "dose adjustment"]}
{"question": "In phase III trials for Parkinson’s disease, how does adding MAO-B inhibitor therapy to levodopa compare with placebo add-on for reducing off time?", "topic": "Drug development/Phase III trials (Neurology)", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "MAO-B inhibitor", "levodopa", "add-on", "phase III", "off time", "randomized"]}
{"question": "How does concomitant use of anticholinergic medications influence cognitive adverse events in phase III trials of overactive bladder treatments in older adults?", "topic": "Drug interactions within trials (Geriatrics/Urology)", "question_type": "epidemiology", "expected_search_terms": ["overactive bladder", "anticholinergic burden", "older adults", "phase III", "cognitive adverse events", "concomitant"]}
{"question": "In phase III trials of osteoporosis therapies, how does baseline vitamin D status affect hypocalcemia risk with potent antiresorptive agents?", "topic": "Clinical trials/Prognosis and safety modifiers (Bone health)", "question_type": "prognosis", "expected_search_terms": ["vitamin D", "hypocalcemia", "antiresorptive", "denosumab", "bisphosphonate", "phase III", "risk modifier"]}
{"question": "In phase III oncology trials, how do rates of treatment-related discontinuation compare between oral targeted therapies and intravenous monoclonal antibody therapies for the same indication?", "topic": "Clinical trials/Safety comparison (Oncology)", "question_type": "efficacy_comparison", "expected_search_terms": ["phase III", "oncology", "treatment discontinuation", "oral targeted therapy", "monoclonal antibody", "adverse events"]}
{"question": "What is the evidence that therapeutic anticoagulation interacts with anti-angiogenic cancer therapies to increase bleeding risk in phase III trials?", "topic": "Drug interactions within trials (Oncology/Hematology)", "question_type": "epidemiology", "expected_search_terms": ["anti-angiogenic", "anti-VEGF", "anticoagulation", "bleeding risk", "phase III", "concomitant therapy"]}
{"question": "In phase III trials for heart failure with preserved ejection fraction, how does SGLT2 inhibitor therapy compare with placebo for improving health status scores?", "topic": "Drug development/Phase III trials (Cardiology/HFpEF)", "question_type": "efficacy_comparison", "expected_search_terms": ["HFpEF", "SGLT2 inhibitor", "phase III", "health status", "KCCQ", "placebo", "randomized"]}
{"question": "In phase III trials for chronic kidney disease, how does combining ACE inhibitors or ARBs with SGLT2 inhibitors compare with ACE inhibitor or ARB alone for hyperkalemia incidence?", "topic": "Drug interactions within trials (Nephrology)", "question_type": "epidemiology", "expected_search_terms": ["chronic kidney disease", "ACE inhibitor", "ARB", "SGLT2 inhibitor", "hyperkalemia", "phase III", "combination"]}
{"question": "In phase III trials of lipid-lowering therapy, how does adding ezetimibe to statin therapy compare with statin uptitration for achieving LDL-C goals?", "topic": "Drug development/Phase III trials (Lipidology)", "question_type": "efficacy_comparison", "expected_search_terms": ["ezetimibe", "statin", "uptitration", "LDL-C goal", "phase III", "combination therapy", "randomized"]}
{"question": "What mechanisms explain the interaction between azole antifungals and calcineurin inhibitors leading to increased nephrotoxicity risk in transplant recipients?", "topic": "Drug interactions/Clinical pharmacology (Transplant medicine)", "question_type": "mechanism", "expected_search_terms": ["azole antifungal", "tacrolimus", "cyclosporine", "CYP3A4 inhibition", "drug interaction", "nephrotoxicity", "transplant"]}
{"question": "In phase III transplant immunosuppression trials, how does tacrolimus compare with cyclosporine for acute rejection rates and nephrotoxicity outcomes?", "topic": "Drug development/Phase III trials (Transplant medicine)", "question_type": "efficacy_comparison", "expected_search_terms": ["tacrolimus", "cyclosporine", "kidney transplant", "phase III", "acute rejection", "nephrotoxicity"]}
{"question": "In phase III trials for ulcer prevention, how does PPI therapy compare with H2 receptor antagonists for preventing NSAID-associated upper GI bleeding in high-risk patients?", "topic": "Drug development/Phase III trials (Gastroenterology/Drug safety)", "question_type": "efficacy_comparison", "expected_search_terms": ["proton pump inhibitor", "H2 receptor antagonist", "NSAID", "upper GI bleeding", "prevention", "phase III", "high-risk"]}
{"question": "In phase III trials of antidiabetic therapies, how does concomitant insulin use influence hypoglycemia rates with GLP-1 receptor agonists compared with placebo?", "topic": "Drug interactions within trials (Endocrinology)", "question_type": "epidemiology", "expected_search_terms": ["GLP-1 receptor agonist", "insulin", "hypoglycemia", "phase III", "concomitant", "placebo"]}
{"question": "In phase III trials of oral iron formulations, how does alternate-day dosing compare with daily dosing for hemoglobin response and gastrointestinal side effects?", "topic": "Drug development/Clinical trials (Hematology/Nutrition)", "question_type": "efficacy_comparison", "expected_search_terms": ["oral iron", "alternate-day", "daily dosing", "phase III", "hemoglobin response", "gastrointestinal side effects"]}
{"question": "In phase III trials for atrial fibrillation rate control, how does beta-blocker therapy compare with non-dihydropyridine calcium channel blockers for exercise tolerance outcomes?", "topic": "Drug development/Phase III trials (Cardiology)", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "rate control", "beta blocker", "diltiazem", "verapamil", "phase III", "exercise tolerance"]}
{"question": "In phase III trials for Helicobacter pylori eradication, how does bismuth quadruple therapy compare with clarithromycin triple therapy for eradication rates in regions with high clarithromycin resistance?", "topic": "Drug development/Phase III trials (Infectious disease/Gastroenterology)", "question_type": "efficacy_comparison", "expected_search_terms": ["Helicobacter pylori", "bismuth quadruple therapy", "clarithromycin triple therapy", "phase III", "eradication rate", "resistance"]}
{"question": "How does coadministration of methotrexate with trimethoprim-sulfamethoxazole influence myelosuppression risk based on clinical reports and pharmacologic evidence?", "topic": "Drug interactions/Clinical pharmacology (Rheumatology/Infectious disease)", "question_type": "mechanism", "expected_search_terms": ["methotrexate", "trimethoprim sulfamethoxazole", "myelosuppression", "drug interaction", "folate", "toxicity"]}
{"question": "In phase III trials for epilepsy, how do enzyme-inducing antiseizure medications affect the efficacy of hormonal contraception as measured by breakthrough bleeding or ovulation markers?", "topic": "Drug interactions/Clinical trials (Neurology/Women’s health)", "question_type": "mechanism", "expected_search_terms": ["epilepsy", "enzyme-inducing", "antiseizure medication", "hormonal contraception", "drug interaction", "breakthrough bleeding", "ovulation"]}
{"question": "In phase III trials for insomnia, how does dual orexin receptor antagonist therapy compare with benzodiazepine receptor agonists for next-day psychomotor impairment?", "topic": "Drug development/Phase III trials (Sleep medicine)", "question_type": "efficacy_comparison", "expected_search_terms": ["dual orexin receptor antagonist", "zolpidem", "benzodiazepine receptor agonist", "phase III", "psychomotor impairment", "next-day"]}
{"question": "In phase III trials for chronic hepatitis B, how does stopping nucleos(t)ide analog therapy compare with continued therapy for rates of relapse and HBsAg loss in selected patients?", "topic": "Drug development/Clinical trials (Hepatology/Strategy)", "question_type": "efficacy_comparison", "expected_search_terms": ["chronic hepatitis B", "nucleoside analog", "treatment cessation", "continued therapy", "phase III", "relapse", "HBsAg loss"]}
{"question": "In phase III trials for gout flare prophylaxis during urate-lowering therapy initiation, how does low-dose colchicine compare with NSAIDs for preventing flares?", "topic": "Drug development/Phase III trials (Rheumatology)", "question_type": "efficacy_comparison", "expected_search_terms": ["gout", "flare prophylaxis", "colchicine", "NSAID", "urate-lowering therapy", "phase III", "randomized"]}
{"question": "In phase III trials for cancer-associated thrombosis, how do direct oral anticoagulants compare with low-molecular-weight heparin for recurrent VTE and major bleeding?", "topic": "Drug development/Phase III trials (Oncology/Hematology)", "question_type": "efficacy_comparison", "expected_search_terms": ["cancer-associated thrombosis", "direct oral anticoagulant", "low-molecular-weight heparin", "phase III", "recurrent VTE", "major bleeding"]}
{"question": "In phase III trials for ulcerative colitis, how does concomitant corticosteroid tapering protocol influence remission rates compared with fixed-dose steroid co-therapy?", "topic": "Clinical trials/Design and concomitant meds (IBD)", "question_type": "review", "expected_search_terms": ["ulcerative colitis", "phase III", "corticosteroid taper", "concomitant medication", "trial protocol", "remission"]}
{"question": "In metastatic non-small cell lung cancer with high PD-L1 expression, how does first-line PD-1/PD-L1 inhibitor monotherapy compare with platinum-doublet chemotherapy in overall survival and grade 3–4 toxicity?", "topic": "NSCLC immunotherapy vs chemotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["non-small cell lung cancer", "PD-L1 high", "PD-1 inhibitor", "PD-L1 inhibitor", "first-line", "chemotherapy", "overall survival", "toxicity"]}
{"question": "In EGFR-mutant non-small cell lung cancer, how does third-generation EGFR inhibition compare with first-generation EGFR inhibition in progression-free survival and central nervous system control?", "topic": "NSCLC EGFR targeted therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["EGFR mutant", "NSCLC", "third-generation EGFR inhibitor", "first-generation EGFR inhibitor", "progression-free survival", "brain metastases", "CNS activity"]}
{"question": "What mechanisms of acquired resistance to EGFR inhibitors in EGFR-mutant lung cancer are most consistently supported by clinical tumor sequencing studies?", "topic": "NSCLC EGFR resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["EGFR inhibitor", "acquired resistance", "NSCLC", "tumor sequencing", "mechanism", "MET amplification", "EGFR secondary mutation"]}
{"question": "In ALK-rearranged lung cancer, how do second-generation ALK inhibitors compare with first-generation ALK inhibition for intracranial response rates?", "topic": "NSCLC ALK targeted therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["ALK rearranged", "lung cancer", "second-generation ALK inhibitor", "first-generation ALK inhibitor", "intracranial response", "brain metastases"]}
{"question": "In HER2-positive metastatic breast cancer, how does antibody–drug conjugate therapy compare with taxane-based chemotherapy in progression-free survival after trastuzumab exposure?", "topic": "Breast cancer HER2 therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["HER2 positive", "metastatic breast cancer", "antibody-drug conjugate", "trastuzumab pretreated", "taxane", "progression-free survival"]}
{"question": "What tumor and treatment factors predict response to antibody–drug conjugates in HER2-low breast cancer?", "topic": "Breast cancer predictive biomarkers", "question_type": "prognosis", "expected_search_terms": ["HER2 low", "breast cancer", "antibody-drug conjugate", "predictive biomarkers", "response", "HER2 IHC", "tumor heterogeneity"]}
{"question": "In triple-negative breast cancer, how does adding a PD-1/PD-L1 inhibitor to chemotherapy compare with chemotherapy alone for pathologic complete response in the neoadjuvant setting?", "topic": "TNBC neoadjuvant immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["triple-negative breast cancer", "neoadjuvant", "PD-1 inhibitor", "PD-L1 inhibitor", "chemotherapy", "pathologic complete response"]}
{"question": "How does BRCA1/2 mutation status influence sensitivity and resistance mechanisms to PARP inhibitors in ovarian cancer?", "topic": "Ovarian cancer PARP therapy", "question_type": "mechanism", "expected_search_terms": ["ovarian cancer", "PARP inhibitor", "BRCA1", "BRCA2", "homologous recombination", "resistance", "reversion mutation"]}
{"question": "In platinum-sensitive recurrent ovarian cancer, how does maintenance PARP inhibition compare with maintenance anti-angiogenic therapy in progression-free survival?", "topic": "Ovarian cancer maintenance therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["platinum-sensitive", "recurrent ovarian cancer", "maintenance", "PARP inhibitor", "bevacizumab", "anti-angiogenic", "progression-free survival"]}
{"question": "What clinical evidence supports combining PARP inhibitors with immune checkpoint blockade to overcome resistance in ovarian cancer?", "topic": "Ovarian cancer combination immunotherapy", "question_type": "review", "expected_search_terms": ["ovarian cancer", "PARP inhibitor", "immune checkpoint", "PD-1", "PD-L1", "combination therapy", "resistance"]}
{"question": "In metastatic colorectal cancer, how does anti-EGFR therapy compare with anti-VEGF therapy as first-line treatment in RAS wild-type left-sided tumors?", "topic": "Colorectal cancer targeted therapy selection", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic colorectal cancer", "RAS wild-type", "left-sided", "anti-EGFR", "anti-VEGF", "first-line", "overall survival"]}
{"question": "What mechanisms explain primary resistance to immune checkpoint inhibitors in mismatch repair–deficient colorectal cancer cases that fail to respond clinically?", "topic": "Colorectal cancer immunotherapy resistance", "question_type": "mechanism", "expected_search_terms": ["mismatch repair deficient", "MSI-H", "colorectal cancer", "checkpoint inhibitor", "primary resistance", "mechanism", "beta-2 microglobulin", "JAK"]}
{"question": "In BRAF V600E-mutant metastatic melanoma, how does combined BRAF plus MEK inhibition compare with PD-1-based immunotherapy for long-term overall survival?", "topic": "Melanoma targeted vs immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["BRAF V600E", "melanoma", "BRAF inhibitor", "MEK inhibitor", "PD-1 inhibitor", "overall survival", "long-term"]}
{"question": "What molecular adaptations in melanoma tumors are associated with acquired resistance to BRAF plus MEK inhibition in patient biopsies?", "topic": "Melanoma resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["melanoma", "BRAF MEK inhibitors", "acquired resistance", "patient biopsy", "MAPK reactivation", "NRAS", "PTEN"]}
{"question": "In metastatic renal cell carcinoma, how does combination immune checkpoint blockade compare with immune checkpoint inhibitor plus VEGF receptor tyrosine kinase inhibitor therapy in progression-free survival and hypertension risk?", "topic": "Renal cell carcinoma immunotherapy combinations", "question_type": "efficacy_comparison", "expected_search_terms": ["renal cell carcinoma", "checkpoint inhibitor", "CTLA-4", "PD-1", "VEGFR TKI", "progression-free survival", "hypertension", "toxicity"]}
{"question": "Which baseline clinical or laboratory features predict hyperprogressive disease during immune checkpoint therapy across solid tumors?", "topic": "Immunotherapy adverse outcomes predictors", "question_type": "prognosis", "expected_search_terms": ["hyperprogression", "immune checkpoint inhibitor", "predictors", "solid tumors", "LDH", "age", "tumor burden"]}
{"question": "In hepatocellular carcinoma, how does immune checkpoint inhibitor plus anti-VEGF therapy compare with tyrosine kinase inhibitor monotherapy for overall survival in first-line treatment?", "topic": "Hepatocellular carcinoma systemic therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["hepatocellular carcinoma", "first-line", "checkpoint inhibitor", "anti-VEGF", "tyrosine kinase inhibitor", "overall survival"]}
{"question": "What evidence supports the role of Wnt/β-catenin pathway activation as a mechanism of immune exclusion and resistance to checkpoint inhibitors in hepatocellular carcinoma?", "topic": "HCC immunotherapy resistance biology", "question_type": "mechanism", "expected_search_terms": ["hepatocellular carcinoma", "Wnt beta-catenin", "immune exclusion", "checkpoint inhibitor", "resistance", "tumor microenvironment"]}
{"question": "In advanced gastric or gastroesophageal junction cancer, how does PD-1 inhibitor plus chemotherapy compare with chemotherapy alone for overall survival in tumors with varying PD-L1 combined positive score levels?", "topic": "Gastric cancer chemo-immunotherapy biomarkers", "question_type": "efficacy_comparison", "expected_search_terms": ["gastric cancer", "gastroesophageal junction", "PD-1 inhibitor", "chemotherapy", "PD-L1 CPS", "overall survival"]}
{"question": "How does Claudin 18.2 expression correlate with response to targeted therapies in gastric cancer based on clinical studies?", "topic": "Gastric cancer targeted therapy biomarkers", "question_type": "prognosis", "expected_search_terms": ["gastric cancer", "Claudin 18.2", "targeted therapy", "response", "biomarker", "expression"]}
{"question": "In esophageal squamous cell carcinoma, how does adding a PD-1 inhibitor to chemoradiotherapy compare with chemoradiotherapy alone in complete response rates?", "topic": "Esophageal cancer combined modality immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["esophageal squamous cell carcinoma", "PD-1 inhibitor", "chemoradiotherapy", "complete response", "combined modality"]}
{"question": "What mechanisms are proposed for chemotherapy-induced immunogenic cell death that may enhance checkpoint inhibitor responses in solid tumors?", "topic": "Chemo-immunotherapy mechanistic synergy", "question_type": "mechanism", "expected_search_terms": ["immunogenic cell death", "chemotherapy", "calreticulin", "HMGB1", "type I interferon", "checkpoint inhibitor synergy"]}
{"question": "In metastatic pancreatic ductal adenocarcinoma, how do FOLFIRINOX and gemcitabine plus nab-paclitaxel compare in overall survival and neuropathy incidence?", "topic": "Pancreatic cancer chemotherapy comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["pancreatic ductal adenocarcinoma", "FOLFIRINOX", "gemcitabine", "nab-paclitaxel", "overall survival", "neuropathy"]}
{"question": "What tumor microenvironment features are associated with resistance to immune checkpoint inhibitors in pancreatic cancer patients?", "topic": "Pancreatic cancer immunotherapy resistance", "question_type": "mechanism", "expected_search_terms": ["pancreatic cancer", "checkpoint inhibitor", "resistance", "tumor microenvironment", "myeloid-derived suppressor", "stroma", "T cell exclusion"]}
{"question": "In cholangiocarcinoma, how does adding immune checkpoint inhibition to gemcitabine-cisplatin compare with chemotherapy alone for overall survival?", "topic": "Biliary tract cancer chemo-immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["cholangiocarcinoma", "biliary tract cancer", "checkpoint inhibitor", "gemcitabine cisplatin", "overall survival"]}
{"question": "In FGFR2-fusion positive intrahepatic cholangiocarcinoma, what are the most common on-target and off-target mechanisms of resistance to FGFR inhibitors reported in clinical series?", "topic": "Cholangiocarcinoma FGFR resistance", "question_type": "mechanism", "expected_search_terms": ["intrahepatic cholangiocarcinoma", "FGFR2 fusion", "FGFR inhibitor", "resistance", "gatekeeper mutation", "bypass pathway"]}
{"question": "In metastatic castration-resistant prostate cancer, how does androgen receptor pathway inhibitor therapy compare with taxane chemotherapy in overall survival after progression on initial hormonal therapy?", "topic": "Prostate cancer sequencing therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic castration-resistant prostate cancer", "androgen receptor inhibitor", "taxane", "post-progression", "overall survival", "sequencing"]}
{"question": "What is the evidence that AR-V7 splice variant status predicts resistance to androgen receptor signaling inhibitors in prostate cancer?", "topic": "Prostate cancer resistance biomarkers", "question_type": "prognosis", "expected_search_terms": ["prostate cancer", "AR-V7", "androgen receptor signaling inhibitor", "resistance", "predictive biomarker", "circulating tumor cells"]}
{"question": "In metastatic hormone receptor–positive breast cancer, how does CDK4/6 inhibitor plus endocrine therapy compare with endocrine therapy alone in overall survival and neutropenia rates?", "topic": "Breast cancer CDK4/6 efficacy and safety", "question_type": "efficacy_comparison", "expected_search_terms": ["HR positive", "metastatic breast cancer", "CDK4/6 inhibitor", "endocrine therapy", "overall survival", "neutropenia"]}
{"question": "What molecular mechanisms are implicated in acquired resistance to CDK4/6 inhibitors in hormone receptor–positive breast cancer?", "topic": "Breast cancer CDK4/6 resistance", "question_type": "mechanism", "expected_search_terms": ["CDK4/6 inhibitor", "breast cancer", "acquired resistance", "RB1 loss", "cyclin E", "PI3K pathway"]}
{"question": "In PIK3CA-mutant hormone receptor–positive breast cancer, how does PI3K inhibition plus endocrine therapy compare with endocrine therapy alone for progression-free survival, considering hyperglycemia risk?", "topic": "Breast cancer PI3K targeted therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["PIK3CA mutant", "breast cancer", "PI3K inhibitor", "endocrine therapy", "progression-free survival", "hyperglycemia"]}
{"question": "In diffuse large B-cell lymphoma, how does CAR T-cell therapy compare with autologous stem cell transplantation in relapsed or refractory disease for event-free survival?", "topic": "Lymphoma cellular therapy vs transplant", "question_type": "efficacy_comparison", "expected_search_terms": ["diffuse large B-cell lymphoma", "CAR T-cell", "autologous stem cell transplant", "relapsed refractory", "event-free survival"]}
{"question": "What patient or disease characteristics predict durable remission after CAR T-cell therapy in B-cell malignancies?", "topic": "CAR T predictors of response", "question_type": "prognosis", "expected_search_terms": ["CAR T-cell", "predictors", "durable response", "B-cell lymphoma", "tumor burden", "LDH", "T-cell phenotype"]}
{"question": "What mechanisms of antigen escape contribute to relapse after CD19-targeted CAR T-cell therapy in B-cell acute lymphoblastic leukemia?", "topic": "CAR T relapse mechanisms", "question_type": "mechanism", "expected_search_terms": ["CD19 CAR T", "B-ALL", "relapse", "antigen escape", "CD19 loss", "splicing", "lineage switch"]}
{"question": "In multiple myeloma, how does anti-BCMA CAR T-cell therapy compare with anti-BCMA bispecific antibodies in overall response rate and cytokine release syndrome incidence?", "topic": "Myeloma BCMA therapies comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple myeloma", "BCMA", "CAR T-cell", "bispecific antibody", "overall response rate", "cytokine release syndrome"]}
{"question": "What evidence supports soluble BCMA as a biomarker of response or resistance to BCMA-directed therapies in multiple myeloma?", "topic": "Myeloma biomarkers", "question_type": "prognosis", "expected_search_terms": ["soluble BCMA", "multiple myeloma", "biomarker", "BCMA therapy", "response", "resistance"]}
{"question": "In acute myeloid leukemia, how does adding a BCL-2 inhibitor to hypomethylating agents compare with hypomethylating agents alone in complete remission rates among older adults?", "topic": "AML targeted combination therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["acute myeloid leukemia", "BCL-2 inhibitor", "hypomethylating agent", "older adults", "complete remission"]}
{"question": "What mechanisms underlie resistance to BCL-2 inhibition in acute myeloid leukemia based on translational and clinical studies?", "topic": "AML BCL-2 resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["AML", "BCL-2 inhibitor", "venetoclax resistance", "MCL1", "BCL-XL", "metabolic adaptation", "monocytic differentiation"]}
{"question": "In chronic myeloid leukemia, how does treatment-free remission success differ between patients stopping first-generation versus second-generation tyrosine kinase inhibitors?", "topic": "CML TKI discontinuation outcomes", "question_type": "prognosis", "expected_search_terms": ["chronic myeloid leukemia", "treatment-free remission", "tyrosine kinase inhibitor", "imatinib", "second-generation", "discontinuation"]}
{"question": "What is the incidence of immune-related myocarditis with immune checkpoint inhibitors across major cancer types in real-world pharmacovigilance studies?", "topic": "Immunotherapy toxicity epidemiology", "question_type": "epidemiology", "expected_search_terms": ["immune checkpoint inhibitor", "myocarditis", "incidence", "real-world", "pharmacovigilance", "cancer types"]}
{"question": "In melanoma, how does PD-1 inhibitor monotherapy compare with combined PD-1 plus CTLA-4 blockade in objective response rate and colitis risk?", "topic": "Melanoma checkpoint regimen comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["melanoma", "PD-1 inhibitor", "CTLA-4", "combination", "objective response rate", "colitis", "toxicity"]}
{"question": "How consistently does tumor mutational burden correlate with response to immune checkpoint inhibitors across different solid tumor types?", "topic": "Immunotherapy biomarkers (TMB)", "question_type": "review", "expected_search_terms": ["tumor mutational burden", "checkpoint inhibitor", "response", "solid tumors", "meta-analysis", "predictive biomarker"]}
{"question": "What is the impact of prior antibiotic exposure on the efficacy of immune checkpoint inhibitors in solid tumors based on clinical cohort studies?", "topic": "Microbiome and immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["antibiotics", "immune checkpoint inhibitor", "microbiome", "overall survival", "progression-free survival", "cohort"]}
{"question": "What evidence supports fecal microbiota composition as a determinant of response to immune checkpoint blockade in melanoma and lung cancer?", "topic": "Microbiome mechanisms in immunotherapy", "question_type": "mechanism", "expected_search_terms": ["fecal microbiota", "checkpoint blockade", "melanoma", "lung cancer", "response", "Akkermansia", "Bifidobacterium"]}
{"question": "In head and neck squamous cell carcinoma, how does PD-1 inhibitor therapy compare with standard single-agent chemotherapy in previously treated recurrent/metastatic disease for overall survival?", "topic": "Head and neck cancer immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["head and neck squamous cell carcinoma", "recurrent metastatic", "PD-1 inhibitor", "single-agent chemotherapy", "overall survival"]}
{"question": "In HPV-positive oropharyngeal cancer, what is the prognostic value of PD-L1 expression for response to checkpoint inhibitor therapy?", "topic": "HPV-related HNSCC biomarker", "question_type": "prognosis", "expected_search_terms": ["HPV positive", "oropharyngeal cancer", "PD-L1", "checkpoint inhibitor", "prognostic", "predictive"]}
{"question": "In cervical cancer, how does checkpoint inhibitor therapy compare with chemotherapy in second-line treatment regarding response rate and duration of response?", "topic": "Cervical cancer immunotherapy vs chemotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["cervical cancer", "second-line", "checkpoint inhibitor", "chemotherapy", "response rate", "duration of response"]}
{"question": "What is the relationship between tumor hypoxia signatures and resistance to radiotherapy plus immunotherapy combinations in solid tumors?", "topic": "Radio-immunotherapy resistance biology", "question_type": "mechanism", "expected_search_terms": ["tumor hypoxia", "radiotherapy", "immunotherapy", "resistance", "hypoxia signature", "HIF-1alpha"]}
{"question": "In glioblastoma, how does temozolomide efficacy differ by MGMT promoter methylation status in terms of overall survival?", "topic": "Glioblastoma chemotherapy biomarker", "question_type": "prognosis", "expected_search_terms": ["glioblastoma", "temozolomide", "MGMT promoter methylation", "overall survival", "predictive biomarker"]}
{"question": "What mechanisms of resistance to temozolomide in glioma are supported by human tumor studies?", "topic": "Glioma chemotherapy resistance", "question_type": "mechanism", "expected_search_terms": ["glioma", "temozolomide", "resistance", "MGMT", "mismatch repair", "tumor study", "mutation"]}
{"question": "In IDH-mutant gliomas, how does IDH inhibition compare with standard chemotherapy regimens in progression-free survival in recurrent disease?", "topic": "Glioma targeted therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["IDH mutant glioma", "IDH inhibitor", "recurrent", "chemotherapy", "progression-free survival"]}
{"question": "In metastatic urothelial carcinoma, how does maintenance immune checkpoint inhibition after platinum chemotherapy compare with observation in overall survival?", "topic": "Bladder cancer maintenance immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["urothelial carcinoma", "maintenance", "checkpoint inhibitor", "after platinum chemotherapy", "overall survival"]}
{"question": "What genomic alterations are associated with response or resistance to FGFR inhibitors in urothelial carcinoma?", "topic": "Bladder cancer FGFR biomarkers", "question_type": "prognosis", "expected_search_terms": ["urothelial carcinoma", "FGFR inhibitor", "genomic alterations", "FGFR3", "response", "resistance"]}
{"question": "In metastatic castration-sensitive prostate cancer, how does adding a novel androgen receptor pathway inhibitor to androgen deprivation therapy compare with adding docetaxel in overall survival?", "topic": "Prostate cancer intensification strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic castration-sensitive prostate cancer", "androgen deprivation therapy", "androgen receptor inhibitor", "docetaxel", "overall survival"]}
{"question": "How does homologous recombination repair deficiency influence response to PARP inhibitors in metastatic prostate cancer?", "topic": "Prostate cancer PARP biomarkers", "question_type": "prognosis", "expected_search_terms": ["metastatic prostate cancer", "PARP inhibitor", "homologous recombination deficiency", "BRCA2", "ATM", "response"]}
{"question": "In estrogen receptor–positive breast cancer, how does ESR1 mutation status affect clinical resistance to aromatase inhibitors?", "topic": "Breast cancer endocrine resistance", "question_type": "mechanism", "expected_search_terms": ["ESR1 mutation", "aromatase inhibitor", "breast cancer", "endocrine resistance", "circulating tumor DNA"]}
{"question": "In metastatic colorectal cancer with BRAF V600E mutation, how does targeted combination therapy compare with standard chemotherapy in overall survival in previously treated patients?", "topic": "Colorectal cancer BRAF targeted therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["colorectal cancer", "BRAF V600E", "targeted therapy", "combination", "standard chemotherapy", "overall survival"]}
{"question": "What are the proposed mechanisms of resistance to anti-VEGF therapy in metastatic colorectal cancer based on translational studies?", "topic": "Anti-angiogenic resistance", "question_type": "mechanism", "expected_search_terms": ["metastatic colorectal cancer", "anti-VEGF", "bevacizumab", "resistance", "angiogenesis", "VEGF-independent pathways"]}
{"question": "In soft tissue sarcoma, how does immune checkpoint inhibitor monotherapy compare with combination checkpoint blockade in response rate for specific histologic subtypes?", "topic": "Sarcoma immunotherapy efficacy by subtype", "question_type": "efficacy_comparison", "expected_search_terms": ["soft tissue sarcoma", "checkpoint inhibitor", "combination", "response rate", "histologic subtype", "undifferentiated pleomorphic sarcoma"]}
{"question": "What biomarkers have been associated with response to immunotherapy in sarcoma across published clinical studies?", "topic": "Sarcoma immunotherapy biomarkers", "question_type": "review", "expected_search_terms": ["sarcoma", "immunotherapy", "biomarkers", "PD-L1", "TMB", "tumor infiltrating lymphocytes", "response"]}
{"question": "In chronic lymphocytic leukemia, how does BTK inhibitor monotherapy compare with venetoclax-based fixed-duration therapy in progression-free survival and infection risk?", "topic": "CLL targeted therapy comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["chronic lymphocytic leukemia", "BTK inhibitor", "venetoclax", "fixed duration", "progression-free survival", "infection"]}
{"question": "What are the most supported mechanisms of resistance to covalent BTK inhibitors in chronic lymphocytic leukemia?", "topic": "CLL BTK resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["CLL", "BTK inhibitor", "covalent", "resistance", "BTK C481", "PLCgamma2 mutation"]}
{"question": "In Philadelphia chromosome–positive acute lymphoblastic leukemia, how does adding a tyrosine kinase inhibitor to chemotherapy compare with chemotherapy alone in complete molecular remission rates?", "topic": "Ph+ ALL targeted therapy integration", "question_type": "efficacy_comparison", "expected_search_terms": ["Philadelphia chromosome positive", "acute lymphoblastic leukemia", "tyrosine kinase inhibitor", "chemotherapy", "complete molecular remission"]}
{"question": "How does minimal residual disease status after induction therapy predict relapse risk in acute lymphoblastic leukemia treated with modern targeted combinations?", "topic": "ALL prognosis with MRD", "question_type": "prognosis", "expected_search_terms": ["acute lymphoblastic leukemia", "minimal residual disease", "targeted therapy", "relapse risk", "prognosis"]}
{"question": "In non-Hodgkin lymphoma, how does PD-1 blockade efficacy differ between classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma in terms of response rate?", "topic": "Lymphoma immunotherapy disease-specific efficacy", "question_type": "efficacy_comparison", "expected_search_terms": ["PD-1 blockade", "classical Hodgkin lymphoma", "primary mediastinal B-cell lymphoma", "response rate", "comparison"]}
{"question": "What tumor microenvironment characteristics explain the high sensitivity of classical Hodgkin lymphoma to PD-1 inhibition?", "topic": "Hodgkin lymphoma immunotherapy mechanism", "question_type": "mechanism", "expected_search_terms": ["classical Hodgkin lymphoma", "PD-1 inhibitor", "microenvironment", "9p24.1 amplification", "PD-L1", "immune evasion"]}
{"question": "In metastatic gastric cancer, how does trastuzumab-based therapy compare with chemotherapy alone in HER2-positive disease for overall survival, and how does benefit vary by HER2 expression level?", "topic": "Gastric cancer HER2 therapy outcomes", "question_type": "efficacy_comparison", "expected_search_terms": ["gastric cancer", "HER2 positive", "trastuzumab", "chemotherapy", "overall survival", "HER2 expression level"]}
{"question": "What mechanisms contribute to loss of HER2 expression and resistance to HER2-targeted therapy in gastric cancer?", "topic": "Gastric cancer HER2 resistance", "question_type": "mechanism", "expected_search_terms": ["gastric cancer", "HER2", "resistance", "heterogeneity", "HER2 loss", "targeted therapy"]}
{"question": "In metastatic non-small cell lung cancer, how does adding anti-angiogenic therapy to PD-1/PD-L1 inhibition influence progression-free survival compared with immunotherapy alone?", "topic": "NSCLC immunotherapy plus anti-angiogenic therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "PD-1", "PD-L1", "anti-angiogenic", "VEGF", "combination", "progression-free survival"]}
{"question": "What is the relationship between baseline corticosteroid use and outcomes of immune checkpoint inhibitor therapy in lung cancer patients?", "topic": "Immunotherapy outcomes modifiers", "question_type": "prognosis", "expected_search_terms": ["lung cancer", "corticosteroids", "baseline use", "immune checkpoint inhibitor", "overall survival", "progression-free survival"]}
{"question": "In advanced endometrial cancer, how does immune checkpoint inhibition plus targeted therapy compare with chemotherapy in previously treated disease for overall survival?", "topic": "Endometrial cancer immunotherapy combinations", "question_type": "efficacy_comparison", "expected_search_terms": ["endometrial cancer", "previously treated", "checkpoint inhibitor", "targeted therapy", "chemotherapy", "overall survival"]}
{"question": "How does mismatch repair deficiency status affect response to immune checkpoint inhibitors in endometrial cancer across clinical studies?", "topic": "Endometrial cancer biomarkers", "question_type": "prognosis", "expected_search_terms": ["endometrial cancer", "mismatch repair deficient", "MSI", "checkpoint inhibitor", "response", "biomarker"]}
{"question": "In HER2-positive breast cancer with brain metastases, how do small-molecule HER2 tyrosine kinase inhibitors compare with antibody-based regimens for intracranial response rates?", "topic": "Breast cancer brain metastases targeted therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["HER2 positive breast cancer", "brain metastases", "HER2 tyrosine kinase inhibitor", "trastuzumab", "antibody", "intracranial response"]}
{"question": "What evidence supports blood–brain barrier penetration as a determinant of efficacy for targeted therapies in brain metastases across tumor types?", "topic": "Targeted therapy CNS pharmacology", "question_type": "review", "expected_search_terms": ["blood-brain barrier", "brain metastases", "targeted therapy", "CNS penetration", "pharmacokinetics", "efficacy"]}
{"question": "In metastatic non-small cell lung cancer, how does KRAS G12C inhibition compare with docetaxel in previously treated patients for progression-free survival?", "topic": "NSCLC KRAS targeted therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "KRAS G12C", "inhibitor", "docetaxel", "previously treated", "progression-free survival"]}
{"question": "What mechanisms of resistance to KRAS G12C inhibitors are most frequently reported in clinical samples from lung cancer patients?", "topic": "NSCLC KRAS resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["KRAS G12C", "lung cancer", "resistance", "clinical samples", "RTK activation", "KRAS mutation", "MAPK"]}
{"question": "In hormone receptor–positive breast cancer, how does adding an mTOR inhibitor to endocrine therapy compare with endocrine therapy alone for progression-free survival after aromatase inhibitor resistance?", "topic": "Breast cancer mTOR targeted therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["breast cancer", "hormone receptor positive", "mTOR inhibitor", "endocrine therapy", "aromatase inhibitor resistance", "progression-free survival"]}
{"question": "What molecular pathways mediate cross-talk between PI3K/AKT/mTOR signaling and estrogen receptor signaling leading to endocrine resistance in breast cancer?", "topic": "Breast cancer endocrine resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["breast cancer", "endocrine resistance", "PI3K", "AKT", "mTOR", "estrogen receptor", "cross-talk"]}
{"question": "In non-small cell lung cancer, what is the comparative effectiveness of EGFR inhibitor rechallenge versus chemotherapy after a drug-free interval following prior EGFR inhibitor response?", "topic": "NSCLC EGFR rechallenge strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "EGFR inhibitor", "rechallenge", "drug holiday", "chemotherapy", "effectiveness", "response"]}
{"question": "How does circulating tumor DNA dynamics during targeted therapy predict early resistance and progression in metastatic cancers?", "topic": "Liquid biopsy for resistance monitoring", "question_type": "prognosis", "expected_search_terms": ["circulating tumor DNA", "ctDNA", "targeted therapy", "early resistance", "progression", "molecular response"]}
{"question": "In metastatic colorectal cancer, how does regorafenib compare with trifluridine-tipiracil in overall survival and hand–foot skin reaction incidence in refractory disease?", "topic": "Refractory colorectal cancer therapy comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic colorectal cancer", "refractory", "regorafenib", "trifluridine tipiracil", "overall survival", "hand-foot skin reaction"]}
{"question": "What mechanisms contribute to multidrug resistance mediated by ABC transporters in solid tumors treated with chemotherapy?", "topic": "Chemotherapy resistance transporters", "question_type": "mechanism", "expected_search_terms": ["ABC transporter", "P-glycoprotein", "multidrug resistance", "chemotherapy", "solid tumor", "mechanism"]}
{"question": "In ovarian cancer, how does intraperitoneal chemotherapy compare with intravenous chemotherapy in overall survival and quality-of-life outcomes in optimally debulked disease?", "topic": "Ovarian cancer chemotherapy route comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["ovarian cancer", "intraperitoneal chemotherapy", "intravenous", "overall survival", "quality of life", "optimally debulked"]}
{"question": "What is the prognostic value of residual disease after interval debulking surgery for predicting chemotherapy resistance and survival in advanced ovarian cancer?", "topic": "Ovarian cancer prognosis and resistance", "question_type": "prognosis", "expected_search_terms": ["advanced ovarian cancer", "interval debulking", "residual disease", "chemotherapy resistance", "survival", "prognostic"]}
{"question": "In metastatic non-small cell lung cancer, how does pemetrexed-based chemotherapy compare with taxane-based chemotherapy in overall survival for non-squamous histology without actionable mutations?", "topic": "NSCLC chemotherapy regimen comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "non-squamous", "pemetrexed", "taxane", "chemotherapy", "overall survival", "no actionable mutation"]}
{"question": "What clinical and molecular features predict exceptional responders to platinum chemotherapy across solid tumors?", "topic": "Chemotherapy response heterogeneity", "question_type": "prognosis", "expected_search_terms": ["platinum chemotherapy", "exceptional responder", "solid tumors", "predictors", "DNA repair deficiency", "clinical features"]}
{"question": "In metastatic triple-negative breast cancer, how does sacituzumab govitecan compare with physician’s choice chemotherapy in overall survival and diarrhea rates?", "topic": "TNBC antibody-drug conjugate comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["triple-negative breast cancer", "sacituzumab govitecan", "chemotherapy", "overall survival", "diarrhea", "toxicity"]}
{"question": "What are the main cellular mechanisms of resistance to antibody–drug conjugates in breast cancer, focusing on antigen modulation and payload efflux?", "topic": "ADC resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["antibody-drug conjugate", "breast cancer", "resistance", "antigen downregulation", "payload efflux", "drug transporter", "lysosome"]}
{"question": "In metastatic melanoma, how does adoptive tumor-infiltrating lymphocyte therapy compare with checkpoint inhibitor therapy in objective response rate after prior immunotherapy exposure?", "topic": "Melanoma cellular therapy comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["melanoma", "tumor-infiltrating lymphocytes", "adoptive cell therapy", "checkpoint inhibitor", "post immunotherapy", "objective response"]}
{"question": "What tumor antigen and HLA-related mechanisms contribute to immune escape from T-cell based therapies in solid tumors?", "topic": "Immune escape mechanisms", "question_type": "mechanism", "expected_search_terms": ["immune escape", "HLA loss", "antigen presentation", "beta-2 microglobulin", "T-cell therapy", "solid tumors"]}
{"question": "In metastatic renal cell carcinoma, what is the comparative efficacy of cabozantinib versus sunitinib in intermediate- and poor-risk patients for progression-free survival?", "topic": "RCC TKI comparison by risk group", "question_type": "efficacy_comparison", "expected_search_terms": ["renal cell carcinoma", "cabozantinib", "sunitinib", "intermediate risk", "poor risk", "progression-free survival"]}
{"question": "What mechanisms of resistance to VEGF-targeted tyrosine kinase inhibitors have been identified in renal cell carcinoma using patient-derived samples?", "topic": "RCC anti-angiogenic resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["renal cell carcinoma", "VEGF TKI", "resistance", "patient-derived", "angiogenesis escape", "MET", "AXL"]}
{"question": "In non-small cell lung cancer, how does the efficacy of PD-1/PD-L1 inhibitors differ between never-smokers and current/former smokers in terms of response rate?", "topic": "NSCLC immunotherapy outcomes by smoking status", "question_type": "epidemiology", "expected_search_terms": ["NSCLC", "PD-1", "PD-L1", "smoking status", "never smoker", "response rate", "immunotherapy"]}
{"question": "What is the incidence and clinical impact of pseudoprogression during immune checkpoint therapy across solid tumors?", "topic": "Immunotherapy response patterns", "question_type": "epidemiology", "expected_search_terms": ["pseudoprogression", "immune checkpoint inhibitor", "incidence", "solid tumors", "clinical outcomes", "RECIST"]}
{"question": "In metastatic colorectal cancer with high microsatellite instability, how does first-line immunotherapy compare with chemotherapy for progression-free survival?", "topic": "MSI-H colorectal cancer first-line immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["MSI-H", "dMMR", "metastatic colorectal cancer", "first-line", "immunotherapy", "chemotherapy", "progression-free survival"]}
{"question": "What baseline immune gene expression signatures predict response to checkpoint inhibitors in MSI-H gastrointestinal cancers?", "topic": "Immunotherapy transcriptomic biomarkers", "question_type": "prognosis", "expected_search_terms": ["MSI-H", "gastrointestinal cancer", "checkpoint inhibitor", "immune gene signature", "interferon gamma", "prediction"]}
{"question": "In HER2-positive metastatic gastric cancer, how does adding a PD-1 inhibitor to HER2-targeted chemotherapy compare with HER2-targeted chemotherapy alone in overall survival?", "topic": "Gastric cancer HER2 plus immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["HER2 positive", "metastatic gastric cancer", "PD-1 inhibitor", "trastuzumab", "chemotherapy", "overall survival"]}
{"question": "What is the role of Fc gamma receptor engagement in the antitumor activity of therapeutic antibodies, and how might it influence clinical outcomes?", "topic": "Antibody therapeutics mechanism", "question_type": "mechanism", "expected_search_terms": ["Fc gamma receptor", "ADCC", "therapeutic antibody", "clinical outcome", "trastuzumab", "rituximab", "mechanism"]}
{"question": "In diffuse large B-cell lymphoma, how does polatuzumab-based chemoimmunotherapy compare with standard chemoimmunotherapy in complete response rate in relapsed disease?", "topic": "DLBCL antibody-drug conjugate regimens", "question_type": "efficacy_comparison", "expected_search_terms": ["diffuse large B-cell lymphoma", "polatuzumab", "chemoimmunotherapy", "relapsed", "complete response rate"]}
{"question": "What are the mechanisms of resistance to anti-CD20 monoclonal antibodies in B-cell lymphomas based on clinical and laboratory studies?", "topic": "Lymphoma anti-CD20 resistance", "question_type": "mechanism", "expected_search_terms": ["B-cell lymphoma", "anti-CD20", "rituximab resistance", "CD20 downregulation", "complement", "Fc receptor", "mechanism"]}
{"question": "In metastatic hormone receptor–positive breast cancer, how does elacestrant compare with standard endocrine therapy after progression on CDK4/6 inhibitors in progression-free survival?", "topic": "Breast cancer post-CDK4/6 endocrine options", "question_type": "efficacy_comparison", "expected_search_terms": ["HR positive breast cancer", "post CDK4/6", "elacestrant", "standard endocrine therapy", "progression-free survival"]}
{"question": "How does ESR1 mutation status predict benefit from selective estrogen receptor degraders compared with aromatase inhibitors in metastatic breast cancer?", "topic": "Breast cancer predictive biomarkers for SERDs", "question_type": "prognosis", "expected_search_terms": ["ESR1 mutation", "selective estrogen receptor degrader", "aromatase inhibitor", "metastatic breast cancer", "predictive", "benefit"]}
{"question": "In metastatic gastric cancer, how does ramucirumab plus paclitaxel compare with paclitaxel alone in overall survival and neutropenia incidence in second-line treatment?", "topic": "Gastric cancer anti-angiogenic therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["gastric cancer", "second-line", "ramucirumab", "paclitaxel", "overall survival", "neutropenia"]}
{"question": "What are the key mechanisms of taxane resistance in breast and ovarian cancers supported by clinical and preclinical evidence?", "topic": "Taxane chemotherapy resistance", "question_type": "review", "expected_search_terms": ["taxane resistance", "paclitaxel", "docetaxel", "breast cancer", "ovarian cancer", "beta-tubulin", "drug efflux"]}
{"question": "In advanced non-small cell lung cancer, how does concurrent versus sequential administration of immunotherapy with chemoradiation affect pneumonitis risk?", "topic": "NSCLC chemoradiation and immunotherapy safety", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "chemoradiation", "immunotherapy", "concurrent", "sequential", "pneumonitis", "toxicity"]}
{"question": "What is the incidence of secondary malignancies after alkylating agent chemotherapy in long-term cancer survivors based on cohort studies?", "topic": "Late effects of chemotherapy", "question_type": "epidemiology", "expected_search_terms": ["alkylating agents", "secondary malignancy", "therapy-related", "long-term survivors", "cohort", "incidence"]}
{"question": "In chronic myeloid leukemia, how does switching to a second-generation tyrosine kinase inhibitor compare with dose escalation of first-generation therapy for achieving deep molecular response?", "topic": "CML optimization strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["CML", "second-generation TKI", "dose escalation", "first-generation", "deep molecular response", "BCR-ABL"]}
{"question": "What BCR-ABL kinase domain mutations are most strongly associated with tyrosine kinase inhibitor resistance in chronic myeloid leukemia?", "topic": "CML resistance biomarkers", "question_type": "mechanism", "expected_search_terms": ["BCR-ABL", "kinase domain mutation", "TKI resistance", "chronic myeloid leukemia", "T315I", "mutation spectrum"]}
{"question": "In metastatic non-small cell lung cancer, how does MET exon 14 skipping targeted therapy compare with platinum chemotherapy in previously untreated patients for response rate?", "topic": "NSCLC MET targeted therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "MET exon 14 skipping", "targeted therapy", "platinum chemotherapy", "first-line", "response rate"]}
{"question": "What are the most common resistance mechanisms to MET inhibitors in MET-altered lung cancer based on clinical sequencing at progression?", "topic": "NSCLC MET resistance", "question_type": "mechanism", "expected_search_terms": ["MET inhibitor", "lung cancer", "resistance", "clinical sequencing", "secondary mutation", "bypass signaling"]}
{"question": "In RET fusion-positive non-small cell lung cancer, how does selective RET inhibition compare with multikinase inhibitor therapy in objective response rate and discontinuation due to toxicity?", "topic": "NSCLC RET targeted therapy comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["RET fusion", "NSCLC", "selective RET inhibitor", "multikinase inhibitor", "objective response rate", "toxicity", "discontinuation"]}
{"question": "In NTRK fusion-positive solid tumors, what is the durability of response to TRK inhibitors across different tumor histologies in pooled clinical reports?", "topic": "Tumor-agnostic TRK inhibition outcomes", "question_type": "review", "expected_search_terms": ["NTRK fusion", "TRK inhibitor", "solid tumors", "tumor agnostic", "durability of response", "histology"]}
{"question": "In metastatic non-small cell lung cancer, how does trastuzumab deruxtecan compare with standard chemotherapy for HER2-mutant disease in response rate and interstitial lung disease risk?", "topic": "NSCLC HER2-targeted ADC", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "HER2 mutant", "trastuzumab deruxtecan", "chemotherapy", "response rate", "interstitial lung disease"]}
{"question": "What are the hypothesized mechanisms and risk factors for antibody–drug conjugate–associated interstitial lung disease across cancers?", "topic": "ADC pulmonary toxicity mechanisms", "question_type": "review", "expected_search_terms": ["antibody-drug conjugate", "interstitial lung disease", "pneumonitis", "risk factors", "mechanism", "toxicity"]}
{"question": "In metastatic colorectal cancer, how does HER2-targeted therapy compare with standard chemotherapy in HER2-amplified, RAS wild-type tumors in terms of response rate?", "topic": "Colorectal cancer HER2 targeted therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic colorectal cancer", "HER2 amplified", "RAS wild-type", "HER2 targeted therapy", "chemotherapy", "response rate"]}
{"question": "What is the prognostic significance of HER2 amplification in colorectal cancer for survival outcomes independent of treatment?", "topic": "Colorectal cancer prognostic biomarkers", "question_type": "prognosis", "expected_search_terms": ["colorectal cancer", "HER2 amplification", "prognostic", "survival", "overall survival", "cohort"]}
{"question": "In metastatic breast cancer, how does the efficacy of checkpoint inhibitors differ between PD-L1-positive and PD-L1-negative triple-negative disease in terms of overall survival?", "topic": "TNBC immunotherapy biomarker effect", "question_type": "efficacy_comparison", "expected_search_terms": ["triple-negative breast cancer", "PD-L1 positive", "PD-L1 negative", "checkpoint inhibitor", "overall survival"]}
{"question": "What are the most reproducible assays and cutoffs for PD-L1 testing that correlate with benefit from immunotherapy in solid tumors?", "topic": "PD-L1 assay harmonization", "question_type": "review", "expected_search_terms": ["PD-L1 testing", "assay", "cutoff", "immunotherapy", "solid tumors", "IHC", "harmonization"]}
{"question": "In advanced non-small cell lung cancer, how does first-line chemoimmunotherapy compare with immunotherapy alone in patients with intermediate PD-L1 expression for overall survival?", "topic": "NSCLC first-line regimen selection by PD-L1", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "intermediate PD-L1", "chemoimmunotherapy", "immunotherapy alone", "first-line", "overall survival"]}
{"question": "What mechanisms explain resistance to platinum chemotherapy in high-grade serous ovarian cancer, focusing on DNA repair restoration and drug uptake changes?", "topic": "Ovarian cancer platinum resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["high-grade serous ovarian cancer", "platinum resistance", "DNA repair restoration", "BRCA reversion", "drug uptake", "CTR1"]}
{"question": "In metastatic colorectal cancer, how does primary tumor sidedness influence benefit from anti-EGFR therapy in RAS wild-type disease?", "topic": "Colorectal cancer predictive clinical factors", "question_type": "prognosis", "expected_search_terms": ["colorectal cancer", "tumor sidedness", "left-sided", "right-sided", "anti-EGFR", "RAS wild-type", "benefit"]}
{"question": "What is the incidence of immune-related endocrinopathies (thyroiditis, hypophysitis, diabetes) with checkpoint inhibitors across cancer populations?", "topic": "Immunotherapy toxicity epidemiology", "question_type": "epidemiology", "expected_search_terms": ["immune-related adverse events", "endocrinopathy", "thyroiditis", "hypophysitis", "diabetes", "checkpoint inhibitor", "incidence"]}
{"question": "In immune checkpoint inhibitor therapy, how does baseline neutrophil-to-lymphocyte ratio predict overall survival across solid tumors?", "topic": "Systemic inflammation biomarkers in immunotherapy", "question_type": "prognosis", "expected_search_terms": ["neutrophil to lymphocyte ratio", "checkpoint inhibitor", "overall survival", "solid tumors", "prognostic biomarker"]}
{"question": "In metastatic melanoma, how does the presence of liver metastases affect response rates to immune checkpoint inhibitors compared with patients without liver metastases?", "topic": "Metastatic site impact on immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["melanoma", "liver metastases", "checkpoint inhibitor", "response rate", "prognosis", "metastatic site"]}
{"question": "What is the evidence that radiotherapy can induce abscopal effects when combined with immune checkpoint inhibitors in metastatic cancers?", "topic": "Radiotherapy-immunotherapy synergy", "question_type": "review", "expected_search_terms": ["abscopal effect", "radiotherapy", "checkpoint inhibitor", "metastatic cancer", "clinical evidence", "case series"]}
{"question": "In metastatic non-small cell lung cancer, how does continuing immunotherapy beyond radiographic progression compare with switching therapy in overall survival among selected patients?", "topic": "NSCLC immunotherapy beyond progression", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "immunotherapy beyond progression", "treatment beyond progression", "switch therapy", "overall survival", "selected patients"]}
{"question": "In metastatic breast cancer, what is the incidence of cardiomyopathy with HER2-targeted therapies, and how does it vary by agent class (antibody vs TKI)?", "topic": "HER2 therapy cardiotoxicity epidemiology", "question_type": "epidemiology", "expected_search_terms": ["HER2 targeted therapy", "cardiomyopathy", "incidence", "trastuzumab", "HER2 TKI", "cardiotoxicity"]}
{"question": "What are the proposed molecular mechanisms of anthracycline-induced cardiotoxicity, and how do they relate to strategies for cardioprotection?", "topic": "Chemotherapy toxicity mechanisms", "question_type": "review", "expected_search_terms": ["anthracycline", "cardiotoxicity", "mechanism", "topoisomerase II beta", "oxidative stress", "dexrazoxane", "cardioprotection"]}
{"question": "In metastatic colorectal cancer, how does adding irinotecan to fluoropyrimidine-based therapy compare with fluoropyrimidine alone in response rate and diarrhea risk?", "topic": "Colorectal cancer chemotherapy intensification", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic colorectal cancer", "irinotecan", "fluoropyrimidine", "response rate", "diarrhea", "chemotherapy"]}
{"question": "How does UGT1A1 genotype influence irinotecan toxicity and dose optimization in gastrointestinal cancers?", "topic": "Pharmacogenomics of chemotherapy", "question_type": "prognosis", "expected_search_terms": ["UGT1A1", "irinotecan", "toxicity", "dose", "neutropenia", "diarrhea", "pharmacogenomics"]}
{"question": "In metastatic non-small cell lung cancer, how does HER3-targeted antibody–drug conjugate therapy compare with docetaxel in previously treated EGFR-mutant disease for response rate?", "topic": "NSCLC HER3 ADC after EGFR therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "EGFR mutant", "HER3", "antibody-drug conjugate", "docetaxel", "previously treated", "response rate"]}
{"question": "What mechanisms are proposed for lineage plasticity and small-cell transformation as resistance pathways in EGFR-mutant lung cancer treated with EGFR inhibitors?", "topic": "NSCLC EGFR resistance via transformation", "question_type": "mechanism", "expected_search_terms": ["EGFR mutant", "lung cancer", "small cell transformation", "lineage plasticity", "resistance", "EGFR inhibitor", "NE differentiation"]}
{"question": "In melanoma and lung cancer, how does baseline lactate dehydrogenase level predict outcomes with immune checkpoint inhibitors?", "topic": "Prognostic lab biomarkers in immunotherapy", "question_type": "prognosis", "expected_search_terms": ["lactate dehydrogenase", "LDH", "melanoma", "lung cancer", "checkpoint inhibitor", "prognosis", "overall survival"]}
{"question": "What is the incidence of chemotherapy-induced peripheral neuropathy with oxaliplatin versus paclitaxel across clinical studies, and what patient factors modify risk?", "topic": "Chemotherapy neuropathy epidemiology", "question_type": "epidemiology", "expected_search_terms": ["chemotherapy-induced peripheral neuropathy", "oxaliplatin", "paclitaxel", "incidence", "risk factors", "patient factors"]}
{"question": "In colorectal cancer, what are the clinical outcomes of rechallenging anti-EGFR therapy after an anti-EGFR-free interval guided by circulating tumor DNA?", "topic": "Colorectal cancer ctDNA-guided rechallenge", "question_type": "efficacy_comparison", "expected_search_terms": ["colorectal cancer", "anti-EGFR rechallenge", "ctDNA", "RAS", "EGFR-free interval", "clinical outcomes", "response"]}
{"question": "How does clonal evolution detected by serial circulating tumor DNA testing explain acquired resistance to targeted therapy in metastatic cancers?", "topic": "Evolutionary mechanisms of resistance", "question_type": "mechanism", "expected_search_terms": ["clonal evolution", "serial ctDNA", "acquired resistance", "targeted therapy", "metastatic cancer", "tumor heterogeneity"]}
{"question": "In advanced non-small cell lung cancer, how does immunotherapy re-challenge after prior immune-related adverse events compare with discontinuation in terms of recurrence of toxicity?", "topic": "Immunotherapy rechallenge safety", "question_type": "epidemiology", "expected_search_terms": ["immunotherapy rechallenge", "immune-related adverse event", "recurrence", "checkpoint inhibitor", "safety", "toxicity"]}
{"question": "What is the comparative effectiveness of prophylactic granulocyte colony-stimulating factor with dose-dense chemotherapy versus standard scheduling in early breast cancer for febrile neutropenia prevention?", "topic": "Supportive care with intensive chemotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["early breast cancer", "dose-dense chemotherapy", "G-CSF prophylaxis", "febrile neutropenia", "standard schedule", "prevention"]}
{"question": "What is the impact of dose intensity reductions due to toxicity on survival outcomes in curative-intent chemotherapy for lymphoma?", "topic": "Chemotherapy dose intensity and outcomes", "question_type": "prognosis", "expected_search_terms": ["lymphoma", "chemotherapy dose intensity", "dose reduction", "toxicity", "survival outcomes", "curative intent"]}
{"question": "In metastatic colorectal cancer, how does adding bevacizumab to first-line chemotherapy compare with chemotherapy alone in overall survival across different age groups?", "topic": "Colorectal cancer anti-VEGF benefit by age", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic colorectal cancer", "bevacizumab", "first-line", "chemotherapy", "overall survival", "age groups", "elderly"]}
{"question": "In older adults with cancer, what is the epidemiology of severe chemotherapy toxicity predicted by geriatric assessment tools?", "topic": "Geriatric oncology chemotherapy toxicity prediction", "question_type": "epidemiology", "expected_search_terms": ["older adults", "chemotherapy toxicity", "geriatric assessment", "prediction", "incidence", "CARG", "CRASH"]}
{"question": "In metastatic non-small cell lung cancer with brain metastases, how does adding stereotactic radiosurgery to checkpoint inhibitor therapy compare with checkpoint inhibitor therapy alone in intracranial control?", "topic": "NSCLC brain metastases combined therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "brain metastases", "stereotactic radiosurgery", "checkpoint inhibitor", "intracranial control", "combination"]}
{"question": "What is the evidence that the gut microbiome modulates immune-related colitis risk during checkpoint inhibitor therapy?", "topic": "Microbiome and immunotherapy toxicity", "question_type": "mechanism", "expected_search_terms": ["gut microbiome", "immune-related colitis", "checkpoint inhibitor", "risk", "mechanism", "toxicity", "bacterial taxa"]}
{"question": "In metastatic breast cancer, how does trastuzumab emtansine compare with trastuzumab deruxtecan in progression-free survival and interstitial lung disease incidence after prior HER2 therapy?", "topic": "HER2 ADC comparative outcomes", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic HER2 positive breast cancer", "trastuzumab emtansine", "trastuzumab deruxtecan", "progression-free survival", "interstitial lung disease"]}
{"question": "What mechanisms drive resistance to platinum-based chemotherapy in non-small cell lung cancer, focusing on DNA repair and apoptotic pathway alterations?", "topic": "NSCLC platinum resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["NSCLC", "platinum resistance", "DNA repair", "ERCC1", "apoptosis", "TP53", "mechanism"]}
{"question": "In metastatic melanoma, what is the epidemiology of long-term survivors treated with checkpoint inhibitors, including the proportion achieving treatment-free survival?", "topic": "Melanoma immunotherapy long-term outcomes", "question_type": "epidemiology", "expected_search_terms": ["melanoma", "checkpoint inhibitor", "long-term survivors", "treatment-free survival", "real-world", "proportion"]}
{"question": "In solid tumors, how does combining anti-PD-1 therapy with CTLA-4 blockade alter peripheral T-cell repertoire dynamics compared with anti-PD-1 alone?", "topic": "Immunotherapy mechanism (T-cell repertoire)", "question_type": "mechanism", "expected_search_terms": ["PD-1", "CTLA-4", "combination", "T-cell repertoire", "TCR sequencing", "peripheral blood", "mechanism"]}
{"question": "In metastatic colorectal cancer, how does the presence of liver metastases influence efficacy of immunotherapy in MSI-H disease compared with non-liver metastatic sites?", "topic": "Site-specific immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["MSI-H colorectal cancer", "immunotherapy", "liver metastases", "response", "outcomes", "metastatic site"]}
{"question": "What is the clinical evidence for targeting TIGIT in combination with PD-1/PD-L1 inhibition in solid tumors, focusing on response rate signals and safety?", "topic": "Next-generation checkpoint combinations", "question_type": "review", "expected_search_terms": ["TIGIT", "PD-1", "PD-L1", "combination immunotherapy", "solid tumor", "response rate", "safety"]}
{"question": "In small cell lung cancer, how does adding PD-L1 inhibition to platinum-etoposide compare with chemotherapy alone for overall survival in extensive-stage disease?", "topic": "SCLC chemo-immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["small cell lung cancer", "extensive-stage", "PD-L1 inhibitor", "platinum etoposide", "overall survival"]}
{"question": "What mechanisms of chemotherapy resistance in small cell lung cancer are supported by studies on neuroendocrine plasticity and DNA damage response pathways?", "topic": "SCLC resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["small cell lung cancer", "chemoresistance", "neuroendocrine plasticity", "DNA damage response", "SLFN11", "PARP", "mechanism"]}
{"question": "In sickle cell disease, how does CRISPR-Cas9 disruption of the BCL11A erythroid enhancer compare with lentiviral beta-globin gene addition in achieving transfusion independence and reducing vaso-occlusive crises?", "topic": "CRISPR vs gene addition therapies", "question_type": "efficacy_comparison", "expected_search_terms": ["sickle cell", "CRISPR", "BCL11A enhancer", "lentiviral", "gene addition", "transfusion independence", "vaso-occlusive"]}
{"question": "In transfusion-dependent beta-thalassemia, what is the durability of hemoglobin response after ex vivo CRISPR editing of hematopoietic stem cells targeting BCL11A compared with lentiviral beta-globin gene therapy?", "topic": "HSC gene therapy durability", "question_type": "prognosis", "expected_search_terms": ["beta thalassemia", "CRISPR", "BCL11A", "hematopoietic stem cell", "lentiviral", "durability", "hemoglobin"]}
{"question": "What mechanisms explain fetal hemoglobin induction following CRISPR-mediated editing of the BCL11A erythroid enhancer in human erythroid cells?", "topic": "Gene regulation mechanisms in editing", "question_type": "mechanism", "expected_search_terms": ["BCL11A enhancer", "CRISPR", "fetal hemoglobin", "erythroid", "mechanism", "globin regulation"]}
{"question": "In in vivo liver-directed gene editing, how do lipid nanoparticle-delivered Cas9 mRNA systems compare with AAV-delivered Cas9 systems for editing efficiency and hepatic toxicity in preclinical models?", "topic": "In vivo CRISPR delivery", "question_type": "efficacy_comparison", "expected_search_terms": ["in vivo gene editing", "liver", "lipid nanoparticle", "AAV", "Cas9 mRNA", "editing efficiency", "hepatotoxicity"]}
{"question": "What is the incidence and nature of immune responses to Cas9 (humoral and cellular) observed in animal models and early human studies of CRISPR-based therapies?", "topic": "Immunogenicity of CRISPR components", "question_type": "epidemiology", "expected_search_terms": ["Cas9", "immunogenicity", "T cell response", "antibodies", "CRISPR therapy", "human", "animal model"]}
{"question": "How do base editors compare with nuclease-based CRISPR-Cas9 for off-target mutagenesis profiles in therapeutically relevant human cell types?", "topic": "Genome editing precision", "question_type": "efficacy_comparison", "expected_search_terms": ["base editor", "CRISPR-Cas9 nuclease", "off-target", "human cells", "genome-wide", "mutagenesis"]}
{"question": "What mechanisms drive bystander edits and unwanted deaminations in cytosine and adenine base editing, and what mitigation strategies are supported by the literature?", "topic": "Base editing mechanisms", "question_type": "mechanism", "expected_search_terms": ["cytosine base editor", "adenine base editor", "bystander editing", "deamination", "mitigation", "mechanism"]}
{"question": "In inherited retinal diseases, how does subretinal AAV gene augmentation compare with CRISPR-based in vivo editing approaches regarding visual function outcomes and ocular adverse events?", "topic": "Ocular gene therapy vs editing", "question_type": "efficacy_comparison", "expected_search_terms": ["inherited retinal disease", "AAV gene therapy", "subretinal", "CRISPR", "in vivo editing", "visual acuity", "ocular adverse events"]}
{"question": "What is known about long-term persistence and integration risk of AAV vectors in hepatocytes after systemic gene therapy for hemophilia?", "topic": "AAV safety and persistence", "question_type": "prognosis", "expected_search_terms": ["hemophilia", "AAV", "vector persistence", "integration", "hepatocyte", "long-term follow-up", "safety"]}
{"question": "In hemophilia A, how do outcomes and safety compare between AAV-mediated factor VIII gene transfer and non-viral gene-editing strategies aimed at restoring factor VIII expression?", "topic": "Hemophilia gene therapy strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["hemophilia A", "AAV", "factor VIII gene transfer", "gene editing", "non-viral", "efficacy", "safety"]}
{"question": "What mechanisms underlie loss of transgene expression after AAV liver gene therapy (such as immune-mediated clearance or epigenetic silencing), and how often are they reported clinically?", "topic": "Transgene expression durability", "question_type": "mechanism", "expected_search_terms": ["AAV gene therapy", "loss of expression", "immune clearance", "epigenetic silencing", "liver", "clinical"]}
{"question": "In spinal muscular atrophy, how does systemic AAV gene replacement compare with intrathecal antisense therapy regarding motor outcomes and serious adverse events in real-world cohorts?", "topic": "Gene therapy vs RNA therapy outcomes", "question_type": "efficacy_comparison", "expected_search_terms": ["spinal muscular atrophy", "AAV gene therapy", "gene replacement", "intrathecal", "antisense", "motor function", "real-world"]}
{"question": "What prognostic factors predict sustained motor improvement after AAV-based gene therapy for spinal muscular atrophy (such as age at treatment or baseline motor score)?", "topic": "Prognostic factors in gene replacement", "question_type": "prognosis", "expected_search_terms": ["spinal muscular atrophy", "AAV gene therapy", "prognostic factors", "age", "baseline motor", "durability"]}
{"question": "How do different AAV serotypes influence biodistribution and transduction efficiency in skeletal muscle for Duchenne muscular dystrophy gene therapy approaches?", "topic": "Vector tropism in muscle gene therapy", "question_type": "mechanism", "expected_search_terms": ["Duchenne muscular dystrophy", "AAV serotype", "biodistribution", "skeletal muscle", "transduction efficiency"]}
{"question": "In Duchenne muscular dystrophy, how does micro-dystrophin AAV gene therapy compare with exon-skipping approaches in improving functional outcomes and muscle pathology markers?", "topic": "DMD therapeutic comparisons", "question_type": "efficacy_comparison", "expected_search_terms": ["Duchenne", "micro-dystrophin", "AAV", "exon skipping", "functional outcomes", "muscle pathology"]}
{"question": "What is the reported frequency and clinical significance of complement activation after systemic AAV gene therapy across different indications?", "topic": "Systemic AAV adverse events", "question_type": "epidemiology", "expected_search_terms": ["AAV", "complement activation", "systemic gene therapy", "adverse events", "incidence", "clinical significance"]}
{"question": "What mechanisms contribute to thrombotic microangiopathy observed after AAV gene therapy, and what preventive or management approaches are supported in the literature?", "topic": "AAV-associated toxicities", "question_type": "mechanism", "expected_search_terms": ["AAV gene therapy", "thrombotic microangiopathy", "mechanism", "complement", "management", "steroids"]}
{"question": "How does pre-existing anti-AAV neutralizing antibody prevalence vary by age and geography, and how does it affect eligibility for systemic AAV gene therapy trials?", "topic": "Seroprevalence and trial eligibility", "question_type": "epidemiology", "expected_search_terms": ["anti-AAV antibodies", "neutralizing antibodies", "seroprevalence", "age", "geography", "eligibility", "gene therapy"]}
{"question": "In transthyretin amyloidosis, how does in vivo CRISPR-based TTR gene knockout compare with RNA interference therapies in lowering serum TTR and improving neuropathy outcomes?", "topic": "Gene editing vs gene silencing", "question_type": "efficacy_comparison", "expected_search_terms": ["transthyretin amyloidosis", "CRISPR", "TTR knockout", "RNA interference", "serum TTR", "neuropathy"]}
{"question": "What are the known mechanisms and frequency of off-target edits detected by unbiased genome-wide assays in CRISPR-edited hematopoietic stem cell products intended for clinical use?", "topic": "Off-target assessment in HSC editing", "question_type": "review", "expected_search_terms": ["CRISPR", "hematopoietic stem cell", "off-target", "GUIDE-seq", "CIRCLE-seq", "DISCOVER-seq", "clinical product"]}
{"question": "How do prime editors compare with base editors for correcting single-nucleotide pathogenic variants in human cells in terms of editing efficiency and indel formation?", "topic": "Prime vs base editing performance", "question_type": "efficacy_comparison", "expected_search_terms": ["prime editing", "base editing", "single nucleotide variant", "editing efficiency", "indels", "human cells"]}
{"question": "What mechanisms limit prime editing efficiency in primary human cells, and what delivery or design optimizations are most supported by published studies?", "topic": "Prime editing mechanisms and optimization", "question_type": "mechanism", "expected_search_terms": ["prime editing", "primary human cells", "pegRNA", "efficiency", "optimization", "delivery"]}
{"question": "In CAR-T cell manufacturing, how does CRISPR-mediated TCR knockout compare with TALEN-mediated TCR knockout regarding graft-versus-host risk and antitumor activity in allogeneic products?", "topic": "Allogeneic CAR-T genome editing", "question_type": "efficacy_comparison", "expected_search_terms": ["allogeneic CAR-T", "CRISPR", "TALEN", "TCR knockout", "graft versus host", "antitumor activity"]}
{"question": "What is the reported incidence of chromosomal translocations in multiplex CRISPR editing of T cells, and which assay methods are commonly used to detect them?", "topic": "Genome integrity in edited cell therapies", "question_type": "epidemiology", "expected_search_terms": ["multiplex CRISPR", "T cells", "chromosomal translocation", "genomic rearrangement", "detection assay", "CAST-seq"]}
{"question": "What mechanisms lead to p53 pathway activation after CRISPR-induced double-strand breaks in human stem cells, and how might this affect clonal selection?", "topic": "DNA damage response to editing", "question_type": "mechanism", "expected_search_terms": ["CRISPR", "double-strand break", "p53 activation", "stem cells", "clonal selection", "DNA damage response"]}
{"question": "In autologous hematopoietic stem cell gene therapy, how does busulfan conditioning intensity relate to engraftment success and toxicity across indications?", "topic": "Conditioning for HSC gene therapy", "question_type": "prognosis", "expected_search_terms": ["autologous HSC gene therapy", "busulfan conditioning", "engraftment", "toxicity", "dose intensity"]}
{"question": "How do non-genotoxic conditioning approaches (such as antibody-drug conjugates targeting stem cell niches) compare with chemotherapy conditioning for enabling HSC gene therapy engraftment?", "topic": "Innovations in conditioning regimens", "question_type": "efficacy_comparison", "expected_search_terms": ["non-genotoxic conditioning", "antibody-drug conjugate", "CD117", "HSC engraftment", "gene therapy", "chemotherapy"]}
{"question": "What is the risk of insertional oncogenesis with modern self-inactivating lentiviral vectors in hematopoietic stem cell gene therapy, based on long-term follow-up studies?", "topic": "Insertional mutagenesis risk", "question_type": "prognosis", "expected_search_terms": ["self-inactivating lentiviral vector", "HSC gene therapy", "insertional oncogenesis", "clonal expansion", "long-term follow-up"]}
{"question": "How does promoter choice in lentiviral vectors influence lineage-specific transgene expression and safety in hematopoietic stem cell gene therapy?", "topic": "Vector design and expression control", "question_type": "mechanism", "expected_search_terms": ["lentiviral vector", "promoter", "lineage-specific expression", "HSC gene therapy", "safety", "enhancer"]}
{"question": "In metachromatic leukodystrophy, how does ex vivo lentiviral gene therapy compare with allogeneic hematopoietic stem cell transplantation in slowing neurocognitive decline?", "topic": "Gene therapy vs transplant in leukodystrophy", "question_type": "efficacy_comparison", "expected_search_terms": ["metachromatic leukodystrophy", "lentiviral gene therapy", "hematopoietic stem cell transplantation", "neurocognitive", "progression"]}
{"question": "What prognostic factors are associated with better neurologic outcomes after gene therapy for metachromatic leukodystrophy (such as presymptomatic treatment or baseline imaging findings)?", "topic": "Prognosis in neurogenetic gene therapy", "question_type": "prognosis", "expected_search_terms": ["metachromatic leukodystrophy", "gene therapy", "prognostic factors", "presymptomatic", "MRI", "neurologic outcome"]}
{"question": "In adenosine deaminase deficiency severe combined immunodeficiency, how does lentiviral gene therapy compare with enzyme replacement therapy in immune reconstitution and infection rates?", "topic": "Immunodeficiency gene therapy outcomes", "question_type": "efficacy_comparison", "expected_search_terms": ["ADA-SCID", "lentiviral gene therapy", "enzyme replacement", "immune reconstitution", "infection rate"]}
{"question": "What is the incidence of autoimmunity or immune dysregulation following gene therapy for primary immunodeficiencies, based on published clinical cohorts?", "topic": "Immune adverse events after gene therapy", "question_type": "epidemiology", "expected_search_terms": ["primary immunodeficiency", "gene therapy", "autoimmunity", "immune dysregulation", "incidence", "clinical cohort"]}
{"question": "In Parkinson’s disease, how do transplanted iPSC-derived dopaminergic neurons compare with fetal ventral mesencephalon cell grafts in motor improvement and graft-induced dyskinesia risk?", "topic": "Cell therapy for neurodegeneration", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson", "iPSC-derived dopaminergic neurons", "fetal ventral mesencephalon", "transplant", "motor improvement", "dyskinesia"]}
{"question": "What mechanisms contribute to tumorigenicity risk in iPSC-derived cell therapies, and which quality control assays best predict residual pluripotent cells?", "topic": "iPSC safety mechanisms", "question_type": "mechanism", "expected_search_terms": ["iPSC", "tumorigenicity", "residual pluripotent cells", "quality control", "teratoma", "assay"]}
{"question": "In retinal pigment epithelium replacement for macular degeneration, how do iPSC-derived RPE sheets compare with cell suspensions in anatomical integration and visual outcomes?", "topic": "iPSC-RPE delivery formats", "question_type": "efficacy_comparison", "expected_search_terms": ["iPSC-derived RPE", "sheet", "cell suspension", "macular degeneration", "integration", "visual outcome"]}
{"question": "What is the reported incidence of immune rejection or need for immunosuppression in allogeneic iPSC-derived cell transplantation trials across different tissues?", "topic": "Allogeneic iPSC immunology", "question_type": "epidemiology", "expected_search_terms": ["allogeneic iPSC", "transplantation", "immune rejection", "immunosuppression", "clinical trial", "incidence"]}
{"question": "In ischemic heart disease, how do intramyocardial mesenchymal stromal cell injections compare with cardiac progenitor cell therapies in improving left ventricular ejection fraction?", "topic": "Cardiac cell therapy comparisons", "question_type": "efficacy_comparison", "expected_search_terms": ["ischemic heart disease", "mesenchymal stromal cell", "cardiac progenitor cell", "intramyocardial", "ejection fraction"]}
{"question": "What mechanisms are most supported for mesenchymal stromal cell therapeutic effects in inflammatory diseases: paracrine immunomodulation, mitochondrial transfer, or engraftment?", "topic": "MSC mechanism of action", "question_type": "review", "expected_search_terms": ["mesenchymal stromal cell", "mechanism", "paracrine", "immunomodulation", "mitochondrial transfer", "engraftment"]}
{"question": "In graft-versus-host disease, how does mesenchymal stromal cell therapy compare with standard second-line immunosuppressants in achieving durable response and survival?", "topic": "MSC therapy in GVHD", "question_type": "efficacy_comparison", "expected_search_terms": ["graft versus host disease", "mesenchymal stromal cell", "second-line therapy", "response", "survival"]}
{"question": "What prognostic biomarkers predict response to mesenchymal stromal cell therapy in acute graft-versus-host disease (such as cytokine profiles or lymphocyte subsets)?", "topic": "Biomarkers for cell therapy response", "question_type": "prognosis", "expected_search_terms": ["acute GVHD", "mesenchymal stromal cell", "biomarker", "cytokines", "lymphocyte subsets", "response prediction"]}
{"question": "In osteoarthritis, how does intra-articular MSC therapy compare with platelet-rich plasma injections in pain reduction and cartilage imaging outcomes?", "topic": "Regenerative therapies in OA", "question_type": "efficacy_comparison", "expected_search_terms": ["osteoarthritis", "mesenchymal stem cell", "intra-articular", "platelet-rich plasma", "pain", "MRI cartilage"]}
{"question": "What is the incidence of serious adverse events (including infection and neoplasia) reported in clinical trials of MSC therapy for osteoarthritis?", "topic": "Safety epidemiology of MSC therapy", "question_type": "epidemiology", "expected_search_terms": ["osteoarthritis", "mesenchymal stem cell", "clinical trial", "serious adverse event", "infection", "neoplasia"]}
{"question": "In type 1 diabetes, how do encapsulated stem-cell-derived islet cell products compare with unencapsulated transplantation approaches in glycemic control and immunosuppression requirements?", "topic": "Stem-cell derived beta cell therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["type 1 diabetes", "stem cell-derived islet", "encapsulation", "glycemic control", "immunosuppression", "C-peptide"]}
{"question": "What mechanisms drive fibrosis and foreign body response around macroencapsulation devices for cell therapy, and what materials strategies reduce this response?", "topic": "Biomaterials in cell encapsulation", "question_type": "mechanism", "expected_search_terms": ["macroencapsulation", "foreign body response", "fibrosis", "biomaterials", "cell therapy", "alginate"]}
{"question": "In cystic fibrosis, how do viral vector CFTR gene addition approaches compare with gene editing strategies aimed at correcting CFTR mutations in airway epithelial cells?", "topic": "CF gene therapy approaches", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "CFTR", "gene therapy", "viral vector", "gene editing", "airway epithelial"]}
{"question": "What are the main delivery barriers for CRISPR components to airway epithelium in vivo, and what delivery platforms show the most evidence for overcoming them?", "topic": "Pulmonary CRISPR delivery", "question_type": "review", "expected_search_terms": ["airway", "CRISPR delivery", "mucus barrier", "aerosol", "nanoparticle", "viral vector"]}
{"question": "In hypercholesterolemia, how does in vivo base editing of PCSK9 compare with monoclonal antibody PCSK9 inhibitors in LDL reduction magnitude and durability in preclinical and early clinical data?", "topic": "Cardiometabolic gene editing", "question_type": "efficacy_comparison", "expected_search_terms": ["PCSK9", "base editing", "in vivo", "LDL reduction", "monoclonal antibody", "durability"]}
{"question": "What is known about liver toxicity and transaminase elevations after LNP-delivered gene editing therapies targeting hepatocytes, and what mechanistic explanations are proposed?", "topic": "LNP editing safety mechanisms", "question_type": "mechanism", "expected_search_terms": ["lipid nanoparticle", "gene editing", "hepatocyte", "transaminase", "toxicity", "mechanism"]}
{"question": "How does mitochondrial gene editing or allotopic expression compare with conventional supportive therapy in primary mitochondrial optic neuropathies regarding visual outcomes?", "topic": "Mitochondrial gene therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["mitochondrial", "optic neuropathy", "gene therapy", "allotopic expression", "gene editing", "visual outcome"]}
{"question": "What mechanisms limit the feasibility of CRISPR-based editing of mitochondrial DNA in human cells, and what alternative strategies are most supported?", "topic": "Mitochondrial genome engineering", "question_type": "mechanism", "expected_search_terms": ["mitochondrial DNA", "CRISPR limitation", "mitochondria editing", "DdCBE", "TALE", "mechanism"]}
{"question": "In glioblastoma, how do locally delivered oncolytic viral gene therapies compare with CAR-T or CAR-NK cell therapies in response rates and neurotoxicity profiles?", "topic": "Gene and cell therapy in neuro-oncology", "question_type": "efficacy_comparison", "expected_search_terms": ["glioblastoma", "oncolytic virus", "gene therapy", "CAR-T", "CAR-NK", "response rate", "neurotoxicity"]}
{"question": "What mechanisms drive antigen escape after CAR-T therapy, and how do gene editing strategies (such as dual targeting) mitigate relapse in hematologic malignancies?", "topic": "Resistance mechanisms in engineered cell therapy", "question_type": "mechanism", "expected_search_terms": ["CAR-T", "antigen escape", "relapse", "dual targeting", "gene editing", "hematologic malignancy"]}
{"question": "In relapsed/refractory B-cell acute lymphoblastic leukemia, how does allogeneic gene-edited CAR-T compare with autologous CAR-T in efficacy and graft-versus-host disease risk?", "topic": "Allogeneic vs autologous CAR-T", "question_type": "efficacy_comparison", "expected_search_terms": ["B-ALL", "allogeneic CAR-T", "gene-edited", "autologous CAR-T", "efficacy", "GVHD"]}
{"question": "What is the incidence of prolonged cytopenias after CAR-T therapy, and what prognostic factors predict persistence of cytopenia?", "topic": "Adverse events in engineered T-cell therapy", "question_type": "prognosis", "expected_search_terms": ["CAR-T", "prolonged cytopenia", "incidence", "risk factors", "prognostic", "bone marrow"]}
{"question": "How do gene-edited CAR-NK cell therapies compare with CAR-T cell therapies in cytokine release syndrome frequency and tumor response in early-phase studies?", "topic": "CAR-NK vs CAR-T safety/efficacy", "question_type": "efficacy_comparison", "expected_search_terms": ["CAR-NK", "CAR-T", "cytokine release syndrome", "tumor response", "early phase", "gene edited"]}
{"question": "What mechanisms explain lower graft-versus-host disease risk with NK cell therapies compared with T cell therapies, and how does gene editing influence this profile?", "topic": "Mechanisms of NK cell therapy safety", "question_type": "mechanism", "expected_search_terms": ["NK cells", "graft versus host disease", "mechanism", "gene editing", "HLA", "TCR"]}
{"question": "In hepatocellular carcinoma, how does CRISPR-based screening identify essential genes for tumor survival, and which pathways are most reproducibly implicated across studies?", "topic": "CRISPR functional genomics in cancer", "question_type": "review", "expected_search_terms": ["hepatocellular carcinoma", "CRISPR screen", "essential genes", "pathways", "dependency"]}
{"question": "How do CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) compare with nuclease CRISPR knockout for identifying drug resistance mechanisms in cancer cell lines?", "topic": "CRISPR screening modalities", "question_type": "efficacy_comparison", "expected_search_terms": ["CRISPRi", "CRISPRa", "CRISPR knockout", "drug resistance", "screen", "cancer cell line"]}
{"question": "What is the frequency and clinical relevance of vector shedding in bodily fluids after AAV gene therapy, and what monitoring practices are reported?", "topic": "Biosafety and shedding in gene therapy", "question_type": "epidemiology", "expected_search_terms": ["AAV", "vector shedding", "bodily fluids", "monitoring", "biosafety", "clinical"]}
{"question": "In lysosomal storage disorders, how does CNS-directed AAV gene therapy compare with systemic enzyme replacement in neurologic outcomes and quality of life?", "topic": "Neuro-lysosomal gene therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["lysosomal storage disorder", "CNS-directed", "AAV", "enzyme replacement therapy", "neurologic outcome", "quality of life"]}
{"question": "What mechanisms limit blood-brain barrier crossing for systemic gene therapy vectors, and which engineered capsids show improved CNS delivery evidence?", "topic": "CNS delivery mechanisms", "question_type": "review", "expected_search_terms": ["blood-brain barrier", "AAV capsid engineering", "CNS delivery", "systemic administration", "tropism"]}
{"question": "In aromatic L-amino acid decarboxylase deficiency, how does intraputaminal AAV gene therapy compare with standard dopaminergic medications in motor outcomes and adverse events?", "topic": "CNS gene therapy efficacy", "question_type": "efficacy_comparison", "expected_search_terms": ["AADC deficiency", "intraputaminal", "AAV gene therapy", "dopaminergic medication", "motor outcome", "adverse events"]}
{"question": "What prognostic indicators (such as age at treatment or baseline motor severity) are associated with response to CNS-targeted AAV gene therapy in pediatric neurogenetic disorders?", "topic": "Prognosis in pediatric CNS gene therapy", "question_type": "prognosis", "expected_search_terms": ["pediatric", "CNS gene therapy", "AAV", "prognostic", "age", "baseline severity", "neurogenetic"]}
{"question": "How does ex vivo CRISPR correction of IL2RG compare with lentiviral gene addition for X-linked SCID in terms of immune reconstitution and genotoxicity risk?", "topic": "Genome editing in immunodeficiency", "question_type": "efficacy_comparison", "expected_search_terms": ["X-linked SCID", "IL2RG", "CRISPR correction", "lentiviral gene addition", "immune reconstitution", "genotoxicity"]}
{"question": "What mechanisms drive large deletions and complex genomic rearrangements at CRISPR cut sites, and which detection methods are most sensitive for clinical product release testing?", "topic": "Genome integrity and QC", "question_type": "mechanism", "expected_search_terms": ["CRISPR", "large deletions", "genomic rearrangements", "cut site", "detection method", "long-read sequencing"]}
{"question": "In alpha-1 antitrypsin deficiency, how do gene augmentation approaches compare with gene editing strategies for restoring functional protein and reducing liver pathology in models?", "topic": "Liver genetic disease interventions", "question_type": "efficacy_comparison", "expected_search_terms": ["alpha-1 antitrypsin deficiency", "gene augmentation", "gene editing", "liver pathology", "functional protein", "model"]}
{"question": "What are the main mechanisms of hepatocyte injury in alpha-1 antitrypsin deficiency, and how do gene editing approaches aim to address toxic gain-of-function effects?", "topic": "Disease mechanism targeted by editing", "question_type": "mechanism", "expected_search_terms": ["alpha-1 antitrypsin", "hepatocyte injury", "toxic gain of function", "polymerization", "gene editing", "mechanism"]}
{"question": "In inherited hearing loss, how does inner ear AAV gene therapy compare with CRISPR-based allele-specific inactivation strategies in restoring auditory function in animal models?", "topic": "Sensory gene therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["inherited hearing loss", "inner ear", "AAV gene therapy", "CRISPR", "allele-specific", "auditory function"]}
{"question": "What delivery routes and vector designs are most effective for targeting cochlear hair cells with gene therapy while minimizing vestibular toxicity?", "topic": "Inner ear delivery optimization", "question_type": "review", "expected_search_terms": ["cochlear hair cells", "gene therapy", "delivery route", "vector design", "vestibular toxicity", "AAV"]}
{"question": "In epidermolysis bullosa, how does ex vivo genetically corrected epidermal stem cell grafting compare with conventional wound care in long-term skin integrity and infection rates?", "topic": "Ex vivo corrected stem cell grafts", "question_type": "efficacy_comparison", "expected_search_terms": ["epidermolysis bullosa", "epidermal stem cells", "ex vivo gene correction", "grafting", "skin integrity", "infection"]}
{"question": "What prognostic factors predict successful long-term engraftment of genetically corrected keratinocyte stem cells in skin gene therapy?", "topic": "Engraftment prognosis in skin gene therapy", "question_type": "prognosis", "expected_search_terms": ["skin gene therapy", "keratinocyte stem cell", "engraftment", "prognostic factor", "long-term", "epidermis"]}
{"question": "In HIV cure research, how does CRISPR-mediated excision or inactivation of proviral DNA compare with gene editing of host co-receptors (such as CCR5) for reducing viral rebound in model systems?", "topic": "Gene editing for HIV", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "CRISPR", "proviral excision", "CCR5 editing", "viral rebound", "model system"]}
{"question": "What mechanisms limit delivery of gene editors to latent HIV reservoirs, and which vector or nanoparticle strategies show the strongest evidence for reservoir targeting?", "topic": "Targeting latent reservoirs", "question_type": "review", "expected_search_terms": ["latent HIV reservoir", "gene editor delivery", "AAV", "nanoparticle", "targeting", "T cells", "macrophage"]}
{"question": "In hereditary angioedema, how does gene silencing or editing of kallikrein pathway genes compare with C1 inhibitor replacement in preventing attacks?", "topic": "Gene-based therapy in rare disease", "question_type": "efficacy_comparison", "expected_search_terms": ["hereditary angioedema", "kallikrein", "gene silencing", "gene editing", "C1 inhibitor", "attack prevention"]}
{"question": "What is the incidence of neutralizing antibodies against therapeutic proteins after liver-directed gene therapy, and how does it vary by disease and transgene type?", "topic": "Immunogenicity of expressed transgenes", "question_type": "epidemiology", "expected_search_terms": ["liver-directed gene therapy", "neutralizing antibodies", "therapeutic protein", "incidence", "transgene", "hemophilia"]}
{"question": "How does codon optimization and transgene cassette design influence protein expression levels and immune recognition in AAV gene therapy?", "topic": "Transgene design considerations", "question_type": "mechanism", "expected_search_terms": ["codon optimization", "transgene cassette", "AAV", "expression level", "immune recognition", "CpG"]}
{"question": "In Pompe disease, how does AAV-mediated gene therapy compare with enzyme replacement therapy in skeletal muscle strength and respiratory outcomes in clinical or advanced preclinical studies?", "topic": "Gene therapy for metabolic myopathy", "question_type": "efficacy_comparison", "expected_search_terms": ["Pompe disease", "AAV gene therapy", "enzyme replacement therapy", "muscle strength", "respiratory function"]}
{"question": "What mechanisms explain variable skeletal muscle transduction in systemic AAV therapy, including effects of muscle fiber type, vascular delivery, and capsid choice?", "topic": "Muscle transduction mechanisms", "question_type": "mechanism", "expected_search_terms": ["skeletal muscle", "AAV transduction", "fiber type", "vascular delivery", "capsid", "mechanism"]}
{"question": "In liver-directed AAV gene therapy, how do prophylactic steroids compare with reactive steroid use for preventing transaminase elevations and preserving transgene expression?", "topic": "Management strategies in gene therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["AAV", "liver-directed", "prophylactic steroids", "transaminase elevation", "transgene expression", "immune response"]}
{"question": "What is the long-term prognosis of patients receiving AAV gene therapy in terms of re-dosing feasibility, and what strategies are supported for overcoming anti-capsid immunity?", "topic": "Re-dosing and immune barriers", "question_type": "prognosis", "expected_search_terms": ["AAV gene therapy", "re-dosing", "anti-capsid immunity", "plasmapheresis", "IgG degradation", "immunosuppression"]}
{"question": "How do CRISPR-Cas12 and CRISPR-Cas9 systems compare for therapeutic genome editing regarding PAM constraints, specificity, and delivery size limitations?", "topic": "Editor platform comparisons", "question_type": "efficacy_comparison", "expected_search_terms": ["Cas12", "Cas9", "therapeutic genome editing", "PAM", "specificity", "delivery size"]}
{"question": "What mechanisms account for collateral cleavage activity in some CRISPR systems, and why is this relevant for therapeutic safety?", "topic": "CRISPR system biochemistry and safety", "question_type": "mechanism", "expected_search_terms": ["collateral cleavage", "Cas12", "Cas13", "CRISPR", "therapeutic safety", "mechanism"]}
{"question": "In transthyretin amyloidosis cardiomyopathy, how does gene editing-based TTR suppression compare with pharmacologic TTR stabilizers in functional endpoints and hospitalization rates?", "topic": "Cardiac amyloidosis gene therapy comparison", "question_type": "efficacy_comparison", "expected_search_terms": ["ATTR cardiomyopathy", "TTR gene editing", "TTR stabilizer", "functional endpoint", "hospitalization"]}
{"question": "What is the reported incidence of infusion reactions to lipid nanoparticle-based nucleic acid therapeutics, and how do premedication strategies affect rates?", "topic": "LNP infusion safety", "question_type": "epidemiology", "expected_search_terms": ["lipid nanoparticle", "infusion reaction", "premedication", "incidence", "nucleic acid therapeutic"]}
{"question": "How do exosomes compare with synthetic nanoparticles for delivering CRISPR ribonucleoproteins into primary cells in terms of efficiency and cytotoxicity?", "topic": "Novel delivery systems", "question_type": "efficacy_comparison", "expected_search_terms": ["exosome", "nanoparticle", "CRISPR RNP delivery", "primary cells", "efficiency", "cytotoxicity"]}
{"question": "What mechanisms govern endosomal escape for lipid nanoparticle delivery of gene editors, and which formulation changes most improve cytosolic release?", "topic": "Intracellular delivery mechanisms", "question_type": "mechanism", "expected_search_terms": ["endosomal escape", "lipid nanoparticle", "gene editor", "formulation", "ionizable lipid", "cytosolic delivery"]}
{"question": "In refractory systemic lupus erythematosus, how does autologous CAR-T cell therapy compare with conventional B-cell-depleting therapies in achieving durable remission?", "topic": "Engineered cell therapy in autoimmunity", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "CAR-T", "B cell depletion", "rituximab", "remission", "durable"]}
{"question": "What is the incidence of serious infections after CAR-T therapy used for autoimmune disease indications, based on reported cohorts?", "topic": "Safety epidemiology in autoimmune CAR-T", "question_type": "epidemiology", "expected_search_terms": ["CAR-T", "autoimmune disease", "serious infection", "incidence", "cohort", "immunosuppression"]}
{"question": "What mechanisms explain long-term B-cell aplasia and hypogammaglobulinemia after CD19-targeted CAR-T therapy, and how are they managed?", "topic": "Mechanisms of CAR-T long-term effects", "question_type": "mechanism", "expected_search_terms": ["CD19 CAR-T", "B-cell aplasia", "hypogammaglobulinemia", "mechanism", "management", "IVIG"]}
{"question": "In Crohn’s disease, how does autologous hematopoietic stem cell transplantation compare with mesenchymal stromal cell therapy for fistula healing and relapse rates?", "topic": "Stem cell therapies in IBD", "question_type": "efficacy_comparison", "expected_search_terms": ["Crohn disease", "autologous hematopoietic stem cell transplantation", "mesenchymal stromal cell", "fistula", "relapse"]}
{"question": "What prognostic factors predict response to local MSC therapy for perianal fistulas in Crohn’s disease (such as fistula complexity or baseline inflammatory markers)?", "topic": "Predictors of MSC response in IBD", "question_type": "prognosis", "expected_search_terms": ["Crohn", "perianal fistula", "mesenchymal stem cell", "predictors", "CRP", "MRI"]}
{"question": "How does gene editing of regulatory T cells compare with unmodified regulatory T cell infusion in preventing transplant rejection in preclinical models?", "topic": "Engineered immune cell therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["regulatory T cells", "gene editing", "transplant rejection", "cell therapy", "preclinical"]}
{"question": "What mechanisms enable engineered regulatory T cells to maintain suppressive function and stability in inflammatory environments?", "topic": "Treg engineering mechanisms", "question_type": "mechanism", "expected_search_terms": ["engineered Treg", "stability", "FoxP3", "inflammatory environment", "suppressive function", "mechanism"]}
{"question": "In age-related macular degeneration, how do complement-inhibiting gene therapies compare with repeated intravitreal pharmacologic inhibitors in reducing lesion growth?", "topic": "Ocular gene therapy for complement pathway", "question_type": "efficacy_comparison", "expected_search_terms": ["age-related macular degeneration", "complement", "gene therapy", "intravitreal", "lesion growth", "pharmacologic inhibitor"]}
{"question": "What is the incidence of intraocular inflammation after intravitreal gene therapy, and which patient or vector factors are associated with higher risk?", "topic": "Ocular gene therapy safety epidemiology", "question_type": "epidemiology", "expected_search_terms": ["intravitreal gene therapy", "intraocular inflammation", "incidence", "risk factors", "AAV", "uveitis"]}
{"question": "How does CRISPR-based epigenome editing compare with conventional genome editing for upregulating fetal hemoglobin without introducing double-strand breaks?", "topic": "Epigenome editing therapeutics", "question_type": "efficacy_comparison", "expected_search_terms": ["epigenome editing", "CRISPR-dCas9", "fetal hemoglobin", "no double-strand break", "BCL11A", "activation"]}
{"question": "What mechanisms determine the stability and heritability of CRISPR-mediated epigenetic modifications in primary human cells?", "topic": "Epigenetic editing mechanisms", "question_type": "mechanism", "expected_search_terms": ["CRISPR epigenetic editing", "dCas9", "heritability", "chromatin", "stability", "primary human cells"]}
{"question": "In acute respiratory distress syndrome, how does MSC therapy compare with standard supportive care in mortality and ventilator-free days across randomized trials?", "topic": "MSC therapy in critical care", "question_type": "efficacy_comparison", "expected_search_terms": ["ARDS", "mesenchymal stem cell", "randomized trial", "mortality", "ventilator-free days"]}
{"question": "What is the incidence of thromboembolic events after intravenous MSC infusion in hospitalized patients, based on published trials and observational studies?", "topic": "MSC systemic safety", "question_type": "epidemiology", "expected_search_terms": ["mesenchymal stem cell", "intravenous infusion", "thromboembolism", "incidence", "trial", "observational"]}
{"question": "How do gene-edited universal donor iPSC lines compare with HLA-matched iPSC lines in reducing immune recognition in transplantation models?", "topic": "Universal donor iPSC engineering", "question_type": "efficacy_comparison", "expected_search_terms": ["universal donor iPSC", "HLA knockout", "HLA-matched", "immune recognition", "transplant model"]}
{"question": "What mechanisms lead to NK cell-mediated clearance of HLA-deficient cells, and what gene engineering strategies are used to prevent this in universal donor cell products?", "topic": "Immune evasion engineering mechanisms", "question_type": "mechanism", "expected_search_terms": ["HLA deficient", "NK cell clearance", "missing-self", "HLA-E", "CD47", "gene engineering"]}
{"question": "In mucopolysaccharidoses, how does intrathecal or intracisternal AAV gene therapy compare with systemic therapy in CSF biomarker reduction and neurocognitive outcomes?", "topic": "CNS-targeted gene therapy in MPS", "question_type": "efficacy_comparison", "expected_search_terms": ["mucopolysaccharidosis", "intrathecal", "intracisternal", "AAV gene therapy", "CSF biomarker", "neurocognitive"]}
{"question": "What prognostic indicators predict neurocognitive benefit after CNS-directed gene therapy for lysosomal storage disorders (such as baseline cognitive level or age at intervention)?", "topic": "Prognosis in CNS lysosomal gene therapy", "question_type": "prognosis", "expected_search_terms": ["lysosomal storage disorder", "CNS gene therapy", "prognostic", "age", "baseline cognition", "neurocognitive outcome"]}
{"question": "How do integrase-defective lentiviral vectors compare with AAV vectors for transient gene delivery in dividing cells in terms of expression duration and genotoxicity risk?", "topic": "Non-integrating vector strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["integrase-defective lentiviral", "AAV", "non-integrating", "dividing cells", "expression duration", "genotoxicity"]}
{"question": "What mechanisms influence episomal persistence of viral vectors in proliferating tissues, and how does cell division rate affect transgene dilution?", "topic": "Vector persistence biology", "question_type": "mechanism", "expected_search_terms": ["episomal persistence", "viral vector", "proliferating tissue", "cell division", "transgene dilution", "mechanism"]}
{"question": "In inherited blood disorders, how does editing efficiency differ between CRISPR ribonucleoprotein electroporation and viral delivery in CD34+ hematopoietic stem cells?", "topic": "HSC editing methods", "question_type": "efficacy_comparison", "expected_search_terms": ["CD34+ cells", "CRISPR RNP", "electroporation", "viral delivery", "editing efficiency", "hematopoietic stem cell"]}
{"question": "What is the incidence of unintended integration of donor DNA templates during HDR-based genome editing in human cells, and how is it typically detected?", "topic": "HDR safety considerations", "question_type": "epidemiology", "expected_search_terms": ["HDR", "donor template", "unintended integration", "genome editing", "detection", "PCR", "sequencing"]}
{"question": "How do small-molecule HDR enhancers compare with cell cycle synchronization strategies for increasing precise genome editing in primary human stem cells?", "topic": "Enhancing precise editing", "question_type": "efficacy_comparison", "expected_search_terms": ["HDR enhancer", "cell cycle synchronization", "precise genome editing", "primary stem cells", "small molecule"]}
{"question": "What mechanisms explain preferential repair pathway choice (NHEJ vs HDR) after CRISPR cutting in hematopoietic stem cells, and how can it be biased toward desired outcomes?", "topic": "DNA repair pathway control", "question_type": "mechanism", "expected_search_terms": ["NHEJ", "HDR", "hematopoietic stem cells", "CRISPR", "repair pathway choice", "bias"]}
{"question": "In inherited liver diseases, how does neonatal administration of gene therapy compare with adult administration in terms of long-term expression durability and immune responses?", "topic": "Developmental timing in gene therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["neonatal gene therapy", "adult", "liver disease", "expression durability", "immune response", "AAV"]}
{"question": "What prognostic evidence exists for long-term outcomes after pediatric systemic gene therapy, including growth, neurodevelopment, and late adverse events?", "topic": "Long-term follow-up in pediatric gene therapy", "question_type": "prognosis", "expected_search_terms": ["pediatric gene therapy", "long-term follow-up", "neurodevelopment", "growth", "late adverse events", "AAV"]}
{"question": "How does CRISPR editing in embryos or germline cells differ mechanistically from somatic cell editing with respect to mosaicism formation?", "topic": "Germline vs somatic editing mechanisms", "question_type": "mechanism", "expected_search_terms": ["germline editing", "embryo", "mosaicism", "CRISPR", "mechanism", "timing"]}
{"question": "What is the landscape of clinical indications most frequently studied for iPSC-derived cell therapies, and how has it changed over the last decade?", "topic": "Clinical trial epidemiology of iPSC therapies", "question_type": "epidemiology", "expected_search_terms": ["iPSC", "cell therapy", "clinical trial", "indications", "trend", "decade"]}
{"question": "In cartilage repair, how do iPSC-derived chondrocytes compare with MSC-derived chondrocytes in generating hyaline-like cartilage and avoiding hypertrophy in vivo?", "topic": "Cell sources for cartilage regeneration", "question_type": "efficacy_comparison", "expected_search_terms": ["iPSC-derived chondrocytes", "MSC-derived chondrocytes", "cartilage repair", "hyaline cartilage", "hypertrophy", "in vivo"]}
{"question": "What mechanisms drive hypertrophic differentiation in stem-cell-derived chondrocyte implants, and what culture or genetic interventions reduce hypertrophy?", "topic": "Mechanisms in cartilage tissue engineering", "question_type": "mechanism", "expected_search_terms": ["chondrocyte hypertrophy", "stem cell-derived", "mechanism", "culture conditions", "genetic intervention", "RUNX2"]}
{"question": "In cirrhosis, how does hepatocyte transplantation compare with MSC therapy in improving liver function scores and survival?", "topic": "Cell therapy for liver failure", "question_type": "efficacy_comparison", "expected_search_terms": ["cirrhosis", "hepatocyte transplantation", "mesenchymal stem cell", "MELD", "Child-Pugh", "survival"]}
{"question": "What prognostic factors predict survival benefit after hepatocyte transplantation (such as etiology of liver disease or baseline portal hypertension)?", "topic": "Prognosis in hepatocyte cell therapy", "question_type": "prognosis", "expected_search_terms": ["hepatocyte transplantation", "prognostic factors", "cirrhosis etiology", "portal hypertension", "survival"]}
{"question": "How do gene-edited macrophages compare with unmodified macrophages for tumor infiltration and antitumor activity in solid tumor models?", "topic": "Engineered myeloid cell therapies", "question_type": "efficacy_comparison", "expected_search_terms": ["gene-edited macrophage", "tumor infiltration", "antitumor activity", "solid tumor", "cell therapy"]}
{"question": "What mechanisms govern macrophage polarization in the tumor microenvironment, and how do genetic modifications aim to sustain an antitumor phenotype?", "topic": "Macrophage engineering mechanisms", "question_type": "mechanism", "expected_search_terms": ["macrophage polarization", "tumor microenvironment", "genetic modification", "M1", "M2", "mechanism"]}
{"question": "In epidermal growth factor receptor inhibitor-related corneal toxicity, how does limbal stem cell transplantation compare with conservative management for restoring epithelial integrity?", "topic": "Stem cell therapy in ocular surface disease", "question_type": "efficacy_comparison", "expected_search_terms": ["limbal stem cell transplantation", "corneal epitheliopathy", "EGFR inhibitor", "epithelial integrity", "outcome"]}
{"question": "What is the incidence of ectopic tissue formation after stem cell-derived product implantation in humans, based on published clinical reports?", "topic": "Ectopic tissue risk in cell therapy", "question_type": "epidemiology", "expected_search_terms": ["stem cell-derived", "ectopic tissue", "heterotopic", "clinical report", "incidence", "safety"]}
{"question": "How does CRISPR-based gene correction compare with antisense oligonucleotide exon skipping for treating splice-site variants in inherited neuromuscular disorders in cellular models?", "topic": "Correction vs splice modulation", "question_type": "efficacy_comparison", "expected_search_terms": ["CRISPR gene correction", "antisense oligonucleotide", "exon skipping", "splice-site variant", "neuromuscular", "cell model"]}
{"question": "What mechanisms determine whether splice-site variants are best addressed by gene correction, exon skipping, or base editing, based on genotype-phenotype evidence?", "topic": "Therapeutic mechanism selection", "question_type": "review", "expected_search_terms": ["splice-site variant", "gene correction", "exon skipping", "base editing", "genotype phenotype", "mechanism"]}
{"question": "In ALS, how does intrathecal antisense therapy compare with AAV-delivered gene silencing approaches for reducing target protein and slowing functional decline?", "topic": "CNS gene silencing strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["ALS", "intrathecal antisense", "AAV gene silencing", "target protein reduction", "functional decline"]}
{"question": "What mechanisms contribute to dorsal root ganglion toxicity in AAV-mediated gene delivery, and what vector or dosing changes reduce this risk?", "topic": "Neurotoxicity mechanisms in AAV", "question_type": "mechanism", "expected_search_terms": ["dorsal root ganglion", "AAV", "toxicity", "mechanism", "dose", "capsid", "promoter"]}
{"question": "In Fabry disease, how does AAV gene therapy compare with enzyme replacement in lyso-Gb3 reduction and renal outcomes?", "topic": "Gene therapy in lysosomal disorders", "question_type": "efficacy_comparison", "expected_search_terms": ["Fabry disease", "AAV gene therapy", "enzyme replacement", "lyso-Gb3", "renal outcome", "proteinuria"]}
{"question": "What prognostic factors are associated with renal outcome trajectories after gene therapy or gene-modifying treatments in Fabry disease?", "topic": "Renal prognosis in gene-modified Fabry", "question_type": "prognosis", "expected_search_terms": ["Fabry", "gene therapy", "prognostic factors", "eGFR slope", "proteinuria", "renal outcome"]}
{"question": "How does dual-AAV vector splitting compare with single-vector mini-gene approaches for delivering large genes in terms of reconstitution efficiency and expression levels?", "topic": "Strategies for large transgenes", "question_type": "efficacy_comparison", "expected_search_terms": ["dual AAV", "split vector", "large gene", "mini-gene", "reconstitution", "expression"]}
{"question": "What mechanisms influence trans-splicing or recombination efficiency in dual-AAV systems, and which design parameters most improve success?", "topic": "Dual-AAV mechanistic optimization", "question_type": "mechanism", "expected_search_terms": ["dual AAV", "trans-splicing", "homologous recombination", "design parameters", "mechanism", "efficiency"]}
{"question": "In retinal gene therapy, how does the choice of promoter (cell-specific versus ubiquitous) affect therapeutic expression patterns and off-target cell transduction risks?", "topic": "Promoter selection in ocular gene therapy", "question_type": "mechanism", "expected_search_terms": ["retinal gene therapy", "promoter", "cell-specific", "ubiquitous", "expression pattern", "off-target transduction"]}
{"question": "What is the incidence of secondary malignancies in patients receiving gene-modified hematopoietic stem cell therapies, based on available long-term follow-up cohorts?", "topic": "Long-term safety epidemiology", "question_type": "epidemiology", "expected_search_terms": ["gene-modified", "hematopoietic stem cell", "secondary malignancy", "incidence", "long-term follow-up", "cohort"]}
{"question": "How do manufacturing variables (such as vector copy number targets and culture duration) correlate with potency and safety outcomes in lentiviral-modified HSC products?", "topic": "Manufacturing and clinical outcomes", "question_type": "prognosis", "expected_search_terms": ["lentiviral", "HSC product", "vector copy number", "culture duration", "potency", "safety outcome"]}
{"question": "In inherited enzyme deficiencies, how does liver-directed gene therapy compare with genome editing at the albumin locus for achieving therapeutic enzyme levels?", "topic": "Safe-harbor editing vs gene transfer", "question_type": "efficacy_comparison", "expected_search_terms": ["liver-directed gene therapy", "albumin locus", "safe harbor", "genome editing", "enzyme deficiency", "therapeutic level"]}
{"question": "What mechanisms support the albumin locus as a safe-harbor site for therapeutic gene insertion, and what safety concerns remain?", "topic": "Safe-harbor locus mechanisms", "question_type": "mechanism", "expected_search_terms": ["albumin locus", "safe harbor", "gene insertion", "mechanism", "liver", "safety concern"]}
{"question": "How does in vivo CRISPR editing in the eye compare with ex vivo edited cell transplantation for treating retinal degeneration in terms of functional rescue in animal studies?", "topic": "In vivo vs ex vivo ocular gene approaches", "question_type": "efficacy_comparison", "expected_search_terms": ["retinal degeneration", "in vivo CRISPR", "ex vivo edited cells", "transplantation", "functional rescue", "animal"]}
{"question": "What is the reported frequency of retinal structural complications (such as retinal detachment or macular holes) after subretinal delivery procedures in gene therapy trials?", "topic": "Procedure-related ocular safety", "question_type": "epidemiology", "expected_search_terms": ["subretinal injection", "gene therapy", "retinal detachment", "macular hole", "frequency", "trial"]}
{"question": "In spinal cord injury, how do neural stem cell transplants compare with olfactory ensheathing cell transplants in motor recovery outcomes reported in clinical studies?", "topic": "Cell therapy for spinal cord injury", "question_type": "efficacy_comparison", "expected_search_terms": ["spinal cord injury", "neural stem cell", "olfactory ensheathing cell", "clinical study", "motor recovery"]}
{"question": "What mechanisms explain poor survival and integration of transplanted neural cells in injured spinal cord, and what biomaterial or immunomodulatory strategies improve outcomes?", "topic": "Neural cell graft integration mechanisms", "question_type": "mechanism", "expected_search_terms": ["spinal cord injury", "neural transplant", "cell survival", "integration", "biomaterial scaffold", "immunomodulation"]}
{"question": "In pulmonary arterial hypertension, how does endothelial progenitor cell therapy compare with standard vasodilator therapy in improving hemodynamics and exercise capacity?", "topic": "Vascular regenerative cell therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["pulmonary arterial hypertension", "endothelial progenitor cells", "vasodilator therapy", "hemodynamics", "6-minute walk"]}
{"question": "What prognostic markers (such as baseline right ventricular function) predict response to cell-based therapies in pulmonary arterial hypertension?", "topic": "Prognosis in vascular cell therapy", "question_type": "prognosis", "expected_search_terms": ["pulmonary arterial hypertension", "cell therapy", "prognostic marker", "right ventricular function", "response"]}
{"question": "How does CRISPR-Cas13 RNA targeting compare with antisense oligonucleotides for reducing pathogenic RNA transcripts in repeat expansion disorders in cellular models?", "topic": "RNA-targeting gene therapies", "question_type": "efficacy_comparison", "expected_search_terms": ["Cas13", "RNA targeting", "antisense oligonucleotide", "repeat expansion", "pathogenic transcript", "cell model"]}
{"question": "What mechanisms determine specificity and collateral effects of RNA-targeting CRISPR systems in mammalian cells, and how are these minimized?", "topic": "RNA editing mechanisms", "question_type": "mechanism", "expected_search_terms": ["Cas13", "RNA specificity", "collateral effect", "mammalian cells", "minimize", "mechanism"]}
{"question": "In early symptomatic Alzheimer's disease, how does the clinical efficacy of anti-amyloid monoclonal antibodies compare with cholinesterase inhibitors on cognitive and functional outcomes over 12–24 months?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Alzheimer disease", "anti-amyloid monoclonal antibody", "cholinesterase inhibitor", "MMSE", "CDR-SB", "activities of daily living"]}
{"question": "In Alzheimer's disease, what is the relationship between ARIA risk and APOE ε4 carrier status among patients treated with anti-amyloid antibodies?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["Alzheimer disease", "ARIA", "amyloid related imaging abnormalities", "APOE epsilon4", "monoclonal antibody", "risk factors"]}
{"question": "In mild cognitive impairment due to Alzheimer's disease, how well do plasma phosphorylated tau biomarkers predict progression to dementia compared with CSF biomarkers?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["mild cognitive impairment", "Alzheimer", "plasma phosphorylated tau", "CSF biomarkers", "conversion to dementia", "predictive value"]}
{"question": "In Alzheimer's disease, does PET-measured amyloid reduction correlate with changes in cognitive outcomes, and how consistent is this association across studies?", "topic": "Alzheimer's disease", "question_type": "review", "expected_search_terms": ["Alzheimer disease", "amyloid PET", "amyloid reduction", "cognitive outcomes", "correlation", "meta-analysis"]}
{"question": "Among older adults, what is the association between midlife hypertension and later-life Alzheimer's disease incidence after adjusting for vascular risk factors?", "topic": "Alzheimer's disease", "question_type": "epidemiology", "expected_search_terms": ["midlife hypertension", "Alzheimer disease incidence", "vascular risk factors", "cohort", "adjusted association"]}
{"question": "In Alzheimer's disease, how does microglial activation measured by TSPO PET relate to disease stage and cognitive decline rate?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["Alzheimer disease", "microglia", "TSPO PET", "neuroinflammation", "cognitive decline", "disease stage"]}
{"question": "In Alzheimer's disease, what evidence supports a causal role of tau propagation along neural networks in driving clinical progression?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["Alzheimer disease", "tau propagation", "network spread", "connectome", "clinical progression", "pathophysiology"]}
{"question": "In early Alzheimer's disease, how does the efficacy of structured aerobic exercise interventions compare with cognitive training on slowing cognitive decline?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Alzheimer disease", "aerobic exercise", "cognitive training", "randomized trial", "cognitive decline", "intervention"]}
{"question": "In Alzheimer's disease, does sleep-disordered breathing treatment with CPAP improve cognition or slow decline compared with usual care?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Alzheimer disease", "sleep apnea", "CPAP", "cognition", "disease progression", "controlled study"]}
{"question": "In Alzheimer's disease, what is the evidence that glymphatic dysfunction contributes to amyloid or tau accumulation?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["glymphatic", "Alzheimer disease", "amyloid clearance", "tau", "sleep", "CSF flow"]}
{"question": "In Alzheimer's disease with agitation, how does the efficacy and safety of atypical antipsychotics compare with SSRIs for reducing agitation symptoms?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Alzheimer disease", "agitation", "atypical antipsychotic", "SSRI", "safety", "efficacy"]}
{"question": "In Alzheimer's disease, how do cholinesterase inhibitors compare with memantine for delaying nursing home placement or institutionalization?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Alzheimer disease", "cholinesterase inhibitors", "memantine", "institutionalization", "nursing home", "time to placement"]}
{"question": "In Alzheimer's disease, what is the association between hearing loss and risk of incident dementia, and does hearing aid use modify this risk?", "topic": "Alzheimer's disease", "question_type": "epidemiology", "expected_search_terms": ["hearing loss", "hearing aids", "incident dementia", "Alzheimer disease", "cohort", "risk modification"]}
{"question": "In Alzheimer's disease, what mechanisms link insulin resistance and impaired brain glucose metabolism to cognitive decline?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["Alzheimer disease", "insulin resistance", "brain glucose metabolism", "FDG PET", "cognitive decline", "mechanism"]}
{"question": "In mild-to-moderate Alzheimer's disease, does intranasal insulin improve cognitive outcomes compared with placebo?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["intranasal insulin", "Alzheimer disease", "placebo", "randomized", "cognitive outcomes", "MMSE"]}
{"question": "In Alzheimer's disease, how do vascular comorbidities influence the rate of cognitive decline and response to symptomatic therapies?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["Alzheimer disease", "vascular comorbidity", "cognitive decline rate", "treatment response", "cholinesterase inhibitor", "memantine"]}
{"question": "In Alzheimer's disease, what is the prognostic value of baseline hippocampal atrophy on MRI for predicting time to severe dementia?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["Alzheimer disease", "hippocampal atrophy", "MRI", "prognostic", "time to severe dementia", "longitudinal"]}
{"question": "In cognitively normal adults, how predictive is amyloid PET positivity for future cognitive decline compared with plasma Aβ42/40 ratio?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["cognitively normal", "amyloid PET", "plasma Aβ42/40", "prediction", "cognitive decline", "preclinical Alzheimer"]}
{"question": "In Alzheimer's disease, what evidence supports synaptic dysfunction as an early driver of cognitive impairment independent of plaque burden?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["Alzheimer disease", "synaptic dysfunction", "cognitive impairment", "amyloid plaques", "synapse loss", "mechanism"]}
{"question": "In Alzheimer's disease, how does the effectiveness of multi-domain lifestyle interventions compare with single-component interventions for slowing cognitive decline?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["multidomain intervention", "lifestyle", "Alzheimer disease", "diet exercise cognitive training", "cognitive decline", "randomized"]}
{"question": "In Parkinson's disease, how does levodopa-carbidopa intestinal gel compare with deep brain stimulation in improving motor fluctuations and quality of life?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "levodopa carbidopa intestinal gel", "deep brain stimulation", "motor fluctuations", "quality of life", "UPDRS"]}
{"question": "In Parkinson's disease, what is the comparative effectiveness of MAO-B inhibitors versus dopamine agonists as add-on therapy for wearing-off?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "wearing off", "MAO-B inhibitor", "dopamine agonist", "add-on", "randomized"]}
{"question": "In early Parkinson's disease, does starting levodopa earlier versus delayed initiation affect long-term dyskinesia risk?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["early Parkinson", "levodopa initiation", "delayed start", "dyskinesia", "long-term", "cohort"]}
{"question": "In Parkinson's disease, what is the evidence that alpha-synuclein seeding and propagation explains the spatial progression of pathology?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["Parkinson disease", "alpha-synuclein", "seeding", "propagation", "prion-like", "pathology spread"]}
{"question": "In Parkinson's disease, how do gut microbiome alterations correlate with motor severity and non-motor symptoms?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["Parkinson disease", "gut microbiome", "dysbiosis", "motor severity", "non-motor symptoms", "constipation"]}
{"question": "In Parkinson's disease, does structured resistance training improve gait and balance outcomes compared with aerobic training?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "resistance training", "aerobic exercise", "gait", "balance", "randomized controlled trial"]}
{"question": "In Parkinson's disease, how effective is rivastigmine compared with donepezil for Parkinson's disease dementia symptoms and tolerability?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease dementia", "rivastigmine", "donepezil", "cognition", "tolerability", "randomized"]}
{"question": "In Parkinson's disease, what clinical factors predict progression from mild cognitive impairment to Parkinson's disease dementia?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson", "mild cognitive impairment", "progression", "dementia", "predictors", "longitudinal"]}
{"question": "In Parkinson's disease, what is the association between REM sleep behavior disorder and future development of dementia or hallucinations?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "REM sleep behavior disorder", "dementia", "hallucinations", "risk", "prospective"]}
{"question": "In Parkinson's disease psychosis, how does pimavanserin compare with quetiapine regarding efficacy and motor symptom worsening?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease psychosis", "pimavanserin", "quetiapine", "motor worsening", "efficacy", "randomized"]}
{"question": "In Parkinson's disease, what evidence links mitochondrial dysfunction and impaired mitophagy to dopaminergic neuron loss?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["Parkinson disease", "mitochondrial dysfunction", "mitophagy", "dopaminergic neuron", "PINK1", "Parkin"]}
{"question": "In Parkinson's disease, how does iron accumulation in the substantia nigra measured by susceptibility MRI relate to disease severity and progression?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "substantia nigra", "iron", "susceptibility MRI", "QSM", "progression"]}
{"question": "In Parkinson's disease, does continuous subcutaneous apomorphine infusion provide similar reduction in off-time compared with DBS in appropriately selected patients?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "apomorphine infusion", "deep brain stimulation", "off time", "motor fluctuations", "comparative"]}
{"question": "In Parkinson's disease, what is the epidemiologic association between pesticide exposure and risk of developing Parkinsonism?", "topic": "Parkinson's disease", "question_type": "epidemiology", "expected_search_terms": ["pesticide exposure", "Parkinson disease", "Parkinsonism", "case-control", "occupational exposure", "risk"]}
{"question": "In Parkinson's disease, how does depression at diagnosis influence subsequent motor progression and mortality?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "depression", "motor progression", "mortality", "baseline predictor", "longitudinal"]}
{"question": "In Parkinson's disease, does safinamide provide superior improvement in motor fluctuations compared with rasagiline when added to levodopa?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "safinamide", "rasagiline", "levodopa add-on", "motor fluctuations", "off time"]}
{"question": "In Parkinson's disease, what mechanisms explain levodopa-induced dyskinesia involving striatal plasticity and glutamatergic signaling?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["levodopa-induced dyskinesia", "Parkinson disease", "striatal plasticity", "glutamate", "NMDA", "mechanism"]}
{"question": "In Parkinson's disease, how effective are wearable-sensor guided interventions compared with standard care for reducing falls?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "wearable sensors", "falls", "digital health", "intervention", "trial"]}
{"question": "In Parkinson's disease, what is the comparative impact of STN versus GPi deep brain stimulation on cognitive outcomes and mood symptoms?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "STN DBS", "GPi DBS", "cognition", "mood", "comparative outcomes"]}
{"question": "In Parkinson's disease, does constipation severity predict motor progression or conversion to dementia?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "constipation", "predict", "motor progression", "dementia conversion", "non-motor symptoms"]}
{"question": "In Parkinson's disease, what evidence supports neuroinflammation as a contributor to neurodegeneration based on imaging and CSF biomarkers?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["Parkinson disease", "neuroinflammation", "TSPO PET", "CSF cytokines", "microglia", "biomarkers"]}
{"question": "In Parkinson's disease, how does amantadine extended-release compare with immediate-release amantadine for reducing dyskinesia and off-time?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "amantadine extended release", "amantadine immediate release", "dyskinesia", "off time", "randomized"]}
{"question": "In Parkinson's disease, what is the prognostic accuracy of dopamine transporter imaging for distinguishing Parkinson's disease from essential tremor in early presentations?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["dopamine transporter imaging", "DaTSCAN", "Parkinson disease", "essential tremor", "diagnostic accuracy", "early"]}
{"question": "In epilepsy, how does levetiracetam compare with lamotrigine as first-line monotherapy for focal seizures in adults regarding seizure freedom and adverse effects?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["focal epilepsy", "levetiracetam", "lamotrigine", "monotherapy", "seizure freedom", "adverse effects"]}
{"question": "In generalized epilepsy, how does valproate compare with levetiracetam for seizure control and treatment discontinuation due to side effects?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["generalized epilepsy", "valproate", "levetiracetam", "seizure control", "discontinuation", "tolerability"]}
{"question": "In women of childbearing potential with epilepsy, how do fetal malformation risks compare between valproate and lamotrigine exposure during pregnancy?", "topic": "Epilepsy", "question_type": "epidemiology", "expected_search_terms": ["epilepsy pregnancy", "valproate", "lamotrigine", "congenital malformations", "teratogenicity", "registry"]}
{"question": "In refractory focal epilepsy, how does vagus nerve stimulation compare with responsive neurostimulation for reducing seizure frequency over 1–3 years?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["refractory focal epilepsy", "vagus nerve stimulation", "responsive neurostimulation", "seizure frequency", "long-term outcomes"]}
{"question": "In drug-resistant temporal lobe epilepsy, how does anterior temporal lobectomy compare with laser interstitial thermal therapy for seizure freedom and neuropsychological outcomes?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["temporal lobe epilepsy", "anterior temporal lobectomy", "laser interstitial thermal therapy", "seizure freedom", "neuropsychological outcomes"]}
{"question": "In status epilepticus, how do levetiracetam, valproate, and fosphenytoin compare as second-line agents after benzodiazepines in terminating seizures?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["status epilepticus", "second-line", "levetiracetam", "valproate", "fosphenytoin", "seizure termination"]}
{"question": "In epilepsy, what mechanisms underlie pharmacoresistance related to drug efflux transporters at the blood–brain barrier?", "topic": "Epilepsy", "question_type": "mechanism", "expected_search_terms": ["epilepsy", "drug resistance", "blood brain barrier", "P-glycoprotein", "ABC transporters", "efflux"]}
{"question": "In temporal lobe epilepsy, what evidence supports a role for hippocampal neuroinflammation in seizure generation and progression?", "topic": "Epilepsy", "question_type": "mechanism", "expected_search_terms": ["temporal lobe epilepsy", "hippocampus", "neuroinflammation", "microglia", "cytokines", "epileptogenesis"]}
{"question": "In epilepsy, what is the incidence of sudden unexpected death in epilepsy (SUDEP) across seizure types, and which clinical factors most strongly predict risk?", "topic": "Epilepsy", "question_type": "epidemiology", "expected_search_terms": ["SUDEP", "incidence", "seizure type", "risk factors", "generalized tonic-clonic", "cohort"]}
{"question": "In newly diagnosed epilepsy, does early achievement of seizure freedom predict long-term remission compared with delayed seizure control?", "topic": "Epilepsy", "question_type": "prognosis", "expected_search_terms": ["newly diagnosed epilepsy", "seizure freedom", "remission", "prognosis", "long-term", "predictor"]}
{"question": "In children with absence epilepsy, how does ethosuximide compare with valproate for seizure control and cognitive/attention outcomes?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["childhood absence epilepsy", "ethosuximide", "valproate", "seizure control", "attention", "cognition"]}
{"question": "In epilepsy patients with comorbid depression, how does lamotrigine compare with levetiracetam regarding mood outcomes and seizure control?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["epilepsy", "depression", "lamotrigine", "levetiracetam", "mood", "seizure control"]}
{"question": "In epilepsy, what is the evidence that ketogenic diet efficacy is mediated by changes in neurotransmitter balance and mitochondrial metabolism?", "topic": "Epilepsy", "question_type": "mechanism", "expected_search_terms": ["ketogenic diet", "epilepsy", "GABA", "glutamate", "mitochondrial metabolism", "mechanism"]}
{"question": "In Dravet syndrome, how does cannabidiol compare with fenfluramine in reducing convulsive seizure frequency and treatment-limiting adverse effects?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["Dravet syndrome", "cannabidiol", "fenfluramine", "convulsive seizures", "adverse effects", "randomized"]}
{"question": "In Lennox–Gastaut syndrome, what is the comparative effectiveness of clobazam versus rufinamide as add-on therapy for drop seizures?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["Lennox-Gastaut", "clobazam", "rufinamide", "drop seizures", "add-on", "efficacy"]}
{"question": "In epilepsy surgery candidates, how does stereo-EEG-guided localization compare with subdural grid monitoring in identifying seizure onset zones and surgical outcomes?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["epilepsy surgery", "stereo-EEG", "subdural grids", "seizure onset zone", "surgical outcome", "localization"]}
{"question": "In focal epilepsy, does the presence of hippocampal sclerosis on MRI predict better seizure outcomes after surgery compared with nonlesional cases?", "topic": "Epilepsy", "question_type": "prognosis", "expected_search_terms": ["focal epilepsy", "hippocampal sclerosis", "MRI", "epilepsy surgery", "seizure outcome", "prognostic"]}
{"question": "In epilepsy, how do sleep deprivation and circadian factors influence seizure threshold through alterations in cortical excitability?", "topic": "Epilepsy", "question_type": "mechanism", "expected_search_terms": ["epilepsy", "sleep deprivation", "circadian", "cortical excitability", "EEG", "seizure threshold"]}
{"question": "In patients with psychogenic nonepileptic seizures, what is the effectiveness of cognitive behavioral therapy compared with standard neurological follow-up in reducing event frequency?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["psychogenic nonepileptic seizures", "cognitive behavioral therapy", "standard care", "event frequency", "randomized", "treatment"]}
{"question": "In older adults with new-onset epilepsy, what are the most common etiologies and how do they influence seizure recurrence risk?", "topic": "Epilepsy", "question_type": "epidemiology", "expected_search_terms": ["late-onset epilepsy", "older adults", "etiology", "stroke", "tumor", "seizure recurrence"]}
{"question": "In epilepsy, what is the association between antiseizure medication polytherapy and cognitive impairment compared with monotherapy?", "topic": "Epilepsy", "question_type": "prognosis", "expected_search_terms": ["epilepsy", "polytherapy", "monotherapy", "cognitive impairment", "neuropsychological", "adverse effects"]}
{"question": "In Alzheimer's disease, how does tau PET signal distribution relate to specific cognitive domain deficits such as memory versus visuospatial impairment?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["Alzheimer disease", "tau PET", "cognitive domains", "memory", "visuospatial", "correlation"]}
{"question": "In atypical Alzheimer's presentations, how do posterior cortical atrophy and logopenic aphasia differ in biomarker profiles and progression rates?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["posterior cortical atrophy", "logopenic aphasia", "Alzheimer biomarkers", "amyloid", "tau", "progression"]}
{"question": "In Alzheimer's disease, what is the comparative effectiveness of transcranial magnetic stimulation versus transcranial direct current stimulation on cognitive outcomes?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Alzheimer disease", "transcranial magnetic stimulation", "tDCS", "cognitive outcomes", "noninvasive brain stimulation", "trial"]}
{"question": "In Alzheimer's disease, does long-term adherence to Mediterranean diet correlate with reduced incident dementia risk compared with low adherence in prospective cohorts?", "topic": "Alzheimer's disease", "question_type": "epidemiology", "expected_search_terms": ["Mediterranean diet", "incident dementia", "Alzheimer disease", "prospective cohort", "diet adherence", "risk reduction"]}
{"question": "In Alzheimer's disease, what is the evidence that blood–brain barrier breakdown precedes cognitive decline and predicts disease progression?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["Alzheimer disease", "blood brain barrier", "permeability", "dynamic contrast MRI", "cognitive decline", "predict"]}
{"question": "In Alzheimer's disease, how does chronic NSAID use relate to disease incidence and what biases or confounders explain differences across observational studies?", "topic": "Alzheimer's disease", "question_type": "review", "expected_search_terms": ["NSAIDs", "Alzheimer disease incidence", "observational", "confounding", "bias", "meta-analysis"]}
{"question": "In Alzheimer's disease, what mechanistic evidence links TREM2 signaling variants to altered microglial response and amyloid plaque compaction?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["TREM2", "Alzheimer disease", "microglia", "amyloid plaque compaction", "genetic variants", "mechanism"]}
{"question": "In Alzheimer's disease, how do CSF neurofilament light levels perform as a marker of neurodegeneration compared with imaging markers for predicting clinical progression?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["CSF neurofilament light", "Alzheimer disease", "neurodegeneration", "MRI atrophy", "FDG PET", "progression"]}
{"question": "In Alzheimer's disease, what is the relationship between comorbid atrial fibrillation and cognitive decline trajectory independent of clinical stroke?", "topic": "Alzheimer's disease", "question_type": "epidemiology", "expected_search_terms": ["atrial fibrillation", "Alzheimer disease", "cognitive decline", "stroke independent", "vascular cognitive impairment", "cohort"]}
{"question": "In Alzheimer's disease, does treatment of depression with SSRIs influence amyloid or tau biomarkers or clinical progression rates?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Alzheimer disease", "SSRI", "depression treatment", "amyloid biomarkers", "tau biomarkers", "progression"]}
{"question": "In Parkinson's disease, how does early autonomic dysfunction predict development of cognitive impairment and mortality?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "autonomic dysfunction", "orthostatic hypotension", "cognitive impairment", "mortality", "predictor"]}
{"question": "In Parkinson's disease, what is the comparative effectiveness of droxidopa versus midodrine for neurogenic orthostatic hypotension symptoms and safety?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "neurogenic orthostatic hypotension", "droxidopa", "midodrine", "symptoms", "safety"]}
{"question": "In Parkinson's disease, what evidence supports peripheral alpha-synuclein pathology in skin or gut biopsies as a diagnostic biomarker?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "alpha-synuclein", "skin biopsy", "colon biopsy", "diagnostic biomarker", "sensitivity specificity"]}
{"question": "In Parkinson's disease, how does cognitive behavioral therapy compare with pharmacologic therapy for treating insomnia and improving daytime function?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "insomnia", "cognitive behavioral therapy", "pharmacologic", "sleep", "daytime function"]}
{"question": "In Parkinson's disease, what is the impact of anticholinergic burden on cognitive decline and fall risk?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "anticholinergic burden", "cognitive decline", "falls", "risk", "medication"]}
{"question": "In Parkinson's disease, what mechanisms link LRRK2 kinase activity to endolysosomal dysfunction and alpha-synuclein aggregation?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["LRRK2", "Parkinson disease", "endolysosomal", "lysosome", "alpha-synuclein aggregation", "mechanism"]}
{"question": "In Parkinson's disease, does GLP-1 receptor agonist therapy improve motor outcomes compared with placebo in randomized studies?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "GLP-1 receptor agonist", "exenatide", "placebo", "motor outcomes", "randomized"]}
{"question": "In Parkinson's disease, how does the prevalence and clinical significance of impulse control disorders vary by dopamine agonist dose and duration?", "topic": "Parkinson's disease", "question_type": "epidemiology", "expected_search_terms": ["Parkinson disease", "impulse control disorders", "dopamine agonists", "dose", "duration", "prevalence"]}
{"question": "In Parkinson's disease, how effective is botulinum toxin compared with anticholinergic medications for sialorrhea control and tolerability?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "sialorrhea", "botulinum toxin", "anticholinergic", "tolerability", "efficacy"]}
{"question": "In Parkinson's disease, what is the association between physical activity levels and risk of developing Parkinson's disease in prospective studies?", "topic": "Parkinson's disease", "question_type": "epidemiology", "expected_search_terms": ["physical activity", "incident Parkinson disease", "prospective cohort", "risk", "exercise", "prevention"]}
{"question": "In Parkinson's disease, how does comorbid diabetes affect motor progression and cognitive outcomes over time?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "diabetes", "motor progression", "cognitive outcomes", "longitudinal", "comorbidity"]}
{"question": "In epilepsy, how does eslicarbazepine compare with carbamazepine for focal seizure control and hyponatremia risk?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["focal seizures", "eslicarbazepine", "carbamazepine", "seizure control", "hyponatremia", "tolerability"]}
{"question": "In epilepsy, what is the comparative effectiveness of brivaracetam versus levetiracetam as adjunctive therapy in patients with behavioral adverse effects on levetiracetam?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["epilepsy", "brivaracetam", "levetiracetam", "behavioral adverse effects", "adjunctive therapy", "switch"]}
{"question": "In refractory epilepsy, how effective is cenobamate compared with perampanel in achieving ≥50% seizure reduction and seizure freedom rates?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["drug-resistant epilepsy", "cenobamate", "perampanel", "responder rate", "seizure freedom", "adjunctive"]}
{"question": "In epilepsy, what evidence supports a role of mTOR pathway activation in epileptogenesis, and how does mTOR inhibition affect seizure outcomes in tuberous sclerosis complex?", "topic": "Epilepsy", "question_type": "mechanism", "expected_search_terms": ["epileptogenesis", "mTOR", "tuberous sclerosis complex", "everolimus", "seizure outcomes", "pathway"]}
{"question": "In tuberous sclerosis complex-associated epilepsy, how does everolimus compare with cannabidiol as add-on therapy for seizure reduction and adverse effects?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["tuberous sclerosis", "epilepsy", "everolimus", "cannabidiol", "add-on", "seizure reduction"]}
{"question": "In epilepsy, what is the association between long-term enzyme-inducing antiseizure medications and reduced bone mineral density or fracture risk?", "topic": "Epilepsy", "question_type": "epidemiology", "expected_search_terms": ["antiepileptic drugs", "enzyme-inducing", "bone mineral density", "fracture", "osteoporosis", "long-term"]}
{"question": "In epilepsy, what prognostic factors predict seizure recurrence after antiseizure medication withdrawal in patients who are seizure-free for at least 2 years?", "topic": "Epilepsy", "question_type": "prognosis", "expected_search_terms": ["antiepileptic drug withdrawal", "seizure recurrence", "seizure free", "prognostic factors", "relapse", "risk"]}
{"question": "In epilepsy, how does comorbid obstructive sleep apnea influence seizure frequency, and does CPAP treatment reduce seizures compared with no treatment?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["epilepsy", "obstructive sleep apnea", "CPAP", "seizure frequency", "sleep disorders", "treatment"]}
{"question": "In epilepsy, what are the mechanisms by which neurosteroids modulate GABA-A receptors to exert antiseizure effects?", "topic": "Epilepsy", "question_type": "mechanism", "expected_search_terms": ["neurosteroids", "GABA-A receptor", "epilepsy", "allopregnanolone", "mechanism", "antiseizure"]}
{"question": "In super-refractory status epilepticus, how does ketamine compare with anesthetic agents such as propofol or midazolam for seizure control and complications?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["super-refractory status epilepticus", "ketamine", "propofol", "midazolam", "seizure control", "complications"]}
{"question": "In epilepsy, how accurate are consumer wearable devices compared with ambulatory EEG for detecting generalized tonic-clonic seizures?", "topic": "Epilepsy", "question_type": "prognosis", "expected_search_terms": ["epilepsy", "wearable device", "seizure detection", "ambulatory EEG", "generalized tonic-clonic", "accuracy"]}
{"question": "In post-stroke epilepsy, what is the incidence of late seizures and which imaging or clinical features predict development of epilepsy?", "topic": "Epilepsy", "question_type": "epidemiology", "expected_search_terms": ["post-stroke epilepsy", "late seizures", "incidence", "predictors", "imaging", "cortical involvement"]}
{"question": "In autoimmune encephalitis-associated seizures, how does immunotherapy (steroids/IVIG/plasmapheresis) compare with antiseizure medications alone in achieving seizure control?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["autoimmune encephalitis", "seizures", "immunotherapy", "IVIG", "plasmapheresis", "seizure control"]}
{"question": "In Alzheimer's disease, what is the comparative diagnostic accuracy of plasma p-tau217 versus p-tau181 for identifying amyloid-positive individuals?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["plasma p-tau217", "p-tau181", "amyloid positivity", "diagnostic accuracy", "Alzheimer biomarkers", "AUC"]}
{"question": "In Alzheimer's disease, does long-term benzodiazepine use associate with increased dementia risk after accounting for prodromal symptoms and confounding by indication?", "topic": "Alzheimer's disease", "question_type": "epidemiology", "expected_search_terms": ["benzodiazepines", "dementia risk", "Alzheimer disease", "confounding by indication", "prodromal", "observational"]}
{"question": "In Alzheimer's disease, what is the evidence that cholinergic basal forebrain degeneration precedes cortical atrophy and predicts cognitive decline?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["basal forebrain", "cholinergic", "Alzheimer disease", "cortical atrophy", "prediction", "longitudinal MRI"]}
{"question": "In Alzheimer's disease, how does cognitive reserve (education/occupation) modify the relationship between biomarker burden and clinical symptoms?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["Alzheimer disease", "cognitive reserve", "education", "biomarkers", "amyloid", "tau", "clinical symptoms"]}
{"question": "In Alzheimer's disease, what is the comparative effectiveness of caregiver-focused multicomponent interventions versus usual care in reducing caregiver burden and delaying institutionalization?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Alzheimer disease", "caregiver intervention", "caregiver burden", "institutionalization", "randomized", "support program"]}
{"question": "In Alzheimer's disease, does white matter hyperintensity burden on MRI predict faster cognitive decline independent of amyloid and tau biomarkers?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["white matter hyperintensities", "Alzheimer disease", "cognitive decline", "amyloid", "tau", "MRI"]}
{"question": "In Parkinson's disease, how does constipation onset timing relative to motor symptoms relate to the likelihood of a more diffuse non-motor phenotype?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "constipation", "prodromal", "non-motor phenotype", "timing", "trajectory"]}
{"question": "In Parkinson's disease, how effective is melatonin compared with clonazepam for treating REM sleep behavior disorder and improving sleep quality?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "REM sleep behavior disorder", "melatonin", "clonazepam", "sleep quality", "treatment"]}
{"question": "In Parkinson's disease, what is the comparative effectiveness of opicapone versus entacapone as adjunct therapy to reduce off-time and improve motor function?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "opicapone", "entacapone", "COMT inhibitor", "off time", "adjunct"]}
{"question": "In Parkinson's disease, what is the association between baseline olfactory dysfunction and risk of developing cognitive impairment or hallucinations?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "hyposmia", "olfactory dysfunction", "cognitive impairment", "hallucinations", "predictor"]}
{"question": "In Parkinson's disease, does treatment of urinary symptoms with antimuscarinics versus beta-3 agonists differ in cognitive safety and efficacy?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "overactive bladder", "antimuscarinic", "beta-3 agonist", "mirabegron", "cognitive safety"]}
{"question": "In epilepsy, how does stereotactic radiosurgery compare with microsurgical resection for seizure control in hypothalamic hamartoma-related epilepsy?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["hypothalamic hamartoma", "epilepsy", "stereotactic radiosurgery", "surgical resection", "seizure outcome", "gelastic seizures"]}
{"question": "In pediatric focal epilepsy, how does oxcarbazepine compare with levetiracetam for seizure freedom and behavioral adverse effects?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["pediatric focal epilepsy", "oxcarbazepine", "levetiracetam", "seizure freedom", "behavioral side effects", "randomized"]}
{"question": "In epilepsy, what is the association between long-term antiseizure medication exposure and risk of major cardiovascular events?", "topic": "Epilepsy", "question_type": "epidemiology", "expected_search_terms": ["epilepsy", "antiseizure medications", "cardiovascular events", "risk", "cohort", "enzyme-inducing"]}
{"question": "In epilepsy, does epilepsy duration and seizure frequency predict hippocampal atrophy progression on longitudinal MRI?", "topic": "Epilepsy", "question_type": "prognosis", "expected_search_terms": ["epilepsy duration", "seizure frequency", "hippocampal atrophy", "longitudinal MRI", "temporal lobe", "progression"]}
{"question": "In Alzheimer's disease, what is the comparative effectiveness of donepezil versus rivastigmine in dementia with Lewy bodies versus Alzheimer's disease dementia?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["donepezil", "rivastigmine", "dementia with Lewy bodies", "Alzheimer dementia", "comparative efficacy", "tolerability"]}
{"question": "In Alzheimer's disease, how does chronic stress and HPA-axis dysregulation relate to amyloid and tau biomarker changes over time?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["Alzheimer disease", "stress", "HPA axis", "cortisol", "amyloid", "tau", "longitudinal biomarkers"]}
{"question": "In Parkinson's disease, what is the evidence that noradrenergic locus coeruleus degeneration contributes to non-motor symptoms such as anxiety and cognitive impairment?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["Parkinson disease", "locus coeruleus", "noradrenergic", "anxiety", "cognitive impairment", "pathophysiology"]}
{"question": "In epilepsy, what is the effectiveness of perampanel compared with lacosamide as adjunctive therapy for refractory focal seizures in adults?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["drug-resistant focal epilepsy", "perampanel", "lacosamide", "adjunctive therapy", "seizure reduction", "tolerability"]}
{"question": "In Alzheimer's disease, what is the association between chronic kidney disease and risk of incident dementia, and does severity of kidney impairment modify risk estimates?", "topic": "Alzheimer's disease", "question_type": "epidemiology", "expected_search_terms": ["chronic kidney disease", "incident dementia", "Alzheimer disease", "eGFR", "albuminuria", "risk"]}
{"question": "In Parkinson's disease, how does speech therapy using intensive voice treatment compare with standard speech therapy for improving communication outcomes?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "speech therapy", "intensive voice treatment", "communication", "dysarthria", "trial"]}
{"question": "In epilepsy, what is the evidence that interictal epileptiform discharges contribute to cognitive impairment and how does suppressing them affect cognition?", "topic": "Epilepsy", "question_type": "mechanism", "expected_search_terms": ["interictal epileptiform discharges", "epilepsy", "cognitive impairment", "EEG", "suppression", "neuropsychological"]}
{"question": "In Alzheimer's disease, what is the effect of long-term statin use on Alzheimer's disease incidence and progression based on observational and randomized evidence?", "topic": "Alzheimer's disease", "question_type": "review", "expected_search_terms": ["statins", "Alzheimer disease incidence", "progression", "randomized", "observational", "meta-analysis"]}
{"question": "In Parkinson's disease, does caffeine intake associate with reduced risk of developing Parkinson's disease and do genetic factors modify this association?", "topic": "Parkinson's disease", "question_type": "epidemiology", "expected_search_terms": ["caffeine", "coffee", "Parkinson disease risk", "genetic modifiers", "epidemiology", "interaction"]}
{"question": "In epilepsy, what is the comparative effectiveness of different rescue therapies (intranasal midazolam versus rectal diazepam) for out-of-hospital seizure clusters?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["seizure clusters", "intranasal midazolam", "rectal diazepam", "rescue therapy", "out-of-hospital", "effectiveness"]}
{"question": "In Alzheimer's disease, how do sex differences influence biomarker trajectories and clinical progression from mild cognitive impairment to dementia?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["Alzheimer disease", "sex differences", "biomarker trajectories", "mild cognitive impairment", "progression", "longitudinal"]}
{"question": "In Parkinson's disease, what is the effectiveness and safety of focused ultrasound thalamotomy compared with deep brain stimulation for medication-refractory tremor?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "focused ultrasound thalamotomy", "deep brain stimulation", "tremor", "safety", "efficacy"]}
{"question": "In epilepsy, what clinical and EEG features predict response to antiseizure medications in juvenile myoclonic epilepsy?", "topic": "Epilepsy", "question_type": "prognosis", "expected_search_terms": ["juvenile myoclonic epilepsy", "EEG features", "predictors", "treatment response", "valproate", "levetiracetam"]}
{"question": "In Alzheimer's disease, what is the evidence that lipid metabolism and APOE-mediated pathways influence amyloid clearance and deposition?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["APOE", "lipid metabolism", "Alzheimer disease", "amyloid clearance", "amyloid deposition", "mechanism"]}
{"question": "In Parkinson's disease, how do cholinergic deficits contribute to gait freezing and falls, and do cholinesterase inhibitors improve these outcomes?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["Parkinson disease", "cholinergic deficit", "freezing of gait", "falls", "cholinesterase inhibitors", "trial"]}
{"question": "In epilepsy, what is the incidence and risk factors for antiseizure medication-induced Stevens–Johnson syndrome across commonly used agents?", "topic": "Epilepsy", "question_type": "epidemiology", "expected_search_terms": ["Stevens-Johnson syndrome", "antiepileptic drugs", "carbamazepine", "lamotrigine", "incidence", "risk factors"]}
{"question": "In Alzheimer's disease, does higher baseline physical frailty predict poorer tolerance and higher discontinuation rates of disease-modifying anti-amyloid therapy?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["Alzheimer disease", "frailty", "anti-amyloid therapy", "tolerability", "discontinuation", "adverse events"]}
{"question": "In Parkinson's disease, what is the association between air pollution exposure and risk of incident Parkinson's disease in population studies?", "topic": "Parkinson's disease", "question_type": "epidemiology", "expected_search_terms": ["air pollution", "PM2.5", "incident Parkinson disease", "epidemiology", "cohort", "environmental exposure"]}
{"question": "In epilepsy, what is the comparative effectiveness of cognitive rehabilitation interventions versus standard care for improving memory and attention in adults with focal epilepsy?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["epilepsy", "cognitive rehabilitation", "memory", "attention", "focal epilepsy", "controlled trial"]}
{"question": "In Alzheimer's disease, how does long-term exposure to fine particulate matter relate to dementia risk and do APOE genotypes modify susceptibility?", "topic": "Alzheimer's disease", "question_type": "epidemiology", "expected_search_terms": ["PM2.5", "air pollution", "dementia risk", "Alzheimer disease", "APOE", "effect modification"]}
{"question": "In Parkinson's disease, what is the prognostic significance of baseline axial symptoms (postural instability and gait difficulty) for subsequent disability?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "postural instability", "gait difficulty", "axial symptoms", "disability", "prognosis"]}
{"question": "In epilepsy, what evidence supports a role for blood–brain barrier disruption in seizure initiation and epileptogenesis following traumatic brain injury?", "topic": "Epilepsy", "question_type": "mechanism", "expected_search_terms": ["traumatic brain injury", "post-traumatic epilepsy", "blood brain barrier disruption", "epileptogenesis", "mechanism", "neurovascular"]}
{"question": "In Alzheimer's disease, what is the comparative effectiveness of different approaches to managing behavioral and psychological symptoms of dementia, such as music therapy versus pharmacologic therapy?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["behavioral and psychological symptoms of dementia", "Alzheimer disease", "music therapy", "pharmacologic therapy", "agitation", "randomized"]}
{"question": "In Parkinson's disease, how does constipation-targeted therapy (osmotic laxatives or prokinetics) affect levodopa absorption and motor fluctuations?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["Parkinson disease", "constipation treatment", "levodopa absorption", "motor fluctuations", "gastric emptying", "prokinetic"]}
{"question": "In epilepsy, what is the incidence and prognosis of postictal psychosis and which patient characteristics predict recurrence?", "topic": "Epilepsy", "question_type": "prognosis", "expected_search_terms": ["postictal psychosis", "epilepsy", "incidence", "recurrence", "risk factors", "prognosis"]}
{"question": "In Alzheimer's disease, what is the evidence that astrocyte dysfunction contributes to synaptic loss and neurodegeneration through altered glutamate homeostasis?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["Alzheimer disease", "astrocytes", "glutamate homeostasis", "synaptic loss", "EAAT2", "neurodegeneration"]}
{"question": "In Parkinson's disease, what is the comparative effectiveness of different antidepressant classes (SSRIs versus SNRIs) for depression without worsening motor symptoms?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "depression", "SSRI", "SNRI", "motor symptoms", "randomized"]}
{"question": "In epilepsy, how does early surgical referral versus prolonged medical therapy affect long-term seizure freedom and quality of life in drug-resistant focal epilepsy?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["drug-resistant focal epilepsy", "early surgery", "medical therapy", "seizure freedom", "quality of life", "timing"]}
{"question": "In Alzheimer's disease, what is the prognostic impact of mixed pathology (Alzheimer plus Lewy body or vascular pathology) on clinical progression compared with pure Alzheimer's pathology?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["mixed dementia", "Alzheimer disease", "Lewy body", "vascular pathology", "clinical progression", "prognosis"]}
{"question": "In Parkinson's disease, what evidence supports the role of oxidative stress in dopaminergic neuron degeneration and how do antioxidant strategies perform in clinical studies?", "topic": "Parkinson's disease", "question_type": "review", "expected_search_terms": ["Parkinson disease", "oxidative stress", "dopaminergic neurons", "antioxidants", "clinical trials", "review"]}
{"question": "In epilepsy, how do inflammatory biomarkers such as IL-6 or CRP relate to seizure frequency and treatment response in observational studies?", "topic": "Epilepsy", "question_type": "epidemiology", "expected_search_terms": ["epilepsy", "IL-6", "CRP", "inflammatory biomarkers", "seizure frequency", "treatment response"]}
{"question": "In Alzheimer's disease, does long-term intensive blood pressure control reduce risk of cognitive decline or incident dementia compared with standard control in older adults?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["intensive blood pressure control", "cognitive decline", "incident dementia", "older adults", "randomized", "hypertension"]}
{"question": "In Parkinson's disease, what is the prognostic value of baseline neurofilament light levels in predicting faster progression or atypical Parkinsonism?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson disease", "neurofilament light", "progression", "atypical parkinsonism", "prognostic biomarker", "plasma"]}
{"question": "In epilepsy, how does lamotrigine compare with carbamazepine for trigeminal neuralgia-like facial pain in patients with comorbid epilepsy regarding efficacy and tolerability?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["lamotrigine", "carbamazepine", "facial pain", "trigeminal neuralgia", "epilepsy comorbidity", "tolerability"]}
{"question": "In Alzheimer's disease, what is the evidence that viral infections or reactivation (such as herpesviruses) contribute to neuroinflammation and amyloid deposition?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["Alzheimer disease", "herpesvirus", "viral reactivation", "neuroinflammation", "amyloid deposition", "mechanism"]}
{"question": "In Parkinson's disease, how does early initiation of physiotherapy compare with delayed referral in improving long-term mobility and fall outcomes?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson disease", "physiotherapy", "early intervention", "mobility", "falls", "long-term outcomes"]}
{"question": "In epilepsy, what is the prognostic significance of interictal high-frequency oscillations on intracranial EEG for postsurgical seizure freedom?", "topic": "Epilepsy", "question_type": "prognosis", "expected_search_terms": ["high-frequency oscillations", "intracranial EEG", "epilepsy surgery", "seizure freedom", "prognostic", "biomarker"]}
{"question": "In Alzheimer's disease, what is the comparative effectiveness of different cognitive screening tools (MoCA versus MMSE) for detecting early Alzheimer's disease in primary care settings?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["MoCA", "MMSE", "early Alzheimer detection", "primary care", "screening", "diagnostic accuracy"]}
{"question": "In Parkinson's disease, does use of statins associate with altered risk of developing Parkinson's disease or differences in progression among diagnosed patients?", "topic": "Parkinson's disease", "question_type": "epidemiology", "expected_search_terms": ["statins", "Parkinson disease risk", "progression", "observational", "cohort", "confounding"]}
{"question": "In epilepsy, what is the comparative risk of major congenital malformations between levetiracetam and lamotrigine monotherapy during pregnancy?", "topic": "Epilepsy", "question_type": "epidemiology", "expected_search_terms": ["epilepsy pregnancy", "levetiracetam", "lamotrigine", "monotherapy", "major congenital malformations", "registry"]}
{"question": "In Alzheimer's disease, how does neurogranin in CSF perform as a synaptic biomarker for predicting progression compared with total tau or phosphorylated tau?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["CSF neurogranin", "synaptic biomarker", "Alzheimer disease", "total tau", "phosphorylated tau", "prediction"]}
{"question": "In first-line metastatic non-small cell lung cancer with high PD-L1 expression, how does PD-1/PD-L1 inhibitor monotherapy compare with chemo-immunotherapy for overall survival and grade ≥3 toxicity?", "topic": "PD-1/PD-L1 inhibitors in lung cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "high PD-L1", "pembrolizumab", "atezolizumab", "monotherapy", "chemoimmunotherapy", "overall survival", "grade 3 toxicity"]}
{"question": "In unresectable hepatocellular carcinoma, how does PD-1/PD-L1 inhibitor plus anti-VEGF therapy compare with PD-1/PD-L1 inhibitor monotherapy for progression-free survival and response rate?", "topic": "Checkpoint inhibitors and anti-angiogenic combinations", "question_type": "efficacy_comparison", "expected_search_terms": ["hepatocellular carcinoma", "PD-1", "PD-L1", "bevacizumab", "anti-VEGF", "combination therapy", "progression-free survival", "objective response"]}
{"question": "In advanced renal cell carcinoma, how do PD-1 inhibitor plus CTLA-4 inhibitor regimens compare with PD-1 inhibitor plus VEGFR tyrosine kinase inhibitor regimens for complete response rate and treatment discontinuation due to adverse events?", "topic": "Combination immunotherapy in renal cell carcinoma", "question_type": "efficacy_comparison", "expected_search_terms": ["renal cell carcinoma", "nivolumab", "ipilimumab", "pembrolizumab", "axitinib", "cabozantinib", "complete response", "treatment discontinuation"]}
{"question": "In first-line treatment of advanced melanoma, how does PD-1 inhibitor monotherapy compare with PD-1 plus CTLA-4 combination therapy for long-term overall survival in real-world cohorts?", "topic": "Checkpoint inhibitors in melanoma", "question_type": "efficacy_comparison", "expected_search_terms": ["melanoma", "PD-1 inhibitor", "CTLA-4 inhibitor", "combination", "real-world", "overall survival", "long-term follow-up"]}
{"question": "In mismatch repair–deficient metastatic colorectal cancer, how does PD-1 inhibitor monotherapy compare with PD-1 plus CTLA-4 blockade for response durability and immune-related adverse events?", "topic": "Checkpoint blockade in MSI-H/dMMR colorectal cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["dMMR", "MSI-H", "metastatic colorectal cancer", "PD-1", "CTLA-4", "durable response", "immune-related adverse events"]}
{"question": "In platinum-refractory head and neck squamous cell carcinoma, how do PD-1 inhibitors compare with standard single-agent chemotherapy for overall survival and quality-of-life outcomes?", "topic": "PD-1 inhibitors in head and neck cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["head and neck squamous cell carcinoma", "platinum-refractory", "PD-1 inhibitor", "chemotherapy", "overall survival", "quality of life"]}
{"question": "In triple-negative breast cancer, how does adding PD-1/PD-L1 inhibition to chemotherapy affect pathological complete response rates in the neoadjuvant setting?", "topic": "Neoadjuvant immunotherapy in breast cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["triple-negative breast cancer", "neoadjuvant", "PD-1", "PD-L1", "chemotherapy", "pathologic complete response", "pCR"]}
{"question": "In resected stage III melanoma, how does adjuvant PD-1 inhibitor therapy compare with observation for recurrence-free survival across different BRAF mutation statuses?", "topic": "Adjuvant checkpoint inhibitors", "question_type": "efficacy_comparison", "expected_search_terms": ["stage III melanoma", "adjuvant", "PD-1 inhibitor", "recurrence-free survival", "BRAF mutation", "subgroup analysis"]}
{"question": "In locally advanced esophageal cancer treated with chemoradiotherapy, how does consolidation PD-1/PD-L1 blockade influence overall survival compared with no immunotherapy?", "topic": "Consolidation immunotherapy after chemoradiation", "question_type": "efficacy_comparison", "expected_search_terms": ["esophageal cancer", "chemoradiotherapy", "consolidation", "PD-1", "PD-L1", "overall survival"]}
{"question": "In metastatic urothelial carcinoma, how does maintenance PD-L1 inhibitor therapy after platinum chemotherapy compare with observation for overall survival and adverse event burden?", "topic": "Maintenance immunotherapy in urothelial cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["urothelial carcinoma", "maintenance", "PD-L1 inhibitor", "platinum chemotherapy", "overall survival", "adverse events"]}
{"question": "In advanced gastric or gastroesophageal junction cancer, how does PD-1 inhibitor plus chemotherapy compare with chemotherapy alone for overall survival in patients with low versus high PD-L1 combined positive score?", "topic": "Biomarker-stratified immunotherapy in GI cancers", "question_type": "efficacy_comparison", "expected_search_terms": ["gastric cancer", "gastroesophageal junction", "PD-1", "chemotherapy", "PD-L1 CPS", "overall survival", "low CPS", "high CPS"]}
{"question": "In recurrent or metastatic cervical cancer, how does adding PD-1 inhibition to chemotherapy with or without anti-VEGF therapy affect overall survival compared with chemotherapy-based therapy alone?", "topic": "Checkpoint inhibitors in gynecologic cancers", "question_type": "efficacy_comparison", "expected_search_terms": ["cervical cancer", "PD-1 inhibitor", "chemotherapy", "bevacizumab", "overall survival", "combination therapy"]}
{"question": "In metastatic castration-resistant prostate cancer, what is the comparative activity of PD-1/PD-L1 inhibitor combinations versus PD-1/PD-L1 monotherapy in terms of PSA response rates?", "topic": "Immunotherapy in prostate cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["mCRPC", "PD-1", "PD-L1", "combination", "monotherapy", "PSA response", "immunotherapy"]}
{"question": "In relapsed/refractory classical Hodgkin lymphoma, how do PD-1 inhibitors compare with brentuximab vedotin for complete response rate and duration of response?", "topic": "PD-1 blockade in lymphoma", "question_type": "efficacy_comparison", "expected_search_terms": ["classical Hodgkin lymphoma", "PD-1 inhibitor", "brentuximab vedotin", "complete response", "duration of response", "relapsed refractory"]}
{"question": "In relapsed/refractory diffuse large B-cell lymphoma, how does CD19 CAR-T therapy compare with standard salvage chemotherapy and autologous transplant strategies for overall survival in transplant-eligible patients?", "topic": "CAR-T versus standard therapy in lymphoma", "question_type": "efficacy_comparison", "expected_search_terms": ["diffuse large B-cell lymphoma", "CD19 CAR-T", "salvage chemotherapy", "autologous transplant", "overall survival", "transplant eligible"]}
{"question": "In relapsed/refractory multiple myeloma, how do BCMA-targeted CAR-T products compare in rates of cytokine release syndrome and neurotoxicity across published clinical cohorts?", "topic": "CAR-T safety in multiple myeloma", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple myeloma", "BCMA", "CAR-T", "cytokine release syndrome", "ICANS", "neurotoxicity", "clinical cohort"]}
{"question": "In B-cell acute lymphoblastic leukemia, how does prior exposure to blinatumomab influence subsequent CD19 CAR-T response rates and relapse patterns?", "topic": "Sequencing immunotherapies in ALL", "question_type": "prognosis", "expected_search_terms": ["B-ALL", "blinatumomab", "CD19 CAR-T", "response rate", "relapse", "antigen loss"]}
{"question": "In patients receiving CAR-T therapy, how does prophylactic versus preemptive use of tocilizumab affect rates of severe cytokine release syndrome without compromising efficacy?", "topic": "CAR-T toxicity management", "question_type": "efficacy_comparison", "expected_search_terms": ["CAR-T", "tocilizumab", "prophylactic", "preemptive", "cytokine release syndrome", "efficacy", "overall response"]}
{"question": "In solid tumors, how does regional (intratumoral or locoregional) delivery of CAR-T cells compare with systemic infusion for objective response and on-target off-tumor toxicity?", "topic": "CAR-T in solid tumors and delivery strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["solid tumor", "CAR-T", "intratumoral", "locoregional", "systemic infusion", "objective response", "off-tumor toxicity"]}
{"question": "In glioblastoma, how does targeting IL13Rα2 with CAR-T compare with EGFRvIII-directed CAR-T approaches in reported safety signals and radiographic responses?", "topic": "CAR-T targets in glioblastoma", "question_type": "efficacy_comparison", "expected_search_terms": ["glioblastoma", "CAR-T", "IL13Rα2", "EGFRvIII", "safety", "radiographic response"]}
{"question": "What tumor-intrinsic signaling pathways are most consistently associated with resistance to PD-1/PD-L1 blockade across multiple cancer types?", "topic": "Mechanisms of checkpoint inhibitor resistance", "question_type": "mechanism", "expected_search_terms": ["PD-1 resistance", "PD-L1 resistance", "tumor intrinsic", "signaling pathway", "WNT beta-catenin", "PTEN", "JAK STAT", "antigen presentation"]}
{"question": "How does loss of antigen presentation machinery (such as HLA class I or beta-2 microglobulin) mechanistically contribute to acquired resistance to checkpoint blockade?", "topic": "Antigen presentation and immune escape", "question_type": "mechanism", "expected_search_terms": ["HLA class I loss", "beta-2 microglobulin", "B2M", "acquired resistance", "checkpoint blockade", "immune escape", "antigen presentation"]}
{"question": "What is the mechanistic role of interferon-gamma signaling defects in primary versus acquired resistance to PD-1/PD-L1 inhibitors?", "topic": "IFN-γ pathway in immunotherapy response", "question_type": "mechanism", "expected_search_terms": ["interferon gamma", "IFN signaling", "primary resistance", "acquired resistance", "PD-1", "JAK1", "JAK2", "STAT1"]}
{"question": "How does tumor mutational burden mechanistically relate to neoantigen quality and T-cell recognition in predicting response to checkpoint inhibitors?", "topic": "TMB and neoantigen biology", "question_type": "mechanism", "expected_search_terms": ["tumor mutational burden", "neoantigen", "T cell recognition", "checkpoint inhibitor response", "immunogenicity"]}
{"question": "What mechanisms link defects in DNA damage repair pathways to enhanced immunogenicity and improved response to PD-1/PD-L1 blockade?", "topic": "DNA repair defects and immunotherapy", "question_type": "mechanism", "expected_search_terms": ["DNA damage repair", "BRCA", "mismatch repair", "STING pathway", "neoantigen", "PD-1 response", "immunogenicity"]}
{"question": "How does activation of the STING pathway in tumor or host cells influence responsiveness to checkpoint blockade in preclinical and translational studies?", "topic": "Innate immunity and checkpoint response", "question_type": "mechanism", "expected_search_terms": ["STING", "cGAS", "checkpoint blockade", "PD-1", "innate immunity", "tumor microenvironment", "type I interferon"]}
{"question": "What is the mechanistic role of tumor-associated macrophage polarization in mediating resistance to PD-1/PD-L1 inhibitors?", "topic": "Macrophages in the tumor microenvironment", "question_type": "mechanism", "expected_search_terms": ["tumor-associated macrophages", "M1 M2", "PD-1 resistance", "PD-L1", "immunosuppression", "myeloid cells"]}
{"question": "How do myeloid-derived suppressor cells suppress antitumor T-cell activity during checkpoint blockade, and which molecular mediators are most implicated?", "topic": "Myeloid suppression mechanisms", "question_type": "mechanism", "expected_search_terms": ["myeloid-derived suppressor cells", "MDSC", "checkpoint blockade", "arginase", "ROS", "NO", "T cell suppression"]}
{"question": "What role does TGF-beta signaling play in T-cell exclusion phenotypes and reduced efficacy of PD-1/PD-L1 inhibitors?", "topic": "T-cell exclusion and stromal signaling", "question_type": "mechanism", "expected_search_terms": ["TGF-beta", "T cell exclusion", "immune excluded", "PD-1", "PD-L1", "tumor stroma", "fibroblasts"]}
{"question": "How do cancer-associated fibroblasts modulate immune infiltration and checkpoint inhibitor response through extracellular matrix remodeling?", "topic": "Stromal biology and immunotherapy", "question_type": "mechanism", "expected_search_terms": ["cancer-associated fibroblasts", "extracellular matrix", "immune infiltration", "checkpoint inhibitor", "tumor microenvironment", "fibrosis"]}
{"question": "What is the mechanistic contribution of hypoxia to immunosuppression and diminished checkpoint inhibitor efficacy in solid tumors?", "topic": "Hypoxia and immunotherapy resistance", "question_type": "mechanism", "expected_search_terms": ["hypoxia", "HIF-1", "tumor microenvironment", "immunosuppression", "PD-L1 expression", "checkpoint inhibitor efficacy"]}
{"question": "How does adenosine signaling via CD39/CD73 pathways suppress antitumor immunity and affect response to PD-1/PD-L1 blockade?", "topic": "Metabolic immunosuppression pathways", "question_type": "mechanism", "expected_search_terms": ["adenosine", "CD39", "CD73", "A2A receptor", "PD-1", "tumor microenvironment", "immunosuppression"]}
{"question": "What are the key mechanisms by which regulatory T cells attenuate responses to checkpoint inhibitors within the tumor microenvironment?", "topic": "Tregs and checkpoint therapy", "question_type": "mechanism", "expected_search_terms": ["regulatory T cells", "Treg", "checkpoint inhibitors", "CTLA-4", "PD-1", "tumor microenvironment", "immunosuppression"]}
{"question": "How does PD-L1 expression on non-tumor stromal or immune cells contribute mechanistically to checkpoint inhibitor response compared with PD-L1 on tumor cells?", "topic": "PD-L1 biology and biomarker interpretation", "question_type": "mechanism", "expected_search_terms": ["PD-L1 expression", "immune cells", "tumor cells", "stromal", "predictive biomarker", "checkpoint inhibitor", "tumor microenvironment"]}
{"question": "What mechanisms underlie hyperprogressive disease observed in a subset of patients treated with PD-1/PD-L1 inhibitors?", "topic": "Atypical responses to checkpoint inhibitors", "question_type": "mechanism", "expected_search_terms": ["hyperprogressive disease", "PD-1", "PD-L1", "mechanism", "MDM2 amplification", "immune checkpoint inhibitor"]}
{"question": "How does gut microbiome composition mechanistically influence systemic immune tone and response to PD-1/PD-L1 blockade?", "topic": "Microbiome and immunotherapy mechanisms", "question_type": "mechanism", "expected_search_terms": ["gut microbiome", "PD-1", "response", "immune tone", "antibiotics", "Bifidobacterium", "Akkermansia"]}
{"question": "What is the mechanistic basis for antibiotic exposure reducing efficacy of checkpoint inhibitors in observational and translational studies?", "topic": "Microbiome perturbation and outcomes", "question_type": "mechanism", "expected_search_terms": ["antibiotics", "checkpoint inhibitor", "PD-1", "microbiome disruption", "overall survival", "mechanism"]}
{"question": "How does corticosteroid use at initiation of PD-1/PD-L1 therapy mechanistically affect T-cell priming and clinical outcomes in cancer patients?", "topic": "Concomitant medications and immunotherapy biology", "question_type": "mechanism", "expected_search_terms": ["corticosteroids", "baseline steroids", "PD-1", "T-cell priming", "clinical outcomes", "immunosuppression"]}
{"question": "What mechanisms drive cytokine release syndrome following CAR-T infusion, and which cytokine pathways are most strongly associated with severe cases?", "topic": "CAR-T inflammatory toxicities", "question_type": "mechanism", "expected_search_terms": ["CAR-T", "cytokine release syndrome", "IL-6", "IL-1", "GM-CSF", "pathophysiology", "severity predictors"]}
{"question": "What is the mechanistic basis of immune effector cell-associated neurotoxicity syndrome after CAR-T therapy?", "topic": "CAR-T neurotoxicity mechanisms", "question_type": "mechanism", "expected_search_terms": ["ICANS", "CAR-T", "neurotoxicity", "blood-brain barrier", "endothelial activation", "cytokines"]}
{"question": "How does tonic signaling from CAR constructs contribute to T-cell exhaustion and reduced CAR-T persistence?", "topic": "CAR design and T-cell exhaustion", "question_type": "mechanism", "expected_search_terms": ["tonic signaling", "CAR construct", "T-cell exhaustion", "persistence", "costimulatory domain", "CD28", "4-1BB"]}
{"question": "What mechanistic factors determine CAR-T cell persistence in vivo, including costimulatory domain choice and memory phenotype?", "topic": "Determinants of CAR-T persistence", "question_type": "mechanism", "expected_search_terms": ["CAR-T persistence", "costimulatory domain", "CD28", "4-1BB", "memory phenotype", "stem cell memory", "TSCM"]}
{"question": "How does antigen density on tumor cells mechanistically influence CAR-T activation thresholds and clinical response probability?", "topic": "CAR-T target biology", "question_type": "mechanism", "expected_search_terms": ["antigen density", "CAR-T activation", "threshold", "tumor antigen", "CD19", "BCMA", "clinical response"]}
{"question": "What are the primary mechanisms of antigen-negative relapse after CAR-T therapy in B-cell malignancies?", "topic": "CAR-T relapse mechanisms", "question_type": "mechanism", "expected_search_terms": ["antigen-negative relapse", "CAR-T", "CD19 loss", "lineage switch", "alternative splicing", "immune escape"]}
{"question": "How does the tumor microenvironment in solid tumors mechanistically limit CAR-T trafficking and function compared with hematologic malignancies?", "topic": "CAR-T barriers in solid tumors", "question_type": "mechanism", "expected_search_terms": ["solid tumor", "CAR-T trafficking", "tumor microenvironment", "chemokines", "extracellular matrix", "immunosuppression"]}
{"question": "What is the mechanistic role of chemokine receptor engineering (such as CXCR2 or CCR2) in improving CAR-T tumor infiltration in solid tumors?", "topic": "Engineered CAR-T trafficking strategies", "question_type": "mechanism", "expected_search_terms": ["CAR-T", "chemokine receptor", "CXCR2", "CCR2", "tumor infiltration", "solid tumors", "trafficking"]}
{"question": "How do bispecific CAR designs or tandem CARs mechanistically reduce antigen escape compared with single-target CAR-T approaches?", "topic": "Multi-target CAR-T engineering", "question_type": "mechanism", "expected_search_terms": ["tandem CAR", "bispecific CAR", "dual target", "antigen escape", "CAR-T", "mechanism"]}
{"question": "What are the mechanistic explanations for differential outcomes between CD28- versus 4-1BB-costimulated CAR-T cells in terms of expansion and persistence?", "topic": "CAR costimulatory domain biology", "question_type": "mechanism", "expected_search_terms": ["CD28", "4-1BB", "CAR-T", "expansion", "persistence", "metabolism", "exhaustion"]}
{"question": "How does radiotherapy modulate the tumor microenvironment to enhance response to PD-1/PD-L1 blockade in solid tumors?", "topic": "Radiation-immunotherapy synergy", "question_type": "mechanism", "expected_search_terms": ["radiotherapy", "abscopal effect", "PD-1 blockade", "tumor microenvironment", "antigen presentation", "type I interferon"]}
{"question": "What are the immunologic mechanisms by which chemotherapy can augment checkpoint inhibitor responses through immunogenic cell death?", "topic": "Chemo-immunotherapy mechanisms", "question_type": "mechanism", "expected_search_terms": ["immunogenic cell death", "chemotherapy", "checkpoint inhibitor", "calreticulin", "HMGB1", "dendritic cells"]}
{"question": "How does VEGF signaling suppression mechanistically enhance T-cell infiltration and efficacy of PD-1/PD-L1 inhibitors?", "topic": "Anti-angiogenic immunomodulation", "question_type": "mechanism", "expected_search_terms": ["VEGF inhibition", "T cell infiltration", "vascular normalization", "PD-1", "tumor microenvironment", "anti-angiogenic"]}
{"question": "What cellular and molecular mechanisms underlie immune-related myocarditis from checkpoint inhibitor therapy?", "topic": "Immune-related adverse events mechanisms", "question_type": "mechanism", "expected_search_terms": ["immune-related myocarditis", "checkpoint inhibitor", "PD-1", "CTLA-4", "T cell infiltration", "autoimmunity", "pathophysiology"]}
{"question": "What mechanisms contribute to checkpoint inhibitor–associated colitis, and how do they differ from inflammatory bowel disease signatures?", "topic": "Immune-related colitis biology", "question_type": "mechanism", "expected_search_terms": ["checkpoint inhibitor colitis", "PD-1", "CTLA-4", "inflammatory bowel disease", "microbiome", "immune signatures"]}
{"question": "What is the incidence of immune-related pneumonitis in patients treated with PD-1 versus PD-L1 inhibitors across solid tumors?", "topic": "Immune-related adverse event epidemiology", "question_type": "epidemiology", "expected_search_terms": ["immune-related pneumonitis", "PD-1 inhibitor", "PD-L1 inhibitor", "incidence", "meta-analysis", "solid tumors"]}
{"question": "What patient or disease factors are associated with higher risk of immune-related pneumonitis during checkpoint inhibitor therapy in lung cancer?", "topic": "Risk factors for irAEs", "question_type": "epidemiology", "expected_search_terms": ["lung cancer", "checkpoint inhibitor", "pneumonitis", "risk factors", "radiation history", "interstitial lung disease", "smoking"]}
{"question": "What is the real-world incidence of immune-related endocrinopathies (thyroiditis, hypophysitis, diabetes) in patients receiving PD-1/PD-L1 inhibitors?", "topic": "Endocrine irAE epidemiology", "question_type": "epidemiology", "expected_search_terms": ["immune-related endocrinopathy", "thyroiditis", "hypophysitis", "checkpoint inhibitor", "incidence", "real-world"]}
{"question": "How frequently does immune-related myocarditis occur with combination PD-1 plus CTLA-4 therapy compared with PD-1 monotherapy?", "topic": "Severe irAE incidence by regimen", "question_type": "epidemiology", "expected_search_terms": ["immune-related myocarditis", "combination immunotherapy", "PD-1", "CTLA-4", "incidence", "pharmacovigilance", "meta-analysis"]}
{"question": "What is the incidence and timing distribution of cytokine release syndrome after CD19 CAR-T therapy in adults compared with pediatric patients?", "topic": "CAR-T toxicity epidemiology", "question_type": "epidemiology", "expected_search_terms": ["CD19 CAR-T", "cytokine release syndrome", "incidence", "timing", "adult", "pediatric"]}
{"question": "What is the incidence of immune effector cell-associated neurotoxicity syndrome across different CAR-T targets (CD19 versus BCMA) reported in clinical practice cohorts?", "topic": "CAR-T neurotoxicity epidemiology", "question_type": "epidemiology", "expected_search_terms": ["ICANS", "CAR-T", "CD19", "BCMA", "incidence", "real-world", "registry"]}
{"question": "How common is prolonged cytopenia after CAR-T therapy, and what baseline factors are associated with its occurrence?", "topic": "CAR-T hematologic toxicity", "question_type": "epidemiology", "expected_search_terms": ["CAR-T", "prolonged cytopenia", "risk factors", "baseline inflammation", "bone marrow reserve", "incidence"]}
{"question": "What is the incidence of infections within the first 90 days after CAR-T therapy, and how does it relate to hypogammaglobulinemia and cytopenias?", "topic": "Post-CAR-T infectious complications", "question_type": "epidemiology", "expected_search_terms": ["CAR-T", "infection", "hypogammaglobulinemia", "neutropenia", "incidence", "90 days", "prophylaxis"]}
{"question": "Among patients treated with checkpoint inhibitors, what is the population-level incidence of new-onset autoimmune diseases after therapy initiation?", "topic": "Autoimmunity after immunotherapy", "question_type": "epidemiology", "expected_search_terms": ["checkpoint inhibitor", "autoimmune disease", "new onset", "incidence", "population-based", "cohort study"]}
{"question": "What is the incidence of immune-related adverse events in older adults (≥75 years) receiving PD-1/PD-L1 inhibitors compared with younger patients?", "topic": "Age-related irAE epidemiology", "question_type": "epidemiology", "expected_search_terms": ["older adults", "elderly", "PD-1", "PD-L1", "immune-related adverse events", "incidence", "toxicity"]}
{"question": "How do response rates to PD-1/PD-L1 inhibitors differ between never-smokers and smokers with non-small cell lung cancer in published cohorts?", "topic": "Clinical predictors of immunotherapy response", "question_type": "epidemiology", "expected_search_terms": ["NSCLC", "never smoker", "smoker", "PD-1", "response rate", "tumor mutational burden"]}
{"question": "What is the frequency of pseudoprogression among patients treated with PD-1/PD-L1 inhibitors in melanoma and lung cancer, based on imaging-based studies?", "topic": "Atypical response patterns", "question_type": "epidemiology", "expected_search_terms": ["pseudoprogression", "PD-1", "PD-L1", "melanoma", "NSCLC", "imaging", "incidence"]}
{"question": "What is the incidence of hyperprogressive disease across tumor types treated with PD-1/PD-L1 inhibitors in observational studies using tumor growth rate definitions?", "topic": "Hyperprogression epidemiology", "question_type": "epidemiology", "expected_search_terms": ["hyperprogression", "tumor growth rate", "PD-1", "PD-L1", "incidence", "observational"]}
{"question": "How does baseline corticosteroid exposure prevalence vary across immunotherapy-treated cohorts, and how is it associated with overall survival in lung cancer?", "topic": "Concomitant medications in immunotherapy cohorts", "question_type": "epidemiology", "expected_search_terms": ["baseline corticosteroids", "immunotherapy", "lung cancer", "overall survival", "real-world", "cohort"]}
{"question": "What is the reported prevalence of PD-L1 expression positivity across different tumor types using immunohistochemistry assays commonly used in clinical practice?", "topic": "PD-L1 biomarker prevalence", "question_type": "epidemiology", "expected_search_terms": ["PD-L1 expression", "prevalence", "immunohistochemistry", "tumor types", "assay", "TPS", "CPS"]}
{"question": "In advanced NSCLC treated with PD-1/PD-L1 inhibitors, how well does baseline tumor mutational burden predict overall survival independent of PD-L1 status?", "topic": "Predictive biomarkers in lung cancer", "question_type": "prognosis", "expected_search_terms": ["NSCLC", "tumor mutational burden", "PD-L1", "PD-1 inhibitor", "overall survival", "predictive", "multivariable"]}
{"question": "In melanoma treated with PD-1 inhibitors, what is the prognostic value of baseline LDH level for overall survival and response durability?", "topic": "Prognostic markers in melanoma immunotherapy", "question_type": "prognosis", "expected_search_terms": ["melanoma", "PD-1 inhibitor", "LDH", "overall survival", "durable response", "prognostic factor"]}
{"question": "In patients receiving checkpoint inhibitors, how predictive is baseline neutrophil-to-lymphocyte ratio for progression-free survival across solid tumors?", "topic": "Inflammatory markers and outcomes", "question_type": "prognosis", "expected_search_terms": ["neutrophil-to-lymphocyte ratio", "NLR", "checkpoint inhibitor", "progression-free survival", "solid tumors", "meta-analysis"]}
{"question": "In urothelial carcinoma treated with PD-1/PD-L1 inhibitors, what is the prognostic significance of FGFR alterations for response and survival outcomes?", "topic": "Genomic predictors of immunotherapy response", "question_type": "prognosis", "expected_search_terms": ["urothelial carcinoma", "PD-1", "PD-L1", "FGFR alteration", "response", "overall survival", "biomarker"]}
{"question": "In MSI-H/dMMR gastrointestinal cancers treated with PD-1 blockade, what factors predict primary resistance despite mismatch repair deficiency?", "topic": "Resistance predictors in MSI-H cancers", "question_type": "prognosis", "expected_search_terms": ["MSI-H", "dMMR", "PD-1", "primary resistance", "predictors", "antigen presentation", "immune microenvironment"]}
{"question": "In patients treated with checkpoint inhibitors, how does occurrence of immune-related adverse events correlate with overall survival after adjusting for treatment duration bias?", "topic": "irAEs as outcome correlates", "question_type": "prognosis", "expected_search_terms": ["immune-related adverse events", "overall survival", "checkpoint inhibitors", "time-dependent bias", "landmark analysis"]}
{"question": "In metastatic renal cell carcinoma treated with PD-1-based combinations, what is the prognostic value of baseline IMDC risk groups for overall survival in immunotherapy-era cohorts?", "topic": "Clinical risk models in immunotherapy", "question_type": "prognosis", "expected_search_terms": ["renal cell carcinoma", "IMDC risk", "PD-1", "combination", "overall survival", "real-world"]}
{"question": "In NSCLC treated with PD-1/PD-L1 inhibitors, how does presence of EGFR activating mutations affect objective response rates and survival outcomes?", "topic": "Oncogenic drivers and immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["NSCLC", "EGFR mutation", "PD-1", "PD-L1", "objective response", "overall survival", "predictive"]}
{"question": "In NSCLC treated with PD-1/PD-L1 inhibitors, how does presence of STK11 or KEAP1 alterations influence response and overall survival?", "topic": "Genomic resistance markers in lung cancer", "question_type": "prognosis", "expected_search_terms": ["NSCLC", "STK11", "KEAP1", "PD-1", "PD-L1", "response", "overall survival"]}
{"question": "In melanoma treated with checkpoint inhibitors, what is the prognostic impact of brain metastases on overall survival and intracranial response rates?", "topic": "Immunotherapy outcomes in CNS disease", "question_type": "prognosis", "expected_search_terms": ["melanoma", "brain metastases", "checkpoint inhibitor", "intracranial response", "overall survival", "PD-1", "CTLA-4"]}
{"question": "In patients receiving CD19 CAR-T for large B-cell lymphoma, what baseline tumor burden measures are most predictive of severe cytokine release syndrome and response outcomes?", "topic": "CAR-T predictors of toxicity and efficacy", "question_type": "prognosis", "expected_search_terms": ["large B-cell lymphoma", "CD19 CAR-T", "tumor burden", "CRP", "ferritin", "cytokine release syndrome", "response"]}
{"question": "In multiple myeloma treated with BCMA CAR-T, how does prior exposure to BCMA-targeted bispecific antibodies affect subsequent CAR-T response and duration of response?", "topic": "Sequencing BCMA-targeted therapies", "question_type": "prognosis", "expected_search_terms": ["multiple myeloma", "BCMA CAR-T", "bispecific antibody", "prior therapy", "response", "duration of response"]}
{"question": "In CAR-T recipients, what is the prognostic value of early post-infusion CAR-T expansion kinetics for durable remission?", "topic": "CAR-T pharmacodynamics and outcomes", "question_type": "prognosis", "expected_search_terms": ["CAR-T expansion", "kinetics", "peak expansion", "area under curve", "durable remission", "persistence"]}
{"question": "In melanoma treated with PD-1 inhibitors, how predictive is baseline intratumoral CD8+ T-cell density for objective response compared with PD-L1 expression alone?", "topic": "Tumor microenvironment biomarkers", "question_type": "prognosis", "expected_search_terms": ["melanoma", "PD-1", "CD8 T cells", "tumor infiltrating lymphocytes", "PD-L1", "objective response", "biomarker"]}
{"question": "In solid tumors treated with checkpoint inhibitors, what is the prognostic value of circulating tumor DNA clearance during therapy for progression-free survival?", "topic": "Liquid biopsy monitoring in immunotherapy", "question_type": "prognosis", "expected_search_terms": ["circulating tumor DNA", "ctDNA clearance", "checkpoint inhibitors", "progression-free survival", "response monitoring"]}
{"question": "In NSCLC treated with immune checkpoint inhibitors, how does baseline tumor immune gene expression profiling (such as interferon-gamma signatures) predict response and survival?", "topic": "Transcriptomic predictors of immunotherapy", "question_type": "prognosis", "expected_search_terms": ["NSCLC", "interferon gamma signature", "gene expression", "immune checkpoint inhibitor", "response", "overall survival"]}
{"question": "In advanced gastric cancer treated with PD-1 blockade, what is the prognostic impact of Epstein–Barr virus positivity on response and survival outcomes?", "topic": "Virus-associated tumor immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["gastric cancer", "Epstein-Barr virus", "EBV-positive", "PD-1", "response", "overall survival", "biomarker"]}
{"question": "In Merkel cell carcinoma treated with PD-1/PD-L1 inhibitors, how do virus-positive and virus-negative tumors differ in response rates and durability?", "topic": "Virus status and checkpoint response", "question_type": "prognosis", "expected_search_terms": ["Merkel cell carcinoma", "polyomavirus", "virus-positive", "virus-negative", "PD-1", "PD-L1", "durable response"]}
{"question": "In patients with pre-existing autoimmune disease receiving PD-1/PD-L1 inhibitors, what is the risk of autoimmune flare and its impact on cancer outcomes?", "topic": "Immunotherapy in special populations", "question_type": "prognosis", "expected_search_terms": ["pre-existing autoimmune disease", "PD-1", "PD-L1", "autoimmune flare", "immune-related adverse events", "cancer outcomes"]}
{"question": "In organ transplant recipients treated with checkpoint inhibitors, what are the observed graft rejection rates and cancer response rates across published case series and cohorts?", "topic": "Checkpoint inhibitors in transplant recipients", "question_type": "prognosis", "expected_search_terms": ["organ transplant", "checkpoint inhibitor", "graft rejection", "response rate", "case series", "cohort"]}
{"question": "What is the comparative effectiveness of PD-1/PD-L1 inhibitors versus CTLA-4 inhibitors for metastatic melanoma in terms of overall survival and immune-related toxicity profiles?", "topic": "Checkpoint inhibitor class comparisons", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic melanoma", "PD-1 inhibitor", "CTLA-4 inhibitor", "overall survival", "immune-related toxicity", "comparison"]}
{"question": "In metastatic NSCLC, how does adding CTLA-4 blockade to PD-1/PD-L1 plus chemotherapy affect overall survival compared with PD-1/PD-L1 plus chemotherapy alone?", "topic": "Triplet immunotherapy regimens in lung cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "CTLA-4", "PD-1", "PD-L1", "chemotherapy", "triplet", "overall survival"]}
{"question": "In microsatellite-stable metastatic colorectal cancer, how effective are combinations of PD-1/PD-L1 inhibitors with multi-kinase inhibitors compared with PD-1/PD-L1 monotherapy?", "topic": "Immunotherapy combinations in MSS colorectal cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["microsatellite stable", "MSS", "metastatic colorectal cancer", "PD-1", "PD-L1", "multikinase inhibitor", "combination", "response rate"]}
{"question": "In advanced ovarian cancer, how does adding checkpoint inhibition to frontline chemotherapy affect progression-free survival compared with chemotherapy alone?", "topic": "Frontline immunotherapy in ovarian cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["ovarian cancer", "frontline", "checkpoint inhibitor", "chemotherapy", "progression-free survival"]}
{"question": "In relapsed small cell lung cancer, how does PD-1/PD-L1 inhibitor therapy compare with topotecan-based chemotherapy for overall survival in second-line treatment?", "topic": "Immunotherapy in small cell lung cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["small cell lung cancer", "second-line", "PD-1", "PD-L1", "topotecan", "overall survival", "comparison"]}
{"question": "In cutaneous squamous cell carcinoma, how do PD-1 inhibitors compare with conventional systemic therapies for objective response rate and durability?", "topic": "Checkpoint blockade in skin cancers", "question_type": "efficacy_comparison", "expected_search_terms": ["cutaneous squamous cell carcinoma", "PD-1 inhibitor", "systemic therapy", "objective response", "durable response"]}
{"question": "In advanced endometrial cancer, how does PD-1 inhibition combined with multikinase inhibition compare with PD-1 inhibition alone for progression-free survival in mismatch repair–proficient disease?", "topic": "Combination strategies in endometrial cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["endometrial cancer", "mismatch repair proficient", "pMMR", "PD-1 inhibitor", "multikinase inhibitor", "progression-free survival"]}
{"question": "In advanced biliary tract cancers, how does adding PD-1/PD-L1 blockade to first-line chemotherapy influence overall survival compared with chemotherapy alone?", "topic": "Checkpoint inhibitors in biliary tract cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["biliary tract cancer", "cholangiocarcinoma", "PD-1", "PD-L1", "first-line", "chemotherapy", "overall survival"]}
{"question": "In metastatic nasopharyngeal carcinoma, how does PD-1 inhibitor plus chemotherapy compare with chemotherapy alone for objective response and progression-free survival?", "topic": "Immunotherapy in virus-associated head and neck cancers", "question_type": "efficacy_comparison", "expected_search_terms": ["nasopharyngeal carcinoma", "PD-1 inhibitor", "chemotherapy", "objective response", "progression-free survival"]}
{"question": "In relapsed/refractory follicular lymphoma, how do CD19 CAR-T therapies compare with bispecific antibodies for complete response rate and infection risk?", "topic": "Cellular therapy versus bispecifics in lymphoma", "question_type": "efficacy_comparison", "expected_search_terms": ["follicular lymphoma", "CD19 CAR-T", "bispecific antibody", "complete response", "infection", "comparison"]}
{"question": "In relapsed/refractory acute lymphoblastic leukemia, how does dual-target CAR-T (e.g., CD19/CD22) compare with CD19-only CAR-T for antigen-negative relapse rates?", "topic": "Multi-antigen CAR-T strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["acute lymphoblastic leukemia", "dual-target CAR-T", "CD19", "CD22", "antigen-negative relapse", "comparison"]}
{"question": "In CAR-T treated B-cell malignancies, how do outcomes differ between patients receiving fludarabine/cyclophosphamide lymphodepletion versus alternative lymphodepletion regimens?", "topic": "Lymphodepletion optimization for CAR-T", "question_type": "efficacy_comparison", "expected_search_terms": ["CAR-T", "lymphodepletion", "fludarabine", "cyclophosphamide", "alternative regimen", "outcomes", "persistence"]}
{"question": "In PD-1/PD-L1 inhibitor therapy, how do circulating soluble PD-L1 levels correlate with treatment response and survival outcomes across cancers?", "topic": "Circulating biomarkers in immunotherapy", "question_type": "prognosis", "expected_search_terms": ["soluble PD-L1", "sPD-L1", "checkpoint inhibitor", "response", "overall survival", "biomarker", "meta-analysis"]}
{"question": "What is the evidence that baseline gut microbiome diversity predicts response to PD-1/PD-L1 inhibitors in melanoma and lung cancer?", "topic": "Microbiome as predictive biomarker", "question_type": "prognosis", "expected_search_terms": ["microbiome diversity", "alpha diversity", "PD-1", "melanoma", "NSCLC", "response prediction"]}
{"question": "In metastatic NSCLC treated with PD-1/PD-L1 inhibitors, what is the prognostic impact of liver metastases on treatment response and overall survival?", "topic": "Site-specific metastases and immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["NSCLC", "liver metastases", "PD-1", "PD-L1", "overall survival", "response", "prognostic"]}
{"question": "In melanoma treated with checkpoint inhibitors, what is the prognostic value of baseline T-cell receptor clonality in tumor tissue for response and survival?", "topic": "TCR repertoire biomarkers", "question_type": "prognosis", "expected_search_terms": ["T cell receptor", "TCR clonality", "melanoma", "checkpoint inhibitor", "response", "survival", "repertoire"]}
{"question": "In patients treated with PD-1 inhibitors, how does low skeletal muscle mass (sarcopenia) relate to immune-related toxicity and overall survival?", "topic": "Body composition and immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["sarcopenia", "body composition", "PD-1 inhibitor", "immune-related adverse events", "overall survival", "CT imaging"]}
{"question": "What is the evidence for using baseline or early on-treatment IL-6 levels to predict severity of cytokine release syndrome after CAR-T therapy?", "topic": "Biomarkers of CAR-T toxicity", "question_type": "prognosis", "expected_search_terms": ["IL-6", "CAR-T", "cytokine release syndrome", "predict", "severity", "biomarker"]}
{"question": "In patients receiving CAR-T therapy, what factors predict long-term hypogammaglobulinemia requiring immunoglobulin replacement?", "topic": "Long-term immune consequences of CAR-T", "question_type": "prognosis", "expected_search_terms": ["CAR-T", "hypogammaglobulinemia", "immunoglobulin replacement", "predictors", "B-cell aplasia", "long-term"]}
{"question": "What is the evidence that PD-L1 immunohistochemistry assay variability affects patient selection and outcomes for PD-1/PD-L1 inhibitor therapy?", "topic": "PD-L1 testing methodology", "question_type": "review", "expected_search_terms": ["PD-L1 assay", "immunohistochemistry", "variability", "TPS", "CPS", "patient selection", "outcomes"]}
{"question": "What is the evidence base supporting tumor mutational burden as a pan-cancer predictive biomarker for checkpoint inhibitor benefit?", "topic": "Pan-cancer biomarkers", "question_type": "review", "expected_search_terms": ["tumor mutational burden", "pan-cancer", "predictive biomarker", "checkpoint inhibitor", "meta-analysis", "response"]}
{"question": "What is known from the literature about mechanisms and clinical impact of PD-L1 amplification as a predictor of checkpoint inhibitor response?", "topic": "Genomic biomarkers of response", "question_type": "review", "expected_search_terms": ["PD-L1 amplification", "CD274 amplification", "checkpoint inhibitor", "predictive biomarker", "response", "tumor genomics"]}
{"question": "What is the current evidence regarding the optimal duration of PD-1 inhibitor therapy in patients achieving complete response across tumor types?", "topic": "Treatment duration and de-escalation", "question_type": "review", "expected_search_terms": ["PD-1 inhibitor", "treatment duration", "complete response", "stop therapy", "discontinuation", "durable remission"]}
{"question": "What is the evidence for retreatment with PD-1/PD-L1 inhibitors after prior discontinuation for immune-related adverse events in terms of recurrence of toxicity and antitumor activity?", "topic": "Immunotherapy rechallenge", "question_type": "review", "expected_search_terms": ["checkpoint inhibitor rechallenge", "immune-related adverse events", "retreatment", "toxicity recurrence", "antitumor activity"]}
{"question": "What is the evidence comparing management strategies for immune-related hepatitis, including corticosteroids versus mycophenolate, for resolution time and outcomes?", "topic": "Management of irAEs", "question_type": "review", "expected_search_terms": ["immune-related hepatitis", "checkpoint inhibitor", "corticosteroids", "mycophenolate", "management", "resolution"]}
{"question": "What is the evidence supporting fecal microbiota transplantation or microbiome modulation to improve checkpoint inhibitor responses in refractory melanoma?", "topic": "Microbiome interventions in immunotherapy", "question_type": "review", "expected_search_terms": ["fecal microbiota transplantation", "microbiome modulation", "melanoma", "checkpoint inhibitor", "refractory", "response"]}
{"question": "What is known about the safety and efficacy of PD-1/PD-L1 inhibitors in patients with chronic viral infections such as HIV, HBV, or HCV?", "topic": "Checkpoint inhibitors in immunocompromised or chronically infected patients", "question_type": "review", "expected_search_terms": ["PD-1 inhibitor", "HIV", "HBV", "HCV", "safety", "efficacy", "immune checkpoint inhibitor"]}
{"question": "What is the evidence for combining PD-1/PD-L1 inhibitors with PARP inhibitors in solid tumors regarding response rates and immune-related toxicity?", "topic": "Combination immunotherapy with DNA repair targeting", "question_type": "review", "expected_search_terms": ["PD-1", "PD-L1", "PARP inhibitor", "combination", "solid tumors", "response rate", "toxicity"]}
{"question": "What is the evidence for combining CAR-T therapy with checkpoint blockade to improve CAR-T persistence and antitumor activity?", "topic": "Combination cellular therapy and checkpoint inhibitors", "question_type": "review", "expected_search_terms": ["CAR-T", "checkpoint blockade", "PD-1", "PD-L1", "persistence", "combination therapy", "clinical outcomes"]}
{"question": "What is known about strategies to mitigate antigen escape after CAR-T therapy, including dual targeting and sequential targeting approaches?", "topic": "Preventing CAR-T relapse", "question_type": "review", "expected_search_terms": ["CAR-T", "antigen escape", "dual targeting", "sequential targeting", "CD19", "CD22", "BCMA", "relapse prevention"]}
{"question": "What is the evidence regarding off-the-shelf allogeneic CAR-T therapies compared with autologous CAR-T in terms of efficacy, graft-versus-host disease risk, and persistence?", "topic": "Allogeneic versus autologous CAR-T", "question_type": "review", "expected_search_terms": ["allogeneic CAR-T", "off-the-shelf", "autologous CAR-T", "efficacy", "graft-versus-host disease", "persistence"]}
{"question": "What is known about the impact of tumor spatial heterogeneity of immune infiltration on prediction of checkpoint inhibitor response?", "topic": "Spatial immuno-oncology biomarkers", "question_type": "review", "expected_search_terms": ["spatial heterogeneity", "immune infiltration", "checkpoint inhibitor response", "multiplex immunofluorescence", "spatial transcriptomics"]}
{"question": "What is the evidence for using radiomics features from CT or PET imaging to predict response to PD-1/PD-L1 inhibitors in lung cancer?", "topic": "Imaging biomarkers for immunotherapy", "question_type": "review", "expected_search_terms": ["radiomics", "PET", "CT", "lung cancer", "PD-1", "PD-L1", "predict response", "imaging biomarker"]}
{"question": "In advanced NSCLC, how does PD-1/PD-L1 inhibitor efficacy differ between patients with high tumor mutational burden but low PD-L1 versus low tumor mutational burden but high PD-L1?", "topic": "Composite biomarker stratification in lung cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "tumor mutational burden", "PD-L1 low", "PD-L1 high", "PD-1", "efficacy", "subgroup"]}
{"question": "In melanoma, how does adding oncolytic virus therapy to PD-1 blockade compare with PD-1 blockade alone for objective response rate and injectable lesion control?", "topic": "Oncolytic virus combinations", "question_type": "efficacy_comparison", "expected_search_terms": ["melanoma", "oncolytic virus", "PD-1", "combination", "objective response", "lesion control"]}
{"question": "In metastatic triple-negative breast cancer, how do outcomes with PD-1/PD-L1 inhibitors vary by tumor-infiltrating lymphocyte levels measured on baseline biopsy?", "topic": "TILs as predictive biomarkers", "question_type": "prognosis", "expected_search_terms": ["triple-negative breast cancer", "tumor-infiltrating lymphocytes", "TIL", "PD-1", "PD-L1", "response", "survival"]}
{"question": "In advanced NSCLC treated with checkpoint inhibitors, how does prior thoracic radiotherapy influence risk of pneumonitis and overall survival?", "topic": "Treatment history effects on immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["NSCLC", "thoracic radiotherapy", "checkpoint inhibitor", "pneumonitis", "overall survival", "risk"]}
{"question": "In CAR-T therapy for lymphoma, how does bridging therapy type (chemotherapy versus radiotherapy versus targeted therapy) relate to subsequent CAR-T response and toxicity?", "topic": "Bridging therapy in CAR-T pathways", "question_type": "prognosis", "expected_search_terms": ["CAR-T", "lymphoma", "bridging therapy", "chemotherapy", "radiotherapy", "targeted therapy", "response", "toxicity"]}
{"question": "In solid tumors treated with PD-1/PD-L1 inhibitors, how does baseline HLA class I heterozygosity versus homozygosity associate with overall survival?", "topic": "Host genetics and immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["HLA heterozygosity", "HLA class I", "checkpoint inhibitor", "PD-1", "overall survival", "host genetics"]}
{"question": "How does clonal versus subclonal neoantigen burden relate to checkpoint inhibitor response in melanoma and lung cancer?", "topic": "Neoantigen clonality and response", "question_type": "prognosis", "expected_search_terms": ["clonal neoantigen", "subclonal neoantigen", "melanoma", "lung cancer", "checkpoint inhibitor", "response", "tumor evolution"]}
{"question": "In patients treated with PD-1/PD-L1 inhibitors, what is the association between baseline obesity and treatment outcomes across major solid tumors?", "topic": "Host factors and immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["obesity", "BMI", "PD-1", "PD-L1", "checkpoint inhibitor", "overall survival", "response", "obesity paradox"]}
{"question": "In advanced melanoma treated with immunotherapy, how does baseline or on-treatment circulating eosinophil count correlate with response and survival?", "topic": "Peripheral blood biomarkers", "question_type": "prognosis", "expected_search_terms": ["melanoma", "eosinophils", "peripheral blood", "checkpoint inhibitor", "response", "overall survival"]}
{"question": "What is the evidence that tumor mutational signatures (such as APOBEC or UV) provide predictive value beyond tumor mutational burden for checkpoint inhibitor response?", "topic": "Mutational signatures and immunotherapy", "question_type": "review", "expected_search_terms": ["mutational signature", "APOBEC", "UV signature", "tumor mutational burden", "checkpoint inhibitor", "predictive value"]}
{"question": "What is known about the role of tertiary lymphoid structures in predicting response to checkpoint blockade across solid tumor types?", "topic": "Tumor microenvironment structures and response", "question_type": "review", "expected_search_terms": ["tertiary lymphoid structures", "TLS", "checkpoint blockade", "PD-1", "predict response", "tumor microenvironment"]}
{"question": "What is the evidence that baseline intratumoral B cells or plasma cell signatures predict checkpoint inhibitor efficacy?", "topic": "B-cell immunity in the tumor microenvironment", "question_type": "review", "expected_search_terms": ["intratumoral B cells", "plasma cells", "gene signature", "checkpoint inhibitor", "response", "tumor microenvironment"]}
{"question": "In melanoma and NSCLC, how does PD-1 inhibitor efficacy compare between patients with mucosal versus cutaneous melanoma or squamous versus adenocarcinoma histology, respectively?", "topic": "Histologic subtype differences in immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["PD-1 inhibitor", "mucosal melanoma", "cutaneous melanoma", "NSCLC", "squamous", "adenocarcinoma", "efficacy"]}
{"question": "In patients with melanoma treated with checkpoint inhibitors, how do outcomes differ between those with baseline anti-PD-1 resistance treated with combination immunotherapy versus alternative sequences?", "topic": "Treatment sequencing after resistance", "question_type": "efficacy_comparison", "expected_search_terms": ["melanoma", "anti-PD-1 resistant", "combination immunotherapy", "CTLA-4", "sequencing", "outcomes"]}
{"question": "In patients with advanced melanoma treated with PD-1 inhibitors, what is the incidence of vitiligo and how strongly is it associated with objective response?", "topic": "Cutaneous irAEs and efficacy correlations", "question_type": "epidemiology", "expected_search_terms": ["melanoma", "PD-1", "vitiligo", "incidence", "objective response", "association"]}
{"question": "In NSCLC treated with PD-1/PD-L1 inhibitors, what is the incidence of immune-related thyroid dysfunction and typical time to onset?", "topic": "Time course of endocrine irAEs", "question_type": "epidemiology", "expected_search_terms": ["NSCLC", "PD-1", "PD-L1", "thyroid dysfunction", "hypothyroidism", "hyperthyroidism", "incidence", "time to onset"]}
{"question": "What is the incidence of infusion reactions with PD-1/PD-L1 monoclonal antibodies in clinical practice and how are they typically managed?", "topic": "Administration-related adverse events", "question_type": "epidemiology", "expected_search_terms": ["infusion reaction", "PD-1 antibody", "PD-L1 antibody", "incidence", "management", "premedication"]}
{"question": "In patients receiving CAR-T, what is the incidence of secondary malignancies or therapy-related myeloid neoplasms reported during long-term follow-up?", "topic": "Long-term safety of CAR-T", "question_type": "epidemiology", "expected_search_terms": ["CAR-T", "long-term follow-up", "secondary malignancy", "therapy-related myeloid neoplasm", "MDS", "AML", "incidence"]}
{"question": "What is the comparative effectiveness of PD-1/PD-L1 inhibitors in patients with brain metastases versus those without brain metastases across solid tumors?", "topic": "Checkpoint inhibitors in CNS metastatic disease", "question_type": "efficacy_comparison", "expected_search_terms": ["brain metastases", "checkpoint inhibitor", "PD-1", "PD-L1", "intracranial response", "overall survival", "comparison"]}
{"question": "In advanced NSCLC with untreated brain metastases, how does PD-1/PD-L1 inhibitor monotherapy compare with combination immunotherapy for intracranial response rates?", "topic": "Intracranial efficacy in lung cancer", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "untreated brain metastases", "PD-1", "PD-L1", "combination immunotherapy", "intracranial response"]}
{"question": "In metastatic melanoma, how does anti-PD-1 plus anti-CTLA-4 therapy compare with anti-PD-1 alone for intracranial control in patients with brain metastases?", "topic": "Combination immunotherapy for melanoma brain metastases", "question_type": "efficacy_comparison", "expected_search_terms": ["melanoma", "brain metastases", "PD-1", "CTLA-4", "combination", "intracranial control", "response"]}
{"question": "In CAR-T therapy for lymphoma, how do manufacturing time and vein-to-vein time correlate with disease progression before infusion and overall outcomes?", "topic": "CAR-T logistics and outcomes", "question_type": "prognosis", "expected_search_terms": ["CAR-T", "manufacturing time", "vein-to-vein", "bridging", "progression before infusion", "outcomes", "lymphoma"]}
{"question": "What is the evidence that baseline metabolic tumor volume on PET predicts response and survival after checkpoint inhibitor therapy in lung cancer?", "topic": "PET biomarkers in immunotherapy", "question_type": "prognosis", "expected_search_terms": ["metabolic tumor volume", "PET", "FDG", "NSCLC", "checkpoint inhibitor", "response", "overall survival"]}
{"question": "What is the evidence for using early PET response criteria to distinguish pseudoprogression from true progression during PD-1/PD-L1 inhibitor therapy?", "topic": "Imaging response assessment in immunotherapy", "question_type": "review", "expected_search_terms": ["PET", "pseudoprogression", "true progression", "PD-1", "immune-related response criteria", "iRECIST", "early response"]}
{"question": "What is known about the role of LAG-3 expression in the tumor microenvironment as a biomarker of resistance to PD-1 blockade?", "topic": "Alternative immune checkpoints and resistance", "question_type": "review", "expected_search_terms": ["LAG-3", "PD-1 resistance", "tumor microenvironment", "immune checkpoint", "biomarker", "T cell exhaustion"]}
{"question": "In melanoma, how does PD-1 blockade plus LAG-3 blockade compare with PD-1 blockade alone for progression-free survival and immune-related toxicity?", "topic": "Checkpoint combination regimens", "question_type": "efficacy_comparison", "expected_search_terms": ["melanoma", "PD-1", "LAG-3", "combination", "progression-free survival", "immune-related toxicity"]}
{"question": "What is the evidence that TIGIT blockade enhances PD-1/PD-L1 inhibitor efficacy in NSCLC in terms of response rates and survival signals?", "topic": "Emerging checkpoint combinations in lung cancer", "question_type": "review", "expected_search_terms": ["TIGIT", "NSCLC", "PD-1", "PD-L1", "combination", "response rate", "overall survival"]}
{"question": "What is the evidence that tumor-associated neutrophils contribute to immunotherapy resistance through suppression of T-cell function?", "topic": "Innate immune cells in resistance", "question_type": "review", "expected_search_terms": ["tumor-associated neutrophils", "immunotherapy resistance", "T cell suppression", "checkpoint inhibitor", "tumor microenvironment"]}
{"question": "What is known about the impact of metabolic competition (glucose, amino acids) within the tumor microenvironment on T-cell function during checkpoint blockade?", "topic": "Immunometabolism in the tumor microenvironment", "question_type": "review", "expected_search_terms": ["tumor microenvironment", "metabolic competition", "glucose", "amino acids", "T cell function", "checkpoint blockade", "immunometabolism"]}
{"question": "How does lactate accumulation in tumors mechanistically impair cytotoxic T-cell activity and affect checkpoint inhibitor response?", "topic": "Tumor metabolism and immune suppression", "question_type": "mechanism", "expected_search_terms": ["lactate", "tumor acidity", "T cell dysfunction", "checkpoint inhibitor response", "tumor metabolism", "LDHA"]}
{"question": "What mechanisms explain differential response to PD-1 blockade between inflamed, immune-excluded, and immune-desert tumor phenotypes?", "topic": "Tumor immune phenotypes", "question_type": "mechanism", "expected_search_terms": ["immune inflamed", "immune excluded", "immune desert", "PD-1 blockade", "tumor phenotype", "mechanism", "T cell infiltration"]}
{"question": "In metastatic NSCLC, how does PD-1/PD-L1 inhibitor therapy compare between patients with high versus low baseline circulating tumor DNA levels for progression-free survival?", "topic": "Liquid biopsy prognostic stratification", "question_type": "prognosis", "expected_search_terms": ["NSCLC", "circulating tumor DNA", "baseline ctDNA", "PD-1", "PD-L1", "progression-free survival", "biomarker"]}
{"question": "In patients receiving checkpoint inhibitors, what is the incidence of immune-related nephritis and what clinical features predict recovery of renal function?", "topic": "Renal irAEs and outcomes", "question_type": "epidemiology", "expected_search_terms": ["immune-related nephritis", "acute interstitial nephritis", "checkpoint inhibitor", "incidence", "renal recovery", "predictors"]}
{"question": "What is the evidence for using baseline autoantibodies as predictors of immune-related adverse events during checkpoint inhibitor therapy?", "topic": "Predicting toxicity in immunotherapy", "question_type": "review", "expected_search_terms": ["autoantibodies", "checkpoint inhibitor", "predict immune-related adverse events", "ANA", "thyroid antibodies", "risk"]}
{"question": "In melanoma treated with PD-1 inhibitors, how does baseline HLA loss of heterozygosity relate to response and acquired resistance?", "topic": "Tumor immune evasion genomics", "question_type": "prognosis", "expected_search_terms": ["melanoma", "HLA loss of heterozygosity", "LOH", "PD-1", "response", "acquired resistance"]}
{"question": "In CAR-T therapy for multiple myeloma, how does baseline soluble BCMA level correlate with depth of response and progression-free survival?", "topic": "CAR-T biomarkers in myeloma", "question_type": "prognosis", "expected_search_terms": ["multiple myeloma", "CAR-T", "soluble BCMA", "depth of response", "progression-free survival", "biomarker"]}
{"question": "What is known about the impact of prior autologous stem cell transplantation on subsequent CAR-T efficacy and toxicity in lymphoma?", "topic": "Prior therapies influencing CAR-T outcomes", "question_type": "review", "expected_search_terms": ["autologous stem cell transplant", "CAR-T", "lymphoma", "efficacy", "toxicity", "prior therapy"]}
{"question": "What is the evidence that tumor-derived exosomes carrying PD-L1 contribute to systemic immunosuppression and reduced response to PD-1 blockade?", "topic": "Extracellular vesicles and immune suppression", "question_type": "review", "expected_search_terms": ["exosomal PD-L1", "tumor exosomes", "systemic immunosuppression", "PD-1 blockade", "biomarker", "mechanism"]}
{"question": "How does epigenetic regulation of antigen presentation genes influence sensitivity to PD-1/PD-L1 inhibitors, and what epigenetic therapies show immunomodulatory effects?", "topic": "Epigenetics and immunotherapy sensitivity", "question_type": "review", "expected_search_terms": ["epigenetic regulation", "antigen presentation", "HLA", "DNA methylation", "HDAC inhibitor", "PD-1", "immunomodulation"]}
{"question": "In melanoma and NSCLC, how does baseline presence of tertiary lymphoid structures compare with PD-L1 expression as a predictor of checkpoint inhibitor response?", "topic": "Comparative predictive biomarkers", "question_type": "prognosis", "expected_search_terms": ["tertiary lymphoid structures", "TLS", "PD-L1", "melanoma", "NSCLC", "checkpoint inhibitor", "predict response"]}
{"question": "In patients treated with checkpoint inhibitors, what is the rate of steroid-refractory immune-related colitis and which second-line immunosuppressants are most commonly used?", "topic": "Refractory irAE patterns", "question_type": "epidemiology", "expected_search_terms": ["steroid-refractory colitis", "checkpoint inhibitor", "infliximab", "vedolizumab", "incidence", "second-line immunosuppression"]}
{"question": "What is the evidence that baseline tumor microbiome (intratumoral bacteria) influences response to checkpoint inhibitors in lung cancer?", "topic": "Tumor microbiome and immunotherapy", "question_type": "review", "expected_search_terms": ["intratumoral microbiome", "lung cancer", "checkpoint inhibitor", "PD-1", "response", "microbiota"]}
{"question": "In melanoma treated with checkpoint inhibitors, how does prior antibiotic exposure within 30–60 days before therapy relate to response rate and overall survival?", "topic": "Antibiotics and immunotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["melanoma", "antibiotic exposure", "PD-1", "checkpoint inhibitor", "response rate", "overall survival", "timing"]}
{"question": "In NSCLC treated with PD-1/PD-L1 inhibitors, how does concurrent proton pump inhibitor use relate to treatment outcomes in observational studies?", "topic": "Concomitant medications affecting immunotherapy", "question_type": "prognosis", "expected_search_terms": ["NSCLC", "proton pump inhibitor", "PPI", "PD-1", "PD-L1", "overall survival", "observational"]}
{"question": "What is the evidence that baseline circulating cytokine profiles predict checkpoint inhibitor response and immune-related toxicity across solid tumors?", "topic": "Systemic immune profiling biomarkers", "question_type": "review", "expected_search_terms": ["circulating cytokines", "immune profiling", "checkpoint inhibitor", "predict response", "predict toxicity", "IL-8", "IL-6"]}
{"question": "In metastatic melanoma, how does PD-1 inhibitor efficacy compare between patients with primary versus acquired resistance to BRAF/MEK inhibitors?", "topic": "Cross-resistance and sequencing in melanoma", "question_type": "efficacy_comparison", "expected_search_terms": ["melanoma", "PD-1 inhibitor", "BRAF inhibitor", "MEK inhibitor", "primary resistance", "acquired resistance", "efficacy"]}
{"question": "In patients receiving PD-1/PD-L1 inhibitors, how does baseline performance status (ECOG 0–1 versus ≥2) affect survival outcomes in real-world studies?", "topic": "Real-world prognostic factors", "question_type": "prognosis", "expected_search_terms": ["ECOG", "performance status", "PD-1", "PD-L1", "real-world", "overall survival", "solid tumors"]}
{"question": "What is known about the impact of sex differences on efficacy and immune-related adverse events with PD-1/PD-L1 inhibitors across cancers?", "topic": "Sex as a modifier of immunotherapy outcomes", "question_type": "review", "expected_search_terms": ["sex differences", "gender", "PD-1", "PD-L1", "efficacy", "immune-related adverse events", "meta-analysis"]}
{"question": "In melanoma, how does baseline sun-exposure–related mutational burden compare with PD-L1 expression for predicting benefit from PD-1 inhibitors?", "topic": "Comparative predictors in melanoma", "question_type": "prognosis", "expected_search_terms": ["melanoma", "UV mutational burden", "PD-L1", "PD-1 inhibitor", "predict benefit", "response"]}
{"question": "What is the evidence for using peripheral blood T-cell exhaustion markers (such as PD-1, TIM-3) to predict response to checkpoint inhibitors?", "topic": "Peripheral immune monitoring", "question_type": "review", "expected_search_terms": ["peripheral blood", "T cell exhaustion", "PD-1", "TIM-3", "predict response", "checkpoint inhibitor", "flow cytometry"]}
{"question": "In people with cystic fibrosis who have at least one F508del CFTR variant, how does elexacaftor/tezacaftor/ivacaftor compare with tezacaftor/ivacaftor in improving percent predicted FEV1 over 24–48 weeks?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "elexacaftor tezacaftor ivacaftor", "tezacaftor ivacaftor", "ppFEV1", "randomized"]}
{"question": "Among cystic fibrosis patients with gating mutations, how does ivacaftor therapy compare with placebo in reducing pulmonary exacerbation rate?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "gating mutation", "ivacaftor", "pulmonary exacerbation", "placebo"]}
{"question": "In cystic fibrosis with residual function CFTR variants, how does tezacaftor/ivacaftor compare with placebo in improving sweat chloride concentration?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "residual function", "tezacaftor", "ivacaftor", "sweat chloride"]}
{"question": "In cystic fibrosis, how does initiation of triple CFTR modulator therapy affect body mass index compared with pre-modulator baseline in real-world cohorts?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "CFTR modulator", "elexacaftor tezacaftor ivacaftor", "body mass index", "real-world"]}
{"question": "In cystic fibrosis, how does chronic azithromycin therapy compare with placebo in reducing frequency of pulmonary exacerbations in patients chronically infected with Pseudomonas aeruginosa?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "azithromycin", "Pseudomonas aeruginosa", "pulmonary exacerbation", "placebo"]}
{"question": "In cystic fibrosis with chronic Pseudomonas infection, how does inhaled tobramycin compare with inhaled aztreonam in improving FEV1 and reducing exacerbations?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "inhaled tobramycin", "inhaled aztreonam", "FEV1", "pulmonary exacerbation"]}
{"question": "In cystic fibrosis, how does hypertonic saline compare with dornase alfa in improving lung function over at least 12 weeks?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "hypertonic saline", "dornase alfa", "lung function", "FEV1"]}
{"question": "In cystic fibrosis, how does long-term dornase alfa use affect the rate of decline in FEV1 compared with no mucolytic therapy?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "dornase alfa", "FEV1 decline", "long-term", "cohort"]}
{"question": "In cystic fibrosis, how does adherence to airway clearance therapy correlate with risk of hospitalization for pulmonary exacerbation?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "airway clearance", "adherence", "hospitalization", "pulmonary exacerbation"]}
{"question": "In cystic fibrosis, what is the association between CFTR modulator therapy and incidence of cystic fibrosis–related diabetes?", "topic": "cystic fibrosis", "question_type": "epidemiology", "expected_search_terms": ["cystic fibrosis", "CFTR modulator", "cystic fibrosis-related diabetes", "incidence", "registry"]}
{"question": "In cystic fibrosis, how does early diagnosis by newborn screening affect long-term lung function compared with symptom-based diagnosis?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "newborn screening", "early diagnosis", "lung function", "long-term outcomes"]}
{"question": "In cystic fibrosis, how does chronic infection with Burkholderia cepacia complex affect survival compared with chronic Pseudomonas aeruginosa infection?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "Burkholderia cepacia complex", "Pseudomonas aeruginosa", "survival", "prognosis"]}
{"question": "In cystic fibrosis, what is the prevalence of nontuberculous mycobacterial pulmonary disease and which species are most commonly isolated?", "topic": "cystic fibrosis", "question_type": "epidemiology", "expected_search_terms": ["cystic fibrosis", "nontuberculous mycobacteria", "Mycobacterium avium", "Mycobacterium abscessus", "prevalence"]}
{"question": "In cystic fibrosis, how does treatment of Mycobacterium abscessus complex infection impact lung function trajectory compared with no targeted therapy?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "Mycobacterium abscessus", "treatment", "lung function", "outcomes"]}
{"question": "In cystic fibrosis patients, how does chronic inhaled antibiotic cycling influence development of antimicrobial resistance in Pseudomonas aeruginosa?", "topic": "cystic fibrosis", "question_type": "mechanism", "expected_search_terms": ["cystic fibrosis", "inhaled antibiotics", "cycling", "Pseudomonas aeruginosa", "antimicrobial resistance"]}
{"question": "In cystic fibrosis, what is the relationship between airway neutrophil elastase levels and subsequent FEV1 decline?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "neutrophil elastase", "biomarker", "FEV1 decline", "longitudinal"]}
{"question": "In cystic fibrosis, how does CFTR dysfunction alter airway surface liquid pH and host antimicrobial activity?", "topic": "cystic fibrosis", "question_type": "mechanism", "expected_search_terms": ["cystic fibrosis", "CFTR dysfunction", "airway surface liquid", "pH", "antimicrobial activity"]}
{"question": "In cystic fibrosis, what molecular pathways link CFTR dysfunction to endoplasmic reticulum stress and epithelial inflammation?", "topic": "cystic fibrosis", "question_type": "mechanism", "expected_search_terms": ["cystic fibrosis", "CFTR", "endoplasmic reticulum stress", "UPR", "epithelial inflammation"]}
{"question": "In cystic fibrosis airway epithelium, how does CFTR modulator therapy affect mucociliary clearance metrics compared with baseline?", "topic": "cystic fibrosis", "question_type": "mechanism", "expected_search_terms": ["cystic fibrosis", "CFTR modulator", "mucociliary clearance", "airway epithelium", "imaging"]}
{"question": "In cystic fibrosis, how does pancreatic insufficiency influence risk of fat-soluble vitamin deficiency in contemporary cohorts?", "topic": "cystic fibrosis", "question_type": "epidemiology", "expected_search_terms": ["cystic fibrosis", "pancreatic insufficiency", "vitamin A", "vitamin D", "vitamin E"]}
{"question": "In cystic fibrosis, how does pancreatic enzyme replacement dosing strategy affect growth outcomes in children?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "pancreatic enzyme replacement", "dosing", "growth", "children"]}
{"question": "In cystic fibrosis, how does long-term proton pump inhibitor use relate to pulmonary exacerbation frequency or airway infection risk?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "proton pump inhibitor", "pulmonary exacerbation", "airway infection", "risk"]}
{"question": "In cystic fibrosis, how does the gut microbiome composition correlate with pulmonary outcomes such as exacerbation frequency?", "topic": "cystic fibrosis", "question_type": "mechanism", "expected_search_terms": ["cystic fibrosis", "gut microbiome", "pulmonary exacerbation", "axis", "metagenomics"]}
{"question": "In cystic fibrosis, what is the effect of CFTR modulator therapy on liver disease markers such as transaminases and hepatic steatosis prevalence?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "CFTR modulator", "liver disease", "transaminases", "steatosis"]}
{"question": "In cystic fibrosis, how does colonization with methicillin-resistant Staphylococcus aureus affect lung function decline compared with methicillin-sensitive strains?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "MRSA", "MSSA", "lung function decline", "FEV1"]}
{"question": "In cystic fibrosis, how effective is eradication therapy for newly acquired Pseudomonas aeruginosa compared with observation in preventing chronic infection?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "Pseudomonas eradication", "newly acquired", "chronic infection", "trial"]}
{"question": "In cystic fibrosis, what is the comparative effectiveness of continuous versus intermittent inhaled antibiotic regimens on exacerbation risk?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "inhaled antibiotics", "continuous", "intermittent", "exacerbation"]}
{"question": "In cystic fibrosis, what is the incidence and risk factor profile for allergic bronchopulmonary aspergillosis?", "topic": "cystic fibrosis", "question_type": "epidemiology", "expected_search_terms": ["cystic fibrosis", "allergic bronchopulmonary aspergillosis", "ABPA", "incidence", "risk factors"]}
{"question": "In cystic fibrosis, how does long-term systemic corticosteroid exposure relate to bone mineral density and fracture risk?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "corticosteroids", "bone mineral density", "fracture", "osteoporosis"]}
{"question": "In cystic fibrosis, how does vitamin D supplementation dose relate to achieved serum 25(OH)D levels and respiratory outcomes?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "vitamin D supplementation", "25-hydroxyvitamin D", "respiratory outcomes", "dose"]}
{"question": "In cystic fibrosis, what are the most consistent predictors of progression to end-stage lung disease requiring transplant referral?", "topic": "cystic fibrosis", "question_type": "review", "expected_search_terms": ["cystic fibrosis", "end-stage lung disease", "lung transplant referral", "predictors", "risk model"]}
{"question": "In cystic fibrosis, how do outcomes after lung transplantation compare between recipients with Burkholderia cepacia complex infection versus those without it?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "lung transplantation", "Burkholderia cepacia", "survival", "outcomes"]}
{"question": "In cystic fibrosis, what is the evidence that airway epithelial ion transport defects drive mucus dehydration and impaired clearance?", "topic": "cystic fibrosis", "question_type": "review", "expected_search_terms": ["cystic fibrosis", "ion transport", "mucus dehydration", "ENaC", "mucociliary clearance"]}
{"question": "In cystic fibrosis, how does transition from pediatric to adult care affect adherence and clinical outcomes such as exacerbations?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "transition of care", "adult clinic", "adherence", "exacerbation"]}
{"question": "In cystic fibrosis, what is the comparative effectiveness of continuous glucose monitoring versus standard monitoring in managing cystic fibrosis–related diabetes?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis-related diabetes", "continuous glucose monitoring", "standard care", "glycemic control", "HbA1c"]}
{"question": "In cystic fibrosis, what is the prevalence of mental health disorders such as depression and anxiety and how do they relate to pulmonary outcomes?", "topic": "cystic fibrosis", "question_type": "epidemiology", "expected_search_terms": ["cystic fibrosis", "depression", "anxiety", "prevalence", "pulmonary outcomes"]}
{"question": "In amyotrophic lateral sclerosis, how does riluzole compare with placebo in extending survival or time to tracheostomy in randomized trials?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "riluzole", "placebo", "survival", "tracheostomy"]}
{"question": "In amyotrophic lateral sclerosis, how does edaravone compare with standard care in slowing functional decline measured by ALSFRS-R?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "edaravone", "ALSFRS-R", "functional decline", "trial"]}
{"question": "In ALS, how does noninvasive ventilation compare with usual care in improving survival in patients with respiratory insufficiency?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "noninvasive ventilation", "respiratory insufficiency", "survival", "management"]}
{"question": "In ALS, how does percutaneous endoscopic gastrostomy placement timing relate to survival compared with delayed placement?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "gastrostomy", "timing", "survival", "nutrition"]}
{"question": "In ALS, what baseline clinical features most strongly predict rate of ALSFRS-R decline over the next 6–12 months?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "ALSFRS-R", "predictors", "progression", "baseline factors"]}
{"question": "In ALS, what is the association between bulbar onset versus limb onset and overall survival?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "bulbar onset", "limb onset", "survival", "prognosis"]}
{"question": "In ALS, how does C9orf72 repeat expansion status influence clinical phenotype such as cognitive impairment prevalence?", "topic": "ALS", "question_type": "epidemiology", "expected_search_terms": ["amyotrophic lateral sclerosis", "C9orf72", "repeat expansion", "frontotemporal dementia", "cognitive impairment"]}
{"question": "In ALS, how do neurofilament light chain levels in blood or cerebrospinal fluid correlate with disease progression rate?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "neurofilament light", "CSF", "blood biomarker", "progression"]}
{"question": "In ALS, what is the evidence that TDP-43 pathology disrupts RNA splicing and transport in motor neurons?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "TDP-43", "RNA splicing", "RNA transport", "motor neuron"]}
{"question": "In ALS models, how does SOD1 misfolding contribute to mitochondrial dysfunction and oxidative stress?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "SOD1", "mitochondrial dysfunction", "oxidative stress", "protein misfolding"]}
{"question": "In ALS, what is the evidence that impaired autophagy contributes to accumulation of toxic protein aggregates in motor neurons?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "autophagy", "protein aggregates", "TDP-43", "pathogenesis"]}
{"question": "In ALS, how does neuroinflammation mediated by microglia activation relate to disease progression in human studies?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "microglia", "neuroinflammation", "PET", "progression"]}
{"question": "In ALS, what is the relationship between excitotoxicity and glutamate transporter dysfunction in the motor cortex and spinal cord?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "excitotoxicity", "glutamate", "EAAT2", "astrocytes"]}
{"question": "In ALS, what is the incidence of venous thromboembolism and which clinical factors increase risk?", "topic": "ALS", "question_type": "epidemiology", "expected_search_terms": ["amyotrophic lateral sclerosis", "venous thromboembolism", "deep vein thrombosis", "incidence", "risk factors"]}
{"question": "In ALS, how does multidisciplinary clinic care compare with standard neurology follow-up in terms of survival and quality of life?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "multidisciplinary care", "survival", "quality of life", "clinic"]}
{"question": "In ALS, how does high-calorie nutritional supplementation compare with usual diet in affecting survival or functional decline?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "high-calorie diet", "nutritional supplementation", "survival", "ALSFRS-R"]}
{"question": "In ALS, what is the association between body mass index at diagnosis and subsequent survival?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "body mass index", "diagnosis", "survival", "prognostic factor"]}
{"question": "In ALS, how does forced vital capacity at baseline predict time to respiratory failure or death?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "forced vital capacity", "respiratory failure", "survival", "prediction"]}
{"question": "In ALS, what is the prevalence of frontotemporal dementia features and how do they affect caregiver burden?", "topic": "ALS", "question_type": "epidemiology", "expected_search_terms": ["amyotrophic lateral sclerosis", "frontotemporal dementia", "prevalence", "caregiver burden", "cognition"]}
{"question": "In ALS, how does the presence of pseudobulbar affect influence quality of life and adherence to supportive therapies?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "pseudobulbar affect", "quality of life", "supportive care", "adherence"]}
{"question": "In ALS, how does dextromethorphan/quinidine compare with placebo in reducing pseudobulbar affect episode frequency?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "pseudobulbar affect", "dextromethorphan quinidine", "placebo", "episodes"]}
{"question": "In ALS, what is the evidence that axonal transport defects precede motor neuron degeneration in human tissue or model systems?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "axonal transport", "motor neuron degeneration", "dynein", "kinesin"]}
{"question": "In ALS, how does repeat-associated non-AUG translation contribute to cellular toxicity in C9orf72-related disease?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "C9orf72", "RAN translation", "dipeptide repeats", "toxicity"]}
{"question": "In ALS, what is the evidence for blood–brain barrier dysfunction and its association with neuroinflammation?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "blood brain barrier", "permeability", "neuroinflammation", "endothelial"]}
{"question": "In ALS, how does physical activity level prior to diagnosis relate to incidence of ALS in population studies?", "topic": "ALS", "question_type": "epidemiology", "expected_search_terms": ["amyotrophic lateral sclerosis", "physical activity", "exercise", "incidence", "case-control"]}
{"question": "In ALS, what is the association between military service or environmental exposures and ALS risk across observational studies?", "topic": "ALS", "question_type": "review", "expected_search_terms": ["amyotrophic lateral sclerosis", "environmental exposure", "military", "risk", "epidemiology"]}
{"question": "In ALS, how does smoking history relate to disease risk and survival based on cohort and case-control evidence?", "topic": "ALS", "question_type": "epidemiology", "expected_search_terms": ["amyotrophic lateral sclerosis", "smoking", "risk", "survival", "cohort"]}
{"question": "In ALS, how does site of onset influence time to gastrostomy requirement?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "bulbar onset", "limb onset", "gastrostomy", "time to event"]}
{"question": "In ALS, what is the diagnostic yield of next-generation sequencing gene panels in apparently sporadic cases?", "topic": "ALS", "question_type": "epidemiology", "expected_search_terms": ["amyotrophic lateral sclerosis", "gene panel", "next-generation sequencing", "sporadic", "diagnostic yield"]}
{"question": "In ALS, how do antisense oligonucleotide approaches targeting SOD1 affect biomarkers and clinical outcomes compared with placebo in early-phase studies?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "SOD1", "antisense oligonucleotide", "biomarker", "placebo"]}
{"question": "In ALS, how does assistive communication technology use influence patient-reported quality of life compared with no device use?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "augmentative communication", "assistive technology", "quality of life", "patient-reported"]}
{"question": "In ALS, what is the evidence that cortical hyperexcitability measured by transcranial magnetic stimulation predicts faster progression?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "cortical hyperexcitability", "transcranial magnetic stimulation", "progression", "prognosis"]}
{"question": "In ALS, what is the prevalence of dysphagia at diagnosis and how does it predict aspiration pneumonia risk?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "dysphagia", "prevalence", "aspiration pneumonia", "risk"]}
{"question": "In ALS, how does early initiation of noninvasive ventilation affect rate of hospitalizations compared with later initiation?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "noninvasive ventilation", "early initiation", "hospitalization", "outcomes"]}
{"question": "In ALS, what mechanisms link FUS mutations to altered stress granule dynamics and motor neuron toxicity?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "FUS", "stress granules", "RNA-binding proteins", "toxicity"]}
{"question": "In ALS, what is the evidence that astrocyte-mediated glutamate dysregulation contributes to motor neuron death in human-derived cell models?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "astrocytes", "glutamate transporter", "iPSC", "motor neuron death"]}
{"question": "In Huntington's disease, how does tetrabenazine compare with deutetrabenazine in reducing chorea severity and causing adverse effects such as depression?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "tetrabenazine", "deutetrabenazine", "chorea", "adverse effects"]}
{"question": "In Huntington's disease, how effective are antipsychotic medications compared with VMAT2 inhibitors for management of chorea in clinical studies?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "chorea", "antipsychotic", "VMAT2 inhibitor", "treatment"]}
{"question": "In Huntington's disease, how does structured exercise therapy compare with usual care in improving motor function and balance?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "exercise", "physical therapy", "motor function", "balance"]}
{"question": "In Huntington's disease, how does cognitive training compare with standard supportive care in improving executive function outcomes?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "cognitive training", "executive function", "rehabilitation", "trial"]}
{"question": "In Huntington's disease, how does CAG repeat length relate to age at onset in large observational cohorts?", "topic": "Huntington's disease", "question_type": "epidemiology", "expected_search_terms": ["Huntington disease", "CAG repeat length", "age at onset", "observational", "genotype phenotype"]}
{"question": "In Huntington's disease, what baseline clinical or imaging markers predict faster progression to loss of independent function?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "predictors", "progression", "functional decline", "imaging biomarker"]}
{"question": "In Huntington's disease, how does striatal volume on MRI correlate with subsequent motor symptom progression?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "MRI", "striatal volume", "motor progression", "longitudinal"]}
{"question": "In Huntington's disease, what is the prevalence of suicidal ideation and which factors are most consistently associated with increased risk?", "topic": "Huntington's disease", "question_type": "epidemiology", "expected_search_terms": ["Huntington disease", "suicidal ideation", "prevalence", "risk factors", "depression"]}
{"question": "In Huntington's disease, how does use of selective serotonin reuptake inhibitors compare with placebo or usual care in treating depression symptoms?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "depression", "SSRI", "placebo", "treatment"]}
{"question": "In Huntington's disease, how does olanzapine compare with risperidone in controlling irritability and aggressive behavior?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "irritability", "aggression", "olanzapine", "risperidone"]}
{"question": "In Huntington's disease, what is the evidence that mutant huntingtin disrupts transcriptional regulation via altered histone acetylation?", "topic": "Huntington's disease", "question_type": "mechanism", "expected_search_terms": ["Huntington disease", "mutant huntingtin", "transcriptional dysregulation", "histone acetylation", "HDAC"]}
{"question": "In Huntington's disease models, how does mutant huntingtin impair mitochondrial dynamics and bioenergetics in neurons?", "topic": "Huntington's disease", "question_type": "mechanism", "expected_search_terms": ["Huntington disease", "mutant huntingtin", "mitochondria", "bioenergetics", "neuronal dysfunction"]}
{"question": "In Huntington's disease, what is the evidence that synaptic dysfunction occurs prior to overt neurodegeneration in the striatum?", "topic": "Huntington's disease", "question_type": "mechanism", "expected_search_terms": ["Huntington disease", "synaptic dysfunction", "early pathology", "striatum", "neurodegeneration"]}
{"question": "In Huntington's disease, how does impairment of autophagy contribute to accumulation of mutant huntingtin aggregates?", "topic": "Huntington's disease", "question_type": "mechanism", "expected_search_terms": ["Huntington disease", "autophagy", "huntingtin aggregates", "proteostasis", "pathogenesis"]}
{"question": "In Huntington's disease, how does peripheral inflammation measured by cytokines correlate with disease severity or progression?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "cytokines", "inflammation", "biomarker", "progression"]}
{"question": "In Huntington's disease, what is the prevalence of sleep disturbances and how do they relate to cognitive decline?", "topic": "Huntington's disease", "question_type": "epidemiology", "expected_search_terms": ["Huntington disease", "sleep disturbance", "insomnia", "cognitive decline", "prevalence"]}
{"question": "In Huntington's disease, how does melatonin therapy compare with placebo in improving sleep quality?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "melatonin", "sleep quality", "placebo", "trial"]}
{"question": "In Huntington's disease, how does weight loss over time relate to disease progression and mortality?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "weight loss", "BMI", "mortality", "progression"]}
{"question": "In Huntington's disease, what is the incidence of aspiration pneumonia and how does dysphagia severity predict risk?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "dysphagia", "aspiration pneumonia", "incidence", "risk"]}
{"question": "In Huntington's disease, how does dysphagia therapy compare with usual care in reducing aspiration events?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "dysphagia therapy", "swallowing therapy", "aspiration", "outcomes"]}
{"question": "In Huntington's disease, how does age at onset influence survival time from diagnosis to death?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "age at onset", "survival", "prognosis", "natural history"]}
{"question": "In Huntington's disease, what is the penetrance of intermediate and reduced-penetrance CAG repeat ranges across population studies?", "topic": "Huntington's disease", "question_type": "epidemiology", "expected_search_terms": ["Huntington disease", "penetrance", "intermediate alleles", "reduced penetrance", "CAG repeats"]}
{"question": "In Huntington's disease, what is the prevalence of psychiatric manifestations preceding motor onset in gene carriers?", "topic": "Huntington's disease", "question_type": "epidemiology", "expected_search_terms": ["Huntington disease", "premanifest", "psychiatric symptoms", "gene carriers", "prodromal"]}
{"question": "In Huntington's disease, how does neurofilament light chain in plasma or CSF relate to disease stage and progression rate?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "neurofilament light", "CSF", "plasma", "progression"]}
{"question": "In Huntington's disease, how does mutant huntingtin affect brain-derived neurotrophic factor transport and signaling in corticostriatal pathways?", "topic": "Huntington's disease", "question_type": "mechanism", "expected_search_terms": ["Huntington disease", "BDNF", "axonal transport", "corticostriatal", "mutant huntingtin"]}
{"question": "In Huntington's disease, what is the evidence supporting antisense oligonucleotide strategies to lower huntingtin protein as measured by CSF biomarkers?", "topic": "Huntington's disease", "question_type": "review", "expected_search_terms": ["Huntington disease", "antisense oligonucleotide", "huntingtin lowering", "CSF biomarker", "clinical trial"]}
{"question": "In Huntington's disease, how do approaches targeting somatic CAG repeat expansion relate to disease modification in preclinical studies?", "topic": "Huntington's disease", "question_type": "mechanism", "expected_search_terms": ["Huntington disease", "somatic expansion", "CAG repeat", "DNA repair", "preclinical"]}
{"question": "In Huntington's disease, how does speech therapy compare with usual care in improving speech intelligibility and communication participation?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "speech therapy", "dysarthria", "intelligibility", "communication"]}
{"question": "In Huntington's disease, what factors predict institutionalization or nursing home placement over the disease course?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "institutionalization", "nursing home", "predictors", "care needs"]}
{"question": "In Huntington's disease, what is the comparative prevalence of metabolic abnormalities such as insulin resistance versus matched controls?", "topic": "Huntington's disease", "question_type": "epidemiology", "expected_search_terms": ["Huntington disease", "metabolic", "insulin resistance", "glucose", "case-control"]}
{"question": "In cystic fibrosis, how does CFTR modulator therapy influence fertility outcomes in males with congenital bilateral absence of the vas deferens?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "CFTR modulator", "male fertility", "CBAVD", "reproductive outcomes"]}
{"question": "In cystic fibrosis, what is the impact of pregnancy on pulmonary outcomes and exacerbation risk in the era of CFTR modulators?", "topic": "cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "pregnancy", "CFTR modulator", "pulmonary exacerbation", "lung function"]}
{"question": "In cystic fibrosis, how does long-term use of inhaled corticosteroids compare with no inhaled corticosteroids in affecting exacerbation rate in patients without asthma?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "inhaled corticosteroids", "exacerbation", "asthma", "trial"]}
{"question": "In cystic fibrosis, what is the comparative effectiveness of airway clearance devices such as oscillatory PEP versus conventional chest physiotherapy on sputum clearance and lung function?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "oscillatory PEP", "chest physiotherapy", "sputum clearance", "lung function"]}
{"question": "In ALS, what is the prevalence of autonomic dysfunction and how does it relate to survival?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "autonomic dysfunction", "heart rate variability", "prevalence", "survival"]}
{"question": "In ALS, how does diaphragm pacing compare with standard respiratory care in terms of survival and adverse events?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "diaphragm pacing", "respiratory care", "survival", "adverse events"]}
{"question": "In ALS, what is the evidence that gut microbiome alterations are associated with disease severity or progression?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "gut microbiome", "dysbiosis", "progression", "severity"]}
{"question": "In ALS, what is the incidence of cognitive impairment without dementia and which neuropsychological domains are most affected?", "topic": "ALS", "question_type": "epidemiology", "expected_search_terms": ["amyotrophic lateral sclerosis", "cognitive impairment", "neuropsychological", "prevalence", "domains"]}
{"question": "In Huntington's disease, how does apathy severity correlate with functional decline and caregiver burden over time?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "apathy", "functional decline", "caregiver burden", "longitudinal"]}
{"question": "In Huntington's disease, how does clozapine compare with other antipsychotics in treating severe chorea or behavioral symptoms while minimizing motor worsening?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "clozapine", "antipsychotic", "chorea", "behavioral symptoms"]}
{"question": "In cystic fibrosis, how does long-term exposure to ambient air pollution relate to lung function decline and exacerbation rates?", "topic": "cystic fibrosis", "question_type": "epidemiology", "expected_search_terms": ["cystic fibrosis", "air pollution", "particulate matter", "lung function decline", "exacerbation"]}
{"question": "In ALS, how does participation in clinical trials relate to survival compared with non-participation after adjusting for disease severity?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "clinical trial participation", "survival", "selection bias", "registry"]}
{"question": "In cystic fibrosis, what is the evidence that early-life antibiotic exposure influences later airway microbiome diversity and clinical outcomes?", "topic": "cystic fibrosis", "question_type": "mechanism", "expected_search_terms": ["cystic fibrosis", "early antibiotic exposure", "airway microbiome", "diversity", "clinical outcomes"]}
{"question": "In Huntington's disease, how does family history of psychiatric illness modify the risk of psychiatric manifestations in gene expansion carriers?", "topic": "Huntington's disease", "question_type": "epidemiology", "expected_search_terms": ["Huntington disease", "family history", "psychiatric illness", "gene carriers", "risk"]}
{"question": "In ALS, how does long-term tracheostomy invasive ventilation compare with noninvasive ventilation in survival and quality of life outcomes?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "tracheostomy ventilation", "noninvasive ventilation", "survival", "quality of life"]}
{"question": "In cystic fibrosis, what is the comparative incidence of acute kidney injury with intravenous aminoglycosides versus alternative antipseudomonal regimens during exacerbation treatment?", "topic": "cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "aminoglycosides", "acute kidney injury", "intravenous antibiotics", "exacerbation treatment"]}
{"question": "In ALS, what is the evidence that dysfunction of nucleocytoplasmic transport contributes to neurodegeneration in C9orf72-associated disease?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["amyotrophic lateral sclerosis", "C9orf72", "nucleocytoplasmic transport", "nuclear pore", "neurodegeneration"]}
{"question": "In Huntington's disease, what is the association between psychiatric medication exposure and risk of falls or injuries?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "psychiatric medications", "falls", "injury", "risk"]}
{"question": "In cystic fibrosis, what are the most consistent predictors of poor response to CFTR modulator therapy as measured by change in FEV1?", "topic": "cystic fibrosis", "question_type": "review", "expected_search_terms": ["cystic fibrosis", "CFTR modulator", "predictors", "FEV1 response", "variability"]}
{"question": "In ALS, what is the evidence that metabolic hypermetabolism is present and how does it relate to survival?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "hypermetabolism", "resting energy expenditure", "survival", "nutrition"]}
{"question": "In Huntington's disease, how does caregiver-focused psychosocial intervention compare with usual support in reducing caregiver distress?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "caregiver intervention", "psychosocial", "caregiver distress", "trial"]}
{"question": "In cystic fibrosis, how does long-term macrolide therapy influence airway microbiome composition compared with no macrolide exposure?", "topic": "cystic fibrosis", "question_type": "mechanism", "expected_search_terms": ["cystic fibrosis", "macrolide", "azithromycin", "airway microbiome", "composition"]}
{"question": "In ALS, how does baseline depression affect survival and functional decline trajectories?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "depression", "survival", "functional decline", "ALSFRS-R"]}
{"question": "In Huntington's disease, what is the evidence that white matter changes on diffusion tensor imaging predict clinical progression?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "diffusion tensor imaging", "white matter", "predict", "progression"]}
{"question": "In rheumatoid arthritis, how does initiating methotrexate with a treat-to-target strategy compare with step-up conventional DMARD therapy in achieving sustained remission at 12 months?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "methotrexate", "treat-to-target", "step-up therapy", "remission", "DAS28"]}
{"question": "In rheumatoid arthritis with inadequate response to methotrexate, how do TNF inhibitors compare with JAK inhibitors for clinical remission and serious infection risk?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "methotrexate inadequate response", "TNF inhibitor", "JAK inhibitor", "remission", "serious infection"]}
{"question": "In seropositive rheumatoid arthritis, does abatacept have comparable efficacy to TNF inhibitors in preventing radiographic progression over one year?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "seropositive", "abatacept", "TNF inhibitor", "radiographic progression", "Sharp score"]}
{"question": "In rheumatoid arthritis, how does IL-6 receptor blockade compare with TNF inhibition in improving anemia of chronic disease?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "IL-6 receptor", "tocilizumab", "TNF inhibitor", "anemia", "hemoglobin"]}
{"question": "In rheumatoid arthritis patients in sustained remission, how do tapering strategies of biologic DMARDs compare with continuation in terms of flare rates and functional outcomes?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "biologic tapering", "remission", "flare", "functional outcome", "HAQ"]}
{"question": "In early rheumatoid arthritis, what is the prognostic value of baseline anti-CCP antibody titers for radiographic joint damage progression?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["early rheumatoid arthritis", "anti-CCP", "ACPA titer", "radiographic progression", "prognosis"]}
{"question": "In rheumatoid arthritis, how does smoking status modify the clinical response to methotrexate-based therapy?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "smoking", "methotrexate", "treatment response", "remission"]}
{"question": "In rheumatoid arthritis, what is the association between periodontal disease and disease activity, and how consistent is this across observational studies?", "topic": "Rheumatoid arthritis", "question_type": "epidemiology", "expected_search_terms": ["rheumatoid arthritis", "periodontal disease", "disease activity", "observational study", "association"]}
{"question": "In rheumatoid arthritis, how do circulating citrullinated protein-specific B cells contribute mechanistically to synovial inflammation?", "topic": "Rheumatoid arthritis", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "citrullinated protein", "B cells", "synovial inflammation", "pathogenesis"]}
{"question": "In rheumatoid arthritis synovium, what is the role of fibroblast-like synoviocyte subsets in driving pannus formation and joint destruction?", "topic": "Rheumatoid arthritis", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "fibroblast-like synoviocytes", "synovial subsets", "pannus", "joint destruction"]}
{"question": "In rheumatoid arthritis, what evidence supports NETosis as a source of citrullinated autoantigens and amplification of autoimmunity?", "topic": "Rheumatoid arthritis", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "NETosis", "neutrophil extracellular traps", "citrullination", "autoantigen"]}
{"question": "In rheumatoid arthritis, how does IL-17 pathway activity correlate with erosive disease and response to therapy?", "topic": "Rheumatoid arthritis", "question_type": "review", "expected_search_terms": ["rheumatoid arthritis", "IL-17", "Th17", "erosive disease", "treatment response"]}
{"question": "In rheumatoid arthritis, what is the incidence of interstitial lung disease among patients treated with methotrexate compared with those not receiving methotrexate?", "topic": "Rheumatoid arthritis", "question_type": "epidemiology", "expected_search_terms": ["rheumatoid arthritis", "interstitial lung disease", "methotrexate", "incidence", "cohort"]}
{"question": "In rheumatoid arthritis-associated interstitial lung disease, how does rituximab compare with mycophenolate mofetil in stabilizing forced vital capacity?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "interstitial lung disease", "rituximab", "mycophenolate", "forced vital capacity"]}
{"question": "In rheumatoid arthritis, what is the magnitude of cardiovascular risk reduction associated with achieving sustained low disease activity?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "cardiovascular risk", "low disease activity", "remission", "cohort study"]}
{"question": "In rheumatoid arthritis, how does long-term low-dose glucocorticoid therapy affect fracture risk compared with glucocorticoid-sparing regimens?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "low-dose glucocorticoid", "fracture risk", "glucocorticoid sparing", "osteoporosis"]}
{"question": "In rheumatoid arthritis, how predictive is baseline ultrasound power Doppler signal for future clinical flares in patients in clinical remission?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "ultrasound", "power Doppler", "clinical remission", "flare prediction"]}
{"question": "In rheumatoid arthritis, what is the comparative effectiveness of subcutaneous versus oral methotrexate on disease activity and gastrointestinal adverse effects?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "methotrexate", "subcutaneous", "oral", "disease activity", "gastrointestinal adverse effects"]}
{"question": "In rheumatoid arthritis, how does obesity influence pharmacokinetics and clinical response to TNF inhibitor therapy?", "topic": "Rheumatoid arthritis", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "obesity", "TNF inhibitor", "pharmacokinetics", "treatment response"]}
{"question": "In rheumatoid arthritis, what evidence supports gut microbiome dysbiosis as a contributor to disease onset or severity?", "topic": "Rheumatoid arthritis", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "gut microbiome", "dysbiosis", "disease onset", "severity"]}
{"question": "In rheumatoid arthritis, how does early intensive therapy impact long-term work disability compared with delayed escalation?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "early intensive therapy", "delayed escalation", "work disability", "long-term outcome"]}
{"question": "In rheumatoid arthritis, how do biosimilar TNF inhibitors compare with originators in real-world persistence and immunogenicity?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "biosimilar", "TNF inhibitor", "persistence", "immunogenicity", "real-world"]}
{"question": "In rheumatoid arthritis, what is the risk of herpes zoster with JAK inhibitors compared with biologic DMARDs, and how does vaccination modify this risk?", "topic": "Rheumatoid arthritis", "question_type": "epidemiology", "expected_search_terms": ["rheumatoid arthritis", "JAK inhibitor", "biologic DMARD", "herpes zoster", "vaccination", "risk"]}
{"question": "In rheumatoid arthritis, how does seronegative disease differ from seropositive disease in clinical course and radiographic progression?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "seronegative", "seropositive", "radiographic progression", "clinical course"]}
{"question": "In rheumatoid arthritis, what mechanisms explain bone erosion mediated by the RANKL-osteoclast axis in inflamed synovium?", "topic": "Rheumatoid arthritis", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "RANKL", "osteoclast", "bone erosion", "synovium"]}
{"question": "In rheumatoid arthritis, how does anti-drug antibody formation affect clinical response to monoclonal antibody TNF inhibitors compared with receptor fusion proteins?", "topic": "Rheumatoid arthritis", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "anti-drug antibodies", "TNF inhibitors", "immunogenicity", "clinical response"]}
{"question": "In systemic lupus erythematosus, how does belimumab plus standard therapy compare with standard therapy alone in reducing flare frequency in patients with high disease activity?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "belimumab", "standard therapy", "flare", "high disease activity"]}
{"question": "In lupus nephritis, how does mycophenolate mofetil compare with cyclophosphamide for induction therapy regarding complete renal response and infertility-related adverse events?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["lupus nephritis", "mycophenolate mofetil", "cyclophosphamide", "induction therapy", "complete renal response", "infertility"]}
{"question": "In proliferative lupus nephritis, how does multitarget therapy with mycophenolate and calcineurin inhibitors compare with mycophenolate alone for proteinuria reduction at 6 to 12 months?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["proliferative lupus nephritis", "multitarget therapy", "mycophenolate", "tacrolimus", "voclosporin", "proteinuria"]}
{"question": "In systemic lupus erythematosus, what is the relationship between type I interferon gene signature levels and disease activity across cohorts?", "topic": "Systemic lupus erythematosus", "question_type": "mechanism", "expected_search_terms": ["systemic lupus erythematosus", "type I interferon", "gene signature", "disease activity", "biomarker"]}
{"question": "In systemic lupus erythematosus, how do anti-dsDNA antibody levels and complement consumption predict impending clinical flares?", "topic": "Systemic lupus erythematosus", "question_type": "prognosis", "expected_search_terms": ["systemic lupus erythematosus", "anti-dsDNA", "complement", "C3", "C4", "flare prediction"]}
{"question": "In systemic lupus erythematosus, how does hydroxychloroquine adherence influence thrombosis risk over time?", "topic": "Systemic lupus erythematosus", "question_type": "prognosis", "expected_search_terms": ["systemic lupus erythematosus", "hydroxychloroquine", "adherence", "thrombosis", "risk"]}
{"question": "In systemic lupus erythematosus, what is the comparative risk of retinal toxicity with different hydroxychloroquine dosing strategies adjusted for body weight?", "topic": "Systemic lupus erythematosus", "question_type": "epidemiology", "expected_search_terms": ["systemic lupus erythematosus", "hydroxychloroquine", "retinal toxicity", "dose", "body weight"]}
{"question": "In systemic lupus erythematosus, what evidence supports defective clearance of apoptotic cells as a driver of autoantigen exposure and autoantibody production?", "topic": "Systemic lupus erythematosus", "question_type": "mechanism", "expected_search_terms": ["systemic lupus erythematosus", "apoptotic cell clearance", "efferocytosis", "autoantigen", "autoantibodies"]}
{"question": "In systemic lupus erythematosus, how does BAFF signaling contribute to B-cell selection and persistence of autoreactive clones?", "topic": "Systemic lupus erythematosus", "question_type": "mechanism", "expected_search_terms": ["systemic lupus erythematosus", "BAFF", "BLyS", "B-cell selection", "autoreactive clones"]}
{"question": "In systemic lupus erythematosus, how do neutrophil extracellular traps influence plasmacytoid dendritic cell activation and interferon production?", "topic": "Systemic lupus erythematosus", "question_type": "mechanism", "expected_search_terms": ["systemic lupus erythematosus", "NETs", "plasmacytoid dendritic cells", "interferon", "TLR9"]}
{"question": "In systemic lupus erythematosus, how does anifrolumab compare with placebo in improving cutaneous manifestations as measured by validated skin activity scores?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "anifrolumab", "cutaneous lupus", "CLASI", "placebo", "skin activity"]}
{"question": "In systemic lupus erythematosus, what is the prevalence and clinical impact of antiphospholipid antibodies in patients without prior thrombosis?", "topic": "Systemic lupus erythematosus", "question_type": "epidemiology", "expected_search_terms": ["systemic lupus erythematosus", "antiphospholipid antibodies", "prevalence", "thrombosis", "risk"]}
{"question": "In antiphospholipid syndrome associated with lupus, how does warfarin compare with direct oral anticoagulants for preventing recurrent arterial thrombosis?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["antiphospholipid syndrome", "systemic lupus erythematosus", "warfarin", "direct oral anticoagulant", "arterial thrombosis", "recurrence"]}
{"question": "In systemic lupus erythematosus, what factors predict progression from mild disease to organ-threatening involvement over five years?", "topic": "Systemic lupus erythematosus", "question_type": "prognosis", "expected_search_terms": ["systemic lupus erythematosus", "progression", "organ involvement", "predictors", "cohort"]}
{"question": "In lupus nephritis, how does achieving early proteinuria reduction predict long-term renal survival and chronic kidney disease progression?", "topic": "Systemic lupus erythematosus", "question_type": "prognosis", "expected_search_terms": ["lupus nephritis", "proteinuria reduction", "renal survival", "chronic kidney disease", "predictor"]}
{"question": "In lupus nephritis, how does repeat kidney biopsy influence management decisions and outcomes compared with clinical monitoring alone?", "topic": "Systemic lupus erythematosus", "question_type": "review", "expected_search_terms": ["lupus nephritis", "repeat biopsy", "management", "outcomes", "clinical monitoring"]}
{"question": "In systemic lupus erythematosus, what is the association between cumulative glucocorticoid exposure and irreversible organ damage indices?", "topic": "Systemic lupus erythematosus", "question_type": "prognosis", "expected_search_terms": ["systemic lupus erythematosus", "cumulative glucocorticoid", "organ damage", "damage index", "SDI"]}
{"question": "In systemic lupus erythematosus, how do biologic therapies affect vaccine immunogenicity to influenza or pneumococcal vaccines compared with standard therapy?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "biologic therapy", "vaccine immunogenicity", "influenza vaccine", "pneumococcal vaccine"]}
{"question": "In systemic lupus erythematosus, what is the incidence of severe infections with mycophenolate compared with azathioprine during maintenance therapy for lupus nephritis?", "topic": "Systemic lupus erythematosus", "question_type": "epidemiology", "expected_search_terms": ["lupus nephritis", "maintenance therapy", "mycophenolate", "azathioprine", "severe infection", "incidence"]}
{"question": "In systemic lupus erythematosus, what are the mechanisms linking complement activation to endothelial dysfunction and vascular events?", "topic": "Systemic lupus erythematosus", "question_type": "mechanism", "expected_search_terms": ["systemic lupus erythematosus", "complement activation", "endothelial dysfunction", "vascular events", "C5a"]}
{"question": "In systemic lupus erythematosus pregnancy, how does continuing hydroxychloroquine compare with discontinuation in preventing maternal flares and adverse pregnancy outcomes?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "pregnancy", "hydroxychloroquine", "flare", "pregnancy outcomes"]}
{"question": "In pregnant patients with anti-Ro/SSA antibodies, how effective is hydroxychloroquine in reducing the risk of congenital heart block recurrence?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["anti-Ro", "SSA antibodies", "pregnancy", "hydroxychloroquine", "congenital heart block", "recurrence"]}
{"question": "In systemic lupus erythematosus, what is the prevalence of cognitive dysfunction and how does it correlate with MRI or neuropsychological testing findings?", "topic": "Systemic lupus erythematosus", "question_type": "epidemiology", "expected_search_terms": ["systemic lupus erythematosus", "cognitive dysfunction", "MRI", "neuropsychological testing", "prevalence"]}
{"question": "In neuropsychiatric lupus, how does immunosuppressive therapy compare with symptomatic management alone for improving neurocognitive outcomes?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["neuropsychiatric lupus", "immunosuppressive therapy", "symptomatic treatment", "neurocognitive outcomes"]}
{"question": "In systemic lupus erythematosus, what evidence supports plasmablast expansion as a marker of active disease and response to therapy?", "topic": "Systemic lupus erythematosus", "question_type": "review", "expected_search_terms": ["systemic lupus erythematosus", "plasmablasts", "disease activity", "biomarker", "treatment response"]}
{"question": "In systemic lupus erythematosus, how do racial and ethnic differences influence incidence rates and severity at presentation?", "topic": "Systemic lupus erythematosus", "question_type": "epidemiology", "expected_search_terms": ["systemic lupus erythematosus", "incidence", "race", "ethnicity", "severity", "disparities"]}
{"question": "In multiple sclerosis, how do high-efficacy disease-modifying therapies compare with escalation strategies in preventing disability progression over two to five years?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "high-efficacy therapy", "escalation", "disability progression", "EDSS"]}
{"question": "In relapsing-remitting multiple sclerosis, how does ocrelizumab compare with interferon beta in reducing annualized relapse rate and new MRI lesions?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["relapsing-remitting multiple sclerosis", "ocrelizumab", "interferon beta", "annualized relapse rate", "MRI lesions"]}
{"question": "In relapsing-remitting multiple sclerosis, how does natalizumab compare with fingolimod for relapse prevention and risk of serious opportunistic infections?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["relapsing-remitting multiple sclerosis", "natalizumab", "fingolimod", "relapse prevention", "opportunistic infection"]}
{"question": "In relapsing multiple sclerosis, how does cladribine compare with dimethyl fumarate in achieving no evidence of disease activity (NEDA) at two years?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "cladribine", "dimethyl fumarate", "NEDA", "no evidence of disease activity"]}
{"question": "In multiple sclerosis, what is the prognostic value of serum neurofilament light chain for future relapse risk and disability accumulation?", "topic": "Multiple sclerosis", "question_type": "prognosis", "expected_search_terms": ["multiple sclerosis", "neurofilament light chain", "serum", "relapse risk", "disability progression", "prognosis"]}
{"question": "In clinically isolated syndrome, how does early initiation of disease-modifying therapy affect conversion rates to clinically definite multiple sclerosis?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["clinically isolated syndrome", "early treatment", "disease-modifying therapy", "conversion", "clinically definite multiple sclerosis"]}
{"question": "In multiple sclerosis, how does vitamin D supplementation influence relapse rate and MRI activity compared with placebo or usual care?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "vitamin D supplementation", "relapse rate", "MRI activity", "placebo"]}
{"question": "In multiple sclerosis, what is the association between Epstein–Barr virus serostatus or antibody titers and the risk of disease development?", "topic": "Multiple sclerosis", "question_type": "epidemiology", "expected_search_terms": ["multiple sclerosis", "Epstein-Barr virus", "serostatus", "antibody titers", "risk"]}
{"question": "In multiple sclerosis, what mechanisms link EBV-infected B cells to CNS autoimmunity and demyelination?", "topic": "Multiple sclerosis", "question_type": "mechanism", "expected_search_terms": ["multiple sclerosis", "Epstein-Barr virus", "B cells", "CNS autoimmunity", "demyelination"]}
{"question": "In multiple sclerosis, how do microglial activation signatures relate to chronic active lesions and neurodegeneration?", "topic": "Multiple sclerosis", "question_type": "mechanism", "expected_search_terms": ["multiple sclerosis", "microglia", "chronic active lesions", "neurodegeneration", "rim lesions"]}
{"question": "In progressive multiple sclerosis, how does ocrelizumab compare with placebo in slowing disability progression and brain volume loss?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["primary progressive multiple sclerosis", "ocrelizumab", "disability progression", "brain volume loss", "placebo"]}
{"question": "In secondary progressive multiple sclerosis, how does siponimod compare with placebo in delaying confirmed disability progression?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["secondary progressive multiple sclerosis", "siponimod", "confirmed disability progression", "placebo"]}
{"question": "In multiple sclerosis, how does early brain atrophy rate predict long-term cognitive decline and disability worsening?", "topic": "Multiple sclerosis", "question_type": "prognosis", "expected_search_terms": ["multiple sclerosis", "brain atrophy", "cognitive decline", "disability", "prediction"]}
{"question": "In multiple sclerosis, how do spinal cord lesions on MRI influence prognosis for mobility outcomes compared with brain lesions alone?", "topic": "Multiple sclerosis", "question_type": "prognosis", "expected_search_terms": ["multiple sclerosis", "spinal cord lesions", "MRI", "mobility", "prognosis"]}
{"question": "In multiple sclerosis, how does switching from a platform therapy to a high-efficacy therapy after breakthrough disease affect subsequent relapse control?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "switching therapy", "platform therapy", "high efficacy", "breakthrough disease", "relapse"]}
{"question": "In multiple sclerosis, what is the incidence of rebound disease activity after discontinuation of sphingosine-1-phosphate receptor modulators?", "topic": "Multiple sclerosis", "question_type": "epidemiology", "expected_search_terms": ["multiple sclerosis", "discontinuation", "S1P receptor modulator", "fingolimod", "rebound", "incidence"]}
{"question": "In multiple sclerosis, how does extended interval dosing of natalizumab compare with standard dosing in maintaining efficacy while reducing PML risk?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "natalizumab", "extended interval dosing", "efficacy", "PML risk"]}
{"question": "In multiple sclerosis, what is the relationship between JC virus antibody index levels and PML risk in patients receiving natalizumab?", "topic": "Multiple sclerosis", "question_type": "prognosis", "expected_search_terms": ["multiple sclerosis", "JC virus antibody index", "natalizumab", "PML risk", "prognosis"]}
{"question": "In multiple sclerosis, how effective are structured exercise programs compared with usual care in improving fatigue and quality of life?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "exercise", "fatigue", "quality of life", "rehabilitation", "randomized trial"]}
{"question": "In multiple sclerosis, what is the comparative effectiveness of amantadine versus modafinil for fatigue reduction?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "fatigue", "amantadine", "modafinil", "comparative effectiveness"]}
{"question": "In multiple sclerosis, how does intrathecal IgG synthesis measured by oligoclonal bands relate mechanistically to B-cell follicle-like structures in the CNS?", "topic": "Multiple sclerosis", "question_type": "mechanism", "expected_search_terms": ["multiple sclerosis", "oligoclonal bands", "intrathecal IgG", "B-cell follicles", "meninges"]}
{"question": "In multiple sclerosis, what is the epidemiologic association between latitude, sunlight exposure, and disease prevalence after adjusting for confounders?", "topic": "Multiple sclerosis", "question_type": "epidemiology", "expected_search_terms": ["multiple sclerosis", "latitude", "sunlight", "prevalence", "epidemiology", "confounding"]}
{"question": "In multiple sclerosis, how does pregnancy affect relapse rates during gestation and the postpartum period across modern treatment eras?", "topic": "Multiple sclerosis", "question_type": "epidemiology", "expected_search_terms": ["multiple sclerosis", "pregnancy", "postpartum", "relapse rate", "treatment era"]}
{"question": "In multiple sclerosis, how does breastfeeding duration relate to postpartum relapse risk in observational studies?", "topic": "Multiple sclerosis", "question_type": "prognosis", "expected_search_terms": ["multiple sclerosis", "breastfeeding", "postpartum relapse", "observational", "risk"]}
{"question": "In multiple sclerosis, what are the risks and outcomes of COVID-19 infection in patients receiving B-cell depleting therapy compared with other disease-modifying therapies?", "topic": "Multiple sclerosis", "question_type": "epidemiology", "expected_search_terms": ["multiple sclerosis", "COVID-19", "B-cell depleting", "ocrelizumab", "rituximab", "outcomes"]}
{"question": "In multiple sclerosis, how does vaccine-induced antibody response to SARS-CoV-2 differ between patients on anti-CD20 therapies and those on other disease-modifying therapies?", "topic": "Multiple sclerosis", "question_type": "mechanism", "expected_search_terms": ["multiple sclerosis", "SARS-CoV-2 vaccination", "anti-CD20", "antibody response", "immunogenicity"]}
{"question": "Across rheumatoid arthritis and systemic lupus erythematosus, how does type I interferon pathway activation differ in peripheral blood immune cell subsets?", "topic": "Cross-disease", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "systemic lupus erythematosus", "type I interferon", "immune cell subsets", "transcriptomics"]}
{"question": "Across rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, what shared genetic risk loci implicate common immune pathways?", "topic": "Cross-disease", "question_type": "review", "expected_search_terms": ["rheumatoid arthritis", "systemic lupus erythematosus", "multiple sclerosis", "genetic risk loci", "GWAS", "shared pathways"]}
{"question": "In autoimmune diseases treated with B-cell depletion, what is the comparative impact on vaccine immunogenicity across rheumatoid arthritis, lupus, and multiple sclerosis?", "topic": "Cross-disease", "question_type": "review", "expected_search_terms": ["B-cell depletion", "rituximab", "ocrelizumab", "vaccination", "immunogenicity", "rheumatoid arthritis", "lupus", "multiple sclerosis"]}
{"question": "In rheumatoid arthritis, how does tofacitinib compare with baricitinib regarding lipid profile changes and major adverse cardiovascular event rates?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "tofacitinib", "baricitinib", "lipids", "MACE", "cardiovascular events"]}
{"question": "In rheumatoid arthritis, what is the incidence of venous thromboembolism among patients using JAK inhibitors compared with TNF inhibitors in observational datasets?", "topic": "Rheumatoid arthritis", "question_type": "epidemiology", "expected_search_terms": ["rheumatoid arthritis", "JAK inhibitor", "TNF inhibitor", "venous thromboembolism", "incidence", "observational study"]}
{"question": "In rheumatoid arthritis, how does rituximab compare with tocilizumab after TNF inhibitor failure in achieving low disease activity?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "TNF inhibitor failure", "rituximab", "tocilizumab", "low disease activity"]}
{"question": "In rheumatoid arthritis, what is the role of synovial macrophage polarization states in mediating response to TNF inhibition?", "topic": "Rheumatoid arthritis", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "synovial macrophages", "polarization", "TNF inhibition", "treatment response"]}
{"question": "In rheumatoid arthritis, how does baseline calprotectin compare with CRP as a predictor of radiographic progression?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "calprotectin", "CRP", "radiographic progression", "predictor"]}
{"question": "In rheumatoid arthritis, how effective is vaccination with recombinant zoster vaccine in reducing herpes zoster incidence among patients on immunosuppressive therapy?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "recombinant zoster vaccine", "immunosuppressive therapy", "herpes zoster", "incidence"]}
{"question": "In rheumatoid arthritis, what is the association between depression and disease activity, and does treating depression improve inflammatory outcomes?", "topic": "Rheumatoid arthritis", "question_type": "review", "expected_search_terms": ["rheumatoid arthritis", "depression", "disease activity", "inflammation", "treatment"]}
{"question": "In rheumatoid arthritis, how does occupational silica exposure relate to disease risk in case-control and cohort studies?", "topic": "Rheumatoid arthritis", "question_type": "epidemiology", "expected_search_terms": ["rheumatoid arthritis", "silica exposure", "occupational", "risk", "case-control", "cohort"]}
{"question": "In systemic lupus erythematosus, how does voclosporin plus mycophenolate compare with mycophenolate alone for complete renal response in lupus nephritis?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["lupus nephritis", "voclosporin", "mycophenolate", "complete renal response", "proteinuria"]}
{"question": "In lupus nephritis, how does tacrolimus compare with cyclophosphamide as induction therapy in terms of remission rates and adverse events?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["lupus nephritis", "tacrolimus", "cyclophosphamide", "induction", "remission", "adverse events"]}
{"question": "In systemic lupus erythematosus, what is the incidence of premature atherosclerosis and how does it relate to disease duration and inflammatory markers?", "topic": "Systemic lupus erythematosus", "question_type": "epidemiology", "expected_search_terms": ["systemic lupus erythematosus", "premature atherosclerosis", "incidence", "disease duration", "inflammatory markers"]}
{"question": "In systemic lupus erythematosus, how does statin therapy affect endothelial function and surrogate markers of cardiovascular risk?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "statin", "endothelial function", "carotid intima-media thickness", "cardiovascular risk"]}
{"question": "In systemic lupus erythematosus, what mechanisms explain TLR7 and TLR9 signaling contributions to autoantibody generation?", "topic": "Systemic lupus erythematosus", "question_type": "mechanism", "expected_search_terms": ["systemic lupus erythematosus", "TLR7", "TLR9", "autoantibody", "B cells", "plasmacytoid dendritic cells"]}
{"question": "In systemic lupus erythematosus, how does gut microbiome composition differ from healthy controls, and how does it relate to disease activity?", "topic": "Systemic lupus erythematosus", "question_type": "mechanism", "expected_search_terms": ["systemic lupus erythematosus", "gut microbiome", "dysbiosis", "healthy controls", "disease activity"]}
{"question": "In systemic lupus erythematosus, how do antimalarials compare with low-dose aspirin for primary thrombosis prevention in antiphospholipid antibody-positive patients without prior thrombosis?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "antiphospholipid antibodies", "primary prevention", "thrombosis", "hydroxychloroquine", "aspirin"]}
{"question": "In systemic lupus erythematosus, what factors predict progression to end-stage kidney disease among patients with lupus nephritis?", "topic": "Systemic lupus erythematosus", "question_type": "prognosis", "expected_search_terms": ["lupus nephritis", "end-stage kidney disease", "predictors", "prognosis", "cohort"]}
{"question": "In systemic lupus erythematosus, what is the prevalence of pulmonary hypertension and what clinical features are associated with it?", "topic": "Systemic lupus erythematosus", "question_type": "epidemiology", "expected_search_terms": ["systemic lupus erythematosus", "pulmonary hypertension", "prevalence", "risk factors", "clinical features"]}
{"question": "In systemic lupus erythematosus, how does rituximab compare with standard immunosuppression for refractory hematologic cytopenias?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "rituximab", "refractory", "thrombocytopenia", "hemolytic anemia", "cytopenia"]}
{"question": "In systemic lupus erythematosus, what evidence supports mitochondria-derived danger signals in driving interferon responses and inflammation?", "topic": "Systemic lupus erythematosus", "question_type": "mechanism", "expected_search_terms": ["systemic lupus erythematosus", "mitochondrial DNA", "DAMPs", "interferon response", "inflammation"]}
{"question": "In systemic lupus erythematosus, how does low complement at diagnosis relate to long-term organ damage accrual?", "topic": "Systemic lupus erythematosus", "question_type": "prognosis", "expected_search_terms": ["systemic lupus erythematosus", "low complement", "diagnosis", "organ damage accrual", "prognosis"]}
{"question": "In multiple sclerosis, how do autologous hematopoietic stem cell transplantation outcomes compare with high-efficacy disease-modifying therapies for aggressive relapsing disease?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "autologous hematopoietic stem cell transplantation", "high-efficacy therapy", "aggressive disease", "relapse", "disability"]}
{"question": "In multiple sclerosis, what is the incidence of hypogammaglobulinemia during long-term anti-CD20 therapy and how does it relate to infection risk?", "topic": "Multiple sclerosis", "question_type": "epidemiology", "expected_search_terms": ["multiple sclerosis", "anti-CD20", "ocrelizumab", "rituximab", "hypogammaglobulinemia", "infection risk"]}
{"question": "In multiple sclerosis, how do remyelination therapies targeting oligodendrocyte differentiation perform in early-phase clinical studies on imaging or functional endpoints?", "topic": "Multiple sclerosis", "question_type": "review", "expected_search_terms": ["multiple sclerosis", "remyelination", "oligodendrocyte differentiation", "clinical trial", "imaging endpoints"]}
{"question": "In multiple sclerosis, what mechanisms contribute to meningeal inflammation and its association with cortical demyelination?", "topic": "Multiple sclerosis", "question_type": "mechanism", "expected_search_terms": ["multiple sclerosis", "meningeal inflammation", "cortical demyelination", "B cells", "tertiary lymphoid structures"]}
{"question": "In multiple sclerosis, how does cognitive rehabilitation compare with usual care in improving processing speed and daily functioning?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "cognitive rehabilitation", "processing speed", "daily functioning", "randomized controlled trial"]}
{"question": "In multiple sclerosis, what is the prognostic value of baseline gadolinium-enhancing lesions for future disability progression in treated patients?", "topic": "Multiple sclerosis", "question_type": "prognosis", "expected_search_terms": ["multiple sclerosis", "gadolinium enhancing lesions", "MRI", "disability progression", "prognosis", "treated"]}
{"question": "In multiple sclerosis, what is the epidemiologic association between adolescent obesity and later multiple sclerosis risk?", "topic": "Multiple sclerosis", "question_type": "epidemiology", "expected_search_terms": ["multiple sclerosis", "adolescent obesity", "risk", "epidemiology", "cohort"]}
{"question": "In multiple sclerosis, how does smoking cessation after diagnosis influence relapse rates and disability progression compared with continued smoking?", "topic": "Multiple sclerosis", "question_type": "prognosis", "expected_search_terms": ["multiple sclerosis", "smoking cessation", "relapse rate", "disability progression", "prognosis"]}
{"question": "In multiple sclerosis, how do dietary interventions such as low-saturated-fat or ketogenic diets affect fatigue and inflammatory activity markers?", "topic": "Multiple sclerosis", "question_type": "review", "expected_search_terms": ["multiple sclerosis", "diet intervention", "low saturated fat", "ketogenic diet", "fatigue", "inflammatory markers"]}
{"question": "Across rheumatoid arthritis and systemic lupus erythematosus, how do anti-TNF therapies differ in their impact on autoantibody development and lupus-like syndromes?", "topic": "Cross-disease", "question_type": "review", "expected_search_terms": ["anti-TNF", "autoantibodies", "lupus-like syndrome", "rheumatoid arthritis", "systemic lupus erythematosus"]}
{"question": "In rheumatoid arthritis and systemic lupus erythematosus, how do interferon-stimulated gene expression profiles relate to response to biologic therapy?", "topic": "Cross-disease", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "systemic lupus erythematosus", "interferon stimulated genes", "biologic therapy", "response", "predictor"]}
{"question": "Across rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, what evidence supports shared roles of Th17 cells in tissue injury?", "topic": "Cross-disease", "question_type": "review", "expected_search_terms": ["Th17", "IL-17", "rheumatoid arthritis", "systemic lupus erythematosus", "multiple sclerosis", "tissue injury"]}
{"question": "In rheumatoid arthritis, what is the comparative effectiveness of triple therapy (methotrexate, sulfasalazine, hydroxychloroquine) versus methotrexate plus a TNF inhibitor in real-world remission rates?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "triple therapy", "methotrexate", "sulfasalazine", "hydroxychloroquine", "TNF inhibitor", "real-world", "remission"]}
{"question": "In rheumatoid arthritis, how does concomitant methotrexate use influence the durability of response to biologic monotherapy?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "concomitant methotrexate", "biologic monotherapy", "durability", "drug survival"]}
{"question": "In rheumatoid arthritis, what is the incidence and risk factors for methotrexate-associated liver fibrosis in long-term users?", "topic": "Rheumatoid arthritis", "question_type": "epidemiology", "expected_search_terms": ["rheumatoid arthritis", "methotrexate", "liver fibrosis", "incidence", "risk factors", "long-term"]}
{"question": "In rheumatoid arthritis, how do anti-carbamylated protein antibodies compare with anti-CCP antibodies as predictors of erosive disease?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "anti-carbamylated protein antibodies", "anti-CCP", "erosive disease", "prediction"]}
{"question": "In systemic lupus erythematosus, how does patient-reported fatigue correlate with objective inflammatory activity and organ involvement?", "topic": "Systemic lupus erythematosus", "question_type": "prognosis", "expected_search_terms": ["systemic lupus erythematosus", "fatigue", "patient-reported outcomes", "inflammatory activity", "organ involvement"]}
{"question": "In systemic lupus erythematosus, how do calcineurin inhibitor-based regimens compare with mycophenolate for maintenance of remission after successful induction of lupus nephritis?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["lupus nephritis", "maintenance", "calcineurin inhibitor", "tacrolimus", "mycophenolate", "remission"]}
{"question": "In systemic lupus erythematosus, what is the prevalence of fibromyalgia comorbidity and its effect on disease activity scoring and treatment decisions?", "topic": "Systemic lupus erythematosus", "question_type": "epidemiology", "expected_search_terms": ["systemic lupus erythematosus", "fibromyalgia", "prevalence", "disease activity score", "treatment decision"]}
{"question": "In multiple sclerosis, how does early initiation of B-cell depleting therapy compare with early initiation of S1P receptor modulators for achieving NEDA in newly diagnosed patients?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "newly diagnosed", "B-cell depleting", "S1P receptor modulator", "NEDA", "early initiation"]}
{"question": "In multiple sclerosis, what is the incidence of malignancy associated with long-term immunosuppressive disease-modifying therapies compared with the general population?", "topic": "Multiple sclerosis", "question_type": "epidemiology", "expected_search_terms": ["multiple sclerosis", "malignancy", "cancer risk", "disease-modifying therapy", "long-term", "general population"]}
{"question": "In multiple sclerosis, how do MRI paramagnetic rim lesions predict conversion to progressive disease and disability accumulation?", "topic": "Multiple sclerosis", "question_type": "prognosis", "expected_search_terms": ["multiple sclerosis", "paramagnetic rim lesions", "MRI", "progression", "disability accumulation", "prognosis"]}
{"question": "In rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, how do sex hormones influence immune cell phenotypes relevant to disease activity?", "topic": "Cross-disease", "question_type": "mechanism", "expected_search_terms": ["sex hormones", "estrogen", "progesterone", "testosterone", "immune cell phenotype", "rheumatoid arthritis", "systemic lupus erythematosus", "multiple sclerosis"]}
{"question": "Across rheumatoid arthritis and systemic lupus erythematosus, how does shared epigenetic dysregulation such as DNA hypomethylation relate to autoreactive T-cell activation?", "topic": "Cross-disease", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "systemic lupus erythematosus", "DNA hypomethylation", "epigenetics", "autoreactive T cells", "activation"]}
{"question": "In rheumatoid arthritis, what is the evidence that preclinical autoimmunity in anti-CCP positive individuals predicts progression to inflammatory arthritis?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["preclinical rheumatoid arthritis", "anti-CCP positive", "progression", "inflammatory arthritis", "prediction"]}
{"question": "In systemic lupus erythematosus, how does early use of steroid-sparing agents affect cumulative damage compared with prolonged moderate-dose glucocorticoids?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "steroid sparing", "glucocorticoids", "cumulative damage", "damage index"]}
{"question": "In multiple sclerosis, how do monoclonal antibody therapies compare with oral agents in treatment persistence and discontinuation due to adverse events in real-world studies?", "topic": "Multiple sclerosis", "question_type": "epidemiology", "expected_search_terms": ["multiple sclerosis", "monoclonal antibody", "oral agents", "treatment persistence", "discontinuation", "adverse events", "real-world"]}
{"question": "In rheumatoid arthritis, what is the comparative effectiveness of ultrasound-guided versus landmark-guided intra-articular corticosteroid injection for symptom relief in active synovitis?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "ultrasound-guided", "landmark-guided", "intra-articular corticosteroid", "synovitis", "pain relief"]}
{"question": "In systemic lupus erythematosus, what is the association between socioeconomic status and time to diagnosis or initiation of effective therapy?", "topic": "Systemic lupus erythematosus", "question_type": "epidemiology", "expected_search_terms": ["systemic lupus erythematosus", "socioeconomic status", "time to diagnosis", "treatment initiation", "disparities"]}
{"question": "In multiple sclerosis, what mechanisms underlie mitochondrial dysfunction in axons and its contribution to neurodegeneration in progressive disease?", "topic": "Multiple sclerosis", "question_type": "mechanism", "expected_search_terms": ["multiple sclerosis", "mitochondrial dysfunction", "axonal degeneration", "progressive", "neurodegeneration"]}
{"question": "In rheumatoid arthritis, how does IL-6 blockade influence lipid metabolism and HDL function compared with TNF inhibition?", "topic": "Rheumatoid arthritis", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "IL-6 blockade", "tocilizumab", "TNF inhibition", "lipid metabolism", "HDL function"]}
{"question": "In systemic lupus erythematosus, how does complement inhibition affect biomarkers of hemolysis and clinical outcomes in complement-mediated hemolytic anemia subsets?", "topic": "Systemic lupus erythematosus", "question_type": "review", "expected_search_terms": ["systemic lupus erythematosus", "complement inhibition", "hemolytic anemia", "biomarkers", "clinical outcomes"]}
{"question": "In multiple sclerosis, how do gut microbiome alterations associate with response to disease-modifying therapies in observational or translational studies?", "topic": "Multiple sclerosis", "question_type": "mechanism", "expected_search_terms": ["multiple sclerosis", "gut microbiome", "disease-modifying therapy", "treatment response", "translational study"]}
{"question": "In patients with heart failure with reduced ejection fraction, how does adding an SGLT2 inhibitor to guideline-directed therapy compare with adding an ARNI in terms of reducing all-cause mortality and heart failure hospitalization?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "SGLT2 inhibitor", "ARNI", "mortality", "heart failure hospitalization", "comparative effectiveness"]}
{"question": "In heart failure with preserved ejection fraction, what is the magnitude of benefit of SGLT2 inhibitors on symptoms and hospitalization across different left ventricular ejection fraction ranges?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFpEF", "SGLT2 inhibitors", "ejection fraction spectrum", "KCCQ", "hospitalization"]}
{"question": "Among patients with ischemic cardiomyopathy, does coronary revascularization plus medical therapy improve long-term survival compared with medical therapy alone?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["ischemic cardiomyopathy", "revascularization", "CABG", "PCI", "medical therapy", "survival"]}
{"question": "In stable coronary artery disease, how do outcomes differ between initial percutaneous coronary intervention versus optimized medical therapy for preventing myocardial infarction and death?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["stable coronary artery disease", "PCI", "optimal medical therapy", "myocardial infarction", "mortality"]}
{"question": "In multivessel coronary artery disease with diabetes, how does coronary artery bypass grafting compare with percutaneous coronary intervention for long-term major adverse cardiovascular events?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["diabetes", "multivessel coronary disease", "CABG", "PCI", "MACE", "long-term outcomes"]}
{"question": "For left main coronary artery disease, how do percutaneous coronary intervention and coronary artery bypass grafting compare in terms of mortality and stroke over intermediate follow-up?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["left main coronary artery disease", "PCI", "CABG", "mortality", "stroke"]}
{"question": "In patients with acute coronary syndrome, how does high-intensity statin therapy initiated early compare with moderate-intensity statin therapy for reducing recurrent ischemic events?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["acute coronary syndrome", "high-intensity statin", "moderate-intensity statin", "recurrent ischemia", "secondary prevention"]}
{"question": "In secondary prevention after myocardial infarction, what incremental benefit do PCSK9 inhibitors provide when added to maximally tolerated statins in reducing cardiovascular events?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["myocardial infarction", "secondary prevention", "PCSK9 inhibitor", "statin", "cardiovascular events"]}
{"question": "Among patients with established coronary artery disease, how does bempedoic acid compare with ezetimibe in lowering LDL-C and reducing clinical cardiovascular outcomes?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["coronary artery disease", "bempedoic acid", "ezetimibe", "LDL cholesterol", "cardiovascular outcomes"]}
{"question": "In acute myocardial infarction treated with primary PCI, does complete revascularization during the index hospitalization improve outcomes compared with culprit-only revascularization?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["STEMI", "primary PCI", "complete revascularization", "culprit-only", "clinical outcomes"]}
{"question": "In patients undergoing PCI for stable coronary disease, how do outcomes compare between radial and femoral arterial access with respect to bleeding and mortality?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["PCI", "radial access", "femoral access", "bleeding", "mortality"]}
{"question": "After drug-eluting stent implantation, how does short-duration dual antiplatelet therapy compare with standard-duration therapy for balancing stent thrombosis and bleeding risk?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["drug-eluting stent", "dual antiplatelet therapy", "short duration", "stent thrombosis", "bleeding"]}
{"question": "In acute coronary syndrome, how does prasugrel compare with ticagrelor for preventing ischemic events while minimizing major bleeding?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["acute coronary syndrome", "prasugrel", "ticagrelor", "ischemic events", "major bleeding"]}
{"question": "For secondary prevention after myocardial infarction, what is the comparative effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone on cardiovascular death and myocardial infarction?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["secondary prevention", "rivaroxaban", "aspirin", "cardiovascular death", "myocardial infarction"]}
{"question": "In patients with atrial fibrillation and stable coronary artery disease beyond one year after PCI, how does oral anticoagulant monotherapy compare with combined anticoagulant plus antiplatelet therapy for bleeding and ischemic events?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "stable coronary disease", "oral anticoagulant monotherapy", "antiplatelet", "bleeding", "ischemic events"]}
{"question": "For stroke prevention in nonvalvular atrial fibrillation, how do direct oral anticoagulants compare with warfarin in patients with moderate chronic kidney disease regarding efficacy and bleeding risk?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["nonvalvular atrial fibrillation", "DOAC", "warfarin", "chronic kidney disease", "stroke", "bleeding"]}
{"question": "In older adults with atrial fibrillation, how does apixaban compare with other direct oral anticoagulants for major bleeding and stroke prevention?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "elderly", "apixaban", "dabigatran", "rivaroxaban", "edoxaban", "major bleeding", "stroke"]}
{"question": "In patients with atrial fibrillation undergoing catheter ablation, how does early rhythm control compare with rate control in terms of long-term stroke and heart failure outcomes?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "catheter ablation", "early rhythm control", "rate control", "stroke", "heart failure outcomes"]}
{"question": "Among patients with paroxysmal atrial fibrillation, how does cryoballoon ablation compare with radiofrequency ablation in maintaining sinus rhythm and reducing complications?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["paroxysmal atrial fibrillation", "cryoballoon", "radiofrequency ablation", "sinus rhythm", "complications"]}
{"question": "In atrial fibrillation with heart failure with reduced ejection fraction, how does catheter ablation compare with medical therapy for improving left ventricular ejection fraction and reducing hospitalization?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "HFrEF", "catheter ablation", "medical therapy", "ejection fraction", "hospitalization"]}
{"question": "For cardioversion in recent-onset atrial fibrillation, how does a pharmacologic strategy compare with an electrical strategy for restoring sinus rhythm and avoiding recurrence?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["recent-onset atrial fibrillation", "pharmacologic cardioversion", "electrical cardioversion", "sinus rhythm", "recurrence"]}
{"question": "In patients with atrial fibrillation at high bleeding risk, how does left atrial appendage occlusion compare with long-term oral anticoagulation for preventing stroke and systemic embolism?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "left atrial appendage occlusion", "oral anticoagulation", "stroke prevention", "bleeding risk"]}
{"question": "In patients with heart failure and iron deficiency, how does intravenous ferric carboxymaltose compare with placebo for improving exercise capacity and reducing hospitalization?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["heart failure", "iron deficiency", "intravenous iron", "ferric carboxymaltose", "exercise capacity", "hospitalization"]}
{"question": "In acute decompensated heart failure, how does acetazolamide added to loop diuretics compare with loop diuretics alone for achieving decongestion without worsening renal function?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["acute decompensated heart failure", "acetazolamide", "loop diuretic", "decongestion", "renal function"]}
{"question": "In patients with HFrEF, how does initiating quadruple therapy early compare with stepwise initiation over months for reducing early mortality and hospitalization?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "quadruple therapy", "early initiation", "GDMT", "mortality", "hospitalization"]}
{"question": "In HFpEF, how do mineralocorticoid receptor antagonists compare with placebo for reducing heart failure hospitalization and improving diastolic function?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFpEF", "mineralocorticoid receptor antagonist", "spironolactone", "hospitalization", "diastolic function"]}
{"question": "In HFrEF, how does ivabradine compare with beta-blocker up-titration strategies for reducing heart failure hospitalization in patients with elevated resting heart rate?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "ivabradine", "beta-blocker titration", "resting heart rate", "hospitalization"]}
{"question": "For patients with HFrEF and left bundle branch block, how does cardiac resynchronization therapy compare with implantable cardioverter-defibrillator therapy alone for mortality and quality of life?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "left bundle branch block", "cardiac resynchronization therapy", "ICD", "mortality", "quality of life"]}
{"question": "In advanced heart failure, how do durable left ventricular assist devices compare with optimal medical management for survival and functional status in transplant-ineligible patients?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["advanced heart failure", "LVAD", "destination therapy", "optimal medical management", "survival", "functional status"]}
{"question": "In ischemic heart disease with refractory angina, how does enhanced external counterpulsation compare with sham or usual care for improving exercise tolerance and angina frequency?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["refractory angina", "enhanced external counterpulsation", "exercise tolerance", "angina frequency", "usual care"]}
{"question": "In stable coronary artery disease, how does a Mediterranean diet intervention compare with low-fat dietary advice in preventing recurrent cardiovascular events?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["stable coronary artery disease", "Mediterranean diet", "low-fat diet", "secondary prevention", "cardiovascular events"]}
{"question": "In patients with atrial fibrillation, how does weight loss intervention compare with usual care for reducing atrial fibrillation burden and improving symptom scores?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "weight loss", "lifestyle intervention", "AF burden", "symptom score"]}
{"question": "In atrial fibrillation patients with obstructive sleep apnea, how does CPAP therapy compare with no CPAP in reducing atrial fibrillation recurrence after ablation?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "obstructive sleep apnea", "CPAP", "ablation", "recurrence"]}
{"question": "In patients after myocardial infarction, how does high-intensity interval training compare with moderate continuous training in improving peak VO2 and left ventricular remodeling?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["myocardial infarction", "cardiac rehabilitation", "high-intensity interval training", "moderate continuous training", "peak VO2", "remodeling"]}
{"question": "In HFrEF, what molecular mechanisms link SGLT2 inhibitor therapy to improved myocardial energetics and reduced ventricular remodeling?", "topic": "Heart Failure", "question_type": "mechanism", "expected_search_terms": ["SGLT2 inhibitors", "HFrEF", "myocardial energetics", "ketone metabolism", "ventricular remodeling", "mechanism"]}
{"question": "What role does myocardial fibrosis measured by cardiac MRI play in the pathophysiology of HFpEF and response to therapy?", "topic": "Heart Failure", "question_type": "mechanism", "expected_search_terms": ["HFpEF", "myocardial fibrosis", "cardiac MRI", "T1 mapping", "extracellular volume", "treatment response"]}
{"question": "How does epicardial adipose tissue contribute mechanistically to atrial fibrillation initiation and maintenance through inflammatory signaling?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["epicardial adipose tissue", "atrial fibrillation", "inflammation", "adipokines", "atrial remodeling"]}
{"question": "What are the key cellular mechanisms by which atrial fibrosis promotes re-entrant circuits in atrial fibrillation?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["atrial fibrillation", "atrial fibrosis", "reentry", "electrophysiology", "connexins", "fibroblasts"]}
{"question": "How do sodium channel and calcium handling abnormalities interact in tachycardia-induced cardiomyopathy associated with persistent atrial fibrillation?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["tachycardia-induced cardiomyopathy", "atrial fibrillation", "sodium channel", "calcium handling", "SERCA", "RyR2"]}
{"question": "What mechanistic pathways link clonal hematopoiesis to accelerated atherosclerosis and coronary artery disease progression?", "topic": "Coronary Artery Disease", "question_type": "mechanism", "expected_search_terms": ["clonal hematopoiesis", "atherosclerosis", "coronary artery disease", "inflammation", "TET2", "DNMT3A"]}
{"question": "How does inflammation mediated by the NLRP3 inflammasome contribute to plaque instability in coronary artery disease?", "topic": "Coronary Artery Disease", "question_type": "mechanism", "expected_search_terms": ["NLRP3 inflammasome", "plaque instability", "coronary artery disease", "IL-1beta", "inflammation"]}
{"question": "What is the mechanistic relationship between endothelial dysfunction and microvascular angina in patients without obstructive coronary artery disease?", "topic": "Coronary Artery Disease", "question_type": "mechanism", "expected_search_terms": ["microvascular angina", "INOCA", "endothelial dysfunction", "coronary microvascular dysfunction", "nitric oxide"]}
{"question": "How do oxidized LDL and macrophage foam cell formation mechanistically drive coronary plaque progression and necrotic core development?", "topic": "Coronary Artery Disease", "question_type": "mechanism", "expected_search_terms": ["oxidized LDL", "foam cells", "macrophages", "atherosclerosis", "necrotic core", "plaque progression"]}
{"question": "What mechanisms explain the association between chronic kidney disease and increased risk of atrial fibrillation onset?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["chronic kidney disease", "atrial fibrillation", "mechanism", "fibrosis", "electrolyte imbalance", "inflammation"]}
{"question": "How do gut microbiome-derived metabolites such as TMAO mechanistically influence coronary atherosclerosis and thrombosis risk?", "topic": "Coronary Artery Disease", "question_type": "mechanism", "expected_search_terms": ["TMAO", "gut microbiome", "atherosclerosis", "thrombosis", "coronary artery disease"]}
{"question": "What is the role of coronary microvascular dysfunction in the development of HFpEF among patients with metabolic syndrome?", "topic": "Heart Failure", "question_type": "mechanism", "expected_search_terms": ["HFpEF", "coronary microvascular dysfunction", "metabolic syndrome", "endothelial inflammation", "nitric oxide"]}
{"question": "How does autonomic imbalance contribute mechanistically to atrial fibrillation triggers, and what biomarkers reflect this imbalance?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["atrial fibrillation", "autonomic nervous system", "sympathetic", "parasympathetic", "heart rate variability", "biomarkers"]}
{"question": "What mechanisms explain exercise intolerance in HFpEF, particularly the roles of chronotropic incompetence and peripheral skeletal muscle abnormalities?", "topic": "Heart Failure", "question_type": "mechanism", "expected_search_terms": ["HFpEF", "exercise intolerance", "chronotropic incompetence", "skeletal muscle", "oxygen extraction"]}
{"question": "How does atrial cardiomyopathy contribute to thromboembolism risk independent of clinically documented atrial fibrillation?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["atrial cardiomyopathy", "thromboembolism", "atrial fibrillation independent", "left atrial appendage", "endothelial dysfunction"]}
{"question": "What is the mechanistic basis for mineralocorticoid receptor activation promoting myocardial fibrosis and arrhythmogenesis in heart failure?", "topic": "Heart Failure", "question_type": "mechanism", "expected_search_terms": ["mineralocorticoid receptor", "myocardial fibrosis", "arrhythmogenesis", "heart failure", "aldosterone"]}
{"question": "How do lipoprotein(a) particles mechanistically promote atherosclerosis and thrombosis in coronary artery disease?", "topic": "Coronary Artery Disease", "question_type": "mechanism", "expected_search_terms": ["lipoprotein(a)", "Lp(a)", "atherosclerosis", "thrombosis", "coronary artery disease", "mechanism"]}
{"question": "What mechanisms underlie sex differences in coronary microvascular dysfunction and ischemia with nonobstructive coronary arteries?", "topic": "Coronary Artery Disease", "question_type": "mechanism", "expected_search_terms": ["sex differences", "coronary microvascular dysfunction", "INOCA", "women", "endothelial function"]}
{"question": "How does myocardial stretch activate natriuretic peptide signaling, and how does neprilysin inhibition modify these pathways in heart failure?", "topic": "Heart Failure", "question_type": "mechanism", "expected_search_terms": ["natriuretic peptides", "neprilysin inhibition", "ARNI", "myocardial stretch", "cGMP"]}
{"question": "What is the mechanistic relationship between atrial dilation, mitral regurgitation, and atrial fibrillation persistence?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["atrial fibrillation", "atrial dilation", "mitral regurgitation", "structural remodeling", "persistence"]}
{"question": "What is the current incidence and prevalence of atrial fibrillation globally, and how do estimates vary by region and age?", "topic": "Atrial Fibrillation", "question_type": "epidemiology", "expected_search_terms": ["atrial fibrillation", "incidence", "prevalence", "global", "age", "regional variation"]}
{"question": "What are the contemporary trends in heart failure hospitalization rates and in-hospital mortality over the past two decades?", "topic": "Heart Failure", "question_type": "epidemiology", "expected_search_terms": ["heart failure", "hospitalization trends", "in-hospital mortality", "temporal trends", "registry"]}
{"question": "Among patients with myocardial infarction, how has the case fatality rate changed with increasing use of primary PCI and modern pharmacotherapy?", "topic": "Coronary Artery Disease", "question_type": "epidemiology", "expected_search_terms": ["myocardial infarction", "case fatality", "primary PCI", "temporal trends", "modern therapy"]}
{"question": "What is the population attributable risk of hypertension, diabetes, smoking, and dyslipidemia for developing coronary artery disease in contemporary cohorts?", "topic": "Coronary Artery Disease", "question_type": "epidemiology", "expected_search_terms": ["coronary artery disease", "population attributable risk", "hypertension", "diabetes", "smoking", "dyslipidemia"]}
{"question": "How strongly is obesity associated with incident atrial fibrillation, and how does the association differ by sex and age?", "topic": "Atrial Fibrillation", "question_type": "epidemiology", "expected_search_terms": ["obesity", "incident atrial fibrillation", "sex differences", "age", "cohort study"]}
{"question": "What is the epidemiologic association between obstructive sleep apnea and atrial fibrillation incidence and recurrence?", "topic": "Atrial Fibrillation", "question_type": "epidemiology", "expected_search_terms": ["obstructive sleep apnea", "atrial fibrillation", "incidence", "recurrence", "meta-analysis"]}
{"question": "What is the burden of ischemia with nonobstructive coronary arteries, and what proportion of patients progress to obstructive coronary disease over time?", "topic": "Coronary Artery Disease", "question_type": "epidemiology", "expected_search_terms": ["INOCA", "nonobstructive coronary arteries", "prevalence", "progression", "longitudinal"]}
{"question": "How common is heart failure with preserved ejection fraction compared with reduced ejection fraction in community-based populations, and how has this distribution changed over time?", "topic": "Heart Failure", "question_type": "epidemiology", "expected_search_terms": ["HFpEF", "HFrEF", "community prevalence", "temporal change", "epidemiology"]}
{"question": "What is the prevalence of atrial fibrillation among patients with heart failure, and how does it differ between HFpEF and HFrEF?", "topic": "Heart Failure", "question_type": "epidemiology", "expected_search_terms": ["atrial fibrillation", "heart failure", "HFpEF", "HFrEF", "prevalence"]}
{"question": "What are the racial and ethnic disparities in coronary artery disease incidence and outcomes after myocardial infarction?", "topic": "Coronary Artery Disease", "question_type": "epidemiology", "expected_search_terms": ["coronary artery disease", "myocardial infarction", "racial disparities", "ethnic disparities", "outcomes"]}
{"question": "How does socioeconomic status relate to heart failure incidence and mortality, and what mediators are supported by observational studies?", "topic": "Heart Failure", "question_type": "epidemiology", "expected_search_terms": ["heart failure", "socioeconomic status", "incidence", "mortality", "social determinants"]}
{"question": "What is the incidence of atrial fibrillation after coronary artery bypass graft surgery, and what perioperative factors are most consistently associated with it?", "topic": "Atrial Fibrillation", "question_type": "epidemiology", "expected_search_terms": ["postoperative atrial fibrillation", "CABG", "incidence", "risk factors", "perioperative"]}
{"question": "Among cancer survivors, what is the incidence of heart failure and atrial fibrillation following exposure to cardiotoxic therapies compared with the general population?", "topic": "Heart Failure", "question_type": "epidemiology", "expected_search_terms": ["cancer survivors", "cardiotoxicity", "heart failure incidence", "atrial fibrillation incidence", "anthracyclines", "radiation"]}
{"question": "What is the relationship between alcohol consumption patterns and the risk of incident atrial fibrillation in prospective cohort studies?", "topic": "Atrial Fibrillation", "question_type": "epidemiology", "expected_search_terms": ["alcohol", "atrial fibrillation", "incident risk", "cohort", "dose response"]}
{"question": "How does air pollution exposure associate with acute coronary syndrome events and cardiovascular mortality in time-series and cohort studies?", "topic": "Coronary Artery Disease", "question_type": "epidemiology", "expected_search_terms": ["air pollution", "acute coronary syndrome", "PM2.5", "cardiovascular mortality", "cohort", "time-series"]}
{"question": "What is the prevalence of silent atrial fibrillation detected by implanted devices in high-risk populations, and how does detection vary by monitoring duration?", "topic": "Atrial Fibrillation", "question_type": "epidemiology", "expected_search_terms": ["silent atrial fibrillation", "subclinical AF", "implanted devices", "monitoring duration", "prevalence"]}
{"question": "What is the incidence of sudden cardiac death among patients with HFrEF receiving contemporary guideline-directed therapy?", "topic": "Heart Failure", "question_type": "epidemiology", "expected_search_terms": ["HFrEF", "sudden cardiac death", "incidence", "guideline-directed therapy", "registry"]}
{"question": "How frequently does coronary microvascular dysfunction occur in patients with HFpEF, and what clinical characteristics predict its presence?", "topic": "Heart Failure", "question_type": "epidemiology", "expected_search_terms": ["HFpEF", "coronary microvascular dysfunction", "prevalence", "predictors", "PET", "coronary flow reserve"]}
{"question": "Among patients with atrial fibrillation, what is the incidence of dementia compared with matched controls, and how does anticoagulation use modify this association?", "topic": "Atrial Fibrillation", "question_type": "epidemiology", "expected_search_terms": ["atrial fibrillation", "dementia", "incidence", "anticoagulation", "cohort study"]}
{"question": "After acute myocardial infarction, which clinical, laboratory, and imaging predictors most strongly stratify risk for developing heart failure within one year?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["myocardial infarction", "incident heart failure", "predictors", "risk stratification", "BNP", "echocardiography"]}
{"question": "In patients with HFpEF, how do natriuretic peptide levels predict mortality and hospitalization, and what thresholds are most consistently associated with poor outcomes?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["HFpEF", "natriuretic peptide", "BNP", "NT-proBNP", "prognosis", "mortality", "hospitalization"]}
{"question": "In HFrEF, does improvement in ejection fraction over time identify a subgroup with better long-term prognosis compared with persistently reduced ejection fraction?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["HFrEF", "recovered ejection fraction", "HFimpEF", "prognosis", "mortality", "hospitalization"]}
{"question": "In atrial fibrillation, how well do left atrial size and fibrosis markers predict recurrence after catheter ablation?", "topic": "Atrial Fibrillation", "question_type": "prognosis", "expected_search_terms": ["atrial fibrillation", "catheter ablation", "recurrence", "left atrial size", "fibrosis", "late gadolinium enhancement"]}
{"question": "For patients with stable coronary artery disease, how does coronary artery calcium score predict future myocardial infarction and cardiovascular death beyond traditional risk factors?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["stable coronary artery disease", "coronary calcium score", "risk prediction", "myocardial infarction", "cardiovascular death"]}
{"question": "In acute coronary syndrome, what is the prognostic value of high-sensitivity troponin kinetics for predicting heart failure and mortality?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["acute coronary syndrome", "high-sensitivity troponin", "kinetics", "prognosis", "mortality", "heart failure"]}
{"question": "Among heart failure patients, how does persistent congestion at discharge predict 30-day readmission and mortality, and which congestion metrics perform best?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["heart failure discharge", "residual congestion", "readmission", "mortality", "diuretic response", "lung ultrasound"]}
{"question": "In atrial fibrillation, how accurately does the CHA2DS2-VASc score predict stroke risk in contemporary cohorts treated with direct oral anticoagulants?", "topic": "Atrial Fibrillation", "question_type": "prognosis", "expected_search_terms": ["CHA2DS2-VASc", "atrial fibrillation", "stroke prediction", "DOAC", "validation", "contemporary cohort"]}
{"question": "In atrial fibrillation patients on oral anticoagulation, what factors most strongly predict major bleeding, and how does HAS-BLED performance compare with alternative bleeding scores?", "topic": "Atrial Fibrillation", "question_type": "prognosis", "expected_search_terms": ["atrial fibrillation", "major bleeding", "HAS-BLED", "bleeding risk score", "predictors", "validation"]}
{"question": "In chronic coronary syndrome, does residual inflammatory risk measured by high-sensitivity CRP predict recurrent events despite optimal LDL lowering?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["chronic coronary syndrome", "hsCRP", "residual inflammatory risk", "LDL lowering", "recurrent events"]}
{"question": "In heart failure, how does renal dysfunction trajectory during hospitalization predict long-term outcomes compared with baseline estimated GFR alone?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["heart failure", "worsening renal function", "trajectory", "eGFR", "prognosis", "outcomes"]}
{"question": "Among patients with atrial fibrillation, how does atrial high-rate episode duration detected by devices relate to future stroke risk?", "topic": "Atrial Fibrillation", "question_type": "prognosis", "expected_search_terms": ["atrial high-rate episodes", "subclinical atrial fibrillation", "device detected", "stroke risk", "duration threshold"]}
{"question": "In patients with myocardial infarction and reduced ejection fraction, what is the prognostic value of microvascular obstruction on cardiac MRI for adverse remodeling and heart failure?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["myocardial infarction", "microvascular obstruction", "cardiac MRI", "remodeling", "heart failure", "prognosis"]}
{"question": "In HFpEF, how do comorbidity-based phenogroups predict differential prognosis and response to therapies?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["HFpEF", "phenogroups", "comorbidities", "cluster analysis", "prognosis", "treatment response"]}
{"question": "After catheter ablation for atrial fibrillation, what is the long-term risk of stroke compared with matched atrial fibrillation patients managed medically?", "topic": "Atrial Fibrillation", "question_type": "prognosis", "expected_search_terms": ["atrial fibrillation", "catheter ablation", "long-term stroke risk", "medical management", "comparative cohort"]}
{"question": "In patients with coronary artery disease, how do plaque characteristics on coronary CT angiography predict future acute coronary syndrome events?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["coronary CT angiography", "plaque characteristics", "low attenuation plaque", "positive remodeling", "acute coronary syndrome prediction"]}
{"question": "In HFrEF patients with implantable cardioverter-defibrillators, what clinical factors best predict appropriate shocks and sudden cardiac death?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["HFrEF", "ICD", "appropriate shocks", "sudden cardiac death", "predictors", "risk stratification"]}
{"question": "In atrial fibrillation, how does left atrial appendage morphology assessed by imaging predict thrombus formation and stroke risk?", "topic": "Atrial Fibrillation", "question_type": "prognosis", "expected_search_terms": ["left atrial appendage morphology", "atrial fibrillation", "thrombus", "stroke risk", "TEE", "CT imaging"]}
{"question": "In chronic coronary artery disease, does achieving very low LDL-C levels increase the risk of hemorrhagic stroke or diabetes in long-term follow-up studies?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["coronary artery disease", "very low LDL", "hemorrhagic stroke", "incident diabetes", "long-term safety"]}
{"question": "In HFrEF, how does sacubitril/valsartan compare with ACE inhibitor therapy in improving reverse remodeling measured by echocardiographic parameters?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["sacubitril valsartan", "ACE inhibitor", "HFrEF", "reverse remodeling", "echocardiography", "LV volumes"]}
{"question": "In HFpEF, how do ARNI therapies compare with renin-angiotensin system inhibitors for reducing heart failure hospitalization and improving quality of life?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFpEF", "ARNI", "angiotensin receptor blocker", "quality of life", "hospitalization"]}
{"question": "In acute coronary syndrome managed invasively, how does early aspirin discontinuation with P2Y12 inhibitor monotherapy compare with continued dual antiplatelet therapy for bleeding and ischemic outcomes?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["acute coronary syndrome", "aspirin discontinuation", "P2Y12 monotherapy", "dual antiplatelet therapy", "bleeding", "ischemic outcomes"]}
{"question": "In patients with atrial fibrillation and recent PCI, how does double therapy (DOAC plus P2Y12 inhibitor) compare with triple therapy for major bleeding and stent thrombosis?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "PCI", "double therapy", "triple therapy", "DOAC", "P2Y12 inhibitor", "bleeding", "stent thrombosis"]}
{"question": "In HFrEF with secondary mitral regurgitation, how does transcatheter edge-to-edge repair compare with medical therapy alone for mortality and heart failure hospitalization?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "secondary mitral regurgitation", "transcatheter edge-to-edge repair", "medical therapy", "mortality", "hospitalization"]}
{"question": "In atrial fibrillation, how does amiodarone compare with dofetilide for maintaining sinus rhythm in patients with structural heart disease?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "amiodarone", "dofetilide", "sinus rhythm maintenance", "structural heart disease"]}
{"question": "In chronic coronary syndrome, how does ranolazine compare with beta-blockers for improving angina frequency and exercise tolerance?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["chronic coronary syndrome", "ranolazine", "beta-blocker", "angina frequency", "exercise tolerance"]}
{"question": "In HFrEF, how does vericiguat compare with placebo in patients with recent worsening heart failure events for reducing cardiovascular death and hospitalization?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "vericiguat", "worsening heart failure", "cardiovascular death", "hospitalization"]}
{"question": "In patients with acute pericoronary inflammation, what evidence supports an anti-inflammatory treatment strategy to reduce recurrent coronary events in secondary prevention?", "topic": "Coronary Artery Disease", "question_type": "review", "expected_search_terms": ["coronary artery disease", "anti-inflammatory therapy", "secondary prevention", "colchicine", "IL-1 inhibition", "recurrent events"]}
{"question": "What is the evidence that colchicine reduces recurrent events in chronic coronary artery disease or after myocardial infarction, and what are the main safety concerns?", "topic": "Coronary Artery Disease", "question_type": "review", "expected_search_terms": ["colchicine", "coronary artery disease", "myocardial infarction", "secondary prevention", "safety", "gastrointestinal", "infection"]}
{"question": "In atrial fibrillation, what is the evidence for using wearable devices and photoplethysmography for population screening and early diagnosis?", "topic": "Atrial Fibrillation", "question_type": "review", "expected_search_terms": ["atrial fibrillation", "wearable", "photoplethysmography", "screening", "diagnosis", "sensitivity", "specificity"]}
{"question": "In heart failure management, what clinical outcomes improve with remote patient monitoring and implantable hemodynamic sensors compared with usual care?", "topic": "Heart Failure", "question_type": "review", "expected_search_terms": ["heart failure", "remote monitoring", "implantable hemodynamic sensor", "pulmonary artery pressure", "hospitalization", "usual care"]}
{"question": "What is the evidence for and against routine use of coronary physiology assessment (FFR or iFR) to guide PCI decisions in intermediate coronary lesions?", "topic": "Coronary Artery Disease", "question_type": "review", "expected_search_terms": ["FFR", "iFR", "intermediate coronary lesion", "PCI guidance", "outcomes", "physiology-guided"]}
{"question": "In atrial fibrillation, how effective is opportunistic screening in primary care compared with systematic screening for increasing detection rates?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "opportunistic screening", "systematic screening", "primary care", "detection rate"]}
{"question": "In patients with atrial fibrillation and heart failure, what is the evidence that rhythm control improves prognosis compared with rate control when modern ablation techniques are available?", "topic": "Atrial Fibrillation", "question_type": "review", "expected_search_terms": ["atrial fibrillation", "heart failure", "rhythm control", "rate control", "catheter ablation", "prognosis"]}
{"question": "In HFrEF, how does hydralazine-isosorbide dinitrate compare with ACE inhibitors or ARBs in improving survival among patients unable to tolerate renin-angiotensin system blockers?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "hydralazine", "isosorbide dinitrate", "ACE inhibitor intolerance", "ARB intolerance", "survival"]}
{"question": "In acute coronary syndrome, how does early invasive strategy compare with initial conservative management in older adults in terms of mortality and bleeding complications?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["acute coronary syndrome", "older adults", "early invasive strategy", "conservative management", "mortality", "bleeding"]}
{"question": "In patients with atrial fibrillation and hypertrophic cardiomyopathy, how do direct oral anticoagulants compare with warfarin for preventing stroke and systemic embolism?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "hypertrophic cardiomyopathy", "DOAC", "warfarin", "stroke prevention", "systemic embolism"]}
{"question": "In patients with atrial fibrillation and bioprosthetic heart valves, how do direct oral anticoagulants compare with warfarin regarding thromboembolism and bleeding outcomes?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "bioprosthetic valve", "DOAC", "warfarin", "thromboembolism", "bleeding"]}
{"question": "In chronic coronary disease, how does cardiac rehabilitation participation impact long-term mortality and rehospitalization compared with non-participation?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["cardiac rehabilitation", "coronary disease", "mortality", "rehospitalization", "observational", "long-term"]}
{"question": "After myocardial infarction, what is the prognostic impact of depression on recurrent events and mortality, and what interventions have evidence for benefit?", "topic": "Coronary Artery Disease", "question_type": "review", "expected_search_terms": ["myocardial infarction", "depression", "prognosis", "mortality", "recurrent events", "intervention"]}
{"question": "In HFpEF, how do GLP-1 receptor agonists affect body weight, exercise capacity, and heart failure symptoms in patients with obesity-related HFpEF?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFpEF", "obesity", "GLP-1 receptor agonist", "exercise capacity", "KCCQ", "weight loss"]}
{"question": "In patients with atrial fibrillation, what is the association between endurance exercise exposure and risk of developing atrial fibrillation in long-term cohort studies?", "topic": "Atrial Fibrillation", "question_type": "epidemiology", "expected_search_terms": ["endurance exercise", "athletes", "atrial fibrillation risk", "cohort", "long-term"]}
{"question": "In patients with chronic coronary syndrome, what is the evidence that coronary CT angiography-guided management improves outcomes compared with functional stress testing-guided management?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["chronic coronary syndrome", "coronary CT angiography", "functional stress testing", "management strategy", "outcomes"]}
{"question": "In atrial fibrillation patients with a prior intracranial hemorrhage, what evidence supports restarting anticoagulation versus withholding it for preventing ischemic stroke and recurrent bleeding?", "topic": "Atrial Fibrillation", "question_type": "review", "expected_search_terms": ["atrial fibrillation", "intracranial hemorrhage", "restart anticoagulation", "ischemic stroke", "recurrent bleeding"]}
{"question": "In HFrEF, what is the comparative effectiveness of dapagliflozin versus empagliflozin on heart failure outcomes and renal endpoints in real-world cohorts?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "dapagliflozin", "empagliflozin", "real-world", "renal outcomes", "heart failure outcomes"]}
{"question": "In patients with coronary artery disease, how does intensive blood pressure lowering compare with standard targets for preventing recurrent cardiovascular events and adverse renal outcomes?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["coronary artery disease", "intensive blood pressure control", "standard targets", "recurrent events", "renal outcomes"]}
{"question": "In patients with atrial fibrillation, how does strict rate control compare with lenient rate control for symptoms, quality of life, and cardiovascular outcomes?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "strict rate control", "lenient rate control", "quality of life", "symptoms", "outcomes"]}
{"question": "In HFrEF patients with persistent symptoms despite optimized therapy, what is the evidence that digoxin reduces hospitalization without increasing mortality?", "topic": "Heart Failure", "question_type": "review", "expected_search_terms": ["HFrEF", "digoxin", "hospitalization", "mortality", "optimized therapy", "safety"]}
{"question": "In acute heart failure, how does vasodilator therapy compare with standard care in improving dyspnea relief and clinical outcomes?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["acute heart failure", "vasodilator", "dyspnea relief", "clinical outcomes", "randomized trial"]}
{"question": "In coronary artery disease patients with elevated triglycerides, what is the clinical outcome benefit of icosapent ethyl compared with other omega-3 formulations or placebo?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["coronary artery disease", "hypertriglyceridemia", "icosapent ethyl", "omega-3", "cardiovascular outcomes"]}
{"question": "What is the evidence that influenza vaccination reduces cardiovascular events in patients with coronary artery disease or heart failure?", "topic": "Coronary Artery Disease", "question_type": "review", "expected_search_terms": ["influenza vaccination", "coronary artery disease", "heart failure", "cardiovascular events", "secondary prevention"]}
{"question": "In atrial fibrillation, how does alcohol abstinence compare with usual intake in reducing atrial fibrillation recurrence and burden?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "alcohol abstinence", "recurrence", "AF burden", "lifestyle intervention"]}
{"question": "In patients with HFpEF, what is the prognostic significance of pulmonary hypertension assessed by echocardiography or right heart catheterization?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["HFpEF", "pulmonary hypertension", "echocardiography", "right heart catheterization", "prognosis", "mortality"]}
{"question": "In coronary artery disease, what is the prognostic value of fractional flow reserve in predicting future events when lesions are deferred from PCI?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["fractional flow reserve", "deferred PCI", "coronary lesions", "prognosis", "future events"]}
{"question": "In atrial fibrillation, how does chronic kidney disease stage modify the effectiveness and safety of different direct oral anticoagulant dosing regimens?", "topic": "Atrial Fibrillation", "question_type": "review", "expected_search_terms": ["atrial fibrillation", "chronic kidney disease stage", "DOAC dosing", "effectiveness", "safety", "bleeding"]}
{"question": "What is the evidence that coronary artery disease patients with elevated lipoprotein(a) benefit from targeted lipoprotein(a)-lowering therapies on imaging or clinical endpoints?", "topic": "Coronary Artery Disease", "question_type": "review", "expected_search_terms": ["lipoprotein(a)", "coronary artery disease", "Lp(a) lowering", "antisense", "siRNA", "clinical endpoints", "imaging"]}
{"question": "In HFrEF, what is the evidence that sodium restriction compared with liberal sodium intake affects hospitalization and mortality?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "sodium restriction", "dietary sodium", "hospitalization", "mortality", "randomized"]}
{"question": "In HFpEF, how does structured exercise training compare with usual care for improving peak VO2 and health-related quality of life?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFpEF", "exercise training", "peak VO2", "quality of life", "randomized trial"]}
{"question": "In coronary artery disease with chronic total occlusion, how does PCI compare with medical therapy for angina relief and long-term clinical outcomes?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["chronic total occlusion", "CTO PCI", "medical therapy", "angina relief", "clinical outcomes"]}
{"question": "In patients with atrial fibrillation, what mechanisms link diabetes to atrial remodeling and increased arrhythmia susceptibility?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["atrial fibrillation", "diabetes", "atrial remodeling", "fibrosis", "oxidative stress", "advanced glycation end products"]}
{"question": "What is the evidence that coronary artery disease outcomes differ between patients with and without familial hypercholesterolemia receiving contemporary lipid-lowering therapies?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["familial hypercholesterolemia", "coronary artery disease", "outcomes", "statins", "PCSK9", "prognosis"]}
{"question": "In atrial fibrillation patients on direct oral anticoagulants, how do drug-drug interactions with common cardiovascular medications affect bleeding and thromboembolic outcomes?", "topic": "Atrial Fibrillation", "question_type": "review", "expected_search_terms": ["DOAC", "atrial fibrillation", "drug interactions", "amiodarone", "verapamil", "diltiazem", "bleeding", "thromboembolism"]}
{"question": "In heart failure, how do sex differences influence response to beta-blockers and renin-angiotensin system inhibitors on mortality outcomes?", "topic": "Heart Failure", "question_type": "review", "expected_search_terms": ["heart failure", "sex differences", "beta-blocker", "ACE inhibitor", "ARB", "mortality", "treatment response"]}
{"question": "In patients with stable coronary artery disease, does aspirin provide net benefit for those already treated with high-intensity statins and optimized risk factor control?", "topic": "Coronary Artery Disease", "question_type": "review", "expected_search_terms": ["stable coronary artery disease", "aspirin", "high-intensity statin", "optimized risk factors", "net clinical benefit", "bleeding"]}
{"question": "In atrial fibrillation, what is the evidence that genetic risk scores improve prediction of incident atrial fibrillation beyond clinical risk factors?", "topic": "Atrial Fibrillation", "question_type": "prognosis", "expected_search_terms": ["atrial fibrillation", "polygenic risk score", "incident prediction", "clinical risk factors", "risk stratification"]}
{"question": "In heart failure, how does frailty status predict benefit and harm from device therapies such as ICD and CRT in older adults?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["heart failure", "frailty", "ICD", "CRT", "older adults", "benefit harm", "outcomes"]}
{"question": "In patients with atrial fibrillation and obesity, how does bariatric surgery compare with medical weight management for long-term atrial fibrillation burden and cardiovascular outcomes?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "obesity", "bariatric surgery", "weight management", "AF burden", "cardiovascular outcomes"]}
{"question": "In acute myocardial infarction, what is the evidence that early beta-blocker initiation improves mortality in the era of reperfusion therapy and modern antithrombotic treatment?", "topic": "Coronary Artery Disease", "question_type": "review", "expected_search_terms": ["acute myocardial infarction", "early beta-blocker", "reperfusion", "primary PCI", "mortality", "modern therapy"]}
{"question": "In heart failure, what mechanisms explain skeletal muscle dysfunction and reduced oxidative capacity contributing to exercise intolerance?", "topic": "Heart Failure", "question_type": "mechanism", "expected_search_terms": ["heart failure", "skeletal muscle dysfunction", "mitochondria", "oxidative capacity", "exercise intolerance", "mechanism"]}
{"question": "In coronary artery disease, how does diabetes alter platelet reactivity and response to P2Y12 inhibitors, and what clinical implications are supported by studies?", "topic": "Coronary Artery Disease", "question_type": "mechanism", "expected_search_terms": ["diabetes", "platelet reactivity", "P2Y12 inhibitors", "clopidogrel resistance", "ticagrelor", "prasugrel"]}
{"question": "In atrial fibrillation, how do inflammatory biomarkers such as CRP and IL-6 correlate with atrial fibrillation burden and recurrence after ablation?", "topic": "Atrial Fibrillation", "question_type": "prognosis", "expected_search_terms": ["atrial fibrillation", "CRP", "IL-6", "inflammatory biomarkers", "AF burden", "ablation recurrence"]}
{"question": "In HFpEF, what is the evidence supporting nitric oxide-cGMP pathway impairment as a therapeutic target, and how have soluble guanylate cyclase stimulators performed clinically?", "topic": "Heart Failure", "question_type": "review", "expected_search_terms": ["HFpEF", "nitric oxide", "cGMP", "soluble guanylate cyclase stimulator", "vericiguat", "exercise capacity"]}
{"question": "In patients with coronary artery disease, what is the prognostic value of residual angina after PCI for subsequent cardiovascular events and quality of life?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["residual angina", "post-PCI", "coronary artery disease", "prognosis", "quality of life", "events"]}
{"question": "In atrial fibrillation, how does left atrial strain measured by echocardiography predict incident heart failure and stroke?", "topic": "Atrial Fibrillation", "question_type": "prognosis", "expected_search_terms": ["atrial fibrillation", "left atrial strain", "echocardiography", "incident heart failure", "stroke prediction"]}
{"question": "In HFrEF, what is the evidence that outpatient initiation of intravenous diuretic clinics reduces emergency visits and hospital admissions compared with usual care?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "outpatient intravenous diuretics", "diuretic clinic", "hospital admission", "emergency visits", "usual care"]}
{"question": "In stable coronary artery disease, how does smoking cessation pharmacotherapy compare with counseling alone for achieving abstinence and reducing cardiovascular events?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["coronary artery disease", "smoking cessation", "varenicline", "bupropion", "nicotine replacement", "counseling", "cardiovascular events"]}
{"question": "In atrial fibrillation, what is the evidence that omega-3 fatty acid supplementation reduces atrial fibrillation incidence or recurrence?", "topic": "Atrial Fibrillation", "question_type": "review", "expected_search_terms": ["atrial fibrillation", "omega-3 fatty acids", "supplementation", "incidence", "recurrence", "meta-analysis"]}
{"question": "In coronary artery disease patients with heart failure, how does beta-blocker type (carvedilol vs metoprolol vs bisoprolol) compare for mortality and hospitalization outcomes?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["coronary artery disease", "heart failure", "carvedilol", "metoprolol", "bisoprolol", "mortality", "hospitalization"]}
{"question": "What is the evidence that high-sensitivity CRP-guided anti-inflammatory therapy selection improves outcomes in patients with coronary artery disease?", "topic": "Coronary Artery Disease", "question_type": "review", "expected_search_terms": ["coronary artery disease", "hsCRP guided", "anti-inflammatory therapy", "precision medicine", "outcomes"]}
{"question": "In atrial fibrillation, how does early rhythm control initiated soon after diagnosis compare with usual care for preventing cardiovascular death, stroke, and heart failure hospitalization?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "early rhythm control", "usual care", "stroke", "heart failure hospitalization", "cardiovascular death"]}
{"question": "In HFpEF, how does presence of atrial fibrillation modify therapeutic responses and prognosis compared with HFpEF patients in sinus rhythm?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["HFpEF", "atrial fibrillation", "treatment response", "prognosis", "sinus rhythm"]}
{"question": "In coronary artery disease, what is the relationship between coronary artery calcium progression and future cardiovascular events in longitudinal imaging studies?", "topic": "Coronary Artery Disease", "question_type": "prognosis", "expected_search_terms": ["coronary artery calcium", "progression", "longitudinal", "cardiovascular events", "risk prediction"]}
{"question": "In heart failure patients with type 2 diabetes, how does finerenone compare with placebo for reducing heart failure hospitalization and renal progression in those with chronic kidney disease?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["finerenone", "type 2 diabetes", "chronic kidney disease", "heart failure hospitalization", "renal progression"]}
{"question": "In atrial fibrillation patients treated with catheter ablation, how does continuous rhythm monitoring compare with intermittent monitoring for detecting recurrence and guiding anticoagulation decisions?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "catheter ablation", "continuous monitoring", "intermittent monitoring", "recurrence detection", "anticoagulation"]}
{"question": "In HFrEF, what is the evidence that iron deficiency without anemia predicts worse outcomes, and which diagnostic thresholds are most prognostic?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["HFrEF", "iron deficiency", "without anemia", "ferritin", "transferrin saturation", "prognosis"]}
{"question": "In coronary artery disease patients with chronic inflammatory diseases such as rheumatoid arthritis, what is the magnitude of increased cardiovascular risk and how does anti-inflammatory treatment modify it?", "topic": "Coronary Artery Disease", "question_type": "epidemiology", "expected_search_terms": ["rheumatoid arthritis", "coronary artery disease", "cardiovascular risk", "anti-inflammatory treatment", "TNF inhibitor", "cohort"]}
{"question": "In atrial fibrillation, what mechanisms explain left atrial appendage thrombogenesis despite therapeutic anticoagulation in some patients?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["atrial fibrillation", "left atrial appendage thrombus", "anticoagulation failure", "hypercoagulability", "endothelial dysfunction", "stasis"]}
{"question": "In heart failure, how do changes in NT-proBNP with treatment correlate with clinical outcomes, and is NT-proBNP-guided therapy superior to standard care?", "topic": "Heart Failure", "question_type": "review", "expected_search_terms": ["heart failure", "NT-proBNP guided therapy", "biomarker guided", "outcomes", "mortality", "hospitalization"]}
{"question": "Among non-hospitalized adults with mild-to-moderate COVID-19 at high risk for progression, how does nirmatrelvir/ritonavir compare with molnupiravir in reducing hospitalization or death?", "topic": "COVID-19 therapeutics", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "nirmatrelvir ritonavir", "molnupiravir", "outpatient", "hospitalization", "mortality", "comparative effectiveness"]}
{"question": "In hospitalized patients with severe COVID-19 requiring oxygen, how does remdesivir plus corticosteroids compare with corticosteroids alone for time to recovery and mortality?", "topic": "COVID-19 therapeutics", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "remdesivir", "dexamethasone", "corticosteroids", "hospitalized", "mortality", "time to recovery"]}
{"question": "In severe COVID-19 with systemic inflammation, how does tocilizumab compare with baricitinib when added to standard care for reducing 28-day mortality?", "topic": "COVID-19 immunomodulators", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "tocilizumab", "baricitinib", "IL-6 inhibitor", "JAK inhibitor", "mortality", "randomized"]}
{"question": "For prevention of symptomatic SARS-CoV-2 infection, how does intranasal vaccination compare with intramuscular vaccination in inducing mucosal immunity and reducing infection risk in humans?", "topic": "COVID-19 vaccines", "question_type": "efficacy_comparison", "expected_search_terms": ["SARS-CoV-2", "intranasal vaccine", "intramuscular vaccine", "mucosal immunity", "IgA", "infection prevention", "clinical"]}
{"question": "How does hybrid immunity (vaccination plus prior infection) compare with vaccination alone in protecting against SARS-CoV-2 Omicron reinfection?", "topic": "COVID-19 immunity", "question_type": "epidemiology", "expected_search_terms": ["hybrid immunity", "vaccination", "prior infection", "Omicron", "reinfection", "risk reduction", "cohort"]}
{"question": "What is the association between SARS-CoV-2 viral load (Ct values) at diagnosis and subsequent risk of hospitalization or death?", "topic": "COVID-19 clinical predictors", "question_type": "prognosis", "expected_search_terms": ["SARS-CoV-2", "viral load", "Ct value", "hospitalization", "mortality", "prognostic", "cohort study"]}
{"question": "How do neutralizing antibody titers correlate with protection against symptomatic COVID-19 across different vaccine platforms?", "topic": "COVID-19 correlates of protection", "question_type": "review", "expected_search_terms": ["COVID-19", "neutralizing antibody", "correlate of protection", "vaccine efficacy", "mRNA vaccine", "viral vector", "protein subunit"]}
{"question": "What is the effectiveness of bivalent mRNA booster vaccination compared with monovalent boosters in preventing COVID-19–related hospitalization during Omicron subvariant circulation?", "topic": "COVID-19 vaccines", "question_type": "efficacy_comparison", "expected_search_terms": ["bivalent booster", "monovalent booster", "mRNA vaccine", "Omicron subvariant", "hospitalization", "vaccine effectiveness", "real-world"]}
{"question": "How does prior COVID-19 vaccination influence the incidence of post-acute sequelae of SARS-CoV-2 infection (long COVID) after breakthrough infection?", "topic": "Long COVID", "question_type": "epidemiology", "expected_search_terms": ["long COVID", "post-acute sequelae", "vaccination", "breakthrough infection", "incidence", "risk", "cohort"]}
{"question": "What immunologic mechanisms are proposed to explain long COVID symptoms, with emphasis on viral persistence, autoimmunity, and microclot formation?", "topic": "Long COVID", "question_type": "mechanism", "expected_search_terms": ["long COVID", "viral persistence", "autoimmunity", "microclots", "endothelial dysfunction", "immune dysregulation", "mechanisms"]}
{"question": "Among older adults, how does early outpatient antiviral therapy for COVID-19 affect the subsequent risk of developing long COVID?", "topic": "Long COVID", "question_type": "prognosis", "expected_search_terms": ["COVID-19", "antiviral", "nirmatrelvir", "molnupiravir", "long COVID", "older adults", "risk"]}
{"question": "How does SARS-CoV-2 infection affect the gut microbiome composition, and what associations exist with disease severity?", "topic": "COVID-19 pathogenesis", "question_type": "mechanism", "expected_search_terms": ["SARS-CoV-2", "gut microbiome", "dysbiosis", "severity", "inflammation", "metagenomics", "COVID-19"]}
{"question": "What is the incidence of bacterial co-infections at hospital admission for COVID-19, and how does it compare with bacterial superinfections acquired during hospitalization?", "topic": "COVID-19 complications", "question_type": "epidemiology", "expected_search_terms": ["COVID-19", "bacterial coinfection", "superinfection", "hospital-acquired", "incidence", "pneumonia", "ICU"]}
{"question": "In mechanically ventilated COVID-19 patients, how does proning compare with standard supine ventilation for improving oxygenation and mortality?", "topic": "COVID-19 critical care", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "ARDS", "prone positioning", "mechanical ventilation", "oxygenation", "mortality", "ICU"]}
{"question": "How does COVID-19–associated coagulopathy differ mechanistically from classical sepsis-associated disseminated intravascular coagulation?", "topic": "COVID-19 pathophysiology", "question_type": "mechanism", "expected_search_terms": ["COVID-19", "coagulopathy", "thrombosis", "DIC", "sepsis", "endotheliitis", "pathophysiology"]}
{"question": "What is the effectiveness of high-flow nasal cannula compared with noninvasive ventilation for preventing intubation in hypoxemic COVID-19 patients?", "topic": "COVID-19 respiratory support", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "high-flow nasal cannula", "noninvasive ventilation", "intubation", "hypoxemic respiratory failure", "ICU"]}
{"question": "How do interferon signaling and innate immune evasion by SARS-CoV-2 contribute to severe disease phenotypes?", "topic": "COVID-19 immunology", "question_type": "mechanism", "expected_search_terms": ["SARS-CoV-2", "interferon", "innate immunity", "immune evasion", "severe COVID-19", "type I interferon", "pathogenesis"]}
{"question": "What is the association between anti-spike antibody waning after vaccination and subsequent risk of breakthrough SARS-CoV-2 infection?", "topic": "COVID-19 immunity", "question_type": "prognosis", "expected_search_terms": ["anti-spike antibody", "waning immunity", "breakthrough infection", "SARS-CoV-2", "vaccine", "risk", "longitudinal"]}
{"question": "How do SARS-CoV-2 variants differ in their ability to escape neutralizing antibodies elicited by vaccination or prior infection?", "topic": "COVID-19 variants", "question_type": "mechanism", "expected_search_terms": ["SARS-CoV-2 variants", "immune escape", "neutralizing antibodies", "Omicron", "vaccine sera", "convalescent sera", "spike mutations"]}
{"question": "What is the risk of myocarditis after mRNA COVID-19 vaccination compared with the risk after SARS-CoV-2 infection in adolescents and young adults?", "topic": "COVID-19 vaccine safety", "question_type": "epidemiology", "expected_search_terms": ["myocarditis", "mRNA vaccine", "SARS-CoV-2 infection", "adolescents", "young adults", "incidence", "risk comparison"]}
{"question": "In immunocompromised patients, how effective are pre-exposure monoclonal antibodies in preventing symptomatic COVID-19 compared with no prophylaxis?", "topic": "COVID-19 prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "pre-exposure prophylaxis", "monoclonal antibody", "immunocompromised", "prevention", "symptomatic infection", "effectiveness"]}
{"question": "How does COVID-19 pregnancy affect the risk of preterm birth and stillbirth compared with uninfected pregnancies?", "topic": "COVID-19 in pregnancy", "question_type": "prognosis", "expected_search_terms": ["COVID-19", "pregnancy", "preterm birth", "stillbirth", "maternal infection", "risk", "meta-analysis"]}
{"question": "What is the effectiveness of maternal COVID-19 vaccination during pregnancy in preventing hospitalization for COVID-19 in infants under 6 months?", "topic": "COVID-19 vaccines", "question_type": "efficacy_comparison", "expected_search_terms": ["maternal vaccination", "COVID-19", "infant hospitalization", "passive immunity", "pregnancy", "vaccine effectiveness"]}
{"question": "How does corticosteroid dosing strategy (standard vs higher dose) influence outcomes in critically ill COVID-19 patients with ARDS?", "topic": "COVID-19 therapeutics", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "ARDS", "corticosteroid dose", "dexamethasone", "critical illness", "mortality", "randomized"]}
{"question": "What clinical and laboratory predictors at initial presentation best forecast progression from mild COVID-19 to severe disease?", "topic": "COVID-19 clinical predictors", "question_type": "prognosis", "expected_search_terms": ["COVID-19", "predictors", "progression", "severity", "CRP", "lymphopenia", "risk model"]}
{"question": "How does SARS-CoV-2 infection alter T cell exhaustion markers, and how are these changes associated with disease severity?", "topic": "COVID-19 immunology", "question_type": "mechanism", "expected_search_terms": ["SARS-CoV-2", "T cell exhaustion", "PD-1", "TIM-3", "severity", "immunophenotyping", "COVID-19"]}
{"question": "What is the incidence of new-onset diabetes after SARS-CoV-2 infection compared with uninfected controls?", "topic": "COVID-19 sequelae", "question_type": "epidemiology", "expected_search_terms": ["SARS-CoV-2", "new-onset diabetes", "post-acute", "incidence", "cohort", "risk", "metabolic outcomes"]}
{"question": "How do antiviral resistance-associated mutations emerge in SARS-CoV-2 after treatment with protease inhibitors in immunocompromised hosts?", "topic": "COVID-19 antiviral resistance", "question_type": "mechanism", "expected_search_terms": ["SARS-CoV-2", "antiviral resistance", "protease inhibitor", "nirmatrelvir", "mutations", "immunocompromised", "within-host evolution"]}
{"question": "In adults with COVID-19 and high thrombotic risk, how does therapeutic-dose anticoagulation compare with prophylactic-dose anticoagulation for mortality and bleeding outcomes?", "topic": "COVID-19 thrombosis management", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "therapeutic anticoagulation", "prophylactic anticoagulation", "thrombosis", "bleeding", "mortality", "randomized"]}
{"question": "How does persistent SARS-CoV-2 antigen or RNA detection after acute infection relate to long COVID symptom duration?", "topic": "Long COVID", "question_type": "prognosis", "expected_search_terms": ["long COVID", "SARS-CoV-2 persistence", "viral RNA", "antigen", "symptom duration", "follow-up", "biomarkers"]}
{"question": "What are the most consistently reported clinical phenotypes of long COVID across cohort studies and how are they operationally defined?", "topic": "Long COVID", "question_type": "review", "expected_search_terms": ["long COVID", "phenotypes", "case definition", "cohort studies", "symptom clusters", "post-acute sequelae", "systematic review"]}
{"question": "How does tenofovir alafenamide compare with tenofovir disoproxil fumarate in long-term renal and bone safety among people with HIV on suppressive therapy?", "topic": "HIV antiretroviral therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "tenofovir alafenamide", "tenofovir disoproxil fumarate", "renal safety", "bone mineral density", "ART", "comparative"]}
{"question": "In treatment-naïve HIV infection, how do integrase inhibitor–based regimens compare with boosted protease inhibitor regimens for virologic suppression and adverse events?", "topic": "HIV antiretroviral therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "treatment-naive", "integrase inhibitor", "boosted protease inhibitor", "virologic suppression", "adverse events", "randomized"]}
{"question": "What is the impact of initiating antiretroviral therapy during acute or early HIV infection on the size of the latent reservoir?", "topic": "HIV cure research", "question_type": "mechanism", "expected_search_terms": ["acute HIV infection", "early ART", "latent reservoir", "HIV DNA", "reservoir size", "viral persistence", "timing of ART"]}
{"question": "How does long-acting injectable antiretroviral therapy compare with daily oral therapy in maintaining viral suppression in routine clinical care?", "topic": "HIV antiretroviral therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "long-acting injectable", "cabotegravir", "rilpivirine", "oral ART", "viral suppression", "real-world"]}
{"question": "Among people using pre-exposure prophylaxis, how does on-demand dosing compare with daily dosing in preventing HIV acquisition in men who have sex with men?", "topic": "HIV prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV PrEP", "on-demand", "daily", "men who have sex with men", "prevention", "effectiveness", "incidence"]}
{"question": "How does long-acting injectable cabotegravir for PrEP compare with oral tenofovir/emtricitabine for preventing HIV infection across different populations?", "topic": "HIV prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["PrEP", "cabotegravir", "tenofovir emtricitabine", "HIV prevention", "injectable", "oral", "comparative efficacy"]}
{"question": "What factors are most strongly associated with virologic failure on first-line integrase inhibitor–based ART in low- and middle-income settings?", "topic": "HIV treatment outcomes", "question_type": "prognosis", "expected_search_terms": ["HIV", "integrase inhibitor", "virologic failure", "predictors", "low- and middle-income countries", "adherence", "drug resistance"]}
{"question": "How do transmitted drug resistance patterns differ between regions and how do they affect selection of first-line ART regimens?", "topic": "HIV drug resistance", "question_type": "epidemiology", "expected_search_terms": ["HIV", "transmitted drug resistance", "genotypic resistance", "regional variation", "first-line therapy", "surveillance"]}
{"question": "What is the relationship between HIV-associated chronic inflammation markers (such as IL-6 and D-dimer) and cardiovascular event risk in virologically suppressed individuals?", "topic": "HIV comorbidities", "question_type": "prognosis", "expected_search_terms": ["HIV", "chronic inflammation", "IL-6", "D-dimer", "cardiovascular disease", "virologic suppression", "risk"]}
{"question": "How does HIV infection influence the incidence of venous thromboembolism compared with HIV-negative populations after adjusting for confounders?", "topic": "HIV comorbidities", "question_type": "epidemiology", "expected_search_terms": ["HIV", "venous thromboembolism", "incidence", "risk", "cohort", "adjusted", "comorbidity"]}
{"question": "In people with HIV and tuberculosis, how does the timing of ART initiation during TB therapy affect mortality and immune reconstitution inflammatory syndrome risk?", "topic": "HIV/TB coinfection", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "tuberculosis", "timing of ART", "IRIS", "mortality", "coinfection", "randomized"]}
{"question": "How effective is cotrimoxazole prophylaxis in reducing mortality and opportunistic infections among adults with HIV in high-burden settings?", "topic": "HIV opportunistic infection prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "cotrimoxazole", "prophylaxis", "mortality", "opportunistic infections", "Africa", "randomized"]}
{"question": "What is the incidence and clinical impact of cryptococcal antigenemia in advanced HIV disease populations before ART initiation?", "topic": "HIV opportunistic infections", "question_type": "epidemiology", "expected_search_terms": ["HIV", "advanced HIV disease", "cryptococcal antigen", "antigenemia", "incidence", "mortality", "screening"]}
{"question": "In HIV-associated cryptococcal meningitis, how does short-course amphotericin-based induction therapy compare with longer-course regimens for survival and toxicity?", "topic": "HIV opportunistic infection treatment", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "cryptococcal meningitis", "amphotericin", "induction therapy", "short course", "survival", "toxicity"]}
{"question": "How does dolutegravir-based ART compare with efavirenz-based ART in pregnancy for maternal viral suppression and adverse pregnancy outcomes?", "topic": "HIV in pregnancy", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "pregnancy", "dolutegravir", "efavirenz", "viral suppression", "birth outcomes", "safety"]}
{"question": "What is the effectiveness of universal HIV screening strategies in emergency departments compared with risk-based testing in identifying new diagnoses?", "topic": "HIV diagnosis strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "screening", "emergency department", "universal testing", "risk-based testing", "new diagnosis", "implementation"]}
{"question": "How does partner notification strategy (provider referral vs patient referral) affect rates of HIV testing and diagnosis among partners?", "topic": "HIV prevention and control", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "partner notification", "provider referral", "patient referral", "testing uptake", "diagnosis", "public health"]}
{"question": "What mechanisms underlie persistent HIV-associated neurocognitive disorder in the era of suppressive ART?", "topic": "HIV neuropathogenesis", "question_type": "mechanism", "expected_search_terms": ["HIV", "neurocognitive disorder", "HAND", "suppressive ART", "neuroinflammation", "CNS reservoir", "mechanisms"]}
{"question": "How does HIV subtype influence disease progression rates and response to first-line ART regimens?", "topic": "HIV virology", "question_type": "prognosis", "expected_search_terms": ["HIV subtype", "disease progression", "CD4 decline", "viral load", "ART response", "subtype differences"]}
{"question": "Among people with HIV on stable ART, how does switching to two-drug maintenance therapy compare with continuing three-drug therapy for long-term viral suppression?", "topic": "HIV antiretroviral therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "two-drug regimen", "maintenance therapy", "three-drug regimen", "switch", "viral suppression", "noninferiority"]}
{"question": "What is the association between intermittent low-level viremia on ART and the risk of future virologic failure?", "topic": "HIV treatment monitoring", "question_type": "prognosis", "expected_search_terms": ["HIV", "low-level viremia", "viral blips", "ART", "virologic failure", "predictive", "cohort"]}
{"question": "How effective are broadly neutralizing antibodies as maintenance therapy compared with standard ART interruption strategies in maintaining viral control?", "topic": "HIV immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "broadly neutralizing antibodies", "maintenance", "ART interruption", "viral control", "clinical trial"]}
{"question": "What are the most common resistance mutations selected by integrase strand transfer inhibitors and how do they affect susceptibility across the class?", "topic": "HIV drug resistance", "question_type": "review", "expected_search_terms": ["HIV", "integrase inhibitor", "resistance mutations", "cross-resistance", "genotype", "susceptibility", "review"]}
{"question": "How does co-infection with hepatitis B virus influence liver-related outcomes in people with HIV receiving tenofovir-containing ART?", "topic": "HIV viral hepatitis coinfection", "question_type": "prognosis", "expected_search_terms": ["HIV", "hepatitis B", "coinfection", "tenofovir", "liver outcomes", "fibrosis", "mortality"]}
{"question": "Among people with HIV and hepatitis C, how do direct-acting antiviral cure rates compare between those on different ART backbones?", "topic": "HIV/HCV coinfection", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "hepatitis C", "direct-acting antivirals", "SVR", "ART backbone", "drug interactions", "outcomes"]}
{"question": "What is the incidence of anal high-grade squamous intraepithelial lesions in men who have sex with men living with HIV compared with HIV-negative controls?", "topic": "HIV-associated malignancy risk", "question_type": "epidemiology", "expected_search_terms": ["HIV", "MSM", "anal HSIL", "incidence", "HPV", "comparison", "screening"]}
{"question": "How does treatment of anal HSIL affect the risk of progression to anal cancer in people living with HIV?", "topic": "HIV-associated malignancies", "question_type": "prognosis", "expected_search_terms": ["HIV", "anal HSIL", "treatment", "anal cancer", "progression", "risk reduction", "follow-up"]}
{"question": "What is the comparative effectiveness of different adherence interventions (digital reminders, peer support, or pharmacist-led counseling) on viral suppression in people with HIV?", "topic": "HIV care delivery", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "adherence intervention", "digital reminder", "peer support", "pharmacist counseling", "viral suppression", "randomized"]}
{"question": "How does stigma reduction intervention implementation influence HIV testing uptake in key populations?", "topic": "HIV prevention and public health", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "stigma reduction", "testing uptake", "key populations", "implementation", "intervention", "community"]}
{"question": "What mechanisms explain weight gain observed after switching to integrase inhibitor–based ART, including potential roles of adipogenesis and appetite regulation?", "topic": "HIV ART metabolic effects", "question_type": "mechanism", "expected_search_terms": ["HIV", "integrase inhibitors", "weight gain", "adipogenesis", "metabolism", "appetite", "mechanism"]}
{"question": "How does HIV-associated immune activation contribute to accelerated atherosclerosis despite virologic suppression?", "topic": "HIV cardiovascular disease", "question_type": "mechanism", "expected_search_terms": ["HIV", "immune activation", "atherosclerosis", "inflammation", "virologic suppression", "endothelial dysfunction", "mechanisms"]}
{"question": "Among hospitalized patients, how does rapid initiation of ART during an opportunistic infection hospitalization affect 6-month mortality compared with delayed initiation?", "topic": "HIV treatment timing", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "opportunistic infection", "ART initiation", "early", "delayed", "hospitalization", "mortality"]}
{"question": "What is the effect of HIV self-testing availability on linkage to care rates compared with standard facility-based testing?", "topic": "HIV diagnosis strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "self-testing", "facility-based testing", "linkage to care", "uptake", "randomized", "implementation"]}
{"question": "How does maternal HIV viral suppression at delivery predict the risk of vertical transmission in the context of contemporary ART regimens?", "topic": "HIV vertical transmission", "question_type": "prognosis", "expected_search_terms": ["HIV", "vertical transmission", "maternal viral load", "delivery", "ART", "risk", "perinatal"]}
{"question": "What is the effectiveness of dolutegravir-based ART compared with protease inhibitor–based ART in children for viral suppression and tolerability?", "topic": "Pediatric HIV treatment", "question_type": "efficacy_comparison", "expected_search_terms": ["pediatric HIV", "dolutegravir", "protease inhibitor", "viral suppression", "tolerability", "children", "trial"]}
{"question": "How do sex differences influence pharmacokinetics and adverse event profiles of commonly used antiretroviral drugs?", "topic": "HIV pharmacology", "question_type": "review", "expected_search_terms": ["HIV", "sex differences", "pharmacokinetics", "antiretroviral", "adverse events", "women", "drug exposure"]}
{"question": "What is the association between baseline CD4 count at ART initiation and long-term life expectancy among people living with HIV?", "topic": "HIV prognosis", "question_type": "prognosis", "expected_search_terms": ["HIV", "baseline CD4", "ART initiation", "life expectancy", "long-term outcomes", "cohort", "mortality"]}
{"question": "How does HIV infection affect the magnitude and durability of antibody responses to COVID-19 vaccination compared with HIV-negative individuals?", "topic": "HIV and COVID-19 immunity", "question_type": "epidemiology", "expected_search_terms": ["HIV", "COVID-19 vaccine", "antibody response", "durability", "immunogenicity", "comparison", "cohort"]}
{"question": "In MRSA bloodstream infection, how does daptomycin compare with vancomycin for clinical cure and nephrotoxicity?", "topic": "Antibiotic-resistant bacterial infections", "question_type": "efficacy_comparison", "expected_search_terms": ["MRSA", "bacteremia", "daptomycin", "vancomycin", "clinical cure", "nephrotoxicity", "comparative"]}
{"question": "For MRSA pneumonia, how does linezolid compare with vancomycin in clinical outcomes and adverse effects?", "topic": "Antibiotic-resistant bacterial infections", "question_type": "efficacy_comparison", "expected_search_terms": ["MRSA", "pneumonia", "linezolid", "vancomycin", "clinical outcomes", "thrombocytopenia", "meta-analysis"]}
{"question": "In carbapenem-resistant Enterobacterales infections, how does ceftazidime-avibactam compare with meropenem-vaborbactam for mortality and microbiologic clearance?", "topic": "Carbapenem-resistant infections", "question_type": "efficacy_comparison", "expected_search_terms": ["carbapenem-resistant Enterobacterales", "ceftazidime-avibactam", "meropenem-vaborbactam", "mortality", "microbiologic clearance", "comparative effectiveness"]}
{"question": "What are the clinical outcomes of polymyxin-based regimens compared with newer beta-lactam/beta-lactamase inhibitor therapies for CRE bloodstream infections?", "topic": "Carbapenem-resistant infections", "question_type": "efficacy_comparison", "expected_search_terms": ["CRE", "polymyxin", "colistin", "beta-lactam beta-lactamase inhibitor", "bloodstream infection", "outcomes", "nephrotoxicity"]}
{"question": "In multidrug-resistant Pseudomonas aeruginosa infections, how does cefiderocol compare with ceftolozane-tazobactam for clinical success?", "topic": "Multidrug-resistant Gram-negative infections", "question_type": "efficacy_comparison", "expected_search_terms": ["multidrug-resistant Pseudomonas", "cefiderocol", "ceftolozane-tazobactam", "clinical success", "hospital-acquired", "comparative"]}
{"question": "What mechanisms drive heteroresistance to colistin in Gram-negative bacteria and how does it affect treatment failure risk?", "topic": "Antibiotic resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["colistin", "heteroresistance", "Gram-negative", "mechanism", "treatment failure", "lipid A modification", "pmrAB"]}
{"question": "How does the presence of specific carbapenemase genes correlate with susceptibility to newer beta-lactam/beta-lactamase inhibitor antibiotics?", "topic": "Carbapenem-resistant infections", "question_type": "mechanism", "expected_search_terms": ["carbapenemase genes", "KPC", "NDM", "OXA-48", "susceptibility", "ceftazidime-avibactam", "aztreonam-avibactam"]}
{"question": "What is the impact of rapid molecular diagnostics for bloodstream infections on time to effective therapy and mortality in settings with high antimicrobial resistance?", "topic": "AMR diagnostics and stewardship", "question_type": "efficacy_comparison", "expected_search_terms": ["rapid molecular diagnostic", "bloodstream infection", "time to effective therapy", "mortality", "antimicrobial resistance", "stewardship", "PCR panel"]}
{"question": "How does an antimicrobial stewardship intervention affect rates of inappropriate antibiotic use in hospitalized COVID-19 patients?", "topic": "AMR and COVID-19", "question_type": "efficacy_comparison", "expected_search_terms": ["antimicrobial stewardship", "COVID-19", "antibiotic use", "inappropriate prescribing", "hospitalized", "intervention", "audit feedback"]}
{"question": "What is the association between prior antibiotic exposure and subsequent colonization or infection with carbapenem-resistant Enterobacterales in hospitalized patients?", "topic": "AMR epidemiology", "question_type": "prognosis", "expected_search_terms": ["carbapenem-resistant Enterobacterales", "prior antibiotic exposure", "colonization", "infection", "risk factors", "hospitalized", "cohort"]}
{"question": "What is the incidence of Candida auris colonization and infection in intensive care units and which patient-level factors predict progression to invasive disease?", "topic": "Antifungal-resistant infections", "question_type": "epidemiology", "expected_search_terms": ["Candida auris", "ICU", "colonization", "invasive infection", "incidence", "risk factors", "candidemia"]}
{"question": "How does echinocandin therapy compare with amphotericin B formulations for treatment of invasive Candida auris infections?", "topic": "Antifungal-resistant infections", "question_type": "efficacy_comparison", "expected_search_terms": ["Candida auris", "echinocandin", "amphotericin B", "treatment", "invasive candidiasis", "outcomes", "mortality"]}
{"question": "What infection-control measures are most effective in reducing hospital transmission of carbapenem-resistant Enterobacterales?", "topic": "AMR infection prevention", "question_type": "review", "expected_search_terms": ["carbapenem-resistant Enterobacterales", "infection control", "contact precautions", "screening", "cohorting", "environmental cleaning", "transmission"]}
{"question": "In complicated urinary tract infections caused by ESBL-producing Enterobacterales, how does piperacillin-tazobactam compare with carbapenems for clinical cure?", "topic": "ESBL infections", "question_type": "efficacy_comparison", "expected_search_terms": ["ESBL", "complicated urinary tract infection", "piperacillin-tazobactam", "carbapenem", "clinical cure", "Enterobacterales", "comparative"]}
{"question": "How does the inoculum effect influence beta-lactam efficacy against ESBL-producing organisms in severe infections?", "topic": "Antibiotic pharmacodynamics", "question_type": "mechanism", "expected_search_terms": ["inoculum effect", "ESBL", "beta-lactam", "pharmacodynamics", "treatment failure", "MIC", "severe infection"]}
{"question": "What is the effectiveness of decolonization strategies (chlorhexidine bathing and nasal mupirocin) in reducing MRSA bloodstream infections in ICUs?", "topic": "AMR infection prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["MRSA", "decolonization", "chlorhexidine bathing", "mupirocin", "ICU", "bloodstream infection", "prevention"]}
{"question": "How does mupirocin resistance affect the success of MRSA decolonization programs in healthcare settings?", "topic": "AMR infection prevention", "question_type": "prognosis", "expected_search_terms": ["mupirocin resistance", "MRSA", "decolonization", "failure", "healthcare settings", "nasal carriage", "outcomes"]}
{"question": "In vancomycin-resistant Enterococcus bacteremia, how does linezolid compare with daptomycin for mortality and microbiologic clearance?", "topic": "VRE infections", "question_type": "efficacy_comparison", "expected_search_terms": ["vancomycin-resistant Enterococcus", "bacteremia", "linezolid", "daptomycin", "mortality", "clearance", "comparative"]}
{"question": "What factors predict recurrence of Clostridioides difficile infection after standard antibiotic therapy?", "topic": "Antibiotic-associated infections", "question_type": "prognosis", "expected_search_terms": ["Clostridioides difficile", "recurrence", "risk factors", "antibiotic therapy", "predictors", "cohort", "severity"]}
{"question": "For recurrent Clostridioides difficile infection, how does fecal microbiota transplantation compare with fidaxomicin in preventing further recurrences?", "topic": "Antibiotic-associated infections", "question_type": "efficacy_comparison", "expected_search_terms": ["recurrent C difficile", "fecal microbiota transplantation", "fidaxomicin", "recurrence prevention", "randomized", "clinical outcomes"]}
{"question": "How does antibiotic exposure during hospitalization influence the risk of subsequent colonization with multidrug-resistant organisms at discharge?", "topic": "AMR epidemiology", "question_type": "prognosis", "expected_search_terms": ["antibiotic exposure", "multidrug-resistant organisms", "colonization", "hospital discharge", "risk", "MDRO", "cohort"]}
{"question": "What is the comparative effectiveness of oral step-down therapy versus continued intravenous therapy for uncomplicated Staphylococcus aureus bacteremia in the context of resistance concerns?", "topic": "Resistant Gram-positive infections", "question_type": "efficacy_comparison", "expected_search_terms": ["Staphylococcus aureus bacteremia", "oral step-down", "intravenous therapy", "MRSA", "treatment duration", "outcomes", "comparative"]}
{"question": "How does biofilm formation contribute to antibiotic tolerance in chronic device-associated infections caused by Staphylococcus epidermidis?", "topic": "AMR mechanisms in biofilms", "question_type": "mechanism", "expected_search_terms": ["biofilm", "Staphylococcus epidermidis", "device-associated infection", "antibiotic tolerance", "mechanisms", "matrix", "persister cells"]}
{"question": "In prosthetic joint infections due to staphylococci, how does rifampin combination therapy compare with non-rifampin regimens for relapse prevention?", "topic": "Resistant staphylococcal infections", "question_type": "efficacy_comparison", "expected_search_terms": ["prosthetic joint infection", "staphylococci", "rifampin", "combination therapy", "relapse", "biofilm", "outcome"]}
{"question": "What is the global epidemiology of community-associated MRSA compared with healthcare-associated MRSA in terms of incidence trends and dominant clones?", "topic": "AMR epidemiology", "question_type": "epidemiology", "expected_search_terms": ["community-associated MRSA", "healthcare-associated MRSA", "incidence trends", "clones", "epidemiology", "global", "surveillance"]}
{"question": "How does prior influenza or viral respiratory infection alter susceptibility to secondary bacterial pneumonia with antibiotic-resistant pathogens?", "topic": "Viral-bacterial interactions and AMR", "question_type": "mechanism", "expected_search_terms": ["influenza", "secondary bacterial pneumonia", "antibiotic-resistant", "MRSA", "pathogenesis", "host defense", "viral-bacterial interaction"]}
{"question": "What is the effect of hospital wastewater antibiotic concentrations on selection for antimicrobial resistance genes in downstream environments?", "topic": "AMR ecology", "question_type": "mechanism", "expected_search_terms": ["hospital wastewater", "antibiotics", "resistance genes", "selection", "environment", "metagenomics", "AMR"]}
{"question": "How effective are bacteriophage therapies compared with antibiotics alone in treating multidrug-resistant bacterial infections in humans?", "topic": "Alternative therapies for AMR", "question_type": "efficacy_comparison", "expected_search_terms": ["bacteriophage therapy", "multidrug-resistant", "clinical", "compassionate use", "adjunctive therapy", "antibiotics", "outcomes"]}
{"question": "What mechanisms enable plasmid-mediated colistin resistance and how does it spread across Enterobacterales populations?", "topic": "AMR mechanisms", "question_type": "mechanism", "expected_search_terms": ["plasmid-mediated colistin resistance", "mcr", "Enterobacterales", "horizontal gene transfer", "mechanism", "spread", "epidemiology"]}
{"question": "In patients with bloodstream infection due to ESBL-producing Enterobacterales, how does definitive oral therapy compare with continued IV carbapenem therapy for relapse and mortality?", "topic": "ESBL infections", "question_type": "efficacy_comparison", "expected_search_terms": ["ESBL bacteremia", "oral step-down", "carbapenem", "definitive therapy", "relapse", "mortality", "observational"]}
{"question": "What is the association between delayed appropriate therapy and mortality in carbapenem-resistant Enterobacterales sepsis?", "topic": "Carbapenem-resistant infections", "question_type": "prognosis", "expected_search_terms": ["CRE", "sepsis", "delayed appropriate therapy", "mortality", "time to effective antibiotics", "outcomes", "cohort"]}
{"question": "How does therapeutic drug monitoring for vancomycin (AUC-guided) compare with trough-guided monitoring in reducing nephrotoxicity while maintaining efficacy in MRSA infections?", "topic": "Antimicrobial dosing strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["vancomycin", "AUC-guided", "trough", "nephrotoxicity", "MRSA", "therapeutic drug monitoring", "efficacy"]}
{"question": "What is the comparative impact of different hospital isolation strategies (single-room isolation vs cohorting) on MDRO transmission rates?", "topic": "AMR infection prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["MDRO", "transmission", "single-room isolation", "cohorting", "infection control", "hospital", "contact precautions"]}
{"question": "How does metagenomic sequencing for pneumonia diagnosis compare with conventional cultures in identifying antibiotic-resistant pathogens and guiding therapy?", "topic": "AMR diagnostics", "question_type": "efficacy_comparison", "expected_search_terms": ["metagenomic sequencing", "pneumonia", "diagnosis", "antibiotic resistance", "culture", "clinical impact", "antibiotic stewardship"]}
{"question": "What are the most effective strategies to prevent emergence of resistance during therapy for multidrug-resistant tuberculosis?", "topic": "Drug-resistant tuberculosis", "question_type": "review", "expected_search_terms": ["multidrug-resistant tuberculosis", "resistance emergence", "treatment strategy", "combination therapy", "adherence", "programmatic management", "review"]}
{"question": "In rifampicin-resistant tuberculosis, how does bedaquiline-containing regimens compare with non-bedaquiline regimens for culture conversion and mortality?", "topic": "Drug-resistant tuberculosis", "question_type": "efficacy_comparison", "expected_search_terms": ["rifampicin-resistant tuberculosis", "bedaquiline", "regimen", "culture conversion", "mortality", "treatment outcomes"]}
{"question": "How do host-directed therapies modulate immune responses in tuberculosis, and what evidence supports clinical benefit in drug-resistant disease?", "topic": "Drug-resistant tuberculosis", "question_type": "review", "expected_search_terms": ["tuberculosis", "host-directed therapy", "immunomodulation", "drug-resistant", "adjunctive", "clinical outcomes", "review"]}
{"question": "What is the incidence of post-COVID invasive fungal infections (such as mucormycosis) and which clinical factors predict occurrence?", "topic": "COVID-19 complications and AMR", "question_type": "epidemiology", "expected_search_terms": ["COVID-19", "mucormycosis", "invasive fungal infection", "incidence", "risk factors", "steroids", "diabetes"]}
{"question": "How does corticosteroid exposure in severe COVID-19 influence subsequent risk of multidrug-resistant bacterial superinfection in the ICU?", "topic": "COVID-19 and AMR", "question_type": "prognosis", "expected_search_terms": ["COVID-19", "corticosteroids", "ICU", "superinfection", "multidrug-resistant", "ventilator-associated pneumonia", "risk"]}
{"question": "What is the effectiveness of antibiotic cycling or mixing policies compared with standard practice in reducing ICU antimicrobial resistance rates?", "topic": "AMR stewardship strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["antibiotic cycling", "antibiotic mixing", "ICU", "antimicrobial resistance", "stewardship", "ecology", "intervention"]}
{"question": "How does outpatient antibiotic prescribing volume correlate with community prevalence of resistant urinary pathogens such as ESBL-producing E. coli?", "topic": "AMR epidemiology", "question_type": "epidemiology", "expected_search_terms": ["outpatient antibiotic prescribing", "community", "ESBL E. coli", "urinary tract infection", "resistance prevalence", "correlation", "ecologic study"]}
{"question": "In neonates with suspected sepsis in settings with high resistance, how does empiric therapy guided by local antibiograms compare with standard WHO-recommended regimens for mortality?", "topic": "AMR in neonatal infections", "question_type": "efficacy_comparison", "expected_search_terms": ["neonatal sepsis", "empiric antibiotics", "antibiogram", "WHO regimen", "antimicrobial resistance", "mortality", "low-resource"]}
{"question": "What is the prognostic value of colonization screening for carbapenem-resistant organisms in predicting subsequent invasive infection during hospitalization?", "topic": "AMR screening", "question_type": "prognosis", "expected_search_terms": ["carbapenem-resistant", "colonization screening", "rectal swab", "predict invasive infection", "hospitalization", "risk", "surveillance"]}
{"question": "How does combination antibiotic therapy compare with monotherapy for treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia?", "topic": "Multidrug-resistant Acinetobacter infections", "question_type": "efficacy_comparison", "expected_search_terms": ["Acinetobacter baumannii", "carbapenem-resistant", "ventilator-associated pneumonia", "combination therapy", "monotherapy", "mortality", "clinical cure"]}
{"question": "What mechanisms drive persistence and relapse in multidrug-resistant Acinetobacter baumannii infections, including roles of biofilms and persister cells?", "topic": "AMR mechanisms", "question_type": "mechanism", "expected_search_terms": ["Acinetobacter baumannii", "persistence", "relapse", "biofilm", "persister cells", "multidrug-resistant", "mechanism"]}
{"question": "How does outpatient treatment with oral antibiotics compare with IV therapy for uncomplicated ESBL pyelonephritis in terms of treatment success?", "topic": "ESBL infections", "question_type": "efficacy_comparison", "expected_search_terms": ["ESBL", "pyelonephritis", "oral antibiotics", "intravenous therapy", "treatment success", "step-down", "comparative"]}
{"question": "What is the comparative effectiveness of different decolonization regimens for carbapenem-resistant Enterobacterales carriage in long-term care facilities?", "topic": "AMR infection prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["carbapenem-resistant Enterobacterales", "decolonization", "long-term care", "carriage", "intervention", "chlorhexidine", "selective digestive decontamination"]}
{"question": "How does antibiotic prophylaxis strategy in colorectal surgery influence subsequent rates of surgical site infections caused by resistant organisms?", "topic": "AMR in surgical infections", "question_type": "prognosis", "expected_search_terms": ["colorectal surgery", "antibiotic prophylaxis", "surgical site infection", "resistant organisms", "ESBL", "MRSA", "risk"]}
{"question": "What are the clinical and microbiological outcomes of ceftaroline compared with daptomycin-based regimens for persistent MRSA bacteremia?", "topic": "Resistant staphylococcal infections", "question_type": "efficacy_comparison", "expected_search_terms": ["persistent MRSA bacteremia", "ceftaroline", "daptomycin", "salvage therapy", "microbiologic clearance", "mortality", "comparative"]}
{"question": "How does vancomycin minimum inhibitory concentration (MIC) creep relate to clinical outcomes in MRSA bloodstream infection?", "topic": "AMR prognosis markers", "question_type": "prognosis", "expected_search_terms": ["MRSA", "vancomycin MIC", "MIC creep", "bacteremia", "treatment failure", "mortality", "outcomes"]}
{"question": "How does hospital implementation of universal gloving and gowning compare with targeted precautions for reducing acquisition of antibiotic-resistant organisms in ICUs?", "topic": "AMR infection prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["universal gloving", "universal gowning", "ICU", "antibiotic-resistant organisms", "acquisition", "contact precautions", "intervention"]}
{"question": "What are the most common causes of breakthrough invasive infections during neutropenia prophylaxis with fluoroquinolones and how often are they resistant?", "topic": "AMR in immunocompromised hosts", "question_type": "epidemiology", "expected_search_terms": ["neutropenia", "fluoroquinolone prophylaxis", "breakthrough infection", "resistance", "hematologic malignancy", "bacteremia", "etiology"]}
{"question": "In febrile neutropenia, how does empiric therapy with antipseudomonal beta-lactam monotherapy compare with combination therapy in settings with high resistance rates?", "topic": "AMR in immunocompromised hosts", "question_type": "efficacy_comparison", "expected_search_terms": ["febrile neutropenia", "empiric therapy", "beta-lactam monotherapy", "combination therapy", "resistance", "Pseudomonas", "outcomes"]}
{"question": "How does HIV coinfection influence clinical outcomes of multidrug-resistant tuberculosis treatment compared with HIV-negative patients?", "topic": "HIV and drug-resistant TB", "question_type": "prognosis", "expected_search_terms": ["multidrug-resistant tuberculosis", "HIV coinfection", "treatment outcomes", "mortality", "culture conversion", "cohort", "programmatic"]}
{"question": "What is the impact of antiretroviral therapy on susceptibility to bacterial infections with antibiotic-resistant organisms among people with HIV?", "topic": "HIV and bacterial infections", "question_type": "epidemiology", "expected_search_terms": ["HIV", "antiretroviral therapy", "bacterial infections", "antibiotic-resistant", "MRSA", "incidence", "risk"]}
{"question": "How does SARS-CoV-2 infection in people living with HIV affect COVID-19 hospitalization risk compared with HIV-negative individuals after adjusting for comorbidities?", "topic": "HIV and COVID-19 outcomes", "question_type": "prognosis", "expected_search_terms": ["HIV", "COVID-19", "hospitalization", "risk", "comorbidities", "adjusted analysis", "cohort"]}
{"question": "What is the association between CD4 count or HIV viral suppression status and COVID-19 mortality among people living with HIV?", "topic": "HIV and COVID-19 outcomes", "question_type": "prognosis", "expected_search_terms": ["HIV", "COVID-19", "CD4 count", "viral suppression", "mortality", "severity", "cohort study"]}
{"question": "How does prior SARS-CoV-2 infection influence HIV viral load dynamics or immune activation markers in people on stable ART?", "topic": "HIV and COVID-19 immunology", "question_type": "mechanism", "expected_search_terms": ["HIV", "SARS-CoV-2 infection", "immune activation", "viral load dynamics", "ART", "inflammation markers", "longitudinal"]}
{"question": "What is the comparative effectiveness of doxycycline post-exposure prophylaxis versus no prophylaxis in reducing bacterial sexually transmitted infections among people on HIV PrEP?", "topic": "HIV prevention and STI control", "question_type": "efficacy_comparison", "expected_search_terms": ["doxycycline", "post-exposure prophylaxis", "HIV PrEP", "sexually transmitted infections", "chlamydia", "syphilis", "gonorrhea"]}
{"question": "How does antimicrobial resistance in Neisseria gonorrhoeae affect the effectiveness of recommended empiric treatment regimens in different regions?", "topic": "AMR in sexually transmitted infections", "question_type": "epidemiology", "expected_search_terms": ["Neisseria gonorrhoeae", "antimicrobial resistance", "ceftriaxone", "treatment effectiveness", "regional", "surveillance", "treatment failure"]}
{"question": "What mechanisms underlie macrolide resistance in Mycoplasma genitalium and how do they affect azithromycin treatment outcomes?", "topic": "AMR mechanisms in STIs", "question_type": "mechanism", "expected_search_terms": ["Mycoplasma genitalium", "macrolide resistance", "23S rRNA mutation", "azithromycin", "treatment failure", "mechanism"]}
{"question": "In hospitalized patients with COVID-19, how does empiric broad-spectrum antibiotic use compare with restrictive antibiotic strategies in terms of mortality and secondary infection outcomes?", "topic": "COVID-19 and antimicrobial stewardship", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "empiric antibiotics", "broad-spectrum", "restrictive strategy", "mortality", "secondary infection", "stewardship"]}
{"question": "What is the prevalence of antibiotic-resistant bacterial pathogens in ventilator-associated pneumonia among COVID-19 ICU patients compared with non-COVID ICU patients?", "topic": "COVID-19 and AMR epidemiology", "question_type": "epidemiology", "expected_search_terms": ["ventilator-associated pneumonia", "COVID-19 ICU", "non-COVID ICU", "antibiotic resistance", "prevalence", "pathogens", "comparison"]}
{"question": "How does SARS-CoV-2 infection impact interferon-stimulated gene expression in the airway epithelium, and how is this linked to viral replication kinetics?", "topic": "COVID-19 virology and immunology", "question_type": "mechanism", "expected_search_terms": ["SARS-CoV-2", "airway epithelium", "interferon-stimulated genes", "viral replication", "transcriptomics", "innate immunity"]}
{"question": "What is the comparative effectiveness of different mask types (cloth, surgical, N95/FFP2) in preventing SARS-CoV-2 infection in community settings?", "topic": "COVID-19 prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["SARS-CoV-2", "mask", "cloth mask", "surgical mask", "N95", "community", "infection prevention"]}
{"question": "How do ventilation and air filtration interventions in schools affect SARS-CoV-2 transmission compared with standard ventilation?", "topic": "COVID-19 prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["schools", "ventilation", "air filtration", "HEPA", "SARS-CoV-2 transmission", "intervention", "indoor air"]}
{"question": "What are the long-term pulmonary function outcomes after severe COVID-19 pneumonia and which early markers predict persistent impairment?", "topic": "COVID-19 prognosis", "question_type": "prognosis", "expected_search_terms": ["severe COVID-19", "pulmonary function", "DLCO", "fibrosis", "long-term outcomes", "predictors", "follow-up"]}
{"question": "How does HIV infection influence the risk of invasive pneumococcal disease in the era of pneumococcal conjugate vaccination?", "topic": "HIV and bacterial infections", "question_type": "epidemiology", "expected_search_terms": ["HIV", "invasive pneumococcal disease", "pneumococcal conjugate vaccine", "incidence", "risk", "post-vaccine era"]}
{"question": "In adults living with HIV, how does PCV vaccination strategy (PCV alone vs PCV followed by PPSV) compare for immunogenicity and clinical protection?", "topic": "HIV vaccination", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "pneumococcal vaccine", "PCV", "PPSV", "immunogenicity", "clinical protection", "strategy"]}
{"question": "What is the effectiveness of isoniazid preventive therapy compared with rifapentine-based regimens in preventing active tuberculosis among people with HIV?", "topic": "HIV/TB prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "tuberculosis prevention", "isoniazid preventive therapy", "rifapentine", "3HP", "active TB incidence", "trial"]}
{"question": "How does antibiotic resistance in Salmonella Typhi affect clinical outcomes and fever clearance times with commonly used therapies?", "topic": "AMR in enteric infections", "question_type": "prognosis", "expected_search_terms": ["Salmonella Typhi", "antibiotic resistance", "fluoroquinolone resistance", "ceftriaxone", "azithromycin", "fever clearance time", "outcomes"]}
{"question": "What is the comparative efficacy of azithromycin versus ceftriaxone for treatment of typhoid fever in regions with high fluoroquinolone resistance?", "topic": "AMR in enteric infections", "question_type": "efficacy_comparison", "expected_search_terms": ["typhoid fever", "azithromycin", "ceftriaxone", "fluoroquinolone resistance", "treatment efficacy", "randomized", "clinical cure"]}
{"question": "How do antibiotic resistance patterns in Shigella species influence empiric treatment recommendations for travelers' diarrhea?", "topic": "AMR in gastrointestinal infections", "question_type": "review", "expected_search_terms": ["Shigella", "antibiotic resistance", "travelers' diarrhea", "empiric therapy", "azithromycin resistance", "fluoroquinolone", "guidelines"]}
{"question": "What is the association between HIV infection and colonization with extended-spectrum beta-lactamase–producing Enterobacterales in community settings?", "topic": "HIV and AMR colonization", "question_type": "epidemiology", "expected_search_terms": ["HIV", "ESBL", "Enterobacterales", "colonization", "community", "prevalence", "risk factors"]}
{"question": "How does gut microbial translocation in HIV contribute mechanistically to systemic immune activation despite virologic suppression?", "topic": "HIV pathogenesis", "question_type": "mechanism", "expected_search_terms": ["HIV", "microbial translocation", "gut barrier", "LPS", "immune activation", "virologic suppression", "mechanism"]}
{"question": "What is the comparative effectiveness of different screening strategies for latent TB infection (IGRA vs TST) in people living with HIV for predicting progression to active TB?", "topic": "HIV/TB diagnostics", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "latent tuberculosis", "IGRA", "tuberculin skin test", "progression", "predictive value", "screening"]}
{"question": "How does early initiation of anti-tuberculosis treatment in HIV/TB coinfection influence inflammatory biomarker trajectories and risk of IRIS?", "topic": "HIV/TB immunopathology", "question_type": "mechanism", "expected_search_terms": ["HIV", "tuberculosis", "IRIS", "biomarkers", "CRP", "cytokines", "treatment initiation"]}
{"question": "What is the effectiveness of community-based ART delivery models compared with clinic-based models in achieving viral suppression in rural settings?", "topic": "HIV care delivery", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "community-based ART", "clinic-based", "viral suppression", "rural", "differentiated service delivery", "outcomes"]}
{"question": "How does telemedicine follow-up compare with in-person visits for retention in care and viral suppression among people living with HIV?", "topic": "HIV care delivery", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "telemedicine", "retention in care", "viral suppression", "in-person visits", "care model", "outcomes"]}
{"question": "What are the key drivers of antimicrobial resistance emergence in hospital settings, including antibiotic selection pressure and patient-to-patient transmission dynamics?", "topic": "AMR drivers", "question_type": "review", "expected_search_terms": ["antimicrobial resistance", "hospital", "selection pressure", "transmission", "antibiotic use", "colonization pressure", "review"]}
{"question": "How does rapid de-escalation based on procalcitonin guidance compare with standard care in reducing antibiotic duration for suspected bacterial pneumonia?", "topic": "AMR stewardship strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["procalcitonin", "antibiotic de-escalation", "pneumonia", "antibiotic duration", "stewardship", "randomized", "clinical outcomes"]}
{"question": "What is the association between procalcitonin-guided antibiotic algorithms and outcomes specifically in COVID-19 patients with suspected bacterial coinfection?", "topic": "COVID-19 and antimicrobial stewardship", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "procalcitonin", "antibiotic stewardship", "coinfection", "antibiotic duration", "mortality", "algorithm"]}
{"question": "How does HIV infection affect the natural history and clearance of high-risk HPV infection compared with HIV-negative individuals?", "topic": "HIV and viral coinfections", "question_type": "prognosis", "expected_search_terms": ["HIV", "HPV", "high-risk HPV", "clearance", "persistence", "natural history", "cohort"]}
{"question": "What is the effectiveness of HPV vaccination in preventing persistent HPV infection among adolescents living with HIV compared with HIV-negative adolescents?", "topic": "HIV vaccination", "question_type": "efficacy_comparison", "expected_search_terms": ["HPV vaccine", "HIV", "adolescents", "immunogenicity", "persistent infection", "effectiveness", "comparison"]}
{"question": "How does SARS-CoV-2 vaccination timing relative to anti-CD20 therapy affect serologic response and breakthrough infection risk?", "topic": "COVID-19 vaccines in immunocompromised", "question_type": "prognosis", "expected_search_terms": ["SARS-CoV-2 vaccine", "anti-CD20", "rituximab", "serologic response", "breakthrough infection", "timing", "immunocompromised"]}
{"question": "In immunocompromised patients with prolonged SARS-CoV-2 infection, how does combination antiviral therapy compare with monotherapy for viral clearance?", "topic": "COVID-19 therapeutics in immunocompromised", "question_type": "efficacy_comparison", "expected_search_terms": ["prolonged SARS-CoV-2 infection", "immunocompromised", "combination antiviral", "remdesivir", "nirmatrelvir", "viral clearance", "case series"]}
{"question": "What are the most common pathways for resistance emergence to protease inhibitors in SARS-CoV-2 and how do these mutations affect viral fitness?", "topic": "COVID-19 antiviral resistance", "question_type": "mechanism", "expected_search_terms": ["SARS-CoV-2", "protease inhibitor", "resistance mutations", "3CLpro", "viral fitness", "selection", "mechanism"]}
{"question": "How does the use of corticosteroids in severe COVID-19 affect reactivation risk of latent infections such as tuberculosis or hepatitis B?", "topic": "COVID-19 complications", "question_type": "prognosis", "expected_search_terms": ["COVID-19", "corticosteroids", "tuberculosis reactivation", "hepatitis B reactivation", "risk", "immunosuppression", "outcomes"]}
{"question": "What is the incidence of HIV acquisition among individuals diagnosed with sexually transmitted infections, and how does it vary by STI type and population?", "topic": "HIV epidemiology", "question_type": "epidemiology", "expected_search_terms": ["HIV acquisition", "sexually transmitted infections", "incidence", "syphilis", "gonorrhea", "chlamydia", "risk"]}
{"question": "How does offering same-day ART initiation at HIV diagnosis compare with standard delayed initiation for retention in care and viral suppression?", "topic": "HIV treatment initiation", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "same-day ART", "rapid start", "retention in care", "viral suppression", "linkage", "comparative"]}
{"question": "What is the prognostic significance of baseline HIV viral load for time to viral suppression after starting modern integrase inhibitor–based ART?", "topic": "HIV prognosis", "question_type": "prognosis", "expected_search_terms": ["HIV", "baseline viral load", "time to suppression", "integrase inhibitor", "ART", "predictor", "cohort"]}
{"question": "How does antibiotic resistance in Streptococcus pneumoniae influence clinical outcomes of community-acquired pneumonia treated with beta-lactams or macrolides?", "topic": "AMR in respiratory infections", "question_type": "prognosis", "expected_search_terms": ["Streptococcus pneumoniae", "antibiotic resistance", "community-acquired pneumonia", "beta-lactam", "macrolide", "treatment outcomes", "failure"]}
{"question": "What is the comparative effectiveness of shorter versus longer antibiotic treatment durations for uncomplicated Gram-negative bacteremia in the context of resistance risk?", "topic": "Antibiotic optimization and AMR", "question_type": "efficacy_comparison", "expected_search_terms": ["Gram-negative bacteremia", "short course", "long course", "antibiotic duration", "relapse", "resistance", "noninferiority"]}
{"question": "How do antibiotic treatment durations influence the emergence of resistance in commensal gut flora during and after therapy?", "topic": "AMR mechanisms and ecology", "question_type": "mechanism", "expected_search_terms": ["antibiotic duration", "gut microbiota", "resistance emergence", "resistome", "commensal", "selection", "longitudinal"]}
{"question": "In adults with type 2 diabetes and established cardiovascular disease, how does a GLP-1 receptor agonist compare with an SGLT2 inhibitor in reducing major adverse cardiovascular events?", "topic": "Type 2 diabetes", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "GLP-1 receptor agonist", "SGLT2 inhibitor", "major adverse cardiovascular events", "cardiovascular outcomes"]}
{"question": "In type 2 diabetes with chronic kidney disease, how do SGLT2 inhibitors compare with finerenone for slowing decline in estimated glomerular filtration rate?", "topic": "Type 2 diabetes/CKD", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "chronic kidney disease", "SGLT2 inhibitors", "finerenone", "eGFR decline", "renal outcomes"]}
{"question": "In overweight or obese adults with type 2 diabetes, how does tirzepatide compare with semaglutide in achieving weight loss and HbA1c reduction?", "topic": "Diabetes and obesity pharmacotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["tirzepatide", "semaglutide", "type 2 diabetes", "weight loss", "HbA1c", "randomized trial"]}
{"question": "In nonalcoholic steatohepatitis, how does pioglitazone compare with vitamin E for improving liver histology in non-cirrhotic patients?", "topic": "NAFLD/NASH", "question_type": "efficacy_comparison", "expected_search_terms": ["nonalcoholic steatohepatitis", "pioglitazone", "vitamin E", "liver histology", "ballooning", "fibrosis"]}
{"question": "In patients with NAFLD and type 2 diabetes, how does a GLP-1 receptor agonist compare with an SGLT2 inhibitor for reducing hepatic fat content measured by imaging?", "topic": "NAFLD with diabetes", "question_type": "efficacy_comparison", "expected_search_terms": ["NAFLD", "type 2 diabetes", "GLP-1 receptor agonist", "SGLT2 inhibitor", "MRI-PDFF", "hepatic steatosis"]}
{"question": "In adults with obesity without diabetes, how does semaglutide compare with lifestyle intervention alone for long-term maintenance of weight loss after initial reduction?", "topic": "Obesity treatment", "question_type": "efficacy_comparison", "expected_search_terms": ["obesity", "semaglutide", "lifestyle intervention", "weight maintenance", "long-term", "randomized"]}
{"question": "In adolescents with severe obesity, what is the comparative effectiveness of bariatric surgery versus pharmacotherapy (GLP-1 receptor agonists) on BMI reduction at 1–2 years?", "topic": "Pediatric obesity", "question_type": "efficacy_comparison", "expected_search_terms": ["adolescent", "severe obesity", "bariatric surgery", "GLP-1 receptor agonist", "BMI reduction", "outcomes"]}
{"question": "In type 2 diabetes inadequately controlled on metformin, how do DPP-4 inhibitors compare with GLP-1 receptor agonists regarding glycemic control and pancreatitis risk?", "topic": "Type 2 diabetes pharmacotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "metformin", "DPP-4 inhibitor", "GLP-1 receptor agonist", "HbA1c", "pancreatitis risk"]}
{"question": "In hospitalized patients with type 2 diabetes, how does basal-bolus insulin compare with basal-plus correction insulin for glycemic control and hypoglycemia rates?", "topic": "Inpatient diabetes management", "question_type": "efficacy_comparison", "expected_search_terms": ["hospitalized", "type 2 diabetes", "basal-bolus", "basal plus", "correction insulin", "hypoglycemia"]}
{"question": "In adults with type 1 diabetes, how does continuous glucose monitoring compare with self-monitoring of blood glucose for reducing time in hypoglycemia?", "topic": "Type 1 diabetes technology", "question_type": "efficacy_comparison", "expected_search_terms": ["type 1 diabetes", "continuous glucose monitoring", "self-monitoring blood glucose", "time in hypoglycemia", "randomized"]}
{"question": "In type 1 diabetes, how does hybrid closed-loop insulin delivery compare with sensor-augmented pump therapy for improving time in range?", "topic": "Type 1 diabetes technology", "question_type": "efficacy_comparison", "expected_search_terms": ["type 1 diabetes", "hybrid closed-loop", "sensor-augmented pump", "time in range", "glycemic variability"]}
{"question": "In adults with metabolic syndrome, how do Mediterranean diet patterns compare with low-carbohydrate diets for improving insulin resistance as measured by HOMA-IR?", "topic": "Metabolic syndrome", "question_type": "efficacy_comparison", "expected_search_terms": ["metabolic syndrome", "Mediterranean diet", "low carbohydrate", "HOMA-IR", "insulin resistance", "trial"]}
{"question": "In NAFLD, how does aerobic exercise compare with resistance training for reducing liver fat and ALT levels independent of weight loss?", "topic": "NAFLD lifestyle", "question_type": "efficacy_comparison", "expected_search_terms": ["NAFLD", "aerobic exercise", "resistance training", "liver fat", "ALT", "weight independent"]}
{"question": "In adults with obesity and obstructive sleep apnea, how does CPAP therapy compare with weight-loss interventions in improving insulin sensitivity?", "topic": "Obesity and comorbidity", "question_type": "efficacy_comparison", "expected_search_terms": ["obesity", "obstructive sleep apnea", "CPAP", "weight loss intervention", "insulin sensitivity", "HOMA-IR"]}
{"question": "In patients with type 2 diabetes and NAFLD, how does bariatric surgery compare with intensive medical therapy for NASH resolution and fibrosis improvement?", "topic": "NAFLD/NASH and diabetes", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "NAFLD", "NASH", "bariatric surgery", "intensive medical therapy", "fibrosis", "resolution"]}
{"question": "In adults with obesity, how does intermittent fasting compare with continuous calorie restriction for changes in resting metabolic rate and lean mass preservation?", "topic": "Obesity nutrition", "question_type": "efficacy_comparison", "expected_search_terms": ["obesity", "intermittent fasting", "calorie restriction", "resting metabolic rate", "lean mass", "body composition"]}
{"question": "In type 2 diabetes, how does initiation of insulin glargine compare with insulin degludec in rates of nocturnal hypoglycemia in real-world studies?", "topic": "Type 2 diabetes insulin", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "insulin glargine", "insulin degludec", "nocturnal hypoglycemia", "real-world"]}
{"question": "In pregnant patients with gestational diabetes, how does metformin compare with insulin for maternal glycemic control and neonatal outcomes such as macrosomia?", "topic": "Gestational diabetes", "question_type": "efficacy_comparison", "expected_search_terms": ["gestational diabetes", "metformin", "insulin", "macrosomia", "neonatal outcomes", "maternal glycemic control"]}
{"question": "In NAFLD screening among people with type 2 diabetes, how does transient elastography compare with serum fibrosis scores for identifying advanced fibrosis?", "topic": "NAFLD diagnostics", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "NAFLD screening", "transient elastography", "FIB-4", "NAFLD fibrosis score", "advanced fibrosis"]}
{"question": "In patients with obesity and prediabetes, how does metformin compare with GLP-1 receptor agonists in preventing progression to type 2 diabetes?", "topic": "Prediabetes prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["prediabetes", "obesity", "metformin", "GLP-1 receptor agonist", "prevention", "progression to type 2 diabetes"]}
{"question": "What molecular mechanisms link hepatic de novo lipogenesis to insulin resistance in NAFLD, focusing on SREBP-1c and ChREBP signaling?", "topic": "NAFLD mechanisms", "question_type": "mechanism", "expected_search_terms": ["NAFLD", "de novo lipogenesis", "insulin resistance", "SREBP-1c", "ChREBP", "hepatic metabolism"]}
{"question": "How does adipose tissue inflammation via macrophage polarization (M1/M2) contribute to systemic insulin resistance in obesity?", "topic": "Obesity mechanisms", "question_type": "mechanism", "expected_search_terms": ["obesity", "adipose tissue inflammation", "macrophage polarization", "M1", "M2", "insulin resistance"]}
{"question": "What is the role of gut microbiome-derived short-chain fatty acids in regulating appetite and insulin sensitivity in obesity?", "topic": "Obesity and microbiome", "question_type": "mechanism", "expected_search_terms": ["gut microbiome", "short-chain fatty acids", "appetite regulation", "insulin sensitivity", "obesity"]}
{"question": "How does hepatic mitochondrial dysfunction contribute to progression from simple steatosis to NASH?", "topic": "NAFLD/NASH mechanisms", "question_type": "mechanism", "expected_search_terms": ["hepatic mitochondrial dysfunction", "NAFLD", "NASH", "oxidative stress", "progression", "pathogenesis"]}
{"question": "What mechanisms explain SGLT2 inhibitor-associated ketogenesis and risk of euglycemic ketoacidosis in diabetes?", "topic": "Diabetes drug mechanisms", "question_type": "mechanism", "expected_search_terms": ["SGLT2 inhibitor", "ketogenesis", "euglycemic ketoacidosis", "mechanism", "glucagon", "lipolysis"]}
{"question": "How do GLP-1 receptor agonists influence gastric emptying and central appetite pathways to produce weight loss?", "topic": "Obesity pharmacology", "question_type": "mechanism", "expected_search_terms": ["GLP-1 receptor agonist", "gastric emptying", "central appetite", "hypothalamus", "weight loss", "mechanism"]}
{"question": "What is the role of FGF21 signaling in obesity-related insulin resistance and NAFLD, and how do pharmacologic analogs mimic these effects?", "topic": "Metabolic endocrine signaling", "question_type": "mechanism", "expected_search_terms": ["FGF21", "insulin resistance", "NAFLD", "obesity", "FGF21 analog", "mechanism"]}
{"question": "How does activation of brown adipose tissue contribute to energy expenditure and glycemic control in humans with obesity?", "topic": "Obesity mechanisms", "question_type": "mechanism", "expected_search_terms": ["brown adipose tissue", "thermogenesis", "energy expenditure", "obesity", "glycemic control", "humans"]}
{"question": "What role does endoplasmic reticulum stress play in pancreatic beta-cell failure during progression of type 2 diabetes?", "topic": "Type 2 diabetes pathophysiology", "question_type": "mechanism", "expected_search_terms": ["endoplasmic reticulum stress", "beta-cell failure", "type 2 diabetes", "UPR", "apoptosis"]}
{"question": "How do advanced glycation end products contribute to vascular inflammation and atherosclerosis risk in diabetes?", "topic": "Diabetes complications mechanisms", "question_type": "mechanism", "expected_search_terms": ["advanced glycation end products", "diabetes", "vascular inflammation", "atherosclerosis", "RAGE"]}
{"question": "What is the mechanistic relationship between ectopic lipid accumulation in skeletal muscle and insulin resistance in obesity?", "topic": "Insulin resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["ectopic fat", "skeletal muscle", "insulin resistance", "lipotoxicity", "diacylglycerol", "ceramides"]}
{"question": "How do ceramides and diacylglycerols modulate insulin signaling pathways in liver and muscle in metabolic disease?", "topic": "Metabolic lipid signaling", "question_type": "mechanism", "expected_search_terms": ["ceramides", "diacylglycerol", "insulin signaling", "AKT", "PKC", "liver", "muscle"]}
{"question": "What mechanisms connect sleep deprivation to insulin resistance and weight gain through hormonal changes such as ghrelin and leptin?", "topic": "Obesity risk mechanisms", "question_type": "mechanism", "expected_search_terms": ["sleep deprivation", "insulin resistance", "weight gain", "ghrelin", "leptin", "hormonal changes"]}
{"question": "How does fructose consumption promote hepatic steatosis through changes in uric acid, lipogenesis, and insulin signaling?", "topic": "NAFLD dietary mechanisms", "question_type": "mechanism", "expected_search_terms": ["fructose", "hepatic steatosis", "uric acid", "de novo lipogenesis", "insulin signaling", "NAFLD"]}
{"question": "What are the proposed mechanisms by which metformin alters the gut microbiome and improves glucose homeostasis?", "topic": "Diabetes drug mechanisms", "question_type": "mechanism", "expected_search_terms": ["metformin", "gut microbiome", "glucose homeostasis", "AMPK", "bile acids", "mechanism"]}
{"question": "How does hepatic stellate cell activation drive fibrosis progression in NASH, and what signaling pathways are most implicated?", "topic": "NASH fibrosis mechanisms", "question_type": "mechanism", "expected_search_terms": ["NASH", "hepatic stellate cell", "fibrosis", "TGF-beta", "PDGF", "activation pathways"]}
{"question": "What is the role of bile acid signaling via FXR and TGR5 in metabolic regulation and NAFLD pathogenesis?", "topic": "NAFLD signaling", "question_type": "mechanism", "expected_search_terms": ["bile acids", "FXR", "TGR5", "metabolic regulation", "NAFLD", "insulin sensitivity"]}
{"question": "How does hypothalamic inflammation contribute to leptin resistance and hyperphagia in diet-induced obesity?", "topic": "Obesity neuroendocrinology", "question_type": "mechanism", "expected_search_terms": ["hypothalamic inflammation", "leptin resistance", "hyperphagia", "diet-induced obesity", "microglia"]}
{"question": "What is the relationship between adiponectin levels and hepatic insulin sensitivity in NAFLD, and what mechanisms mediate this association?", "topic": "NAFLD adipokines", "question_type": "mechanism", "expected_search_terms": ["adiponectin", "hepatic insulin sensitivity", "NAFLD", "adipokines", "AMPK", "inflammation"]}
{"question": "How does muscle contraction-induced myokine signaling (such as irisin or IL-6) influence glucose uptake and insulin sensitivity in obesity?", "topic": "Exercise and metabolism", "question_type": "mechanism", "expected_search_terms": ["myokines", "irisin", "IL-6", "glucose uptake", "insulin sensitivity", "exercise", "obesity"]}
{"question": "What is the prevalence of NAFLD among patients with type 2 diabetes across different geographic regions, and how consistent are diagnostic criteria between studies?", "topic": "NAFLD epidemiology", "question_type": "epidemiology", "expected_search_terms": ["NAFLD prevalence", "type 2 diabetes", "geographic variation", "diagnostic criteria", "meta-analysis"]}
{"question": "What is the incidence of progression from prediabetes to type 2 diabetes in adults stratified by baseline BMI category?", "topic": "Prediabetes epidemiology", "question_type": "epidemiology", "expected_search_terms": ["prediabetes", "incidence", "progression", "type 2 diabetes", "BMI", "cohort study"]}
{"question": "How does socioeconomic status influence obesity prevalence and trends over time in high-income countries?", "topic": "Obesity epidemiology", "question_type": "epidemiology", "expected_search_terms": ["obesity prevalence", "socioeconomic status", "health disparities", "trend", "high-income countries"]}
{"question": "What is the association between ultra-processed food intake and risk of developing type 2 diabetes in prospective cohorts?", "topic": "Diabetes risk epidemiology", "question_type": "epidemiology", "expected_search_terms": ["ultra-processed foods", "type 2 diabetes", "prospective cohort", "incidence", "dietary pattern"]}
{"question": "What is the relationship between sugar-sweetened beverage consumption and incident NAFLD in observational studies?", "topic": "NAFLD risk epidemiology", "question_type": "epidemiology", "expected_search_terms": ["sugar-sweetened beverages", "NAFLD", "incident", "observational study", "risk"]}
{"question": "How does exposure to endocrine-disrupting chemicals (such as bisphenols or phthalates) correlate with obesity and insulin resistance in human studies?", "topic": "Environmental metabolic epidemiology", "question_type": "epidemiology", "expected_search_terms": ["endocrine disrupting chemicals", "bisphenol", "phthalates", "obesity", "insulin resistance", "human study"]}
{"question": "What is the prevalence of lean NAFLD and how do metabolic risk factors differ from obese NAFLD in population studies?", "topic": "NAFLD phenotypes", "question_type": "epidemiology", "expected_search_terms": ["lean NAFLD", "prevalence", "metabolic risk factors", "obese NAFLD", "population study"]}
{"question": "What is the incidence and prevalence of type 2 diabetes in youth, and how have these rates changed over the past two decades?", "topic": "Youth diabetes epidemiology", "question_type": "epidemiology", "expected_search_terms": ["youth", "type 2 diabetes", "incidence", "prevalence", "time trends", "two decades"]}
{"question": "How does gestational diabetes history affect long-term risk of type 2 diabetes and cardiovascular disease in mothers?", "topic": "Gestational diabetes outcomes", "question_type": "epidemiology", "expected_search_terms": ["gestational diabetes", "type 2 diabetes risk", "cardiovascular disease", "long-term", "cohort"]}
{"question": "What is the association between polycystic ovary syndrome and NAFLD prevalence independent of BMI?", "topic": "NAFLD comorbidity epidemiology", "question_type": "epidemiology", "expected_search_terms": ["polycystic ovary syndrome", "NAFLD", "prevalence", "independent of BMI", "meta-analysis"]}
{"question": "How does obstructive sleep apnea severity relate to incident type 2 diabetes risk in longitudinal studies?", "topic": "Diabetes risk epidemiology", "question_type": "epidemiology", "expected_search_terms": ["obstructive sleep apnea", "severity", "incident type 2 diabetes", "longitudinal", "risk"]}
{"question": "What is the association between nonalcoholic fatty liver disease and incident chronic kidney disease in observational cohorts?", "topic": "NAFLD complications epidemiology", "question_type": "epidemiology", "expected_search_terms": ["NAFLD", "chronic kidney disease", "incident", "cohort", "risk"]}
{"question": "How does visceral adiposity measured by imaging compare with BMI in predicting incident type 2 diabetes in population studies?", "topic": "Diabetes risk epidemiology", "question_type": "epidemiology", "expected_search_terms": ["visceral adiposity", "CT", "MRI", "BMI", "incident type 2 diabetes", "prediction"]}
{"question": "What is the relationship between sarcopenic obesity and risk of developing NAFLD in older adults?", "topic": "NAFLD risk epidemiology", "question_type": "epidemiology", "expected_search_terms": ["sarcopenic obesity", "older adults", "NAFLD", "risk", "epidemiology"]}
{"question": "How do ethnicity and genetic ancestry modify the risk of NAFLD and NASH in multiethnic cohorts?", "topic": "NAFLD disparities", "question_type": "epidemiology", "expected_search_terms": ["NAFLD", "NASH", "ethnicity", "genetic ancestry", "multiethnic cohort", "risk"]}
{"question": "What are the global trends in obesity prevalence among women of reproductive age and their association with gestational diabetes rates?", "topic": "Obesity and pregnancy epidemiology", "question_type": "epidemiology", "expected_search_terms": ["global trends", "obesity prevalence", "reproductive age", "gestational diabetes", "association"]}
{"question": "How common is metabolic-associated fatty liver disease among patients with normal liver enzymes, and what clinical features predict it?", "topic": "NAFLD detection epidemiology", "question_type": "epidemiology", "expected_search_terms": ["fatty liver", "normal ALT", "prevalence", "predictors", "metabolic associated fatty liver disease"]}
{"question": "What is the risk of hepatocellular carcinoma in NAFLD patients without cirrhosis compared with those with cirrhosis in cohort studies?", "topic": "NAFLD outcomes epidemiology", "question_type": "prognosis", "expected_search_terms": ["NAFLD", "hepatocellular carcinoma", "non-cirrhotic", "cirrhosis", "cohort", "risk"]}
{"question": "In individuals with prediabetes, which baseline biomarkers best predict progression to type 2 diabetes over 3–5 years?", "topic": "Prediabetes prognosis", "question_type": "prognosis", "expected_search_terms": ["prediabetes", "biomarkers", "progression", "type 2 diabetes", "prediction", "cohort"]}
{"question": "In type 2 diabetes, how strongly does time in range from continuous glucose monitoring predict microvascular complications compared with HbA1c?", "topic": "Diabetes prognosis/monitoring", "question_type": "prognosis", "expected_search_terms": ["type 2 diabetes", "time in range", "continuous glucose monitoring", "HbA1c", "microvascular complications", "prediction"]}
{"question": "In NAFLD, how does baseline fibrosis stage predict liver-related mortality and all-cause mortality in longitudinal studies?", "topic": "NAFLD prognosis", "question_type": "prognosis", "expected_search_terms": ["NAFLD", "fibrosis stage", "liver-related mortality", "all-cause mortality", "longitudinal"]}
{"question": "In patients with type 2 diabetes, what is the prognostic significance of albuminuria for cardiovascular events independent of eGFR?", "topic": "Diabetes complications prognosis", "question_type": "prognosis", "expected_search_terms": ["type 2 diabetes", "albuminuria", "cardiovascular events", "eGFR", "prognosis", "independent"]}
{"question": "After bariatric surgery, which preoperative factors predict durable remission of type 2 diabetes at 5 years?", "topic": "Diabetes remission", "question_type": "prognosis", "expected_search_terms": ["bariatric surgery", "type 2 diabetes remission", "predictors", "5-year", "durable remission"]}
{"question": "In gestational diabetes, how does degree of maternal hyperglycemia predict neonatal hypoglycemia and NICU admission risk?", "topic": "Gestational diabetes prognosis", "question_type": "prognosis", "expected_search_terms": ["gestational diabetes", "maternal hyperglycemia", "neonatal hypoglycemia", "NICU admission", "risk prediction"]}
{"question": "In youth with obesity, which clinical or laboratory markers best predict persistence of obesity into adulthood?", "topic": "Obesity life-course prognosis", "question_type": "prognosis", "expected_search_terms": ["childhood obesity", "adolescents", "predictors", "adult obesity", "persistence", "cohort"]}
{"question": "In NAFLD, how does the presence of type 2 diabetes influence the rate of fibrosis progression compared with non-diabetic patients?", "topic": "NAFLD progression", "question_type": "prognosis", "expected_search_terms": ["NAFLD", "type 2 diabetes", "fibrosis progression", "rate", "comparative", "cohort"]}
{"question": "In type 1 diabetes, what is the relationship between hypoglycemia unawareness and severe hypoglycemia risk in prospective studies?", "topic": "Type 1 diabetes prognosis", "question_type": "prognosis", "expected_search_terms": ["type 1 diabetes", "hypoglycemia unawareness", "severe hypoglycemia", "prospective", "risk"]}
{"question": "In patients with NAFLD, what is the prognostic value of noninvasive fibrosis scores for predicting future cirrhosis and decompensation?", "topic": "NAFLD prognosis/diagnostics", "question_type": "prognosis", "expected_search_terms": ["NAFLD", "noninvasive fibrosis score", "FIB-4", "cirrhosis", "decompensation", "prediction"]}
{"question": "In type 2 diabetes, how does early intensive glycemic control influence long-term risk of cardiovascular events compared with standard control in long follow-up studies?", "topic": "Type 2 diabetes long-term outcomes", "question_type": "prognosis", "expected_search_terms": ["type 2 diabetes", "early intensive glycemic control", "cardiovascular events", "long-term follow-up", "legacy effect"]}
{"question": "In obesity, how does baseline weight variability (weight cycling) predict future risk of incident type 2 diabetes and cardiovascular disease?", "topic": "Obesity prognosis", "question_type": "prognosis", "expected_search_terms": ["weight cycling", "weight variability", "obesity", "incident type 2 diabetes", "cardiovascular disease", "risk"]}
{"question": "In NAFLD patients, what factors predict regression of fibrosis with lifestyle intervention over 12–24 months?", "topic": "NAFLD prognosis/treatment response", "question_type": "prognosis", "expected_search_terms": ["NAFLD", "fibrosis regression", "lifestyle intervention", "predictors", "12 months", "24 months"]}
{"question": "In type 2 diabetes, how does presence of diabetic retinopathy predict subsequent nephropathy or cardiovascular risk?", "topic": "Diabetes complications prognosis", "question_type": "prognosis", "expected_search_terms": ["type 2 diabetes", "diabetic retinopathy", "nephropathy", "cardiovascular risk", "prediction"]}
{"question": "In NAFLD, how does baseline controlled attenuation parameter or MRI-PDFF predict histologic response to therapy in clinical studies?", "topic": "NAFLD prognosis/biomarkers", "question_type": "prognosis", "expected_search_terms": ["controlled attenuation parameter", "MRI-PDFF", "NAFLD", "histologic response", "biomarker", "prediction"]}
{"question": "In type 2 diabetes, what is the comparative effect of adding a GLP-1 receptor agonist versus initiating basal insulin on weight change and hypoglycemia rates?", "topic": "Type 2 diabetes treatment", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "GLP-1 receptor agonist", "basal insulin", "weight change", "hypoglycemia", "add-on therapy"]}
{"question": "In patients with NASH and significant fibrosis, how do FXR agonists compare with placebo regarding fibrosis improvement and pruritus incidence?", "topic": "NASH pharmacotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["NASH", "FXR agonist", "placebo", "fibrosis improvement", "pruritus", "randomized"]}
{"question": "In NAFLD, how does omega-3 fatty acid supplementation compare with placebo for reducing hepatic triglyceride content and improving lipid profiles?", "topic": "NAFLD supplements", "question_type": "efficacy_comparison", "expected_search_terms": ["NAFLD", "omega-3", "fish oil", "hepatic triglyceride", "lipid profile", "placebo"]}
{"question": "In adults with type 2 diabetes, how does a low-carbohydrate diet compare with a low-fat diet for HbA1c reduction at 6–12 months?", "topic": "Diabetes lifestyle therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "low carbohydrate diet", "low fat diet", "HbA1c", "6 months", "12 months"]}
{"question": "In obesity management, how does combined pharmacotherapy (e.g., GLP-1 receptor agonist plus another anti-obesity agent) compare with GLP-1 receptor agonist monotherapy for weight loss?", "topic": "Obesity pharmacotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["obesity", "combination pharmacotherapy", "GLP-1 receptor agonist", "monotherapy", "weight loss", "randomized"]}
{"question": "In NAFLD, how does weight loss achieved via diet compare with weight loss achieved via bariatric surgery for improving liver inflammation markers?", "topic": "NAFLD interventions", "question_type": "efficacy_comparison", "expected_search_terms": ["NAFLD", "diet weight loss", "bariatric surgery", "liver inflammation", "ALT", "CRP"]}
{"question": "In adults with type 2 diabetes, how does once-weekly GLP-1 receptor agonist therapy compare with daily therapy for adherence and glycemic outcomes?", "topic": "Diabetes treatment adherence", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "once-weekly", "daily", "GLP-1 receptor agonist", "adherence", "glycemic outcomes"]}
{"question": "In people with type 2 diabetes, how does switching from sulfonylurea to an SGLT2 inhibitor affect hypoglycemia risk and body weight?", "topic": "Type 2 diabetes medication optimization", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "sulfonylurea", "switch", "SGLT2 inhibitor", "hypoglycemia", "body weight"]}
{"question": "In NAFLD patients with obesity, how does pharmacologic weight loss compare with lifestyle weight loss in improving noninvasive fibrosis markers?", "topic": "NAFLD and obesity treatment", "question_type": "efficacy_comparison", "expected_search_terms": ["NAFLD", "obesity", "pharmacologic weight loss", "lifestyle", "FIB-4", "transient elastography"]}
{"question": "In type 2 diabetes, how does time-restricted eating compare with standard meal timing for improvements in fasting glucose and insulin sensitivity?", "topic": "Diabetes nutrition", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "time-restricted eating", "meal timing", "fasting glucose", "insulin sensitivity"]}
{"question": "In adults with obesity, how does high-protein diet compare with standard protein diet for preserving lean mass during calorie restriction?", "topic": "Obesity nutrition", "question_type": "efficacy_comparison", "expected_search_terms": ["obesity", "high-protein diet", "lean mass", "calorie restriction", "body composition"]}
{"question": "In NAFLD, how does coffee consumption relate to fibrosis severity and risk of progression in observational studies?", "topic": "NAFLD lifestyle epidemiology", "question_type": "epidemiology", "expected_search_terms": ["NAFLD", "coffee", "fibrosis severity", "progression", "observational"]}
{"question": "What is the association between physical activity levels and incident NAFLD independent of BMI in cohort studies?", "topic": "NAFLD risk epidemiology", "question_type": "epidemiology", "expected_search_terms": ["physical activity", "incident NAFLD", "independent of BMI", "cohort", "risk"]}
{"question": "How does long-term statin use affect incidence or progression of NAFLD and liver enzyme elevations in adults with metabolic risk factors?", "topic": "NAFLD pharmacoepidemiology", "question_type": "epidemiology", "expected_search_terms": ["statins", "NAFLD", "progression", "liver enzymes", "metabolic risk factors", "cohort"]}
{"question": "What is the incidence of hypoglycemia in older adults with type 2 diabetes treated with sulfonylureas compared with DPP-4 inhibitors in real-world studies?", "topic": "Diabetes medication safety", "question_type": "epidemiology", "expected_search_terms": ["older adults", "type 2 diabetes", "sulfonylurea", "DPP-4 inhibitor", "hypoglycemia", "real-world"]}
{"question": "What is the association between NAFLD and atrial fibrillation incidence in longitudinal studies?", "topic": "NAFLD cardiovascular epidemiology", "question_type": "epidemiology", "expected_search_terms": ["NAFLD", "atrial fibrillation", "incidence", "longitudinal", "risk"]}
{"question": "How do urban versus rural environments influence obesity incidence and related metabolic outcomes in adults?", "topic": "Obesity epidemiology", "question_type": "epidemiology", "expected_search_terms": ["urban", "rural", "obesity incidence", "metabolic outcomes", "environment", "adults"]}
{"question": "What is the prevalence of diabetic neuropathy in type 2 diabetes across different durations of disease and glycemic control strata?", "topic": "Diabetes complications epidemiology", "question_type": "epidemiology", "expected_search_terms": ["diabetic neuropathy", "type 2 diabetes", "prevalence", "disease duration", "glycemic control"]}
{"question": "How does breastfeeding duration after gestational diabetes affect maternal risk of subsequent type 2 diabetes in cohort studies?", "topic": "Gestational diabetes epidemiology", "question_type": "epidemiology", "expected_search_terms": ["gestational diabetes", "breastfeeding duration", "type 2 diabetes", "risk", "cohort"]}
{"question": "What is the association between vegetarian or plant-forward dietary patterns and incidence of type 2 diabetes in prospective studies?", "topic": "Diabetes prevention epidemiology", "question_type": "epidemiology", "expected_search_terms": ["plant-based diet", "vegetarian", "type 2 diabetes", "incidence", "prospective cohort"]}
{"question": "What are the most consistent genetic variants associated with NAFLD susceptibility and severity in genome-wide association studies?", "topic": "NAFLD genetics", "question_type": "review", "expected_search_terms": ["NAFLD", "genetic variants", "genome-wide association", "susceptibility", "severity", "review"]}
{"question": "What is the current evidence on the effectiveness of vitamin D supplementation for improving insulin resistance or glycemic control in type 2 diabetes?", "topic": "Diabetes supplements", "question_type": "review", "expected_search_terms": ["vitamin D supplementation", "type 2 diabetes", "insulin resistance", "glycemic control", "systematic review"]}
{"question": "What is the evidence that probiotics or synbiotics improve hepatic steatosis or inflammation in NAFLD?", "topic": "NAFLD microbiome interventions", "question_type": "review", "expected_search_terms": ["NAFLD", "probiotics", "synbiotics", "hepatic steatosis", "inflammation", "randomized", "systematic review"]}
{"question": "What are the benefits and harms of very-low-calorie diets for inducing remission of type 2 diabetes in adults?", "topic": "Type 2 diabetes remission", "question_type": "review", "expected_search_terms": ["very low calorie diet", "type 2 diabetes", "remission", "benefits", "harms", "trial", "review"]}
{"question": "What is the evidence comparing different noninvasive biomarkers and imaging modalities for diagnosing NASH without liver biopsy?", "topic": "NASH diagnostics", "question_type": "review", "expected_search_terms": ["NASH", "noninvasive diagnosis", "biomarkers", "imaging", "MRI", "elastography", "accuracy"]}
{"question": "What is known about the long-term safety profile of GLP-1 receptor agonists regarding gallbladder disease and pancreatitis risk?", "topic": "Obesity/diabetes drug safety", "question_type": "review", "expected_search_terms": ["GLP-1 receptor agonist", "gallbladder disease", "pancreatitis", "safety", "meta-analysis", "pharmacovigilance"]}
{"question": "What is the evidence that bariatric surgery reduces long-term cardiovascular mortality in patients with obesity and type 2 diabetes compared with nonsurgical management?", "topic": "Bariatric surgery outcomes", "question_type": "review", "expected_search_terms": ["bariatric surgery", "obesity", "type 2 diabetes", "cardiovascular mortality", "long-term", "cohort", "meta-analysis"]}
{"question": "What is the current evidence that continuous glucose monitoring improves outcomes in non–insulin-treated type 2 diabetes?", "topic": "Type 2 diabetes technology", "question_type": "review", "expected_search_terms": ["continuous glucose monitoring", "type 2 diabetes", "non-insulin treated", "HbA1c", "outcomes", "systematic review"]}
{"question": "What is the evidence that hepatic fat reduction measured by MRI-PDFF predicts histologic improvement in NASH treatment studies?", "topic": "NASH clinical trial endpoints", "question_type": "review", "expected_search_terms": ["MRI-PDFF", "hepatic fat reduction", "NASH", "histologic improvement", "surrogate endpoint", "trial"]}
{"question": "What is known about the role of circadian rhythm disruption in the development of obesity and type 2 diabetes in human studies?", "topic": "Metabolic chronobiology", "question_type": "review", "expected_search_terms": ["circadian rhythm", "shift work", "obesity", "type 2 diabetes", "human studies", "review"]}
{"question": "In NAFLD, how do GLP-1 receptor agonists compare with pioglitazone for changes in fibrosis biomarkers and liver enzymes in randomized studies?", "topic": "NAFLD pharmacotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["NAFLD", "GLP-1 receptor agonist", "pioglitazone", "fibrosis biomarker", "ALT", "randomized"]}
{"question": "In adults with type 2 diabetes, how does adding an SGLT2 inhibitor compare with adding a sulfonylurea to metformin regarding weight, hypoglycemia, and HbA1c?", "topic": "Type 2 diabetes combination therapy", "question_type": "efficacy_comparison", "expected_search_terms": ["metformin", "SGLT2 inhibitor", "sulfonylurea", "type 2 diabetes", "hypoglycemia", "weight", "HbA1c"]}
{"question": "In adults with obesity, how does naltrexone-bupropion compare with phentermine-topiramate for weight loss and discontinuation due to adverse events?", "topic": "Obesity pharmacotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["naltrexone bupropion", "phentermine topiramate", "obesity", "weight loss", "adverse events", "discontinuation"]}
{"question": "In type 2 diabetes with heart failure, how do SGLT2 inhibitors compare with GLP-1 receptor agonists for reducing hospitalization for heart failure?", "topic": "Diabetes and heart failure", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "heart failure", "SGLT2 inhibitor", "GLP-1 receptor agonist", "hospitalization", "outcomes"]}
{"question": "In adults with obesity and NAFLD, how does supervised exercise compare with unsupervised exercise counseling for reducing hepatic steatosis?", "topic": "NAFLD lifestyle intervention", "question_type": "efficacy_comparison", "expected_search_terms": ["obesity", "NAFLD", "supervised exercise", "unsupervised", "counseling", "hepatic steatosis"]}
{"question": "In patients with type 2 diabetes, how does early combination therapy (metformin plus another agent) compare with stepwise intensification for long-term glycemic durability?", "topic": "Type 2 diabetes treatment strategy", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "early combination therapy", "stepwise intensification", "glycemic durability", "metformin"]}
{"question": "In NAFLD, how does weight loss magnitude (e.g., 5%, 7%, 10%) relate to probability of NASH resolution in clinical studies?", "topic": "NAFLD outcomes", "question_type": "prognosis", "expected_search_terms": ["NAFLD", "weight loss", "NASH resolution", "dose response", "percentage weight loss", "clinical study"]}
{"question": "In adults with type 2 diabetes, what factors predict gastrointestinal intolerance leading to discontinuation of metformin?", "topic": "Diabetes medication tolerability", "question_type": "prognosis", "expected_search_terms": ["metformin", "gastrointestinal intolerance", "discontinuation", "predictors", "type 2 diabetes"]}
{"question": "In obesity, how well do baseline eating behavior phenotypes (e.g., binge eating, emotional eating) predict response to pharmacologic weight-loss therapy?", "topic": "Obesity treatment response", "question_type": "prognosis", "expected_search_terms": ["obesity", "binge eating", "emotional eating", "predict response", "pharmacologic weight loss"]}
{"question": "In NAFLD, what is the prognostic significance of elevated serum ferritin for fibrosis progression and liver-related outcomes?", "topic": "NAFLD biomarkers", "question_type": "prognosis", "expected_search_terms": ["NAFLD", "serum ferritin", "fibrosis progression", "liver outcomes", "prognostic"]}
{"question": "In type 2 diabetes, how does variability in HbA1c over time relate to risk of microvascular complications independent of mean HbA1c?", "topic": "Diabetes prognosis", "question_type": "prognosis", "expected_search_terms": ["type 2 diabetes", "HbA1c variability", "microvascular complications", "independent", "risk"]}
{"question": "In NAFLD, how does presence of obstructive sleep apnea predict histologic severity and fibrosis stage?", "topic": "NAFLD comorbidity prognosis", "question_type": "prognosis", "expected_search_terms": ["NAFLD", "obstructive sleep apnea", "histologic severity", "fibrosis stage", "association"]}
{"question": "In adults with type 2 diabetes, how does adding a thiazolidinedione compare with adding an SGLT2 inhibitor for improving nonalcoholic fatty liver disease markers?", "topic": "Diabetes therapy and NAFLD", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "thiazolidinedione", "SGLT2 inhibitor", "NAFLD markers", "ALT", "liver fat"]}
{"question": "In patients with obesity, how does resistance training combined with caloric restriction compare with caloric restriction alone for improving insulin sensitivity?", "topic": "Obesity lifestyle", "question_type": "efficacy_comparison", "expected_search_terms": ["obesity", "resistance training", "caloric restriction", "insulin sensitivity", "HOMA-IR", "trial"]}
{"question": "In NAFLD, how do PNPLA3 risk variants influence response to lifestyle or pharmacologic interventions reported in clinical studies?", "topic": "NAFLD pharmacogenomics", "question_type": "prognosis", "expected_search_terms": ["NAFLD", "PNPLA3", "genotype", "treatment response", "lifestyle", "pharmacologic"]}
{"question": "What mechanisms explain the increased risk of hepatocellular carcinoma in metabolic-associated fatty liver disease, focusing on lipotoxicity and chronic inflammation?", "topic": "NAFLD cancer mechanisms", "question_type": "mechanism", "expected_search_terms": ["metabolic associated fatty liver disease", "hepatocellular carcinoma", "lipotoxicity", "chronic inflammation", "mechanism"]}
{"question": "How does glucagon signaling contribute to hyperglycemia in type 2 diabetes, and what is the evidence for therapeutic targeting of glucagon pathways?", "topic": "Type 2 diabetes mechanisms", "question_type": "mechanism", "expected_search_terms": ["glucagon", "type 2 diabetes", "hyperglycemia", "glucagon receptor antagonist", "mechanism", "therapy"]}
{"question": "What is the role of adipose tissue fibrosis in limiting healthy adipose expansion and promoting insulin resistance in obesity?", "topic": "Obesity adipose biology", "question_type": "mechanism", "expected_search_terms": ["adipose tissue fibrosis", "obesity", "adipose expansion", "insulin resistance", "extracellular matrix"]}
{"question": "How does impaired incretin effect develop in type 2 diabetes, and what cellular mechanisms underlie reduced GIP or GLP-1 responsiveness?", "topic": "Type 2 diabetes incretin biology", "question_type": "mechanism", "expected_search_terms": ["incretin effect", "type 2 diabetes", "GIP", "GLP-1 responsiveness", "beta cell", "mechanism"]}
{"question": "What mechanisms link branched-chain amino acid metabolism to insulin resistance and risk of type 2 diabetes?", "topic": "Metabolomics and diabetes", "question_type": "mechanism", "expected_search_terms": ["branched-chain amino acids", "insulin resistance", "type 2 diabetes risk", "metabolism", "mechanism"]}
{"question": "How does chronic low-grade inflammation mediated by IL-1beta contribute to beta-cell dysfunction in type 2 diabetes?", "topic": "Type 2 diabetes inflammation", "question_type": "mechanism", "expected_search_terms": ["IL-1beta", "beta-cell dysfunction", "type 2 diabetes", "inflammation", "mechanism"]}
{"question": "What is the evidence that anti-inflammatory therapies targeting IL-1 pathways improve glycemic control in type 2 diabetes?", "topic": "Type 2 diabetes immunometabolism", "question_type": "review", "expected_search_terms": ["type 2 diabetes", "IL-1 blockade", "anti-inflammatory therapy", "glycemic control", "clinical trial", "systematic review"]}
{"question": "What is known about the impact of menopause and hormone changes on visceral fat accumulation and insulin resistance?", "topic": "Sex differences in metabolic disease", "question_type": "review", "expected_search_terms": ["menopause", "visceral fat", "insulin resistance", "estrogen", "metabolic syndrome", "review"]}
{"question": "What is the comparative accuracy of HOMA-IR, OGTT-derived indices, and clamp studies for assessing insulin resistance in obesity research?", "topic": "Metabolic measurement methods", "question_type": "review", "expected_search_terms": ["insulin resistance assessment", "HOMA-IR", "oral glucose tolerance test", "euglycemic clamp", "accuracy", "comparison"]}
{"question": "In adults with type 2 diabetes and obesity, how does adding an anti-obesity medication compare with intensifying glucose-lowering therapy for improving cardiometabolic risk factors?", "topic": "Integrated cardiometabolic management", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "obesity", "anti-obesity medication", "intensify glucose lowering", "cardiometabolic risk factors"]}
{"question": "In NAFLD with advanced fibrosis, how does weight loss via bariatric surgery compare with endoscopic bariatric therapies for fibrosis and metabolic outcomes?", "topic": "NAFLD procedural therapies", "question_type": "efficacy_comparison", "expected_search_terms": ["NAFLD", "advanced fibrosis", "bariatric surgery", "endoscopic bariatric therapy", "fibrosis", "metabolic outcomes"]}
{"question": "In type 2 diabetes, how do GLP-1 receptor agonists compare with basal insulin for improving postprandial glucose excursions?", "topic": "Type 2 diabetes glycemic patterns", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "GLP-1 receptor agonist", "basal insulin", "postprandial glucose", "excursions"]}
{"question": "In adults with NAFLD, how does treatment with an SGLT2 inhibitor compare with placebo for changes in liver stiffness measured by elastography?", "topic": "NAFLD pharmacotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["NAFLD", "SGLT2 inhibitor", "placebo", "liver stiffness", "elastography", "trial"]}
{"question": "In obesity, what is the effect of GLP-1 receptor agonist discontinuation on weight regain trajectories in follow-up studies?", "topic": "Obesity pharmacotherapy outcomes", "question_type": "prognosis", "expected_search_terms": ["GLP-1 receptor agonist", "discontinuation", "weight regain", "obesity", "follow-up"]}
{"question": "In patients with NASH, which noninvasive biomarker changes during treatment best predict histologic fibrosis improvement?", "topic": "NASH biomarkers", "question_type": "prognosis", "expected_search_terms": ["NASH", "noninvasive biomarkers", "predict", "fibrosis improvement", "histology", "treatment response"]}
{"question": "In adults with type 2 diabetes, what is the association between severe hypoglycemia and subsequent risk of dementia or cognitive decline?", "topic": "Diabetes complications prognosis", "question_type": "prognosis", "expected_search_terms": ["type 2 diabetes", "severe hypoglycemia", "dementia", "cognitive decline", "risk", "cohort"]}
{"question": "In NAFLD, what is the rate of spontaneous regression of steatosis or fibrosis without targeted therapy reported in longitudinal cohorts?", "topic": "NAFLD natural history", "question_type": "epidemiology", "expected_search_terms": ["NAFLD", "natural history", "regression", "steatosis", "fibrosis", "longitudinal cohort"]}
{"question": "How do GLP-1 receptor agonists affect renal outcomes such as albuminuria progression in type 2 diabetes compared with placebo or active comparators?", "topic": "Diabetes renal outcomes", "question_type": "efficacy_comparison", "expected_search_terms": ["GLP-1 receptor agonist", "type 2 diabetes", "albuminuria", "renal outcomes", "placebo", "comparator"]}
{"question": "In adults with obesity, how do different sleep interventions (sleep extension programs) compare with control for reducing caloric intake and weight gain risk?", "topic": "Obesity behavioral intervention", "question_type": "efficacy_comparison", "expected_search_terms": ["sleep extension", "obesity", "caloric intake", "weight gain", "behavioral intervention", "trial"]}
{"question": "In patients with type 2 diabetes, how does structured diabetes education compare with usual care for long-term HbA1c and hospitalization outcomes?", "topic": "Diabetes care delivery", "question_type": "efficacy_comparison", "expected_search_terms": ["structured diabetes education", "type 2 diabetes", "usual care", "HbA1c", "hospitalization", "long-term"]}
{"question": "What is the evidence that metabolically healthy obesity transitions to metabolically unhealthy phenotypes over time, and what predictors drive this transition?", "topic": "Obesity phenotypes", "question_type": "prognosis", "expected_search_terms": ["metabolically healthy obesity", "transition", "metabolically unhealthy", "predictors", "longitudinal"]}
{"question": "In patients with NAFLD, how does alcohol intake below traditional thresholds influence fibrosis progression risk in observational studies?", "topic": "NAFLD lifestyle risk", "question_type": "epidemiology", "expected_search_terms": ["NAFLD", "moderate alcohol", "low-level alcohol", "fibrosis progression", "observational"]}
{"question": "In type 2 diabetes, how does remission achieved through lifestyle intervention compare with remission achieved through bariatric surgery in durability over 2–5 years?", "topic": "Type 2 diabetes remission strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "remission", "lifestyle intervention", "bariatric surgery", "durability", "follow-up"]}
